<SEC-DOCUMENT>0001178913-22-003472.txt : 20220920
<SEC-HEADER>0001178913-22-003472.hdr.sgml : 20220920
<ACCEPTANCE-DATETIME>20220920163031
ACCESSION NUMBER:		0001178913-22-003472
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20220920
DATE AS OF CHANGE:		20220920

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioLineRx Ltd.
		CENTRAL INDEX KEY:			0001498403
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-251857
		FILM NUMBER:		221254041

	BUSINESS ADDRESS:	
		STREET 1:		2 HAMA-AYAN STREET
		STREET 2:		MODI-IN TECHNOLOGY PARK
		CITY:			MODI-IN
		STATE:			L3
		ZIP:			7177871
		BUSINESS PHONE:		972-2-548-9100

	MAIL ADDRESS:	
		STREET 1:		2 HAMA-AYAN STREET
		STREET 2:		MODI-IN TECHNOLOGY PARK
		CITY:			MODI-IN
		STATE:			L3
		ZIP:			7177871

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioLineRX, Ltd.
		DATE OF NAME CHANGE:	20100805
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>zk2228486.htm
<DESCRIPTION>424B5
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 22.7.2.5063
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: right; line-height: 1.25; font-weight: bold;">Filed pursuant to Rule 424(b)(5)<br>
      Registration No. 333-251857</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">PROSPECTUS SUPPLEMENT<br>
      (To Prospectus Dated January 11, 2021)</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">______________________</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">13,636,365 American Depositary Shares Representing 204,545,475 Ordinary Shares</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Warrants to Purchase 13,636,365 American Depositary Shares Representing 204,545,475 Ordinary Shares</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Placement Agent Warrants to Purchase 681,818 American Depositary Shares Representing 10,227,270 Ordinary Shares</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><img width="243" height="23" src="image0.jpg"><br>
      _______________________</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">
        <div style="text-indent: 36pt; line-height: 1.25;">We are offering 13,636,365 American Depositary Shares, or ADSs, representing 204,545,475 of our ordinary shares, and warrants to purchase up to an aggregate of 13,636,365 ADSs, representing
          204,545,475 of our ordinary shares, at a combined purchase price of $1.10 per ADS and associated warrant, to certain institutional investors pursuant to this prospectus supplement and accompanying prospectus. The warrants are exercisable at an
          exercise price of $1.15 per ADS at any time upon issuance and will expire five years from the date of issuance. Each ADS represents 15 ordinary shares. We are also registering pursuant to this prospectus supplement and the accompanying prospectus
          the ADSs representing ordinary shares issuable from time to time upon exercise of the warrants. See &#8220;Description of American Depositary Shares&#8221; and &#8220;Description of Ordinary Shares&#8221; in the accompanying prospectus for more information.</div>
      </div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our ADSs representing our ordinary shares are listed on The Nasdaq Capital Market, or Nasdaq, under the symbol &#8220;BLRX.&#8221; On September 16, 2022, the last reported sale price of the
      ADSs on Nasdaq was $1.54 per ADS. Our ordinary shares currently trade on the Tel Aviv Stock Exchange, or the TASE, under the symbol &#8220;BLRX.&#8221; On September 18, 2022, the last reported sale price of our ordinary shares on the TASE was NIS 0.356, or $0.10
      per share (based on the exchange rate reported by the Bank of Israel on such date).&#160;We do not intend to apply for listing of the warrants on The Nasdaq Capital Market or any securities exchange or nationally recognized trading system. Without an
      active trading market, the liquidity of the warrants will be limited.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Investing in our securities involves a high degree of risk. See &#8220;Risk Factors&#8221; beginning on page S-8 of this prospectus supplement and the documents we
      incorporate by reference in this prospectus supplement and the accompanying prospectus to read about factors you should consider before investing in our securities.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Neither the Securities and Exchange Commission, the Israel Securities Authority nor any state or other foreign securities commission has approved or disapproved
      of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">
        <div style="text-indent: 36pt; line-height: 1.25;">We have engaged H.C. Wainwright &amp; Co., LLC, or the placement agent, to act as our exclusive placement agent for this offering. The placement agent has agreed to use its &#8220;reasonable best
          efforts&#8221; to arrange for the sale of our securities offered by this prospectus supplement and the accompanying prospectus, but the placement agent has no obligation to purchase or sell any of such securities or to arrange for the purchase or sale
          of any specific number or dollar amount of such securities. There is no required minimum number of our securities that must be sold as a condition to completion of this offering. Pursuant to this prospectus supplement and the accompanying
          prospectus, we will also issue warrants to purchase up to 681,818 ADSs, representing 10,227,270 of our ordinary shares, to the placement agent, or its designees, as part of the compensation payable to the placement agent. The placement agent
          warrants will have an exercise price of $1.375 per share (which represents 125% of the offering price per ADS and associated warrant sold in this offering) and will expire five years following the commencement of the sales under this offering. We
          are also registering pursuant to this prospectus supplement and the accompanying prospectus the ADSs representing ordinary shares issuable from time to time upon exercise of the placement agent warrants. See &#8220;Plan of Distribution&#8221; beginning on
          page S-15 of this prospectus supplement for more information regarding these arrangements.</div>
      </div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have agreed to pay the placement agent the fees set forth in the table below in connection with this offering.</div>
    </div>
    <div style="line-height: 1.25;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="z4bcc0134842740bba883ea5646126704" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 72.92%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.53%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Per ADS and Warrant</div>
          </td>
          <td nowrap="nowrap" style="width: 0.53%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.53%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Total</div>
          </td>
          <td nowrap="nowrap" style="width: 0.53%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 72.92%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">Offering price</div>
          </td>
          <td style="width: 0.53%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td style="width: 9%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; line-height: 1.25;">1.100</div>
          </td>
          <td nowrap="nowrap" style="width: 0.53%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.53%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td style="width: 9%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; line-height: 1.25;">15,000,001.50</div>
          </td>
          <td nowrap="nowrap" style="width: 0.53%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 72.92%; vertical-align: top;">
            <div style="line-height: 1.25;">Placement agent&#8217;s fees<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div>
          </td>
          <td style="width: 0.53%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom;">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td style="width: 9%; vertical-align: bottom;">
            <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">0.077</div>
          </td>
          <td nowrap="nowrap" style="width: 0.53%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.53%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom;">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td style="width: 9%; vertical-align: bottom;">
            <div style="text-align: right; line-height: 1.25;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">1,050,000.11</div>
            </div>
          </td>
          <td nowrap="nowrap" style="width: 0.53%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 72.92%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">Proceeds, before expenses, to us<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div>
          </td>
          <td style="width: 0.53%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td style="width: 9%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; line-height: 1.25;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">1.023</div>
            </div>
          </td>
          <td nowrap="nowrap" style="width: 0.53%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.53%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td style="width: 9%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">13,950,001.39</div>
          </td>
          <td nowrap="nowrap" style="width: 0.53%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z9bdfca814ac4458fadce4d980d72860c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right;">(1)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
                <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">We will pay the placement agent a cash fee equal to 7% of the aggregate gross proceeds. We have also agreed to (i) pay the placement agent a
                  management fee equal to 1% of the aggregate gross proceeds, (ii) pay the placement agent $60,000 from non-accountable expenses, and (iii) issue to the placement agent, or its designees, warrants. For additional information regarding the
                  placement agent&#8217;s compensation please refer to &#8220;Plan of Distribution&#8221; on page S-15 of this prospectus supplement.</div>
              </div>
            </div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="za35ae7155ff347d3909c888cbdc532d4" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right;">(2)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>
              <div style="text-align: left; line-height: 1.25;">
                <div style="text-align: justify; text-indent: -27pt; margin-left: 27pt; line-height: 1.25;">The amount of the offering proceeds to us presented in this table does not give effect to the exercise, if any, of the warrants or the placement
                  agent warrants.</div>
              </div>
            </div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 35.8pt; margin-right: 0.1pt; margin-left: 0.3pt; line-height: 1.25;">
        <div style="text-indent: 36pt; line-height: 1.25;">Delivery of the ADSs and the warrants is expected to be made on or about September 21, 2022.</div>
      </div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold; font-size: 16pt;">H.C. Wainwright &amp; Co.</div>
    <div style="text-align: center; line-height: 1.25;">____________________________________</div>
    <div style="text-align: center; line-height: 1.25;"><br style="line-height: 1.25;">
      <br>
      Prospectus Supplement dated September 18, 2022</div>
    &#160;
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">TABLE OF CONTENTS</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Prospectus Supplement</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="1" border="0" id="ze374dca6004a481890e6f8a45c8bb507" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 91.98%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="#ABOUTTHISPROSPECTUSSUPPLE">About this Prospectus Supplement</a></div>
          </td>
          <td style="width: 8.02%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="text-align: right; line-height: 1.25;">S-ii</div>
          </td>
        </tr>
        <tr>
          <td style="width: 91.98%; vertical-align: top;">
            <div style="line-height: 1.25;"><a href="#SUMMARY">Summary</a></div>
          </td>
          <td style="width: 8.02%; vertical-align: bottom;">
            <div style="text-align: right; line-height: 1.25;">S-1</div>
          </td>
        </tr>
        <tr>
          <td style="width: 91.98%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="#THEOFFERING">Offering</a></div>
          </td>
          <td style="width: 8.02%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="text-align: right; line-height: 1.25;">S-6</div>
          </td>
        </tr>
        <tr>
          <td style="width: 91.98%; vertical-align: top;">
            <div style="line-height: 1.25;"><a href="#FORWARD-LOOKINGSTATEMENTS">Forward-Looking Statements</a></div>
          </td>
          <td style="width: 8.02%; vertical-align: bottom;">
            <div style="text-align: right; line-height: 1.25;">S-7</div>
          </td>
        </tr>
        <tr>
          <td style="width: 91.98%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="#RISKFACTORS">Risk Factors</a></div>
          </td>
          <td style="width: 8.02%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="text-align: right; line-height: 1.25;">S-8</div>
          </td>
        </tr>
        <tr>
          <td style="width: 91.98%; vertical-align: middle;">
            <div style="line-height: 1.25;"><a href="#USEOFPROCEEDS">Use of Proceeds</a></div>
          </td>
          <td style="width: 8.02%; vertical-align: bottom;">
            <div style="text-align: right; line-height: 1.25;">S-10</div>
          </td>
        </tr>
        <tr>
          <td style="width: 91.98%; vertical-align: middle; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="#CAPITALIZATION">Capitalization</a></div>
          </td>
          <td style="width: 8.02%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="text-align: right; line-height: 1.25;">S-11</div>
          </td>
        </tr>
        <tr>
          <td style="width: 91.98%; vertical-align: top;">
            <div style="line-height: 1.25;"><a href="#DILUTION">Dilution</a></div>
          </td>
          <td style="width: 8.02%; vertical-align: bottom;">
            <div style="text-align: right; line-height: 1.25;">S-12</div>
          </td>
        </tr>
        <tr>
          <td style="width: 91.98%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="#DESCRIPTIONOFSECURITIESWE">Description of Securities We are Offering</a></div>
          </td>
          <td style="width: 8.02%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="text-align: right; line-height: 1.25;">S-13</div>
          </td>
        </tr>
        <tr>
          <td style="width: 91.98%; vertical-align: top;">
            <div style="line-height: 1.25;"><a href="#PLANOFDISTRIBUTION">Plan of Distribution</a></div>
          </td>
          <td style="width: 8.02%; vertical-align: bottom;">
            <div style="text-align: right; line-height: 1.25;">S-15</div>
          </td>
        </tr>
        <tr>
          <td style="width: 91.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;"><a href="#LEGALMATTERS">Legal Matters</a></div>
          </td>
          <td style="width: 8.02%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; line-height: 1.25;">S-18</div>
          </td>
        </tr>
        <tr>
          <td style="width: 91.98%; vertical-align: top;">
            <div style="line-height: 1.25;"><a href="#LEGALMATTERS">Experts</a></div>
          </td>
          <td style="width: 8.02%; vertical-align: bottom;">
            <div style="text-align: right; line-height: 1.25;">S-18</div>
          </td>
        </tr>
        <tr>
          <td style="width: 91.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;"><a href="#LEGALMATTERS">Expenses</a></div>
          </td>
          <td style="width: 8.02%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; line-height: 1.25;">S-18</div>
          </td>
        </tr>
        <tr>
          <td style="width: 91.98%; vertical-align: top;">
            <div style="line-height: 1.25;"><a href="#DOCUMENTSINCORPORATEDBYRE">Documents Incorporated by Reference</a></div>
          </td>
          <td style="width: 8.02%; vertical-align: bottom;">
            <div style="text-align: right; line-height: 1.25;">S-19</div>
          </td>
        </tr>
        <tr>
          <td style="width: 91.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;"><a href="#WHEREYOUCANFINDMOREINFORM">Where You Can Find More Information</a></div>
          </td>
          <td style="width: 8.02%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; line-height: 1.25;">S-20</div>
          </td>
        </tr>
        <tr>
          <td style="width: 91.98%; vertical-align: top;">
            <div style="line-height: 1.25;"><a href="#ENFORCEABILITYOFCIVILLIAB">Enforceability of Civil Liabilities</a></div>
          </td>
          <td style="width: 8.02%; vertical-align: bottom;">
            <div style="text-align: right; line-height: 1.25;">S-21</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Prospectus</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br>
        <div style="text-align: center; line-height: 1.25;">
          <table cellspacing="0" cellpadding="2" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 92%; vertical-align: top; background-color: #CCEEFF;">
                  <div style="line-height: 1.25;"><a href="#ABOUTTHISPROSPECTUS">About this Prospectus</a></div>
                </td>
                <td style="width: 8%; vertical-align: top; background-color: #CCEEFF;">
                  <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">1<br>
                  </div>
                </td>
              </tr>
              <tr>
                <td style="width: 92%; vertical-align: top;">
                  <div style="line-height: 1.25;"><a href="#OURBUSINESS">Our Business</a></div>
                </td>
                <td style="width: 8%; vertical-align: top;">
                  <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">2<br>
                  </div>
                </td>
              </tr>
              <tr>
                <td style="width: 92%; vertical-align: top; background-color: #CCEEFF;">
                  <div style="line-height: 1.25;"><a href="#OURBUSINESS">Risk Factors</a></div>
                </td>
                <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: right;">2<br>
                </td>
              </tr>
              <tr>
                <td rowspan="1" style="width: 92%; vertical-align: top;">
                  <div style="line-height: 1.25;"><a href="#OFFERSTATISTICSANDEXPECTE">Offer Statistics and Expected Timetable</a></div>
                </td>
                <td rowspan="1" style="width: 8%; vertical-align: top; text-align: right;">2 <br>
                </td>
              </tr>
              <tr>
                <td style="width: 92%; vertical-align: top; background-color: rgb(204, 238, 255);">
                  <div style="line-height: 1.25;"><a href="#OURBUSINESS">Forward-Looking Statements</a></div>
                </td>
                <td style="width: 8%; vertical-align: top; text-align: right; background-color: rgb(204, 238, 255);">2<br>
                </td>
              </tr>
              <tr>
                <td style="width: 92%; vertical-align: top;">
                  <div style="line-height: 1.25;"><a href="#ABOUTTHISPROSPECTUS">Capitalization</a></div>
                </td>
                <td style="width: 8%; vertical-align: top; text-align: right;">4<br>
                </td>
              </tr>
              <tr>
                <td style="width: 92%; vertical-align: middle; background-color: rgb(204, 238, 255);">
                  <div style="line-height: 1.25;"><a href="#USEOF">Use of Proceeds</a></div>
                </td>
                <td style="width: 8%; vertical-align: top; text-align: right; background-color: rgb(204, 238, 255);">5<br>
                </td>
              </tr>
              <tr>
                <td style="width: 92%; vertical-align: top;">
                  <div style="line-height: 1.25;"><a href="#USEOF">Description of Ordinary Shares</a></div>
                </td>
                <td style="width: 8%; vertical-align: top; text-align: right;">5<br>
                </td>
              </tr>
              <tr>
                <td style="width: 92%; vertical-align: top; background-color: rgb(204, 238, 255);">
                  <div style="line-height: 1.25;"><a href="#DESCRIPTIONOFAMERICANDEPO">Description of American Depositary Shares</a></div>
                </td>
                <td style="width: 8%; vertical-align: top; text-align: right; background-color: rgb(204, 238, 255);">9<br>
                </td>
              </tr>
              <tr>
                <td style="width: 92%; vertical-align: top;">
                  <div style="line-height: 1.25;"><a href="#DESCRIPTIONOFDEBTSECURITI">Description of Debt Securities</a></div>
                </td>
                <td style="width: 8%; vertical-align: top; text-align: right;">14<br>
                </td>
              </tr>
              <tr>
                <td style="width: 92%; vertical-align: top; background-color: rgb(204, 238, 255);">
                  <div style="line-height: 1.25;"><a href="#DESCRIPTIONOFSUBSCRIPTION">Description of Subscription Rights</a></div>
                </td>
                <td style="width: 8%; vertical-align: top; text-align: right; background-color: rgb(204, 238, 255);">26<br>
                </td>
              </tr>
              <tr>
                <td style="width: 92%; vertical-align: top;">
                  <div style="line-height: 1.25;"><a href="#DESCRIPTIONOFWARRANTS">Description of Warrants</a></div>
                </td>
                <td style="width: 8%; vertical-align: top; text-align: right;">26<br>
                </td>
              </tr>
              <tr>
                <td style="width: 92%; vertical-align: top; background-color: rgb(204, 238, 255);">
                  <div style="line-height: 1.25;"><a href="#DESCRIPTIONOFUNITS">Description of Units</a></div>
                </td>
                <td style="width: 8%; vertical-align: top; text-align: right; background-color: rgb(204, 238, 255);">28<br>
                </td>
              </tr>
              <tr>
                <td style="width: 92%; vertical-align: top;">
                  <div style="line-height: 1.25;"><a href="#DESCRIPTIONOFUNITS">Taxation</a></div>
                </td>
                <td style="width: 8%; vertical-align: top; text-align: right;">28<br>
                </td>
              </tr>
              <tr>
                <td style="width: 92%; vertical-align: top; background-color: rgb(204, 238, 255);">
                  <div style="line-height: 1.25;"><a href="#PLANOFD">Plan of Distribution</a></div>
                </td>
                <td style="width: 8%; vertical-align: top; text-align: right; background-color: rgb(204, 238, 255);">29<br>
                </td>
              </tr>
              <tr>
                <td style="width: 92%; vertical-align: top;">
                  <div style="line-height: 1.25;"><a href="#LEGAL">Legal Matters</a></div>
                </td>
                <td style="width: 8%; vertical-align: top; text-align: right;">31<br>
                </td>
              </tr>
              <tr>
                <td style="width: 92%; vertical-align: top; background-color: rgb(204, 238, 255);">
                  <div style="line-height: 1.25;"><a href="#LEGAL">Experts</a></div>
                </td>
                <td style="width: 8%; vertical-align: top; text-align: right; background-color: rgb(204, 238, 255);">31<br>
                </td>
              </tr>
              <tr>
                <td style="width: 92%; vertical-align: top;">
                  <div style="line-height: 1.25;"><a href="#LEGAL">Where You Can Find More Information</a></div>
                </td>
                <td style="width: 8%; vertical-align: top; text-align: right;">31<br>
                </td>
              </tr>
              <tr>
                <td style="width: 92%; vertical-align: top; background-color: rgb(204, 238, 255);">
                  <div style="line-height: 1.25;"><a href="#INCORPORATION">Incorporation of Certain Documents by Reference</a></div>
                </td>
                <td style="width: 8%; vertical-align: top; text-align: right; background-color: rgb(204, 238, 255);">32<br>
                </td>
              </tr>
              <tr>
                <td style="width: 92%; vertical-align: top;">
                  <div style="line-height: 1.25;"><a href="#ENFORCEABILITY">Enforceability of Civil Liabilities</a></div>
                </td>
                <td style="width: 8%; vertical-align: top; text-align: right;">32<br>
                </td>
              </tr>
              <tr>
                <td style="width: 92%; vertical-align: top; background-color: rgb(204, 238, 255);">
                  <div style="line-height: 1.25;"><a href="#EXP">Expenses</a></div>
                </td>
                <td style="width: 8%; vertical-align: top; text-align: right; background-color: rgb(204, 238, 255);">33<br>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br>
          </div>
        </div>
      </div>
    </div>
    <div style="text-align: center; line-height: 1.25;"><u>______________________________</u></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Unless the context otherwise requires, all references to &#8220;BioLineRx,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; the &#8220;Company&#8221; and similar designations refer to BioLineRx Ltd. and its consolidated
      subsidiaries.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">You should rely only on the information contained or incorporated by reference in this prospectus supplement and the accompanying prospectus. We have not authorized anyone to
      provide you with information different from that contained or incorporated by reference in this prospectus supplement and the accompanying prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. We
      are not offering to sell or soliciting any offer to buy any security other than the ADSs offered by this prospectus supplement and the accompanying prospectus. In addition, we are not offering to sell or soliciting any offer to buy any securities to
      or from any person in any jurisdiction where it is unlawful to make this offer to or solicitation from a person in that jurisdiction. The information contained or incorporated by reference in this prospectus supplement is accurate as of the date on
      the front of this prospectus supplement only, regardless of the time of delivery of this prospectus supplement or of any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have obtained the statistical data, market data and other industry data and forecasts used throughout this prospectus supplement and the accompanying prospectus from publicly
      available information and from reports we commissioned. We have not sought the consent of the sources to refer to the publicly available reports in this prospectus supplement and the accompanying prospectus.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; text-align: center;">S - i<br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="ABOUTTHISPROSPECTUSSUPPLE"><!--Anchor--></a>ABOUT THIS PROSPECTUS SUPPLEMENT</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">This prospectus supplement is a supplement to the accompanying prospectus dated January 11, 2021 that is also a part of this document. This prospectus supplement and the accompanying prospectus are
        part of a registration statement that we filed with the Securities and Exchange Commission, or the SEC, using a &#8220;shelf&#8221; registration process. Under the shelf registration process, from time to time, we may sell any of the securities described in
        the accompanying prospectus in one or more offerings. In this prospectus supplement, we provide you with specific information about this offering. This prospectus supplement, the accompanying prospectus and the documents incorporated by reference
        herein and therein include important information about us, the ADSs and warrants and other information you should know before investing in the ADSs and warrants. This prospectus supplement also adds, updates and changes information contained in the
        accompanying prospectus. To the extent that any statement we make in this prospectus supplement is inconsistent with the statements made in the accompanying prospectus or in any document incorporated by reference that was filed with the SEC before
        the date of this prospectus supplement, the statements made in the accompanying prospectus, or such an earlier filing, as applicable, are deemed modified or superseded by the statements made in this prospectus supplement. You should read both this
        prospectus supplement and the accompanying prospectus as well as the additional information described in this prospectus supplement under the headings &#8220;Documents Incorporated by Reference&#8221; and &#8220;Where You Can Find More Information&#8221; on page S-19 and
        page S-20 before investing in the ADSs.</div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">All references in this prospectus supplement to &#8220;$,&#8221; &#8220;U.S. Dollars&#8221; and &#8220;dollars&#8221; are to United States dollars and all references to &#8220;NIS&#8221; are to New Israeli Shekels.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This prospectus supplement, the accompanying prospectus and the information incorporated by reference herein and therein include trademarks, service marks and trade names owned by
      us or other companies. Solely for convenience, trademarks referred to in this prospectus, including logos, artwork and other visual displays, may appear without the&#160;<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>&#160;or &#8482; symbols. We do not intend our use or display of other companies&#8217;
      trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. All trademarks, service marks and trade names included or incorporated by reference into this prospectus supplement or the
      accompanying prospectus are the property of their respective owners.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; text-align: center;">S - ii </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%1%S - %%-->
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="SUMMARY"><!--Anchor--></a>SUMMARY</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic;">
      <div style="text-indent: 36pt; line-height: 1.25; font-style: italic;">This summary highlights selected information contained elsewhere in, or incorporated by reference into, this prospectus supplement and the accompanying prospectus that we consider
        important. This summary does not contain all of the information you should consider before investing in our securities. You should read this summary together with the entire prospectus supplement, the accompanying prospectus and the information
        incorporated by reference herein and therein, including the risks related to our main therapeutic candidates, BL-8040 and AGI-134, our therapeutic product, BL-5010, our business, our industry, investing in our securities and our location in Israel,
        that we describe under &#8220;Risk Factors,&#8221; and our consolidated financial statements and the related notes, which are incorporated by reference herein and therein, before making an investment in our securities.</div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Our Business</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;We are a pre-commercial-stage biopharmaceutical company focused on oncology. Our current development and commercialization pipeline consists of two clinical-stage therapeutic candidates &#8211; motixafortide
        (BL-8040), a novel peptide for the treatment of stem-cell mobilization, solid tumors and acute myeloid leukemia, or AML, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, we have an off-strategy, legacy therapeutic
        product called BL-5010 for the treatment of skin lesions. We have generated our pipeline by systematically identifying, rigorously validating and in-licensing therapeutic candidates that we believe exhibit a high probability of therapeutic and
        commercial success. To date, except for BL-5010, none of our therapeutic candidates have been approved for marketing or sold commercially. Our strategy includes commercializing our therapeutic candidates through out-licensing arrangements with
        biotechnology and pharmaceutical companies and evaluating, on a case-by-case basis, the commercialization of our therapeutic candidates independently.</div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Motixafortide</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">Motixafortide is a novel, short peptide that functions as a high-affinity antagonist for CXCR4, which we are developing for the treatment of stem-cell mobilization, solid tumors and AML.</div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-style: italic;">Stem cell mobilization</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In March 2015, we reported successful top-line results from a Phase 1 safety and efficacy trial for the use of motixafortide as a novel stem cell mobilization treatment for
      allogeneic bone marrow transplantation at Hadassah Medical Center in Jerusalem.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In March 2016, we initiated a Phase 2 trial for motixafortide in allogeneic stem cell transplantation, conducted in collaboration with the Washington University School of Medicine,
      Division of Oncology and Hematology. In May 2018, we announced positive top-line results of this study showing, among other things, that a single injection of motixafortide mobilized sufficient amounts of CD34+ cells required for transplantation at a
      level of efficacy similar to that achieved by using 4-6 injections of G-CSF, the current standard of care.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In December 2017, we commenced a randomized, placebo-controlled Phase 3 registrational trial for motixafortide, known as the GENESIS trial, for the mobilization of HSCs, for
      autologous transplantation in patients with multiple myeloma. The trial began with a lead-in period for dose confirmation, which was to include 10-30 patients and then progress to the placebo-controlled main part, which was designed to include 177
      patients in more than 25 centers. Following review of the positive results from treatment of the first 11 patients, the Data Monitoring Committee, or DMC, recommended that the lead-in part of the study be stopped and that we should move immediately
      to the second part. Additional positive results from the lead-in period were reported at the annual meeting of the European Society for Blood and Marrow Transplantation held in March 2019, where it was announced that HSCs mobilized by motixafortide
      in combination with G-CSF were successfully engrafted in all 11 patients.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">S - 1</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In August 2020, we announced a decision to perform an interim analysis on approximately 65% of the original study sample size, primarily based on a significantly
      lower-than-anticipated patient-dropout rate in the study. In October 2020, we announced positive results from the interim analysis. Based on the statistically significant evidence favoring treatment with motixafortide, the study&#8217;s independent DMC
      issued a recommendation to us that patient enrollment may be ceased immediately, without the need to recruit all 177 patients originally planned for the study. In accordance with the DMC&#8217;s recommendation, study enrollment was complete at 122
      patients.&#160; In May 2021, we announced positive top-line results from the Phase 3 trial. Based on an analysis of data on all 122 enrolled patients (the intent to treat population) we found highly statistically significant evidence across all primary
      and secondary endpoints favoring motixafortide in addition to G-CSF, as compared to placebo plus G-CSF (p&lt;0.0001). The addition of motixafortide to G-CSF also allowed 88.3% of patients to undergo transplantation after only one apheresis session,
      compared to 10.8% in the G-CSF arm &#8211; an 8.2-fold increase. The combination was also found to be safe and well tolerated.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We continue to follow-up on the GENESIS study patients for relapse-free and overall survival. In addition, we continue to perform detailed analyses of the data according to the
      statistical analysis plan agreed-upon with the U.S. Food and Drug Administration, or FDA, as well as certain post hoc analyses. In December 2021, we held a pre-New Drug Application, or NDA, meeting with the FDA. The purpose of the meeting was to
      obtain agreement from the FDA on the content of the proposed NDA, and, in particular, to confirm that our single Phase 3 pivotal study, GENESIS, is sufficient to support an NDA submission. During the pre-NDA meeting,&#8239;the FDA agreed that the proposed
      data package is sufficient to support an NDA submission. In September 2022, we submitted an NDA to the FDA for motixafortide in stem cell mobilization for autologous bone marrow transplantation for multiple myeloma patients.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; In October 2021, we announced positive results from a pharmacoeconomic study evaluating the cost-effectiveness of using investigational drug motixafortide as a primary stem cell
      mobilization agent on top of granulocyte colony stimulating factor (G-CSF), versus G-CSF alone, in multiple myeloma patients undergoing autologous stem-cell transplantation (ASCT). The study was performed by the Global Health Economics and Outcomes
      Research (HEOR) team of IQVIA, and was a pre-planned study conducted in parallel with the GENESIS Phase 3 trial. The study concluded that the addition of motixafortide to G-CSF (the current standard of care) is associated with a statistically
      significant decrease in health resource utilization (HRU) during the ASCT process, compared to G-CSF alone. Based on the significantly higher number of mobilized cells and the lower number of apheresis sessions, lifetime estimates show
      quality-adjusted-life-year benefits and net cost savings of ~$19,000 (not including the cost of motixafortide), versus G-CSF alone.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; In March 2022, we announced results from a follow-on pharmacoeconomic study performed by the HEOR team of IQVIA. This study indirectly evaluated the cost-effectiveness of using
      motixafortide as a primary stem cell mobilization agent in combination with G-CSF, against plerixafor in combination with G-CSF, in multiple myeloma patients undergoing ASCT. The additional study results show that motixafortide in combination with
      G-CSF, versus plerixafor in combination with G-CSF, demonstrates a statistically significant decrease in HRU during the ASCT process. Based on the significantly higher number of mobilized cells and the lower number of apheresis sessions, lifetime
      estimates show QALY benefits and net cost savings of ~$30,000 (not including the cost of motixafortide), versus plerixafor plus G-CSF. The study findings strengthen the assessment that the use of motixafortide in combination with G-CSF, as the
      potential new standard of care in mobilization for ASCT, would be a cost-effective option in the US, based on accepted willingness-to-pay (WTP) values for healthcare payers.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
      <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; We believe these results, together with the highly significant and clinically meaningful data from the GENESIS trial, strongly support the potential use of
        motixafortide, on top of G-CSF, as the standard of care in stem cell mobilization for autologous stem cell transplantation. While we continue to evaluate commercialization alternatives, we are finalizing our commercialization plans for
        motixafortide in the US and continue to advance critical pre-launch commercialization activities, required under any commercialization scenario, for a timely launch, if approved by the FDA, with a view to obtaining potential FDA approval and
        potentially launching sales in 2023. In this regard, in June 2022, we appointed biopharmaceutical veteran executive, Holly W. May as our Chief Commercial Officer who is responsible for the commercial planning, positioning, and launch oversight for
        motixafortide in the stem cell mobilization indication across the U.S. market, assuming FDA approval.</div>
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"> <br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">S - 2</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"> <br>
    </div>
    <div style="text-align: justify; line-height: 1.25; font-style: italic;">Solid tumors</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160; In January 2016, we entered into a clinical collaboration with MSD (a tradename of Merck &amp; Co., Inc., Kenilworth, New Jersey) in the field of cancer immunotherapy. Based on this
      collaboration, in September 2016 we initiated a Phase 2a study, known as the COMBAT/KEYNOTE-202 study, focusing on evaluating the safety and efficacy of motixafortide in combination with KEYTRUDA&#174; (pembrolizumab), MSD&#8217;s anti-PD-1 therapy, in 37
      patients with metastatic pancreatic adenocarcinoma, or PDAC. The study was an open-label, multicenter, single-arm trial designed to evaluate the clinical response, safety and tolerability of the combination of these therapies as well as multiple
      pharmacodynamic parameters, including the ability to improve infiltration of T-cells into the tumor and their reactivity. Top-line results showed that the dual combination demonstrated encouraging disease control and overall survival in patients with
      metastatic pancreatic cancer. In addition, assessment of patient biopsies supported motixafortide&#8217;s ability to induce infiltration of tumor-reactive T-cells into the tumor, while reducing the number of immune regulatory cells.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; In July 2018, we announced the expansion of the COMBAT/KEYNOTE-202 study under the collaboration to include a triple combination arm investigating the safety, tolerability and efficacy of
      motixafortide, KEYTRUDA &#174; and chemotherapy. We initiated this arm of the trial in December 2018. In December 2019, we announced that preliminary data from the study indicated that the triple combination therapy showed a high level of disease control,
      including seven partial responders and 10 patients with stable disease out of 22 evaluable patients. In February 2020, we completed recruiting a total of 43 patients for the study and in December 2020, we announced the final results of the study. The
      results of the study showed substantial improvement as compared to comparable historical results of other pancreatic cancer studies across all study endpoints. Of the 38 evaluable patients, median overall survival was 6.5 months, median progression
      free survival was 4.0 months, confirmed overall response rate was 13.2%, overall response rate was 21.2% and disease control rate was 63.2%. The combination was generally well tolerated, with a safety profile consistent with the individual safety
      profile of each component alone; adverse event and severe adverse event profiles were as expected with chemotherapy-based treatment regimens.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; In August 2016, in the framework of an agreement with MD Anderson Cancer Center, or MD Anderson, we entered into an additional collaboration for the investigation of motixafortide in
      combination with KEYTRUDA in pancreatic cancer. The focus of this study, in addition to assessing clinical response, was the mechanism of action by which both drugs might synergize, as well as multiple assessments to evaluate the biological
      anti-tumor effects induced by the combination. We supplied motixafortide for this Phase 2b study, which commenced in January 2017. Final results from this study (based on a cut-off in July 2019 from 20 enrolled patients out of which 15 were
      evaluable) showed that the dual combination demonstrated clinical activity and encouraging overall survival in patients with metastatic pancreatic cancer. In addition, assessment of patient biopsies supported motixafortide&#8217;s ability to induce
      infiltration of tumor-reactive T-cells into the tumor.</div>
    <div style="line-height: 1.25">&#160; <br>
    </div>
    <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; In October 2020, we announced that motixafortide will be tested in combination with the anti-PD-1 cemiplimab (LIBTAYO&#174;) and standard-of-care chemotherapy (gemcitabine and nab-paclitaxel)
      in first-line PDAC. This investigator-initiated Phase 2 study, led by Columbia University, will initially enroll 10-12 PDAC patients, and will be expanded to a total of 40 patients following an evaluation of the initial 10-12 patients based on
      pre-defined criteria. The primary endpoint of the study is the overall response rate. Secondary endpoints include safety and tolerability, progression free survival, duration of clinical benefit and overall survival. Data from the study is
      anticipated in the second half of 2022 (although timelines are ultimately controlled by the independent investigator and are therefore subject to change).</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In June 2022, we entered into a collaboration agreement with GenFleet Therapeutics, an immuno-oncology focused biopharmaceutical company based in China, to advance motixafortide
      through a randomized Phase 2b clinical trial in PDAC. Under the terms of the agreement, GenFleet will fully fund, design and execute a randomized Phase 2b clinical trial that will enroll approximately 200 first-line metastatic PDAC patients in China.
      This randomized controlled study will aim to evaluate the superiority of motixafortide in combination with an anti-PD-1 and chemotherapy compared to chemotherapy alone, the current standard of care. As part of the collaboration, we will supply
      motixafortide, while GenFleet will supply the other study drugs for the trial. Trial oversight will be administered by a Joint Development Committee. GenFleet will be eligible to receive low-to-mid-single digit tiered percentage royalties on future
      motixafortide sales, if approved.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">S - 3</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-style: italic;">AML</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">During 2016, we completed and reported on a Phase 2a proof-of-concept trial for the treatment of relapsed or refractory acute myeloid leukemia, or r/r AML, which was conducted on
      42 patients at six world-leading cancer research centers in the United States and at five premier sites in Israel. The study included both a dose-escalation and a dose-expansion phase. Results from the trial showed positive safety and response rate
      data for subjects treated with a combination of motixafortide and high-dose cytarabine (Ara-C), or HiDAC. At the annual meeting of the European Hematology Association, or EHA, in June 2018, we presented positive overall survival data from the
      long-term follow-up part of this study. In March 2021, we completed the monitoring of long-term survival data for patients in the study and, in parallel, are evaluating our next clinical development steps in this indication.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; In August 2015, we conducted a double-blind, placebo-controlled, randomized, multi-center, Phase 2b trial in Germany, in collaboration with the German Study Alliance Leukemia Group, to
      assess the efficacy of motixafortide in addition to standard consolidation therapy (cytarabine) in AML patients who have responded to standard induction treatment and are in complete remission. During 2020, we finalized plans with our collaboration
      partners to conduct an interim analysis on 2/3 (N=128) of the 194 patients originally planned in the study, all of which had already completed treatment. Based on the interim analysis, the investigational arm of motixafortide combined with cytarabine
      did not demonstrate a statistically significant effect in the study&#8217;s primary endpoint, and therefore, the DMC recommended not to continue the study. We continue to believe in the relevance of CXCR4 as a viable target in other AML treatment lines,
      such as rr/AML and induction treatment, and we intend to decide on next steps in AML once we have had an opportunity to review and analyze the unblinded data, including detailed biomarker and subpopulation data, from the study.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-style: italic;">ARDS secondary to COVID-19 and other viral infections</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">During the first half of 2020, we initiated the evaluation of motixafortide as a potential therapy for acute respiratory distress syndrome, or ARDS, resulting from COVID-19 and
      other viral infections In this regard, substantial data is emerging regarding the involvement of neutrophils, neutrophil extracellular traps (NETs), monocytes and macrophages in the development of ARDS secondary to COVID-19 and other viral
      infections; as well as the key involvement of CXCR4 as a mediator of those cells in the inflamed pulmonary tissue. Based on the scientific data indicating the importance of blocking the CXCR4/CXCL12 axis during ARDS, we believe that motixafortide may
      be of potential benefit for patients with ARDS. Following our initial evaluation, in November 2020, we announced initiation of a Phase 1b study in patients with ARDS secondary to COVID-19 and other respiratory viral infections. The study is an
      investigator-initiated study, led by Wolfson Medical Center, in Israel, to evaluate motixafortide in patients hospitalized with ARDS. The primary endpoint of the study is to assess the safety of motixafortide in these patients; respiratory parameters
      and inflammatory biomarkers will be assessed as exploratory endpoints. Up to 25 patients will be enrolled in the study, with a preliminary analysis planned after ten patients have completed the initial treatment period. Results of the preliminary
      analysis are expected in the second half of 2022 (although timelines are ultimately controlled by the independent investigator and are therefore subject to change).</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-style: italic;">Other matters</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition to the above, we are currently conducting, or planning to conduct, a number of investigator-initiated, open-label studies in a variety of indications, to support the
      interest of the scientific and medical communities in exploring additional uses for motixafortide. These studies serve to further elucidate the mechanism of action for motixafortide. The results of studies such as these are presented from time to
      time at relevant professional conferences.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Motixafortide has been granted three Orphan Drug Designations by the FDA: for use to mobilize HSCs from the bone marrow to peripheral blood for collection in autologous or
      allogeneic transplantation (granted in July 2012); for the treatment of AML (granted in September 2013); and for the treatment of pancreatic cancer (granted in February 2019). In January 2020, the European Medicines Agency, or EMA, granted Orphan
      Drug Designation to motixafortide for the treatment of pancreatic cancer.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">S - 4</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">AGI-134</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">AGI-134, a clinical therapeutic candidate in-licensed by our subsidiary, Agalimmune Ltd., is a synthetic alpha-Gal glycolipid immunotherapy in development for solid tumors. AGI-134
      harnesses the body&#8217;s pre-existing, highly abundant, anti-alpha-Gal antibodies to induce a hyper-acute, systemic, specific anti-tumor response to the patient&#8217;s own tumor neo-antigens. This response not only kills the tumor cells at the site of
      injection, but also brings about a durable, follow-on, anti-metastatic immune response. In August 2018, we initiated a Phase 1/2a clinical study for AGI-134 that is primarily designed to evaluate the safety and tolerability of AGI-134 in unresectable
      metastatic solid tumors. The multi-center, open-label study is currently being carried out in the United Kingdom, Spain and Israel. Initial safety results from the first part of the study were announced at the beginning of September 2019; at the end
      of the same month, the second part of the study was commenced. Due to clinical operating issues associated with the COVID-19 pandemic, in April 2020, enrollment to the clinical trial was temporarily suspended. In August 2020, we renewed study
      enrollment, and in January 2022, we completed enrollment. Initial proof-of-mechanism of action and efficacy results are now expected in the second half of 2022.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Scientific Advisory Board</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In December 2021, we established a Scientific Advisory Board (SAB) to provide insight and guidance on our activities in the field of immuno-oncology. The SAB is comprised of
      recognized leaders in cancer immunology, intra-tumoral injections and clinical development.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Listed in alphabetical order, the founding SAB members are: Ronald Levy, MD, the Robert K. and Helen K. Summy Professor and Director of the Lymphoma Program at Stanford University
      School of Medicine, Palo Alto, CA; Aur&#233;lien Marabelle, MD, PhD, Clinical Director, Cancer Immunotherapy Program, Gustave Roussy, Paris, France and Director, Translational Research Laboratory in Immunotherapy, INSERM, Paris, France; Ignacio Melero MD,
      PhD, Professor of Immunology at the Academic Hospital of Navarra, Spain and at the Center for Applied Medical Research (CIMA) of the University of Navarra, Spain; and Jon Wigginton, MD, Chair of the SAB and Senior Advisor at Cullinan Oncology, former
      Chief Medical Officer of MacroGenics, and former Therapeutic Area Head, Immuno-Oncology, Early Clinical Research at Bristol-Myers Squibb.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">BL-5010</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our commercialized, legacy therapeutic product, BL-5010, is a customized, proprietary pen-like applicator containing a novel, acidic, aqueous solution for the non-surgical removal
      of skin lesions. In December 2014, we entered into an exclusive out-licensing arrangement with Perrigo Company plc, or Perrigo, for the rights to BL-5010 for over-the-counter, or OTC, indications in Europe, Australia and additional selected
      countries. In March 2016, Perrigo received CE Mark approval for BL-5010 as a novel OTC treatment for the non-surgical removal of warts. The commercial launch of products for treatment of this first OTC indication (warts/verrucas) commenced in Europe
      in the second quarter of 2016. Since then, Perrigo has invested in improving the product and during 2019 launched an improved version of the product in several European countries. In March 2020, we agreed that Perrigo could relinquish its license
      rights for certain countries that had been included in its territory according to the original license agreement, and was also no longer obligated to develop, obtain regulatory approval for and commercialize products for a second OTC indication. In
      turn, in March 2020, we agreed with our licensor of the rights to BL-5010, Innovative Pharmaceutical Concepts (IPC) Inc., or IPC, to return to IPC those license rights no longer out-licensed to Perrigo as a result of the agreement described in the
      preceding sentence, in consideration of the payment to us of royalties or fees on sublicense receipts.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Recent Developments</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">On September 12, 2022, we announced the submission of an NDA to the FDA, for motixafortide in stem cell mobilization for autologous bone marrow transplantation for multiple myeloma patients.&#160;The
        FDA&#8217;s decision on acceptance of BioLineRx&#8217;s NDA filing is expected in November 2022. Assuming the filing is accepted, the potential Prescription Drug User Fee Act (PDUFA) date is expected to be in the second quarter of 2023 (under a priority review
        process, if applicable) or the third quarter of 2023 (under a standard review process). <br>
      </div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">On September 14, 2022, we entered into an Agreement for the Provision of a Loan Facility, or the Loan Agreement, with Kreos Capital VII Aggregator SCSP, or the Lender. Under the
      Loan Agreement, the Lender will provide the Company with access to term loans in an aggregate principal amount of up to $40 million in three tranches as follows: (a) a loan in the aggregate principal amount of up to $10 million, available for
      drawdown upon closing of the Loan Agreement and until April 1, 2023, (b) a loan in the aggregate principal amount of up to $20 million, available for drawdown upon achievement of certain milestones and until April 1, 2024, and (c) a loan in the
      aggregate principal amount of up to $10 million, available for drawdown upon achievement of certain milestones and until October 1, 2024. The provision of the Loan is subject to customary closing conditions as well as obtaining approval from the
      Israel Innovation Authority.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Our Corporate Information</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">Our principal executive offices are located at 2 HaMa&#8217;ayan Street, Modi&#8217;in 7177871, Israel, and our telephone number is +972 (8) 642-9100. Our website is <u>www.biolinerx.com</u>. Information
        contained in our website is not incorporated by reference into and does not constitute part of this prospectus supplement&#160;and the accompanying prospectus.</div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">S - 5</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="THEOFFERING"><!--Anchor--></a>THE OFFERING</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z24947d3d8b914e34ac6f4decbcf87254" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 49.9%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Issuer</div>
          </td>
          <td style="width: 50.1%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">BioLineRx Ltd.</div>
            <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.9%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">ADSs offered by us</div>
          </td>
          <td style="width: 50.1%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">13,636,365 ADSs representing 204,545,475&#160;ordinary shares.</div>
            <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.9%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Warrants offered by us</div>
          </td>
          <td style="width: 50.1%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">
              <div style="line-height: 1.25;">For each ADS purchased in this offering, each investor will receive a warrant to purchase one ADS (a total of warrants to purchase up to an aggregate of 13,636,365 ADSs representing 204,545,475&#160;ordinary
                shares). The warrants have an exercise price of $1.15 per ADS, are immediately exercisable from the date of issuance and will expire five years from the date of issuance. We are also registering pursuant to this prospectus supplement and
                the accompanying prospectus the ADSs representing ordinary shares issuable from time to time upon the exercise of the warrants in this offering.</div>
            </div>
            <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.9%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Offering price</div>
            <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
          </td>
          <td style="width: 50.1%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">$1.10 per ADS and accompanying warrant.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.9%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Ordinary shares outstanding after this offering</div>
          </td>
          <td style="width: 50.1%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">922,867,375 ordinary shares.</div>
            <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.9%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">The ADSs</div>
          </td>
          <td style="width: 50.1%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Each ADS represents 15 ordinary shares.</div>
            <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
            <div style="text-align: justify; line-height: 1.25;">The Bank of New York Mellon, or the Depositary, will be the holder of the ordinary shares underlying your ADSs and you will have rights as provided in the Deposit Agreement dated July 21,
              2011 among BioLineRx Ltd., The Bank of New York Mellon, as Depositary, and all owners and holders from time to time of ADSs issued thereunder, or the Deposit Agreement, which has been filed as an exhibit to the registration statement of which
              this prospectus supplement forms a part.</div>
            <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
            <div style="text-align: justify; line-height: 1.25;">Subject to compliance with the relevant requirements set out herein, you may turn in your ADSs to the Depositary in exchange for ordinary shares underlying your ADSs.</div>
            <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
            <div style="text-align: justify; line-height: 1.25;">The Depositary will charge you fees for exchanges.</div>
            <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
            <div style="text-align: justify; line-height: 1.25;">You should carefully read the &#8220;Description of American Depositary Shares&#8221; section of the accompanying prospectus and the Deposit Agreement to better understand the terms of the ADSs.</div>
            <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 49.9%; vertical-align: top;">
            <div style="line-height: 1.25;">Placement Agent Warrants</div>
          </td>
          <td rowspan="1" style="width: 50.1%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;">We will also issue warrants to the placement agent (or its designees) to purchase up to 681,818 ADSs, representing 10,227,270 of our ordinary shares, to the
                placement agent, or its designees, as part of the compensation payable to the placement agent. The placement agent warrants will have an exercise price of $1.375 per share (which represents 125% of the offering price per ADS and associated
                warrant sold in this offering) and will expire five years following the commencement of the sales under this offering. We are also registering pursuant to this prospectus supplement and the accompanying prospectus the ADSs representing
                ordinary shares issuable from time to time upon exercise of the placement agent warrants. Please refer to &#8220;Plan of Distribution&#8221; for additional information with respect to the placement agent warrants.</div>
            </div>
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"> <br>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.9%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Use of proceeds</div>
          </td>
          <td style="width: 50.1%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25;">We expect the net proceeds from this offering will be approximately $13.5 million, after deducting the placement agent fees and estimated offering expenses payable by us. We currently expect to use the net
                  proceeds of this offering &#8203;to facilitate the commercial launch of motixafortide in autologous stem cell mobilization for multiple myeloma patients and general corporate purposes, which may include working capital and funding clinical
                  trials. See &#8220;Use of Proceeds&#8221; on page S-8 of this prospectus supplement.</div>
              </div>
            </div>
            <div style="text-align: justify; line-height: 1.25;"> <br>
            </div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="z8282f1b5633a42eaa89775502065726f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 49.9%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Listings</div>
          </td>
          <td style="width: 50.1%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">
              <div style="line-height: 1.25;">The ADSs are listed on Nasdaq under the symbol &#8220;BLRX.&#8221; Our ordinary shares currently trade on the TASE under the symbol &#8220;BLRX.&#8221; There is no established public trading market for the warrants, and we do not
                expect a market to develop. We do not intend to apply for listing of the warrants on any securities exchange or other nationally recognized trading system. Without an active trading market, the liquidity of the warrants will be limited.</div>
            </div>
            <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.9%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Risk factors</div>
          </td>
          <td style="width: 50.1%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Investing in our securities involves risks.&#160; Before investing in the ADSs, you should carefully read and consider the &#8220;Risk Factors&#8221; beginning on page S-8 of this prospectus supplement and in
              the documents we incorporate by reference in this prospectus supplement and the accompanying prospectus.</div>
            <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.9%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Depositary</div>
            <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
          </td>
          <td style="width: 50.1%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">The Bank of New York Mellon.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">S - 6</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Unless otherwise indicated, the number of ordinary shares outstanding prior to and after this offering is based on 718,321,900 ordinary shares outstanding as of September 18, 2022,
      and excludes:</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="ze4b2b9a001e44b8ea4afa3f8bd7e167a" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 7.7%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#9642;</div>
          </td>
          <td style="width: 92.3%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">74,179,714 ordinary shares issuable upon the exercise of outstanding warrants, at a weighted average exercise price of&#8201;$0.39 per share;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z2528309c56bb49fc9dd401365cb2cc92" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 7.7%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 92.3%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">91,332,682 ordinary shares issuable upon the exercise of outstanding options, at a weighted average exercise price of&#8201;$0.14 per share;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zcb5a077046924da0a11be48d320312e1" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 7.7%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 92.3%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">204,545,475 ordinary shares represented by 13,636,365 ADSs issuable upon exercise of warrants to be issued to the investors in this offering, at an exercise price of $1.15 per ADS; and</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zf77e38990ff14967acb9c7c0f8cf4bb8" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 7.7%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 92.3%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">
              <div style="line-height: 1.25;">10,227,270 ordinary shares represented by 681,818 ADSs issuable upon exercise of placement agent warrants to be issued to the placement agent or its designees as compensation in connection with this offering,
                at an exercise price of $1.375 per ADS.</div>
            </div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Unless otherwise indicated, all information in this prospectus supplement assumes no exercise of the options or warrants described above.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="FORWARD-LOOKINGSTATEMENTS"><!--Anchor--></a>FORWARD-LOOKING STATEMENTS</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This prospectus supplement, the accompanying prospectus and the documents incorporated herein and therein by reference contain statements and information that involve known and
      unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In
      some cases, you can identify forward-looking statements by terms including &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions
      intended to identify forward-looking statements, but these are not the only ways these statements are identified. Forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and
      uncertainties. You should not put undue reliance on any forward-looking statements. Unless we are required to do so under U.S. federal securities laws or other applicable laws, we do not intend to update or revise any forward-looking statements.
      Readers are encouraged to consult the Company&#8217;s filings made on Form 6-K, which are periodically filed with or furnished to the SEC.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Factors that could cause our actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to:</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z20925774e3e64d24b2c1c6e08d6f727f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 7.7%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 92.3%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">the initiation, timing, progress and results of our preclinical studies, clinical trials and other therapeutic candidate development efforts;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.7%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 92.3%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">our ability to advance our therapeutic candidates into clinical trials or to successfully complete our preclinical studies or clinical trials;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.7%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 92.3%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">our receipt of regulatory approvals for our therapeutic candidates, and the timing of other regulatory filings and approvals;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.7%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 92.3%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">the clinical development, commercialization and market acceptance of our therapeutic candidates;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.7%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 92.3%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">our ability to establish and maintain corporate collaborations;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.7%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 92.3%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">our ability to integrate new therapeutic candidates and new personnel;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.7%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 92.3%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">the interpretation of the properties and characteristics of our therapeutic candidates and of the results obtained with our therapeutic candidates in preclinical studies or clinical trials;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.7%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 92.3%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">the implementation of our business model and strategic plans for our business and therapeutic candidates;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.7%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 92.3%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">the scope of protection we are able to establish and maintain for intellectual property rights covering our therapeutic candidates and our ability to operate our business without infringing
              the intellectual property rights of others;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.7%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 92.3%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">estimates of our expenses, future revenues, capital requirements and our needs for additional financing;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.7%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 92.3%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">risks related to changes in healthcare laws, rules and regulations in the United States or elsewhere;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.7%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 92.3%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">competitive companies, technologies and our industry;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.7%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#8226;</div>
            <div style="text-align: justify; line-height: 1.25;">&#8226;</div>
            <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
          </td>
          <td style="width: 92.3%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">statements as to the impact of the political and security situation in Israel on our business; and</div>
            <div style="text-align: justify; line-height: 1.25;">the impact of the COVID-19 pandemic and the Russian invasion of Ukraine, which may exacerbate the magnitude of the factors discussed above.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">S - 7</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="RISKFACTORS"><!--Anchor--></a>RISK FACTORS</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic;">Investing in our securities involves a high degree of risk. You should carefully consider the specific risks described below and the risk factors and matters
      set forth in &#8220;Item 3.D. Risk Factors&#8221; in Part I of our Annual Report on Form 20-F for the fiscal year ended December 31, 2021, which is incorporated by reference herein, together with the other information in this prospectus supplement, the
      accompanying prospectus, our Annual Report on Form 20-F and the other information and documents incorporated by reference herein, before making an investment decision. See the section of this prospectus supplement entitled &#8220;Where You Can Find More
      Information.&#8221; Any of the risks we describe below and in our documents incorporated by reference could cause our business, financial condition or operating results to suffer. The market price of our ordinary shares and ADSs could decline if one or
      more of these risks and uncertainties develop into actual events. You could lose all or part of your investment.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Risks Related to this Offering</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">We will require substantial additional capital to finance our operations, which may not be available to us on acceptable terms, or at all.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">We expect that we will need to raise substantial future capital to continue to complete clinical development and commercialize our products and therapeutic candidates and to conduct the research and
        development and clinical and regulatory activities necessary to bring our therapeutic candidates to market. Any required additional financing may not be available on terms acceptable to us, or at all.&#160; In order to raise additional capital, we may
        at any time (subject to restrictions contained in the securities purchase agreement entered into with the investors in this offering), offer additional ADSs, ordinary shares or other securities convertible into or exchangeable for our ADSs or
        ordinary shares at prices that may not be the same as the price per ADS in this offering. We may sell shares or other securities in any other offering at a price per share that is less than the price per ADS and associated warrant paid by investors
        in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing shareholders, including investors who purchase ADSs in this offering. The price per share at which we sell additional
        ordinary shares or securities convertible into ordinary shares in future transactions may be higher or lower than the price per ADS in this offering.</div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Management has broad discretion as to the use of proceeds of this offering, and we may not use these proceeds in a manner desired by our shareholders.</div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our management will have broad discretion as to the use of the net proceeds from this offering and could use them for purposes other than those contemplated at the time of this
      offering. Accordingly, you will be relying on the judgment of our management with regard to the use of these net proceeds, and you will not have the opportunity as part of your investment decision to assess whether the proceeds are being used
      appropriately. Our needs may change as our business evolves. As a result, the proceeds to be received in this offering may be used in a manner significantly different from our current expectations. It is possible that the proceeds will be invested in
      a way that does not yield a favorable, or any, return.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">You will experience immediate dilution in book value of any securities you purchase.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">
        <div style="text-indent: 36pt; line-height: 1.25;">Because the price per ADS and associated warrant being offered is substantially higher than our net tangible book value per ADS, you will suffer substantial dilution in the net tangible book value
          of any securities you purchase in this offering. After giving effect to the sale by us of&#8201;13,636,365&#160;ADSs and warrants to purchase up to an aggregate of 13,636,365 ADSs in this offering, based on a combined offering price of&#8201;$1.10 per ADS, the as
          adjusted net tangible book value of our ADSs would have been approximately $48.3 million or $0.79&#160;per ADS, as of June 30, 2022 (an increase in net tangible book value of approximately $0.06&#160;per ADS to our existing shareholders). If you purchase
          ADSs and associated warrants in this offering, you will suffer immediate and substantial dilution of approximately $0.31&#160;per ADS, after deducting the placement agent fees and estimated offering expenses payable by us. See &#8220;Dilution&#8221; on page S-12
          for a more detailed discussion of the dilution you will incur in connection with this offering.</div>
      </div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">S - 8</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">
      <div style="line-height: 1.25; font-style: italic; font-weight: bold;">A substantial number of ADSs will be sold in this offering, which could cause the price of our ADSs and ordinary shares to decline.</div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">
        <div style="text-indent: 36pt; line-height: 1.25;">In this offering we will sell 13,636,365 ADSs representing 204,545,475 ordinary shares which represent approximately 22.2% of our outstanding ordinary shares as of September 18, 2022. In addition,
          for each ADS purchased in this offering, the investors will receive a warrant to purchase one ADS (a total of warrants to purchase an aggregate of 13,636,365 ADSs represented by 204,545,475 ordinary shares), and the placement agent will receive
          placement agent warrants to purchase up to an aggregate of 681,818 ADS, representing 10,227,270 ordinary shares. This sale and any future sales of a substantial number of ADSs or ordinary shares in the public market, or the perception that such
          sales may occur, could adversely affect the price of the ADSs on the Nasdaq Capital Market or our ordinary shares on the TASE. We cannot predict the effect, if any, that market sales of those ADSs or ordinary shares or the availability of those
          ADSs or ordinary shares for sale will have on the market price of the ADSs or our ordinary shares. As result of the dilution experienced by existing shareholders due to this offering, we may be subject to class action litigation based on this
          dilution. In addition, a decline in the price of our ADSs or ordinary shares might impede our ability to raise capital through the issuance of additional ADSs, ordinary shares or other equity securities, and may cause you to lose part or all of
          your investment in our ordinary shares. The sale of ADSs or ordinary shares issued upon the exercise of our outstanding options and warrants could further dilute the holdings of our then existing shareholders.</div>
      </div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">There has been and may continue to be significant volatility in the volume and price of our ADSs and ordinary shares.</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The market price of our ADSs and ordinary shares has been and may continue to be highly volatile. Factors, including timing, progress and results of current and future
        preclinical studies and clinical trials and our research and development programs; regulatory matters, concerns about our financial position, operations results, litigation, government regulation, developments or disputes relating to agreements,
        patents or proprietary rights, and general economic conditions may have a significant impact on the market volume and price of our stock. Unusual trading volume in our shares occurs from time to time.</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">There is no public market for warrants or placement agent warrants being offered by us in this offering.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">There is no established public trading market for the warrants and the placement agent warrants being offered in this offering.&#160; We do not intend to list the warrants or
        placement agent warrants on any securities exchange or other nationally recognized trading system. There is no established public trading market for the warrants or the placement agent warrants and we do not expect a market to develop. Without an
        active trading market, the liquidity of the pre-funded warrants and the placement agent warrants will be limited.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">The warrants and placement agent warrants are speculative in nature.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25; font-style: italic; font-weight: bold;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
        <div style="text-indent: 36pt; line-height: 1.25;">The warrants and the placement agent warrants do not confer any rights of ordinary share ownership on its holders, such as voting rights or the right to receive dividends, but rather merely
          represent the right to acquire ADSs at a fixed price. For example, commencing on the date of issuance, holders of the warrants may exercise their right to acquire the ADSs and pay an exercise price for the warrants, subject to certain
          adjustments, prior to the fifth year anniversary of the date of issuance, after which date any unexercised warrants will expire and have no further value. Moreover, following this offering, the market value of the warrants, if any, is uncertain
          and there can be no assurance that the market value of warrants will equal or exceed their imputed offering price. There can be no assurance that the market price of the ADSs will ever equal or exceed the exercise price of the warrants or the
          placement agent warrants, and consequently, whether it will ever be profitable for holders of the warrants or placement agent warrant to exercise their respective warrants.</div>
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Holders of our warrants and placement agent warrants will have no rights as ADS holders until such holders exercise their respective warrants and placement
        agent warrants and acquire our ADSs.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25; font-style: italic; font-weight: bold;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Until holders of the warrants and placement agent warrants acquire our ADSs upon exercise of their respective warrants and placement agent warrants, such holders will have no
        rights with respect to the ADSs underlying such warrants.&#160; Upon exercise of the warrants or the placement agent warrants, the holders thereof will be entitled to exercise the rights of a holder of ADSs only as to matters for which the record date
        occurs after the exercise date.</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">S - 9</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25; font-style: italic; font-weight: bold;">
        <div style="line-height: 1.25; font-style: italic; font-weight: bold;">We may not receive any additional funds upon the exercise of the warrants or placement agent warrants being offered.</div>
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
        <div style="text-indent: 36pt; line-height: 1.25;">In certain limited circumstances, each warrant or placement agent warrant may be exercised by way of a cashless exercise, meaning that the holder may not pay a cash purchase price upon exercise,
          but instead would receive upon such exercise the net number of ADSs determined according to the formula set forth in the warrant. Accordingly, we may not receive any additional funds upon the cashless exercise of the warrants or if the warrants
          altogether are not exercised at all.</div>
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">
        <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Our ADSs and ordinary shares are listed in two trading markets, and this may result in price variations that could affect the trading price of our ADSs and ordinary shares.</div>
      </div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our ADSs are listed on Nasdaq, and our ordinary shares are listed on the TASE, both under the symbol &#8220;BLRX.&#8221; Trading in our securities on these markets is made in different
        currencies (U.S. dollars on Nasdaq and New Israeli Shekels on the TASE), and at different times (due to the different time zones, different trading days and different public holidays in the United States and Israel). The relative trading prices of
        our securities on these two markets may differ due to these and other factors. Any decrease in the trading price of our securities on one exchange could cause a decrease in the trading price of our securities on the other exchange.</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="USEOFPROCEEDS"><!--Anchor--></a>USE OF PROCEEDS</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We expect the net proceeds from this offering will be approximately $13.5 million, after deducting the placement agent fees and estimated offering expenses payable by us.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25"></div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">These estimates exclude the proceeds, if any, from the exercise warrants sold in this offering. If all of the warrants and placement agent warrants sold in this offering, were to be exercised, we
        would receive additional net proceeds of approximately $16.6 million. We cannot predict when or if these warrants will be exercised. It is possible that these warrants may expire and may never be exercised.</div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We intend to use the net proceeds from the offering to facilitate the commercial launch of motixafortide in autologous stem cell mobilization for multiple myeloma patients and
      general corporate purposes, which may include working capital and funding clinical trials. Our management will have significant discretion and flexibility in applying the net proceeds from the sale of these securities. The amounts and timing of our
      actual expenditures may vary significantly depending upon numerous factors, including the progress of our development and commercialization efforts, the status of and results from any clinical trials, and the scope and results of our regulatory
      activities.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">S - 10</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="CAPITALIZATION"><!--Anchor--></a>CAPITALIZATION</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The following table presents our capitalization as determined in accordance with International Financial Reporting Standards, or IFRS, as of June 30, 2022:</div>
    <div style="line-height: 1.25"><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z8f6f70fa7ed5466490adc1655e4d9e7a" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 7.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 92.54%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">on an actual basis; and</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z08a083456613458dbe1a09a3179743a2" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 7.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 92.54%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">on an as adjusted basis, to give effect to the sale of&#8201;13,636,365 ADSs representing 204,545,475 ordinary shares, and warrants to purchase up to an aggregate of 13,636,365 ADSs, representing
              204,545,475 of our ordinary shares, at a combined purchase price of $1.10 per ADS and associated warrant after deducting the placement agent fees and estimated offering expenses payable by us, resulting in net proceeds of approximately $13.5
              million.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This table should be read in conjunction with our financial statements and the notes thereto incorporated by reference herein and the accompanying prospectus.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
      <table cellspacing="0" cellpadding="0" border="0" align="center" class="cfttable" id="z6c6127d29817469da0101022cf3753e7" style="width: 85%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">

          <tr>
            <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">As of June 30, 2022</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; line-height: 1.25;">Actual</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; line-height: 1.25;">As Adjusted</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; line-height: 1.25;">(U.S.$ in thousands)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25; font-weight: bold;">Non-Current Liabilities:</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: top; background-color: #CCEEFF;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: top; background-color: #CCEEFF;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 76%;">
              <div style="line-height: 1.25;">Warrants</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">186</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">9,262</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; background-color: #CCEEFF; width: 76%; padding-bottom: 2px;">
              <div style="line-height: 1.25;">Lease liabilities</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
              <div style="line-height: 1.25;">1,452</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
              <div style="line-height: 1.25;">1,452</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
              <div style="line-height: 1.25;">Total non-current liabilities</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">1,638</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">10,714</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; background-color: #CCEEFF; width: 76%;">
              <div style="line-height: 1.25; font-weight: bold;">Shareholders&#8217; equity:</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 76%;">
              <div style="line-height: 1.25;">Ordinary shares, NIS 0.1 par value, 2,500,000,000 authorized; 718,283,665 shares issued and outstanding (actual); and 922,829,140 shares issued and outstanding (as adjusted)</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">21,157</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">27,096</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; background-color: #CCEEFF; width: 76%;">
              <div style="line-height: 1.25;">Share premium</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">339,670</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">338,507</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 76%;">
              <div style="line-height: 1.25;">Warrants</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">975</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">1,408</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; background-color: #CCEEFF; width: 76%;">
              <div style="line-height: 1.25;">Capital reserve</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">13,596</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">13,596</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 76%;">
              <div style="line-height: 1.25;">Other comprehensive loss</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">(1,416</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">)</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">(1,416</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">)</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; background-color: #CCEEFF; width: 76%; padding-bottom: 2px;">
              <div style="line-height: 1.25;">Accumulated deficit</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
              <div style="line-height: 1.25;">(317,414</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 2px;">
              <div style="line-height: 1.25;">)</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
              <div style="line-height: 1.25;">(318,173</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 2px;">
              <div style="line-height: 1.25;">)</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
              <div style="line-height: 1.25;">Total shareholders&#8217; equity</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">56,568</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">61,018</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; background-color: #CCEEFF; width: 76%; padding-bottom: 2px;">
              <div style="line-height: 1.25; font-weight: bold;">Total capitalization</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; border-bottom: #000000 double 2px;">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 2px;">
              <div style="line-height: 1.25;">58,206</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; border-bottom: #000000 double 2px;">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 2px;">
              <div style="line-height: 1.25;">71,732</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          </tr>

      </table>
      <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The above calculation is based on 718,283,665 ordinary shares outstanding as of June 30, 2022, and excludes as of that date:</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zb77aabdd28fa42c681672b3ca8c764fc" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 7.7%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 92.3%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">74,179,714 ordinary shares issuable upon the exercise of outstanding warrants, at a weighted average exercise price of&#8201;$0.39 per share;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;"></div>
    <table cellspacing="0" cellpadding="0" id="zbcdcdf1ad3034a589b715ecbd779cb93" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 7.7%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 92.3%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">91,332,682 ordinary shares issuable upon the exercise of outstanding options, at a weighted average exercise price of&#8201;$0.14 per share;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;"></div>
    <table cellspacing="0" cellpadding="0" id="zf85acac490b049f2bce01bc25da43eeb" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 7.7%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 92.3%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">204,545,475 ordinary shares represented by 13,636,365 ADSs issuable upon exercise of warrants to be issued to the investors in this offering, at an exercise price of $1.15 per ADS; and</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;"></div>
    <table cellspacing="0" cellpadding="0" id="zf4e1c1e40f2e468d883345e5be235fdc" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 7.7%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 92.3%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">
              <div style="line-height: 1.25;">10,227,270 ordinary shares represented by 681,818 ADSs issuable upon exercise of placement agent warrants to be issued to the placement agent or its designees as compensation in connection with this offering,
                at an exercise price of $1.375 per ADS.</div>
            </div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">S - 11</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="DILUTION"><!--Anchor--></a>DILUTION</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">
        <div style="text-indent: 36pt; line-height: 1.25;">If you invest in the ADSs and accompanying warrants, your interest will be diluted immediately to the extent of the difference between the offering price per ADS and associated warrant and the as
          adjusted net tangible book value per ADS after this offering.</div>
      </div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The net tangible book value of our ADSs as of June 30, 2022 was $34.9 million, or $0.73 per ADS. Net tangible book value per ADS represents the amount of our total tangible assets
      less total liabilities divided by the total number of our ordinary shares outstanding as of June 30, 2022, multiplied by 15 (i.e., the number of ordinary shares underlying each ADS).</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">After giving effect to the sale of the ADSs and accompanying warrants offered by this prospectus supplement at a combined offering price of $1.10 per ADS and accompanying warrant and after deducting
        the placement agent fees and estimated offering expenses payable by us, our as adjusted net tangible book value as of June 30, 2022 would have been approximately $48.3 million, or approximately $0.79 per ADS. This represents an immediate increase
        in net tangible book value of approximately $0.06 per ADS to our existing shareholders and an immediate dilution in net tangible book value of approximately $0.31 per ADS to purchasers of the ADSs and accompanying warrants in this offering, as
        illustrated by the following table:</div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="ze5cff6015b6a441a845253e06ee17796" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 75.58%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">Offering price per ADS and accompanying warrant</div>
          </td>
          <td style="width: 0.94%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 10.28%; vertical-align: top; background-color: #CCEEFF;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.94%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.28%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td style="width: 8.97%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="text-align: right; line-height: 1.25;">1.10</div>
          </td>
          <td nowrap="nowrap" style="width: 1.01%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 75.58%; vertical-align: top;">
            <div style="line-height: 1.25;">Net tangible book value per ADS at June 30, 2022</div>
          </td>
          <td style="width: 0.94%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.28%; vertical-align: bottom;">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td style="width: 9%; vertical-align: bottom;">
            <div style="text-align: right; line-height: 1.25;">0.73</div>
          </td>
          <td nowrap="nowrap" style="width: 1%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.94%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.28%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 8.97%; vertical-align: bottom;">
            <div style="text-align: right; line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 1.01%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 75.58%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">Increase in net tangible book value per ADS attributable to investors purchasing the ADSs and accompanying warrants in this offering</div>
          </td>
          <td style="width: 0.94%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.28%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td style="width: 9%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="text-align: right; line-height: 1.25;">0.06</div>
          </td>
          <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.94%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.28%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 8.97%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="text-align: right; line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 1.01%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 75.58%; vertical-align: top;">
            <div style="line-height: 1.25;">As adjusted net tangible book value per ADS as of June 30, 2022 after giving effect to this offering</div>
          </td>
          <td style="width: 0.94%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.28%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 9%; vertical-align: bottom;">
            <div style="text-align: right; line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 1%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.94%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.28%; vertical-align: bottom;">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td style="width: 8.97%; vertical-align: bottom;">
            <div style="text-align: right; line-height: 1.25;">0.79</div>
          </td>
          <td nowrap="nowrap" style="width: 1.01%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 75.58%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">Dilution per ADS to investors purchasing the ADSs and accompanying warrants in this offering</div>
          </td>
          <td style="width: 0.94%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.28%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 9%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="text-align: right; line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.94%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.28%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td style="width: 8.97%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="text-align: right; line-height: 1.25;">&#160;0.31</div>
          </td>
          <td nowrap="nowrap" style="width: 1.01%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The above calculation is based on 718,283,665 ordinary shares outstanding as of June 30, 2022, and excludes as of that date:</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z742823431c62422a9b0c0e12c05be2bc" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 7.7%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 92.3%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">74,179,714 ordinary shares issuable upon the exercise of outstanding warrants, at a weighted average exercise price of&#8201;$0.39 per share;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z8197865cbb134d989fb0a89240fb95df" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 7.7%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 92.3%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">91,332,682 ordinary shares issuable upon the exercise of outstanding options, at a weighted average exercise price of&#8201;$0.14 per share;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25"><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z581bc3b1fa1d41579cf78897b21b3700" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 7.7%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 92.3%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">204,545,475 ordinary shares represented by 13,636,365 ADSs issuable upon exercise of warrants to be issued to the investors in this offering, at an exercise price of $1.15 per ADS; and</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25"><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z809f29a1a153431194a84221e9f1c437" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 7.7%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 92.3%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">
              <div style="line-height: 1.25;">10,227,270 ordinary shares represented by 681,818 ADSs issuable upon exercise of placement agent warrants to be issued to the placement agent or its designees as compensation in connection with this offering,
                at an exercise price of $1.375 per ADS.</div>
            </div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">To the extent that any of our options or warrants listed above are exercised, new options are issued and subsequently exercised or we issue additional shares of ADSs or ordinary
      shares in the future, there will be further dilution to new investors participating in this offering.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">S - 12</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="DESCRIPTIONOFSECURITIESWE"><!--Anchor--></a>DESCRIPTION OF SECURITIES WE ARE OFFERING</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">ADSs</div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The material terms&#160;and&#160;provisions of our ADSs&#160;are described under the caption &#8220;Description of American Depositary Shares&#8221; in the accompanying prospectus.&#160;</div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Warrants</div>
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The following is a summary of the material terms and provisions of the warrants that are being offered hereby. This summary is subject to and qualified in its entirety by the
        form of warrant, which has been provided to the investors in this offering and will be filed with the SEC as an exhibit to a Report on Form&#160;6-K&#160;in connection with this offering and incorporated by reference into the registration statement of which
        this prospectus forms a part. Prospective investors should carefully review the terms and provisions of the form of warrant for a complete description of the terms and conditions of the warrants.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">Duration and Exercise Price</div>
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
        <div style="text-indent: 36pt; line-height: 1.25;">The warrants offered hereby will have an exercise price of $1.15 per ADS. The warrants will be immediately exercisable and may be exercised until the fifth anniversary of the issuance date. The
          exercise price and numbers of ADSs issuable upon exercise are subject to appropriate adjustment in the event of share dividends, share splits, reorganizations or similar events affecting our ordinary shares. The warrants will be issued separately
          from the ordinary shares offered hereby, and may be transferred separately immediately thereafter. Warrants will be issued in certificated form only.</div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">Exercisability</div>
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for the
        number of ADSs purchased upon such exercise (except in the case of a cashless exercise as discussed below). A holder (together with its affiliates) may not exercise any portion of such holder&#8217;s warrants to the extent that the holder would own more
        than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding ordinary shares immediately after exercise, except that upon at least 61 days&#8217; prior notice from the holder to us, the holder may increase the amount of ownership of
        outstanding ordinary shares after exercising the holder&#8217;s warrants up to 9.99% of the number of ordinary shares outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of
        the warrants. Purchasers in this offering may also elect prior to the issuance of warrants to have the initial exercise limitation set at 9.99% of our outstanding ordinary shares.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25;">&#160;&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">Cashless Exercise</div>
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
        <div style="text-indent: 36pt; line-height: 1.25;">If, at the time a holder exercises its warrants, a registration statement registering the issuance of the ordinary shares underlying the warrants under the Securities Act, is not then effective or
          available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise
          (either in whole or in part) the net number of ADSs determined according to a formula set forth in the warrant.</div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">S - 13</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">Fundamental Transactions</div>
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In the event of any fundamental transaction, as described in the warrants and generally including any merger with or into another entity, sale of all or substantially all of our
        assets, tender offer or exchange offer, or reclassification of our ordinary shares, then upon any subsequent exercise of a ordinary shares warrant, the holder will have the right to receive as alternative consideration, for each share of our
        ordinary shares that would have been issuable upon such exercise immediately prior to the occurrence of such fundamental transaction, the number of ordinary shares of the successor or acquiring corporation or of our company, if it is the surviving
        corporation, and any additional consideration receivable upon or as a result of such transaction by a holder of the number of ordinary shares for which the ordinary shares warrant is exercisable immediately prior to such event. In certain
        circumstances, the holder will have the right to receive the Black Scholes Value of the warrant calculated pursuant to a formula set forth in the warrants, payable either in cash or in the same type or form of consideration that is being offered
        and being paid to the holders of our ADSs as described in the warrants.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">Transferability</div>
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In accordance with its terms and subject to applicable laws, a warrant may be transferred at the option of the holder upon surrender of the warrant to us together with the
        appropriate instruments of transfer and payment of funds sufficient to pay any transfer taxes (if applicable).</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">Fractional Shares</div>
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
        <div style="text-indent: 36pt; line-height: 1.25;">No fractional ADSs will be issued upon the exercise of the warrants. Rather, the number of ADSs to be issued will, at our election, either be rounded up to the nearest whole number or we will pay a
          cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the exercise price.</div>
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">Trading Market</div>
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">There is no established trading market for any of the warrants, and we do not expect a market to develop. We do not intend to apply for a listing for any of the warrants on any
        securities exchange or other nationally recognized trading system. Without an active trading market, the liquidity of the warrants will be limited.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">Rights as an ADS holder</div>
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Except as otherwise provided in the warrants or by virtue of the holders&#8217; ownership of ordinary shares, the holders of warrants do not have the rights or privileges of holders of
        our ordinary shares, including any voting rights, until such warrant holders exercise their warrants.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Placement Agent Warrants</div>
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This summary is subject to and qualified in its entirety by the form of placement agent warrant, which has been provided to the placement agent in this offering and will be filed
        with the SEC as an exhibit to a Report on Form 6-K in connection with this offering and incorporated by reference into the registration statement of which this prospectus forms a part.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
        <div style="text-indent: 36pt; line-height: 1.25;">The material terms of the placement agent warrants are substantially the same as those issuable to the investors, as described above, with the exception of the following terms:&#160; (a) the exercise
          price of the placement agent warrants is $1.375 per ADS, (b) the Beneficial Ownership Limitation is 4.99%, (c) holders of placement agent warrants are not entitled to receive cash dividends or distribution or return of capital in the form of cash
          made to holders of ordinary shares or ADSs and (d) the placement agent warrants have a term of five years from the commencement of the sales pursuant to this offering.&#160; See &#8220;Plan of Distribution&#8221;.</div>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">S - 14</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="PLANOFDISTRIBUTION"><!--Anchor--></a>PLAN OF DISTRIBUTION</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">Pursuant to an engagement agreement dated July 21, 2022, we have engaged H.C. Wainwright &amp; Co., LLC, or the placement agent, to act as our exclusive placement agent in connection with this
        offering of our ADSs and warrants pursuant to this prospectus supplement and accompanying prospectus. Under the terms of the engagement agreement, the placement agent has agreed to be our exclusive placement agent, on a reasonable best efforts
        basis, in connection with the issuance and sale by us of our ADSs in this takedown from our shelf registration statement. The terms of this offering were subject to market conditions and negotiations between us, the placement agent and prospective
        investors. The engagement agreement does not give rise to any commitment by the placement agent to purchase any of our securities, and the placement agent will have no authority to bind us by virtue of the engagement agreement. Further, the
        placement agent does not guarantee that it will be able to raise new capital in any prospective offering.</div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have entered into a securities purchase agreement directly with investors in connection with this offering, and we will only sell our securities offered hereby to investors who
      have entered into the securities purchase agreement.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We expect to deliver the ADSs and the warrants being offered pursuant to this prospectus supplement and the accompanying prospectus on or about September 21, 2022, subject to
      satisfaction of certain customary closing conditions.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have agreed to pay the placement agent a total cash fee equal to 7.0% of the gross proceeds of this offering. We will also pay the placement agent a management fee equal to 1.0%
      of the gross proceeds raised in this offering, a non-accountable expense allowance of $60,000 and clearing fees of $15,950. We estimate our total expenses associated with the offering, excluding placement agent fees and expenses, will be
      approximately $200,000.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">In addition, we agreed to issue warrants to the placement agent to purchase a number of ADSs equal to 5% of the aggregate number of ADSs sold to the investors in this offering, or 681,818 ADSs. The
        placement agent warrants will have an exercise price of $1.375 per ADS, which is equal to 125% of the combined offering price per ADS and accompanying warrant in this offering, and will have a term of five years from the commencement of the sales
        pursuant to this offering. The placement agent warrants will be exercisable immediately. The placement agent warrants will have substantially the same terms as the warrants being sold to the investors, with the exception of the following terms: (a)
        the exercise price of the placement agent warrants is $1.375 per ADS, (b) the Beneficial Ownership Limitation is 4.99%, (c) holders of placement agent warrants are not entitled to receive cash dividends or distribution or return of capital in the
        form of cash made to holders of ordinary shares or ADSs and (d) the placement agent warrants have a term of five years from the commencement of the sales pursuant to this offering.&#160; The placement agent warrants and the ADSs representing ordinary
        shares issuable upon exercise thereof are being registered hereby.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">S - 15</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">The following table sets forth the per ADS and accompanying warrant and total cash placement agent&#8217;s fees we will pay to the placement agent in connection with the sale of the ADSs pursuant to this
        prospectus supplement and the accompanying&#160;prospectus:</div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" id="z43ef08b33ccc48bf81306be9bdaa627f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 71.41%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.64%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;" colspan="2">
            <div style="line-height: 1.25; font-weight: bold;">Per ADS and Warrant</div>
          </td>
          <td nowrap="nowrap" style="width: 0.64%; vertical-align: bottom; text-align: center;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.64%; vertical-align: bottom; text-align: center;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;" colspan="2">
            <div style="line-height: 1.25; font-weight: bold;">Total</div>
          </td>
          <td nowrap="nowrap" style="width: 0.64%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.41%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">Offering price</div>
          </td>
          <td style="width: 0.64%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td style="width: 8.71%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="text-align: right; line-height: 1.25;">1.100</div>
          </td>
          <td nowrap="nowrap" style="width: 0.64%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.64%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td style="width: 9%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; line-height: 1.25;">15,000,001.50</div>
          </td>
          <td nowrap="nowrap" style="width: 0.64%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.41%; vertical-align: top;">
            <div style="line-height: 1.25;">Placement agent&#8217;s fees<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div>
          </td>
          <td style="width: 0.64%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom;">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td style="width: 8.71%; vertical-align: bottom;">
            <div style="text-align: right; line-height: 1.25;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">0.077</div>
            </div>
          </td>
          <td nowrap="nowrap" style="width: 0.64%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.64%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom;">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td style="width: 9%; vertical-align: bottom;">
            <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">1,050,000.11</div>
          </td>
          <td nowrap="nowrap" style="width: 0.64%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.41%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">Proceeds, before expenses, to us</div>
          </td>
          <td style="width: 0.64%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td style="width: 8.71%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">1.023</div>
          </td>
          <td nowrap="nowrap" style="width: 0.64%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.64%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td style="width: 9%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">13,950,001.39</div>
          </td>
          <td nowrap="nowrap" style="width: 0.64%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">After deducting those fees and expenses due to the placement agent and our other estimated offering expenses, we expect the net proceeds from this offering to be approximately
      $13.5 million.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Tail Financing Payments</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have agreed that the placement agent shall be entitled to compensation, with respect to any public or private offering or other financing or capital-raising transaction of any
        kind, a Tail Financing, to the extent that such financing or capital is provided to the Company by investors whom the placement agent had contacted during the term of its engagement or introduced to the Company during the term of the placement
        agent&#8217;s engagement by the Company if such Tail Financing is consummated at any time within the ten-month period following the expiration or termination of the placement agent&#8217;s engagement by the Company.</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Lock-up Restrictions</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">Pursuant to the securities purchase agreement with the investors in this offering, we have agreed that, for a period of 90 days following the closing of this offering, we will not issue, enter into
        an agreement to issue or announce the issuance or proposed issuance of our ADSs, ordinary shares or ordinary shares equivalents.</div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have also agreed that, for a period of twelve months following the closing date of this offering, we will not (i) issue or sells any debt or equity securities that are
      convertible into, exchangeable or exercisable for, or include the right to receive, additional ADSs or ordinary shares either (A) at a conversion price, exercise price or exchange rate or other price that is based upon, and/or varies with, the
      trading prices of or quotations for the ADSs or ordinary shares at any time after the initial issuance of such debt or equity securities or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the
      initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related to our business or the market for the ADSs or ordinary shares or (ii) enter into, or effects a transaction under,
      any agreement, including, but not limited to, an equity line of credit, &#8220;at-the-market&#8221; offering or similar transactions whereby we may issue securities at a future determined price, such transactions in (i) and (ii) above being &#8220;Variable Rate
      Transactions&#8221;. However, the prohibition of Variable Rate Transactions as described above shall not restrict us from issuing ADSs and/or ordinary shares under an at the market offering program with the placement agent as the sales agent following the
      date that is 90 days after the closing date of this offering.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"></div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Indemnification</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have agreed to indemnify the placement agent and specified other persons against certain civil liabilities, including liabilities under the Securities Act, and the Securities
        Exchange Act of 1934, as amended, or the Exchange Act, and to contribute to payments that the placement agent may be required to make in respect of such liabilities.</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">S - 16</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25; font-weight: bold;">Regulation M</div>
      <div style="line-height: 1.25;">&#160;
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The placement agent may be deemed to be an underwriter within the meaning of Section 2(a)(11) of the Securities Act, and any commissions received by it, and any profit realized
          on the resale of the securities sold by it while acting as principal, might be deemed to be underwriting discounts or commissions under the Securities Act. As an underwriter, the placement agent would be required to comply with the requirements
          of the Securities Act and the Securities Exchange Act of 1934, as amended, or Exchange Act, including, without limitation, Rule 415(a)(4) under the Securities Act, Rule 10b-5 and Regulation M under the Exchange Act. These rules and regulations
          may limit the timing of purchases and sales of ADSs, ordinary shares and warrants by the placement agent acting as principal. Under these rules and regulations, the placement agent:</div>
        <div style="line-height: 1.25"><br>
        </div>
      </div>
    </div>
    <table cellspacing="0" cellpadding="0" id="z6c3c63752e5c45e594fa8cd973cd05c9" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 7.7%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 92.3%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">may not engage in any stabilization activity in connection with our securities; and</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z4a0be96782ef433c9df234eba12c48a0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 7.7%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 92.3%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">may not bid for or purchase any of our securities, or attempt to induce any person to purchase any of our securities, other than as permitted under the Exchange Act, until it has completed
              its participation in the distribution in the securities offered by this prospectus supplement.</div>
          </td>
        </tr>

    </table>
    <br>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Other Relationships</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The placement agent and its affiliates may have provided us and our affiliates in the past, and may provide from time to time in the future, certain commercial banking, financial
        advisory, investment banking and other services for us and such affiliates in the ordinary course of their business, for which they have received, and may continue to receive, customary fees and commissions. In addition, from time to time, the
        placement agent and their affiliates may effect transactions for their own account or the account of customers, and hold on behalf of themselves or their customers, long or short positions in our debt or equity securities or loans, and may do so in
        the future.&#160;However, except as disclosed in this prospectus supplement, we have no present arrangements with the placement agent for any further services.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
        <div style="text-indent: 36pt; line-height: 1.25;">
          <div style="text-indent: 36pt; line-height: 1.25;">The placement agent acted as our exclusive placement agent in connection with our registered direct offerings we consummated in May and June 2020, our sole underwriter in connection with the
            bought deal offering we consummated in January 2021, and as our sales agent in our at-the-market offering programs for which it received compensation.</div>
        </div>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">S - 17</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="LEGALMATTERS"><!--Anchor--></a>LEGAL MATTERS</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">McDermott Will &amp; Emery LLP has passed upon certain legal matters regarding the securities offered hereby under U.S. law, and Yigal Arnon &amp; Co., Jerusalem, Israel, has
      passed upon certain legal matters regarding the securities offered hereby under Israeli law.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">EXPERTS</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The financial statements and management&#8217;s assessment of the effectiveness of internal control over financial reporting (which is included in Management&#8217;s Report on Internal Control
      over Financial Reporting) incorporated in this prospectus supplement by reference to the Annual Report on Form 20-F for the year December 31, 2021 have been so incorporated in reliance on the report of Kesselman and Kesselman, Certified Public
      Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">EXPENSES</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The following table sets forth costs and expenses, other than any placement agent fees and expenses, we expect to incur in connection with the offering.</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" id="z39b7d3ef531d41eb93b8c174a137c878" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 87.64%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">Legal fees and expenses</div>
          </td>
          <td style="width: 0.95%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.28%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td style="width: 9.1%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="text-align: right; line-height: 1.25;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">120,000</div>
            </div>
          </td>
          <td nowrap="nowrap" style="width: 1.03%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 87.64%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Accounting fees and expenses</div>
          </td>
          <td style="width: 0.95%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.28%; vertical-align: bottom;">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td style="width: 9.1%; vertical-align: bottom;">
            <div style="text-align: right; line-height: 1.25;">10,000</div>
          </td>
          <td nowrap="nowrap" style="width: 1.03%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 87.64%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">Depositary fees</div>
          </td>
          <td rowspan="1" style="width: 0.95%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 1.28%; vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
          <td rowspan="1" style="width: 9.1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">68,000</div>
          </td>
          <td nowrap="nowrap" rowspan="1" style="width: 1.03%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 87.64%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Miscellaneous fees and expenses</div>
          </td>
          <td style="width: 0.95%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.28%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td style="width: 9.1%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">2,000</div>
          </td>
          <td nowrap="nowrap" style="width: 1.03%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 87.64%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">Total</div>
          </td>
          <td style="width: 0.95%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.28%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td style="width: 9.1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; line-height: 1.25;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">200,000</div>
            </div>
          </td>
          <td nowrap="nowrap" style="width: 1.03%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">S - 18</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="DOCUMENTSINCORPORATEDBYRE"><!--Anchor--></a>DOCUMENTS INCORPORATED BY REFERENCE</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The SEC allows us to incorporate by reference our publicly filed reports into this prospectus supplement, which means that information included in those reports is considered part
      of this prospectus supplement.&#160; Information that we file with the SEC after the date of this prospectus supplement will automatically update and supersede the information contained in this prospectus supplement.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This prospectus supplement incorporates by reference the documents listed below, which have been previously filed with the SEC:</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zf872637af2744c3297a2369c8b1718fb" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 7.7%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 92.3%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">our Annual Report on Form 20-F for the year ended December 31, 2021, filed on <a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891322001134/0001178913-22-001134-index.htm">March







                16, 2022</a>, as amended on <a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891322003376/0001178913-22-003376-index.htm">September 9, 2022</a>;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z594349352985412ab96be28f6cf29d61" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 7.7%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8226;</div>
            <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
          </td>
          <td style="width: 92.3%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">our Reports on Form 6-K filed with the SEC on <a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891322001863/0001178913-22-001863-index.htm">May 11, 2022</a>, <a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891322002221/0001178913-22-002221-index.htm">May 27, 2022</a>, <a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891322002388/0001178913-22-002388-index.htm">June 16,
                2022</a>, <a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891322002488/0001178913-22-002488-index.htm">June 28, 2022</a>, <a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891322002567/0001178913-22-002567-index.htm">July 5, 2022</a>, <a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891322003141/0001178913-22-003141-index.htm">August
                16, 2022</a>, <a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891322003388/0001178913-22-003388-index.htm">September 12, 2022</a> and <a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891322003437/0001178913-22-003437-index.htm">September 15, 2022</a> (in each case, to the extent expressly incorporated by reference into our effective registration statements
              filed by us under the Securities Act); and</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 7.7%; vertical-align: top;">
              <div style="line-height: 1.25;">&#8226;</div>
            </td>
            <td style="width: 92.3%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">
                <div style="line-height: 1.25;">the description of our ordinary shares contained in <a href="https://www.sec.gov/Archives/edgar/data/1498403/000117891321000741/exhibit_2-2.htm">Exhibit 2.2</a> to our Annual Report on Form 20-F for the year
                  ended December 31, 2020, filed with the SEC on February 23, 2021, and any amendment or report filed for the purpose of further updating that description.</div>
              </div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">All subsequent annual reports filed by us pursuant to the Exchange Act on Form 20-F prior to the termination of the offering shall be deemed to be incorporated by reference to this
      prospectus and to be a part hereof from the date of filing of such documents. We may also incorporate part or all of any Form 6-K subsequently submitted by us to the SEC prior to the termination of the offering by identifying in such Forms 6-K that
      they, or certain parts of their contents, are being incorporated by reference herein, and any Forms 6-K so identified shall be deemed to be incorporated by reference in this prospectus and to be a part hereof from the date of submission of such
      documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained herein or in any
      other subsequently filed document which also is incorporated or deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or
      superseded, to constitute a part of this prospectus.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;"></div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The SEC maintains an Internet site at http://www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers like us that file
      electronically with the SEC.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We will furnish without charge to you, on written or oral request, a copy of any or all of the above documents, other than exhibits to such documents which are not specifically
      incorporated by reference therein. You should direct any requests for documents to:</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="margin-left: 37.05pt; line-height: 1.25;">BioLineRx Ltd.</div>
    <div style="margin-left: 37.05pt; line-height: 1.25;">Modi&#8217;in Technology Park</div>
    <div style="margin-left: 37.05pt; line-height: 1.25;">2 HaMa&#8217;ayan Street</div>
    <div style="margin-left: 37.05pt; line-height: 1.25;">Modi&#8217;in 7177871, Israel</div>
    <div style="margin-left: 37.05pt; line-height: 1.25;">Attention: Corporate Secretary</div>
    <div style="margin-left: 37.05pt; line-height: 1.25;">Tel.: +972-8-642-9100</div>
    <div style="margin-left: 37.05pt; line-height: 1.25;">e-mail: info@BioLineRx.com</div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The information relating to us contained in this prospectus is not comprehensive and should be read together with the information contained in the incorporated documents.
      Descriptions contained in the incorporated documents as to the contents of any contract or other document may not contain all of the information which is of interest to you. You should refer to the copy of such contract or other document filed as an
      exhibit to our filings.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">S - 19</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="WHEREYOUCANFINDMOREINFORM"><!--Anchor--></a>WHERE YOU CAN FIND MORE INFORMATION</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have filed with the SEC a registration statement on Form F-3 under the Securities Act, relating to this offering of securities. This prospectus supplement does not contain all
      of the information contained in the registration statement. The rules and regulations of the SEC allow us to omit certain information from this prospectus supplement that is included in the registration statement. Statements made in this prospectus
      supplement concerning the contents of any contract, agreement or other document are summaries of all material information about the documents summarized, but are not complete descriptions of all terms of these documents. If we filed any of these
      documents as an exhibit to the registration statement, you may read the document itself for a complete description of its terms.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We are subject to the informational requirements of the Exchange Act applicable to foreign private issuers. In accordance with the Exchange Act, we file reports, including annual
      reports on Form 20-F containing financial statements audited by an independent accounting firm. We also furnish to the SEC, under over of Reports of Foreign Private Issuer on Form 6-K, material information required to be made public by us or filed by
      us with and made public by any stock exchange or distributed by us to our shareholders.&#160; Such reports and other information filed with the SEC are available to the public over the Internet at the SEC&#8217;s website at http://www.sec.gov. These SEC filings
      are also available to the public on the Israel Securities Authority&#8217;s Magna website at www.magna.isa.gov.il and from commercial document retrieval services. We also generally make available on our own website (www.biolinerx.com) our quarterly and
      year-end financial statements as well as other information.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">As a foreign private issuer, we are exempt from the rules under the Exchange Act prescribing the furnishing and content of proxy statements to shareholders, and our officers,
      directors and principal shareholders are exempt from the &#8220;short-swing profits&#8221; reporting and liability provisions contained in Section 16 of the Exchange Act and related Exchange Act rules. In addition, we are not required under the Exchange Act to
      file periodic reports and financial statements as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition, since our ordinary shares are traded on the TASE, in the past we filed Hebrew language periodic and immediate reports with, and furnished information to, the TASE and
      the ISA, as required under Chapter Six of the Israel Securities Law, 1968. On August 31, 2011, our shareholders approved a transition solely to U.S. reporting standards after listing the ADSs on Nasdaq, in accordance with an applicable exemption
      under the Israel Securities Law. Copies of our SEC filings and submissions are now submitted to the ISA and the TASE. Such copies can be retrieved electronically through the MAGNA distribution site of the ISA (www.magna.isa.gov.il) and the TASE
      website (maya.tase.co.il).</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">As of the date of this prospectus supplement, we received approximately $22.0 million in funding from the Innovation Authority, or the IIA (formerly known as the Office of the
      Chief Scientist), which has provided funding in relation to our programs.&#160;Through the date of this prospectus supplement we have paid the IIA an aggregate amount of approximately $7.0 million in royalties in relation to such programs. As of the date
      of this prospectus supplement, our contingent obligation to the IIA is approximately $3.6 million (including accrued interest). For a description of our obligations in connection with the grants from the IIA, see &#8220;Item 3D. &#8211; Risk Factors - Risks
      Related to our Operations in Israel&#8221; and &#8220;Item 4.B. &#8211; Business Overview - Israeli Government Programs&#8221; in our Annual Report on Form 20-F for the year ended December 31, 2021.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We maintain a corporate website at www.biolinerx.com. Information contained on, or that can be accessed through, our website does not constitute a part of this prospectus
      supplement. We have included our website address in this prospectus supplement solely as an inactive textual reference.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">S - 20</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="ENFORCEABILITYOFCIVILLIAB"><!--Anchor--></a>ENFORCEABILITY OF CIVIL LIABILITIES</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We are incorporated under the laws of the State of Israel. Service of process upon us and upon our directors and officers and the Israeli experts named in this registration
      statement, substantially all of whom reside outside of the United States, may be difficult to obtain within the United States. Furthermore, because substantially all of our assets and substantially all of our directors and officers are located
      outside the United States, any judgment obtained in the United States against us or any of our directors and officers may not be collectible within the United States.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have been informed by our legal counsel in Israel, Yigal Arnon &amp; Co., that it may be difficult to assert U.S. securities law claims in original actions instituted in Israel.
      Israeli courts may refuse to hear a claim based on a violation of U.S. securities laws because Israel is not the most appropriate forum to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli
      law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact which can be a time-consuming and costly process. Certain matters of procedure will also be governed
      by Israeli law.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Subject to specified time limitations and legal procedures, Israeli courts may enforce a United States judgment in a civil matter which, subject to certain exceptions, is
      non-appealable, including judgments based upon the civil liability provisions of the Securities Act and the Exchange Act and including a monetary or compensatory judgment in a non-civil matter, provided that among other things:</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z888a55105d9640279e3b055ad713b3be" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 7.7%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 92.3%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">the judgments are obtained after due process before a court of competent jurisdiction, according to the laws of the state in which the judgment is given and the rules of private international
              law currently prevailing in Israel;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.7%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 92.3%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">the prevailing law of the foreign state in which the judgments were rendered allows for the enforcement of judgments of Israeli courts;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.7%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 92.3%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">adequate service of process has been effected and the defendant has had a reasonable opportunity to be heard and to present his or her evidence;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.7%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 92.3%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">the judgments are not contrary to public policy of Israel, and the enforcement of the civil liabilities set forth in the judgment is not likely to impair the security or sovereignty of
              Israel;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.7%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 92.3%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">the judgments were not obtained by fraud and do not conflict with any other valid judgments in the same matter between the same parties;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.7%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 92.3%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">an action between the same parties in the same matter is not pending in any Israeli court at the time the lawsuit is instituted in the foreign court; and</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.7%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 92.3%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">the judgment is enforceable according to the laws of Israel and according to the law of the foreign state in which the relief was granted.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Generally, an Israeli court will not enforce a foreign judgment if the motion for enforcement was filed more than five years after the date of its award in the United States,
      unless Israel and the United States have agreed otherwise on a different period, or if an Israeli court finds exceptional reasons justifying the delay.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If a foreign judgment is enforced by an Israeli court, it generally will be payable in Israeli currency, which can then be converted into non-Israeli currency and transferred out
      of Israel. Under existing Israeli law, a foreign judgment payable in foreign currency may be paid in Israeli currency at the rate of exchange reported by the Bank of Israel on the date of the payment. A judgment debtor may also make payment in
      foreign currency. Pending collection, the amount of the judgment of an Israeli court stated in Israeli currency ordinarily will be linked to the Israeli consumer price index plus interest at the annual statutory rate set by Israeli regulations
      prevailing at the time. Judgment creditors must bear the risk of unfavorable exchange rates.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">S - 21</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;
      <div><br>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold;">PROSPECTUS</div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="text-align: center; line-height: 1.25;">&#160;<img width="243" height="23" src="image0.jpg"></div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">BioLineRx Ltd.</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">$150,000,000</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">Ordinary Shares</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">American Depositary Shares Representing Ordinary Shares</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">Debt Securities</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">Subscription Rights</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">Warrants<br>
          Units</div>
        <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 1pt;">&#160; <br>
        </div>
        <div style="text-align: center; line-height: 1.25;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We may offer, issue and sell from time to time up to US $150,000,000 of our ordinary shares, including in the form of American Depositary Shares, or ADSs, warrants to purchase
          ordinary shares, including in the form of ADSs, debt securities, subscription rights and a combination of such securities, separately or as units, in one or more offerings.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Each ADS represents 15 ordinary shares. This prospectus provides a general description of offerings of these securities that we may undertake.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We refer to the ADSs, ordinary shares, debt securities, subscription rights, warrants and units, collectively, as the &#8220;securities&#8221; in this prospectus. We may offer, issue and
          sell the securities at an aggregate public offering price that will not exceed $150,000,000.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Each time we sell securities pursuant to this prospectus, we will provide in a supplement to this prospectus the price and any other material terms of any such offering. Any
          prospectus supplement may also add, update or change information contained in this prospectus. You should read this prospectus and any applicable prospectus supplement, as well as the documents incorporated by reference or deemed incorporated by
          reference into this prospectus, carefully before you invest in any securities. <font style="font-weight: bold;">This prospectus may not be used to offer or sell securities unless accompanied by a prospectus supplement.</font></div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We may, from time to time, offer to sell the securities, through public or private transactions, directly or through underwriters, agents or dealers, on or off the Nasdaq
          Capital Market, at prevailing market prices or at privately negotiated prices. If any underwriters, agents or dealers are involved in the sale of any of these securities, the applicable prospectus supplement will set forth the names of the
          underwriter, agent or dealer and any applicable fees, commissions or discounts.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our ADSs are listed on Nasdaq under the symbol &#8220;BLRX&#8221;. On December 30, 2020, the closing price of our ADSs on Nasdaq was US$2.55 per ADS. Our ordinary shares also trade on the
          Tel Aviv Stock Exchange, or the TASE, under the symbol &#8220;BLRX&#8221;. On December 30, 2020, the last reported sale price of our ordinary shares on the TASE was NIS 0.53 or $0.167 per share (based on the exchange rate reported by the Bank of Israel on
          the same day).</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Investing in our securities involves a high degree of risk. Please carefully consider the risks discussed in this prospectus under &#8220;Risk Factors&#8221; beginning
          on page 2 and the &#8220;Risk Factors&#8221; in &#8220;Item 3: Key Information- Risk Factors&#8221; of our most recent Annual Report on Form 20-F incorporated by reference in this prospectus and in any applicable prospectus supplement for a discussion of the factors you
          should consider carefully before deciding to purchase these securities.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Neither the Securities and Exchange Commission, the Israel Securities Authority nor any state or other foreign securities commission has approved or
          disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">The date of this prospectus is &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font>, <font style="font-weight: bold;">2021</font></div>
        <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;"> <br>
          </font></div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div style="page-break-after: always;" id="DSPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="text-align: center; margin-left: 5.75pt; line-height: 1.25; font-weight: bold;">TABLE OF CONTENTS</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="2" border="0" id="z1784831ab9344bbe8d55b9d5fff11532" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 92%; vertical-align: top; background-color: #CCEEFF;">
                <div style="line-height: 1.25;"><a href="#ABOUTTHISPROSPECTUS">About this Prospectus</a></div>
              </td>
              <td style="width: 8%; vertical-align: top; background-color: #CCEEFF;">
                <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">1<br>
                </div>
              </td>
            </tr>
            <tr>
              <td style="width: 92%; vertical-align: top;">
                <div style="line-height: 1.25;"><a href="#OURBUSINESS">Our Business</a></div>
              </td>
              <td style="width: 8%; vertical-align: top;">
                <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">2<br>
                </div>
              </td>
            </tr>
            <tr>
              <td style="width: 92%; vertical-align: top; background-color: #CCEEFF;">
                <div style="line-height: 1.25;"><a href="#OURBUSINESS">Risk Factors</a></div>
              </td>
              <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: right;">2<br>
              </td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 92%; vertical-align: top;">
                <div style="line-height: 1.25;"><a href="#OFFERSTATISTICSANDEXPECTE">Offer Statistics and Expected Timetable</a></div>
              </td>
              <td rowspan="1" style="width: 8%; vertical-align: top; text-align: right;">2 <br>
              </td>
            </tr>
            <tr>
              <td style="width: 92%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;"><a href="#OURBUSINESS">Forward-Looking Statements</a></div>
              </td>
              <td style="width: 8%; vertical-align: top; text-align: right; background-color: rgb(204, 238, 255);">2<br>
              </td>
            </tr>
            <tr>
              <td style="width: 92%; vertical-align: top;">
                <div style="line-height: 1.25;"><a href="#ABOUTTHISPROSPECTUS">Capitalization</a></div>
              </td>
              <td style="width: 8%; vertical-align: top; text-align: right;">4<br>
              </td>
            </tr>
            <tr>
              <td style="width: 92%; vertical-align: middle; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;"><a href="#USEOF">Use of Proceeds</a></div>
              </td>
              <td style="width: 8%; vertical-align: top; text-align: right; background-color: rgb(204, 238, 255);">5<br>
              </td>
            </tr>
            <tr>
              <td style="width: 92%; vertical-align: top;">
                <div style="line-height: 1.25;"><a href="#USEOF">Description of Ordinary Shares</a></div>
              </td>
              <td style="width: 8%; vertical-align: top; text-align: right;">5<br>
              </td>
            </tr>
            <tr>
              <td style="width: 92%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;"><a href="#DESCRIPTIONOFAMERICANDEPO">Description of American Depositary Shares</a></div>
              </td>
              <td style="width: 8%; vertical-align: top; text-align: right; background-color: rgb(204, 238, 255);">9<br>
              </td>
            </tr>
            <tr>
              <td style="width: 92%; vertical-align: top;">
                <div style="line-height: 1.25;"><a href="#DESCRIPTIONOFDEBTSECURITI">Description of Debt Securities</a></div>
              </td>
              <td style="width: 8%; vertical-align: top; text-align: right;">14<br>
              </td>
            </tr>
            <tr>
              <td style="width: 92%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;"><a href="#DESCRIPTIONOFSUBSCRIPTION">Description of Subscription Rights</a></div>
              </td>
              <td style="width: 8%; vertical-align: top; text-align: right; background-color: rgb(204, 238, 255);">26<br>
              </td>
            </tr>
            <tr>
              <td style="width: 92%; vertical-align: top;">
                <div style="line-height: 1.25;"><a href="#DESCRIPTIONOFWARRANTS">Description of Warrants</a></div>
              </td>
              <td style="width: 8%; vertical-align: top; text-align: right;">26<br>
              </td>
            </tr>
            <tr>
              <td style="width: 92%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;"><a href="#DESCRIPTIONOFUNITS">Description of Units</a></div>
              </td>
              <td style="width: 8%; vertical-align: top; text-align: right; background-color: rgb(204, 238, 255);">28<br>
              </td>
            </tr>
            <tr>
              <td style="width: 92%; vertical-align: top;">
                <div style="line-height: 1.25;"><a href="#DESCRIPTIONOFUNITS">Taxation</a></div>
              </td>
              <td style="width: 8%; vertical-align: top; text-align: right;">28<br>
              </td>
            </tr>
            <tr>
              <td style="width: 92%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;"><a href="#PLANOFD">Plan of Distribution</a></div>
              </td>
              <td style="width: 8%; vertical-align: top; text-align: right; background-color: rgb(204, 238, 255);">29<br>
              </td>
            </tr>
            <tr>
              <td style="width: 92%; vertical-align: top;">
                <div style="line-height: 1.25;"><a href="#LEGAL">Legal Matters</a></div>
              </td>
              <td style="width: 8%; vertical-align: top; text-align: right;">31<br>
              </td>
            </tr>
            <tr>
              <td style="width: 92%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;"><a href="#LEGAL">Experts</a></div>
              </td>
              <td style="width: 8%; vertical-align: top; text-align: right; background-color: rgb(204, 238, 255);">31<br>
              </td>
            </tr>
            <tr>
              <td style="width: 92%; vertical-align: top;">
                <div style="line-height: 1.25;"><a href="#LEGAL">Where You Can Find More Information</a></div>
              </td>
              <td style="width: 8%; vertical-align: top; text-align: right;">31<br>
              </td>
            </tr>
            <tr>
              <td style="width: 92%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;"><a href="#INCORPORATION">Incorporation of Certain Documents by Reference</a></div>
              </td>
              <td style="width: 8%; vertical-align: top; text-align: right; background-color: rgb(204, 238, 255);">32<br>
              </td>
            </tr>
            <tr>
              <td style="width: 92%; vertical-align: top;">
                <div style="line-height: 1.25;"><a href="#ENFORCEABILITY">Enforceability of Civil Liabilities</a></div>
              </td>
              <td style="width: 8%; vertical-align: top; text-align: right;">32<br>
              </td>
            </tr>
            <tr>
              <td style="width: 92%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;"><a href="#EXP">Expenses</a></div>
              </td>
              <td style="width: 8%; vertical-align: top; text-align: right; background-color: rgb(204, 238, 255);">33<br>
              </td>
            </tr>

        </table>
        <div style="text-align: center; line-height: 1.25;"><br>
        </div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div style="page-break-after: always;" id="DSPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <!--PROfilePageNumberReset%Num%1%%%-->
        <div style="text-align: center; line-height: 1.25; font-weight: bold;"><br>
          <a name="ABOUTTHISPROSPECTUS"><!--Anchor--></a>ABOUT THIS PROSPECTUS</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This prospectus is part of a Registration Statement on Form F-3 that we filed with the Securities and Exchange Commission, or the SEC, utilizing a &#8220;shelf&#8221; registration process.
          Under this shelf registration process, we may sell our securities described in this prospectus in one or more offerings up to a total dollar amount of $150,000,000.&#160; This prospectus does not contain all of the information set forth in the
          registration statement, certain parts of which are omitted in accordance with the rules and regulations of the SEC. Accordingly, you should refer to the registration statement and its exhibits for further information about us and our securities.
          Copies of the registration statement and its exhibits are on file with the SEC. Statements contained in this prospectus concerning the documents we have filed with the SEC are not intended to be comprehensive, and in each instance we refer you to
          a copy of the actual document filed as an exhibit to the registration statement or otherwise filed with the SEC.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Each time we offer our securities, we will provide you with a prospectus supplement that will describe the specific amounts, prices and terms of the securities we offer. The
          prospectus supplement may also add, update or change information contained in this prospectus.&#160; This prospectus, together with applicable prospectus supplements and the documents incorporated by reference in this prospectus and any prospectus
          supplements, includes all material information relating to this offering. Please read carefully both this prospectus and any prospectus supplement together with additional information described below under &#8220;Where You Can Find More Information&#8221;
          and &#8220;Incorporation of Certain Documents by Reference.&#8221;</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This prospectus does not contain all of the information provided in the registration statement that we filed with the Commission. For further information about us or our
          securities, you should refer to that registration statement, which you can obtain from the Commission as described below under &#8220;Where You Can Find More Information&#8221; and &#8220;Incorporation of Certain Documents by Reference.&#8221;</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">You should rely only on the information incorporated by reference or provided in this prospectus or any prospectus supplement. &#8220;Incorporated by reference&#8221; means that we can
          disclose important information to you by referring you to another document filed separately with the SEC. We have not authorized anyone to provide you with different information. We are offering to sell, and seeking offers to buy, our securities
          only in jurisdictions where offers and sales are permitted. We are not making, nor will we make, an offer to sell securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this
          prospectus and any supplement to this prospectus is current only as of the dates on their respective covers. Our business, financial condition, results of operations and prospects may have changed since that date.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We prepare our financial statements in United States dollars and in accordance with International Financial Reporting Standards.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Certain figures included in this prospectus have been subject to rounding adjustments. Accordingly, figures shown as totals in certain tables may not be an arithmetic
          aggregation of the figures that precede them.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">All references in this prospectus to &#8220;$,&#8221; &#8220;U.S. Dollars&#8221; and &#8220;dollars&#8221; are to United States dollars and all references to &#8220;NIS&#8221; are to New Israeli Shekels.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;This prospectus and the information incorporated by reference herein and therein include trademarks, service marks and trade names owned by us or other companies. Solely for
          convenience, trademarks referred to in this prospectus, including logos, artwork and other visual displays, may appear without the &#174; or &#8482; symbols. We do not intend our use or display of other companies&#8217; trade names or trademarks to imply a
          relationship with, or endorsement or sponsorship of us by, any other companies. All trademarks, service marks and trade names included or incorporated by reference into this prospectus or an accompanying prospectus supplement are the property of
          their respective owners.</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">1</font></div>
          <div style="page-break-after: always;" id="DSPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="OURBUSINESS"><!--Anchor--></a>OUR BUSINESS</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This summary highlights selected information contained elsewhere in this prospectus that we consider important. This summary does not contain all of the information you should
          consider before investing in our securities. You should read this summary together with the entire prospectus, including the risks related to our business, our industry, investing in our ADSs and our location in Israel, that we describe under
          &#8220;Risk Factors&#8221; and our consolidated financial statements and the related notes included at the end of this prospectus before making an investment in our securities.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We are a late clinical-stage biopharmaceutical development company with a strategic focus on oncology. Our current development and commercialization pipeline consists of two
          clinical-stage therapeutic candidates &#8211; motixafortide (BL-8040), a novel peptide for the treatment of solid tumors, acute myeloid leukemia, or AML, and stem cell mobilization, and AGI-134, an immuno-oncology agent in development for solid tumors.
          In addition, we have an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. We have generated our pipeline by systematically identifying, rigorously validating and in-licensing therapeutic candidates that we
          believe exhibit a high probability of therapeutic and commercial success. To date, except for BL-5010, none of our therapeutic candidates have been approved for marketing or sold commercially. Our strategy includes commercializing our therapeutic
          candidates through out-licensing arrangements with biotechnology and pharmaceutical companies and evaluating, on a case-by-case basis, the commercialization of our therapeutic candidates independently.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Corporate Information</div>
        <div style="text-align: justify; line-height: 1.25;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our legal and commercial name is BioLineRx Ltd. We are a company limited by shares organized under the laws of the State of Israel. Our principal executive offices are located
          at 2 HaMa&#8217;ayan Street, Modi&#8217;in 7177871, Israel, and our telephone number is +972 (8) 642-9100.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We were founded in 2003 by leading institutions in the Israeli life sciences industry. We completed our initial public offering in Israel in February 2007 and our ordinary
          shares are traded on the TASE under the symbol &#8220;BLRX.&#8221; In July 2011, we listed our ADSs on Nasdaq and they are traded under the symbol &#8220;BLRX.&#8221; In March 2017, we acquired Agalimmune Ltd., a private U.K.-based company, and its U.S. subsidiary,
          Agalimmune Inc. Agalimmune Inc. was dissolved on December 31, 2017.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers like BioLineRx that file electronically with
          the SEC. The address of that site is www.sec.gov. We maintain a corporate website at <u>www.biolinerx.com</u></div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The information contained on, or that can be accessed through, our website is neither a part of nor incorporated into this prospectus. We have included our website address in
          this prospectus solely as an inactive textual reference. We have duly designated Puglisi &amp; Associates, with offices at 850 Library Avenue, Newark, Delaware 1971, as our authorized agent in the United States in connection with this offering. &#160;</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">RISK FACTORS</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Investing in our securities involves significant risks. Before making an investment decision, you should carefully consider the risks described under &#8220;Risk Factors&#8221; in the
          applicable prospectus supplement and under Item 3.D. &#8211; &#8220;Risk Factors&#8221; in our most recent Annual Report on Form 20-F, or any updates in our Reports on Form 6-K, together with all of the other information appearing in this prospectus or
          incorporated by reference into this prospectus and any applicable prospectus supplement, in light of your particular investment objectives and financial circumstances. The risks so described are not the only risks facing us. Additional risks not
          presently known to us or that we currently deem immaterial may also impair our business operations. Our business, financial condition and results of operations could be materially adversely affected by any of these risks. The trading price of our
          securities could decline due to any of these risks, and you may lose all or part of your investment. The discussion of risks includes or refers to forward-looking statements; you should read the explanation of the qualifications and limitations
          on such forward-looking statements discussed elsewhere in this prospectus.</div>
        <div style="line-height: 1.25">&#160;
          <div style="text-align: center; text-indent: 36pt; margin-right: 0.1pt; margin-left: 0.1pt; line-height: 1.25; font-weight: bold;"><a name="OFFERSTATISTICSANDEXPECTE"><!--Anchor--></a>OFFER STATISTICS AND EXPECTED TIMETABLE</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We may sell from time to time pursuant to this prospectus (as may be detailed in prospectus supplements) an indeterminate number of securities as shall have a maximum
            aggregate offering price of $150,000,000.&#160; The actual per share price of the securities that we will offer pursuant hereto will depend on a number of factors that may be relevant as of the time of offer (see &#8220;Plan of Distribution&#8221; below).</div>
        </div>
        <div style="line-height: 1.25"> <br>
        </div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">FORWARD-LOOKING STATEMENTS</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This prospectus and the documents incorporated herein and therein by reference contain statements and information that involve known and unknown risks, uncertainties and other
          factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify
          forward-looking statements by terms including &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions intended to identify
          forward-looking statements, but these are not the only ways these statements are identified. Forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties.
          You should not put undue reliance on any forward-looking statements. Unless we are required to do so under U.S. federal securities laws or other applicable laws, we do not intend to update or revise any forward-looking statements. Readers are
          encouraged to consult the Company&#8217;s filings made on Form 6-K, which are periodically filed with or furnished to the SEC.</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">2</font></div>
          <div style="page-break-after: always;" id="DSPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Factors that could cause our actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to:</div>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zb8cf9cbcf28a4dd78d407c5de78d866e" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 10%; vertical-align: top;">&#160;</td>
              <td style="width: 3.33%; vertical-align: top;">
                <div style="line-height: 1.25;">&#8226;</div>
              </td>
              <td style="width: 86.67%; vertical-align: top;">
                <div style="line-height: 1.25;">the initiation, timing, progress and results of our preclinical studies, clinical trials and other therapeutic candidate development efforts;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 10%; vertical-align: top;">&#160;</td>
              <td style="width: 3.33%; vertical-align: top;">&#160;</td>
              <td style="width: 86.67%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 10%; vertical-align: top;">&#160;</td>
              <td style="width: 3.33%; vertical-align: top;">
                <div style="line-height: 1.25;">&#8226;</div>
              </td>
              <td style="width: 86.67%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">the impact of the COVID-19 pandemic on our operations;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 10%; vertical-align: top;">&#160;</td>
              <td style="width: 3.33%; vertical-align: top;">&#160;</td>
              <td style="width: 86.67%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 10%; vertical-align: top;">&#160;</td>
              <td style="width: 3.33%; vertical-align: top;">
                <div style="line-height: 1.25;">&#8226;</div>
              </td>
              <td style="width: 86.67%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">our ability to advance our therapeutic candidates into clinical trials or to successfully complete our preclinical studies or clinical trials;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" id="zec620e0b4e654f1586066f707efd3fa3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 10%; vertical-align: top;">&#160;</td>
              <td style="width: 3.33%; vertical-align: top;">
                <div style="line-height: 1.25;">&#8226;</div>
              </td>
              <td style="width: 86.67%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">our receipt of regulatory approvals for our therapeutic candidates, and the timing of other regulatory filings and approvals;</div>
              </td>
            </tr>

        </table>
        <div style="text-align: justify; text-indent: -18pt; margin-left: 72pt; line-height: 1.25;">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zcc27109e6ef34d5daa72c2fb930f5d56" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 10%; vertical-align: top;">&#160;</td>
              <td style="width: 3.33%; vertical-align: top;">
                <div style="line-height: 1.25;">&#8226;</div>
              </td>
              <td style="width: 86.67%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">the clinical development, commercialization and market acceptance of our therapeutic candidates;</div>
              </td>
            </tr>

        </table>
        <div style="text-align: justify; text-indent: -18pt; margin-left: 72pt; line-height: 1.25;">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z2dec48e9bd504194b789019f8e41d9e4" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 10%; vertical-align: top;">&#160;</td>
              <td style="width: 3.33%; vertical-align: top;">
                <div style="line-height: 1.25;">&#8226;</div>
              </td>
              <td style="width: 86.67%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">our ability to establish and maintain corporate collaborations;</div>
              </td>
            </tr>

        </table>
        <div style="text-align: justify; text-indent: -18pt; margin-left: 72pt; line-height: 1.25;">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z4249fca3c08f43899ea62e085a433014" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 10%; vertical-align: top;">&#160;</td>
              <td style="width: 3.33%; vertical-align: top;">
                <div style="line-height: 1.25;">&#8226;</div>
              </td>
              <td style="width: 86.67%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">our ability to integrate new therapeutic candidates and new personnel;</div>
              </td>
            </tr>

        </table>
        <div style="text-align: justify; text-indent: -18pt; margin-left: 72pt; line-height: 1.25;">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z8b5273c80f5d452aa0c0e87fb1c1e976" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 10%; vertical-align: top;">&#160;</td>
              <td style="width: 3.33%; vertical-align: top;">
                <div style="line-height: 1.25;">&#8226;</div>
              </td>
              <td style="width: 86.67%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">the interpretation of the properties and characteristics of our therapeutic candidates and of the results obtained with our therapeutic candidates in preclinical studies or clinical
                  trials;</div>
              </td>
            </tr>

        </table>
        <div style="text-align: justify; text-indent: -18pt; margin-left: 72pt; line-height: 1.25;">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z5ebecfbc34904266aa9508d3ed091649" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 10%; vertical-align: top;">&#160;</td>
              <td style="width: 3.33%; vertical-align: top;">
                <div style="line-height: 1.25;">&#8226;</div>
              </td>
              <td style="width: 86.67%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">the implementation of our business model and strategic plans for our business and therapeutic candidates;</div>
              </td>
            </tr>

        </table>
        <div style="text-align: justify; text-indent: -18pt; margin-left: 72pt; line-height: 1.25;">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z6401d6bfccbf4fb29dcd0f7998659822" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 10%; vertical-align: top;">&#160;</td>
              <td style="width: 3.33%; vertical-align: top;">
                <div style="line-height: 1.25;">&#8226;</div>
              </td>
              <td style="width: 86.67%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">the scope of protection we are able to establish and maintain for intellectual property rights covering our therapeutic candidates and our ability to operate our business without
                  infringing the intellectual property rights of others;</div>
              </td>
            </tr>

        </table>
        <div style="text-align: justify; text-indent: -18pt; margin-left: 72pt; line-height: 1.25;">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zfcc65b82a35841d2b64b75d21a2de56d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 10%; vertical-align: top;">&#160;</td>
              <td style="width: 3.33%; vertical-align: top;">&#8226; <br>
              </td>
              <td style="width: 86.61%; vertical-align: top;">
                <div>estimates of our expenses, future revenues, capital requirements and our needs for and ability to access sufficient additional financing;</div>
                <div> <br>
                </div>
              </td>
              <td style="width: 0.06%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 10%; vertical-align: top;">&#160;</td>
              <td style="width: 3.33%; vertical-align: top;">
                <div style="line-height: 1.25;">&#8226;</div>
              </td>
              <td style="width: 86.61%; vertical-align: top;">
                <div style="line-height: 1.25;">risks related to changes in healthcare laws, rules and regulations in the United States or elsewhere;</div>
              </td>
              <td style="width: 0.06%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 10%; vertical-align: top;">&#160;</td>
              <td style="width: 3.33%; vertical-align: top;">&#160;</td>
              <td style="width: 86.61%; vertical-align: top;">&#160;</td>
              <td style="width: 0.06%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 10%; vertical-align: top;">&#160;</td>
              <td style="width: 3.33%; vertical-align: top;">
                <div style="line-height: 1.25;">&#8226;</div>
              </td>
              <td style="width: 86.61%; vertical-align: top;">
                <div style="line-height: 1.25;">competitive companies, technologies and our industry;</div>
              </td>
              <td style="width: 0.06%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 10%; vertical-align: top;">&#160;</td>
              <td style="width: 3.33%; vertical-align: top;">&#160;</td>
              <td style="width: 86.61%; vertical-align: top;">&#160;</td>
              <td style="width: 0.06%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 10%; vertical-align: top;">&#160;</td>
              <td style="width: 3.33%; vertical-align: top;">
                <div style="line-height: 1.25;">&#8226;</div>
              </td>
              <td style="width: 86.61%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">statements as to the impact of the political and security situation in Israel on our business.</div>
              </td>
              <td style="width: 0.06%; vertical-align: top;">&#160;</td>
            </tr>

        </table>
        <div style="text-align: justify; text-indent: -18pt; margin-left: 72pt; line-height: 1.25;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We believe these forward-looking statements are reasonable; however, these statements are only current predictions and are subject to known and unknown risks, uncertainties and
          other factors that may cause our or our industry&#8217;s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. We discuss many of these risks in Item 3.D. &#8211;
          &#8220;Risk Factors&#8221; in our most recent Annual Report on Form 20-F, or any updates in our Reports on Form 6-K. Given these uncertainties, you should not rely upon forward-looking statements as predictions of future events.&#160;</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">All forward-looking statements attributable to us or to any person acting on our behalf speak only as of the date hereof and are expressly qualified in their entirety by the
          cautionary statements included in this report. We undertake no obligations to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events. In
          evaluating forward-looking statements, you should consider these risks and uncertainties.</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">3</font></div>
          <div style="page-break-after: always;" id="DSPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="CAPITALIZATION"><!--Anchor--></a>CAPITALIZATION</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The following table presents our capitalization as of September 30, 2020 on an actual basis.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This table should be read in conjunction with our financial statements and the notes thereto incorporated by reference herein and the accompanying prospectus.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" border="0" align="center" style="width: 85%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;" id="zbebb13d2f509403795c687a26f381d5b">

            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; width: 80%;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" colspan="1">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
                <div style="text-align: center; line-height: 1.25; font-weight: bold;">September 30, 2020</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;" colspan="1">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 80%;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom;" colspan="2">
                <div style="text-align: center; line-height: 1.25; font-weight: bold;">(U.S. Dollars in<br>
                  thousands, except share<br>
                  data)</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 80%;">
                <div style="line-height: 1.25; font-weight: bold;">Non-Current Liabilities:</div>
              </td>
              <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;" colspan="1">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="2">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;" colspan="1">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; width: 80%;">
                <div style="line-height: 1.25;">Warrants</div>
              </td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 15%;" colspan="1">
                <div style="line-height: 1.25;">5,600</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; width: 80%; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;">Long-term loans, net of current maturities</div>
              </td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 15%; background-color: rgb(204, 238, 255);" colspan="1">
                <div style="line-height: 1.25;">3,554</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; width: 80%;">
                <div style="line-height: 1.25;">Lease liabilities</div>
              </td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 15%;" colspan="1">
                <div style="line-height: 1.25;">1,601</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; width: 80%; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;">Total non-current liabilities</div>
              </td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 15%; background-color: rgb(204, 238, 255);" colspan="1">
                <div style="line-height: 1.25;">10,755</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; width: 80%;">
                <div style="line-height: 1.25; font-weight: bold;">Shareholders&#8217; equity:</div>
              </td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 15%;" colspan="1">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; width: 80%; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;">Ordinary shares, par value NIS 0.10 per share; Authorized 1,500,000,000 shares; Issued and outstanding: 296,508,550 shares as of September 30, 2020</div>
              </td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 15%; background-color: rgb(204, 238, 255);" colspan="1">
                <div style="line-height: 1.25;">8,281</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; width: 80%;">
                <div style="line-height: 1.25;">Share premium</div>
              </td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 15%;" colspan="1">
                <div style="line-height: 1.25;">271,107</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; width: 80%; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;">Capital reserve</div>
              </td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 15%; background-color: rgb(204, 238, 255);" colspan="1">
                <div style="line-height: 1.25;">12,835</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; width: 80%;">
                <div style="line-height: 1.25;">Other comprehensive loss</div>
              </td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 15%;" colspan="1">
                <div style="line-height: 1.25;">(1,416</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">
                <div style="line-height: 1.25;">)</div>
              </td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; width: 80%; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;">Accumulated deficit</div>
              </td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 15%; background-color: rgb(204, 238, 255);" colspan="1">
                <div style="line-height: 1.25;">(265,999</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                <div style="line-height: 1.25;">)</div>
              </td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; width: 80%; padding-bottom: 2px;">
                <div style="line-height: 1.25;">Total shareholders&#8217; equity</div>
              </td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 15%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                <div style="line-height: 1.25;">24,808</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; width: 80%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25; font-weight: bold;">Total capitalization</div>
              </td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 15%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                <div style="line-height: 1.25;">35,563</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Unless otherwise indicated, the number of ordinary shares outstanding prior to and after this offering is based on 296,508,550 ordinary shares outstanding as of September 30,
          2020, and excludes as of such date:</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z5fbdb3bbb5254fb9a278484e18249a0f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 10%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 3.33%; vertical-align: top;">
                <div style="line-height: 1.25;">&#8226;</div>
              </td>
              <td style="width: 86.67%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">34,904,449 ordinary shares issuable upon the exercise of outstanding warrants, at a weighted average exercise price of&#8201;$1.14 per share, as of September 30, 2020;</div>
              </td>
            </tr>

        </table>
        <div style="text-align: justify; text-indent: -18pt; margin-left: 72pt; line-height: 1.25;">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zb5894aac07f4470f989c0f45ec159121" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 10%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 3.33%; vertical-align: top;">
                <div style="line-height: 1.25;">&#8226;</div>
              </td>
              <td style="width: 86.67%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">18,913,808 ordinary shares issuable upon the exercise of outstanding options, at a weighted average exercise price of $0.77 per share, as of September 30, 2020;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 10%; vertical-align: top;">&#160;</td>
              <td style="width: 3.33%; vertical-align: top;">&#160;</td>
              <td style="width: 86.67%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 10%; vertical-align: top;">&#160;</td>
              <td style="width: 3.33%; vertical-align: top;">
                <div style="line-height: 1.25;">&#8226;</div>
              </td>
              <td style="width: 86.67%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">77,142,885 ordinary shares represented by 5,142,859 ADSs issuable upon exercise of unregistered warrants issued to the investors in a private placement we completed in May 2020, or the
                  May 2020 Private Placement, at an exercise price of $2.25 per ADS;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 10%; vertical-align: top;">&#160;</td>
              <td style="width: 3.33%; vertical-align: top;">&#160;</td>
              <td style="width: 86.67%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 10%; vertical-align: top;">&#160;</td>
              <td style="width: 3.33%; vertical-align: top;">
                <div style="line-height: 1.25;">&#8226;</div>
              </td>
              <td style="width: 86.67%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">3,857,145 ordinary shares represented by 257,143 ADSs issuable upon exercise of unregistered warrants issued to the placement agent or its designees as compensation in connection the May
                  2020 Private Placement, at an exercise price of $2.1875 per ADS;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 10%; vertical-align: top;">&#160;</td>
              <td style="width: 3.33%; vertical-align: top;">&#160;</td>
              <td style="width: 86.67%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 10%; vertical-align: top;">&#160;</td>
              <td style="width: 3.33%; vertical-align: top;">
                <div style="line-height: 1.25;">&#8226;</div>
              </td>
              <td style="width: 86.67%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">37,654,290 ordinary shares represented by 2,510,286 ADSs issuable upon exercise of unregistered warrants issued to the investors in a private placement we completed in June 2020, or the
                  June 2020 Private Placement, at an exercise price of $2.25 per ADS;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 10%; vertical-align: top;">&#160;</td>
              <td style="width: 3.33%; vertical-align: top;">&#160;</td>
              <td style="width: 86.67%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 10%; vertical-align: top;">&#160;</td>
              <td style="width: 3.33%; vertical-align: top;">
                <div style="line-height: 1.25;">&#8226;</div>
              </td>
              <td style="width: 86.67%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">1,882,710 ordinary shares represented by 125,514 ADSs issuable upon exercise of unregistered warrants issued to the placement agent or its designees as compensation in connection with the
                  June 2020 Private Placement, at an exercise price of $2.1875 per ADS;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 10%; vertical-align: top;">&#160;</td>
              <td style="width: 3.33%; vertical-align: top;">&#160;</td>
              <td style="width: 86.67%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 10%; vertical-align: top;">&#160;</td>
              <td style="width: 3.33%; vertical-align: top;">
                <div style="line-height: 1.25;">&#8226;</div>
              </td>
              <td style="width: 86.67%; vertical-align: top;">
                <div style="line-height: 1.25;">39,535,995 ordinary shares represented by 2,635,733 ADSs issued in an &#8220;at the market&#8221; equity offering under the Offering Agreement since September 30, 2020; and</div>
              </td>
            </tr>
            <tr>
              <td style="width: 10%; vertical-align: top;">&#160;</td>
              <td style="width: 3.33%; vertical-align: top;">&#160;</td>
              <td style="width: 86.67%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 10%; vertical-align: top;">&#160;</td>
              <td style="width: 3.33%; vertical-align: top;">
                <div style="line-height: 1.25;">&#8226;</div>
              </td>
              <td style="width: 86.67%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">13,125,000 ordinary shares represented by 875,000 ADSs issued upon exercise of unregistered warrants issued to investors at an exercise price of $2.25 per ADS since September 30, 2020.</div>
              </td>
            </tr>
            <tr>
              <td style="width: 10%; vertical-align: top;">&#160;</td>
              <td style="width: 3.33%; vertical-align: top;">&#160;</td>
              <td style="width: 86.67%; vertical-align: top;">&#160;</td>
            </tr>

        </table>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">4</font></div>
          <div style="page-break-after: always;" id="DSPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
        </div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="USEOFPROCEEDS"><!--Anchor--></a><a name="USEOF"><!--Anchor--></a>USE OF PROCEEDS</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Except as otherwise provided in the applicable prospectus supplement, we intend to use the net proceeds of this offering for general corporate purposes, which may include but
          are not limited to working capital and funding clinical trials.</div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The intended application of proceeds from the sale of any particular offering of securities using this prospectus will be described in the accompanying prospectus supplement
          relating to such offering. The precise amount and timing of the application of these proceeds will depend on our funding requirements and the availability and costs of other funds.</div>
        <div style="line-height: 1.25;">&#160;&#160;</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">DESCRIPTION OF ORDINARY SHARES</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic;">The following description of our share capital is a summary of the material terms of our Articles and Israeli corporate law regarding our ordinary shares
          and the holders thereof. This description contains all material information concerning our ordinary shares but does not purport to be complete.</div>
        <div style="text-align: justify; line-height: 1.25;">&#160;</div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Ordinary Shares</div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">As of December 30, 2020, our authorized share capital consists of 1,500,000,000 ordinary shares, par value NIS 0.10 per share. As of December 30, 2020, there are 349,169,545
          ordinary shares issued and outstanding. All of our outstanding ordinary shares are validly issued, fully paid and non-assessable. Our ordinary shares are not redeemable and do not have any preemptive rights.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Pursuant to Israeli securities laws, a company whose shares are traded on the TASE may not have more than one class of shares (subject to an exception that is not applicable to
          us), and all outstanding shares must be validly issued and fully paid.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Articles of Association</div>
        <div style="text-align: justify; line-height: 1.25;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The following are summaries of material provisions of our articles of association and the Israeli Companies Law, as amended, or the Companies Law, insofar as they relate to the
          material terms of our ordinary shares.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our ordinary shares that are fully paid for are issued in registered form and may be freely transferred under our Articles of Association, unless the transfer is restricted or
          prohibited by applicable law or the rules of a stock exchange on which the shares are traded. The ownership or voting of our ordinary shares by non-residents of Israel is not restricted in any way by our Articles of Association or the laws of the
          State of Israel.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Pursuant to the Companies Law and our Articles of Association, our Board of Directors may exercise all powers and take all actions that are not required under law or under our
          Articles of Association to be exercised or taken by our shareholders, including the power to borrow money for company purposes.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our Articles of Association enable us to increase or reduce our share capital. Any such changes are subject to the provisions of the Companies Law and must be approved by a
          resolution duly passed by our shareholders at a general or extraordinary meeting by voting on such change in the capital. In addition, transactions that have the effect of reducing capital, such as the declaration and payment of dividends in the
          absence of sufficient retained earnings and profits and an issuance of shares for less than their nominal value (under certain circumstances), require a resolution of our Board of Directors and court approval.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Registration Number and Purposes of the Company</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our number with the Israeli Registrar of Companies is 513398750. Our purpose is set forth in Section 2 of our Articles of Association and includes every lawful purpose.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Dividends</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We may declare a dividend to be paid to the holders of our ordinary shares in proportion to their respective shareholdings. Under the Companies Law, dividend distributions are
          determined by the board of directors and do not require the approval of the shareholders of a company unless the company&#8217;s articles of association provide otherwise. Our Articles of Association do not require shareholder approval of a dividend
          distribution and provide that dividend distributions may be determined by our Board of Directors.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Pursuant to the Companies Law, we may only distribute dividends out of the higher of (a) cash surplus and (b) cash accrued over the previous two years, as such terms are
          defined in the Companies Law, according to our then last reviewed or audited financial reports, provided that the date of the financial reports is not more than six months prior to the date of distribution, or we may distribute dividends with
          court approval. In each case, we are only permitted to pay a dividend if there is no reasonable concern that payment of the dividend will prevent us from satisfying our existing and foreseeable obligations as they become due.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In the event of our liquidation, after satisfaction of liabilities to creditors, our assets will be distributed to the holders of our ordinary shares in proportion to their
          shareholdings. This right, as well as the right to receive dividends, may be affected by the grant of preferential dividend or distribution rights to the holders of a class of shares with preferential dividend or distribution rights that may be
          authorized in the future.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">5</font></div>
          <div style="page-break-after: always;" id="DSPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Election of Directors</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our ordinary shares do not have cumulative voting rights in the election of directors. As a result, the holders of a majority of the voting power represented at a shareholders
          meeting have the power to elect all of our directors, other than with respect to the special approval requirements for the election of external directors (unless we qualify as an Eligible Company and opt to follow the exemption provided under the
          Relief Regulations regarding appointment of external directors and composition of the Audit and Compensation Committees) described under &#8220;Item 6. Directors, Senior Management and Employees &#8212; Board Practices &#8212; External Directors&#8221; of our most
          recent Annual Report on Form 20-F.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Pursuant to our Articles of Association, other than the external directors, for whom special election requirements apply under the Companies Law (unless we qualify as an
          Eligible Company and opt to follow the exemption provided under the Relief Regulations regarding appointment of external directors and composition of the Audit and Compensation Committees), our directors are elected at a general or extraordinary
          meeting of our shareholders and serve on the Board of Directors until they are removed by the majority of our shareholders at a general or extraordinary meeting of our shareholders or upon the occurrence of certain events, in accordance with the
          Companies Law and our Articles of Association. In addition, our Articles of Association allow our Board of Directors to appoint directors (who are not external directors) to fill vacancies on the Board of Directors to serve until the next general
          meeting or extraordinary meeting, or earlier if required by our Articles of Association or applicable law. We have held elections for each of our non-external directors at each annual meeting of our shareholders since our initial public offering
          in Israel. Unless we qualify as an Eligible Company and opt to follow the exemption provided under the Amendment to the Relief Regulations regarding appointment of external directors and composition of the Audit and Compensation Committees,
          external directors are elected for an initial term of three years and may be removed from office pursuant to the terms of the Companies Law. See &#8220;Item 6. Directors, Senior Management and Employees &#8212; Board Practices &#8212; External Directors&#8221; of our
          most recent Annual Report on Form 20-F.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Shareholder Meetings</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under Israeli law, we are required to hold an annual general meeting of our shareholders once every calendar year that must be no later than 15 months after the date of the
          previous annual general meeting. All meetings other than the annual general meeting of shareholders are referred to as extraordinary meetings. Our Board of Directors may call extraordinary meetings whenever it sees fit, at such time and place,
          within or outside of Israel, as it may determine. In addition, the Companies Law and our Articles of Association provide that our Board of Directors is required to convene an extraordinary meeting upon the written request of (a) any two of our
          directors or one quarter of our Board of Directors or (b) one or more shareholders holding, in the aggregate, either (1) at least 5% of our outstanding shares and at least 1% of our outstanding voting power or (2) at least 5% of our outstanding
          voting power.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Subject to the provisions of the Companies Law and the regulations promulgated thereunder, shareholders entitled to participate and vote at general meetings are the
          shareholders of record on a date to be decided by the board of directors, which may be between four and 40 days prior to the date of the meeting. Furthermore, the Companies Law and our Articles of Association require that resolutions regarding
          the following matters must be passed at a general meeting of our shareholders:</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;amendments to our Articles of Association;</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;appointment or termination of our auditors;</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;appointment of directors and appointment and dismissal of external directors;</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;approval of acts and transactions requiring general meeting approval pursuant to the Companies Law;</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;director compensation, indemnification and change of the principal executive officer;</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;increases or reductions of our authorized share capital;</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a merger; and</div>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z2578a146011c4bc1b75ced808ee34fff" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="vertical-align: top; width: 28pt;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the exercise of our Board of Director&#8217;s powers by a general meeting, if our Board of Directors is unable to exercise its powers and the exercise of any of its powers is required for our proper management.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">6</font></div>
          <div style="page-break-after: always;" id="DSPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Companies Law requires that a notice of any annual or extraordinary shareholders meeting be provided at least 21 days prior to the meeting and if the agenda of the meeting
          includes the appointment or removal of directors, the approval of transactions with office holders, a controlling shareholder or parties related to the foregoing, the approval of a compensation policy with respect to office holders or an approval
          of a merger, notice must be provided at least 35 days prior to the meeting.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Pursuant to our Articles of Association, holders of our ordinary shares have one vote for each ordinary share held on all matters submitted to a vote before the shareholders at
          a general meeting.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Quorum</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The quorum required for our general meetings of shareholders consists of at least two shareholders present in person, by proxy or written ballot who hold or represent between
          them at least 25% of the total outstanding voting rights.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">A meeting adjourned for lack of a quorum is adjourned to the same day in the following week at the same time and place or on a later date if so specified in the summons or
          notice of the meeting. At the reconvened meeting, any number of our shareholders present in person or by proxy shall constitute a lawful quorum.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Resolutions</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our Articles of Association provide that all resolutions of our shareholders require a simple majority vote, unless otherwise required by applicable law.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Israeli law provides that a shareholder of a public company may vote in a meeting and in a class meeting by means of a written ballot in which the shareholder indicates how he
          or she votes on resolutions relating to the following matters:</div>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z32b2bc2f87034f92b54dfe2d2d746838" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>an appointment or removal of directors;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zcbc277a83d7b40109b33284b5268f393">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>an approval of transactions with office holders, a controlling shareholder or parties related to the foregoing;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
        </div>
        <div style="line-height: 1.25">
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z6015687ad03c46939edbbd60b0b1b807">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>an approval of a merger;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
        </div>
        <table cellspacing="0" cellpadding="0" id="z01e56e71b65a491fbaa9b68867e48bf0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>authorizing the chairman of the board of directors or his relative to act as the company&#8217;s chief executive officer or act with such authority; or authorize the company&#8217;s chief executive officer or his relative to act as the chairman of
                  the board of directors or act with such authority;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zff563636f1a14894958477192f501288" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>any other matter in respect of which there is a provision in the articles of association providing that decisions of the general meeting may also be passed by written ballot; and</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zfd04ba5b6b124a75936c772f0d1dca71" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>other matters which may be prescribed by Israel&#8217;s Minister of Justice.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The provision allowing the vote by written ballot does not apply where the voting power of the controlling shareholder is sufficient to determine the vote.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Companies Law provides that a shareholder, in exercising his or her rights and performing his or her obligations toward the company and its other shareholders, must act in
          good faith and in a customary manner, and avoid abusing his or her power. This is required when voting at general meetings on matters such as changes to the articles of association, increasing the company&#8217;s registered capital, mergers and
          approval of related party transactions. A shareholder also has a general duty to refrain from depriving any other shareholder of its rights as a shareholder. In addition, any controlling shareholder, any shareholder who knows that its vote can
          determine the outcome of a shareholder vote and any shareholder who, under the company&#8217;s articles of association, can appoint or prevent the appointment of an office holder, is required to act with fairness towards the company. The Companies Law
          does not describe the substance of this duty except to state that the remedies generally available upon a breach of contract will also apply to a breach of the duty to act with fairness.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Access to Corporate Records</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the Companies Law, all shareholders of a company generally have the right to review minutes of the company&#8217;s general meetings, its shareholders register and principal
          shareholders register, articles of association, financial statements and any document it is required by law to file publicly with the Israeli Companies Registrar and the ISA. Furthermore, any of our shareholders may request access to review any
          document in our possession that relates to any action or transaction with a related party, interested party or office holder that requires shareholder approval under the Companies Law. However, we may deny such a request to review a document if
          we determine that the request was not made in good faith, that the document contains a trade secret or a patent or that the document&#8217;s disclosure may otherwise prejudice our interests.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">7</font></div>
          <div style="page-break-after: always;" id="DSPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Acquisitions under Israeli Law</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Full Tender Offer</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">A person wishing to acquire shares of a public Israeli company and who would as a result hold over 90% of the target company&#8217;s issued and outstanding share capital is required
          by the Companies Law to make a tender offer to all of the company&#8217;s shareholders for the purchase of all of the issued and outstanding shares of the company. A person wishing to acquire shares of a public Israeli company and who would as a result
          hold over 90% of the issued and outstanding share capital of a certain class of shares is required to make a tender offer to all of the shareholders who hold shares of the same class for the purchase of all of the issued and outstanding shares of
          the same class. If the shareholders who do not accept the offer hold less than 5% of the issued and outstanding share capital of the company or of the applicable class, all of the shares that the acquirer offered to purchase will be transferred
          to the acquirer by operation of law (provided that a majority of the offerees that do not have a personal interest in such tender offer shall have approved the tender offer except that if the total votes to reject the tender offer represent less
          than 2% of the company&#8217;s issued and outstanding share capital, in the aggregate, approval by a majority of the offerees that do not have a personal interest in such tender offer is not required to complete the tender offer). However, a
          shareholder that had its shares so transferred may petition the court within six months from the date of acceptance of the full tender offer, whether or not such shareholder agreed to the tender, to determine whether the tender offer was for less
          than fair value and whether the fair value should be paid as determined by the court unless the acquirer stipulated in the tender offer that a shareholder that accepts the offer may not seek appraisal rights. If the shareholders who did not
          accept the tender offer hold 5% or more of the issued and outstanding share capital of the company or of the applicable class, the acquirer may not acquire shares of the company that will increase its holdings to more than 90% of the company&#8217;s
          issued and outstanding share capital or of the applicable class from shareholders who accepted the tender offer.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Special Tender Offer</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Companies Law provides that an acquisition of shares of a public Israeli company must be made by means of a special tender offer if as a result of the acquisition the
          purchaser would become a holder of 25% or more of the voting rights in the company, unless one of the exemptions in the Companies Law is met. This rule does not apply if there is already another holder of at least 25% of the voting rights in the
          company. Similarly, the Companies Law provides that an acquisition of shares in a public company must be made by means of a tender offer if as a result of the acquisition the purchaser would become a holder of 45% or more of the voting rights in
          the company, if there is no other shareholder of the company who holds 45% or more of the voting rights in the company, unless one of the exemptions in the Companies Law is met.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">A special tender offer must be extended to all shareholders of a company. A special tender offer may be consummated only if (i) at least 5% of the voting power attached to the
          company&#8217;s outstanding shares will be acquired by the offeror and (ii) the number of shares tendered in the offer exceeds the number of shares whose holders objected to the offer.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If a special tender offer is accepted, then the purchaser or any person or entity controlling it or under common control with the purchaser or such controlling person or entity
          may not make a subsequent tender offer for the purchase of shares of the target company and may not enter into a merger with the target company for a period of one year from the date of the offer, unless the purchaser or such person&#160; or entity
          undertook to effect such an offer or merger in the initial special tender offer.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Merger</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Companies Law permits merger transactions if approved by each party&#8217;s board of directors and, unless certain requirements described under the Companies Law are met, a
          majority of each party&#8217;s shares voted on the proposed merger at a shareholders&#8217; meeting called with at least 35 days&#8217; prior notice.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">For purposes of the shareholder vote, unless a court rules otherwise, the merger will not be deemed approved if, in a company in which the other merging company holds shares,
          or in which shares are held by any person who either (a) holds 25% or more of the outstanding shares or (b) has the right to appoint 25% or more of the directors of the other merging company (or Controlling Shareholders), the majority of the
          shareholders voting in such meeting (who are not also shareholders or Controlling Shareholders of the other merging company) vote against the merger. If the aforementioned majority of the shareholders was not obtained, a court may still approve
          the merger upon the request of holders of at least 25% of the voting rights of a company, if the court holds that the merger is fair and reasonable, taking into account the value of the parties to the merger and the consideration offered to the
          shareholders.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">8</font></div>
          <div style="page-break-after: always;" id="DSPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Upon the request of a creditor of either party to the proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern that, as
          a result of the merger, the surviving company will be unable to satisfy the obligations of any of the parties to the merger, and may further give instructions to secure the rights of creditors.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition, a merger may not be completed unless at least 50 days have passed from the date that a proposal for approval of the merger was filed by each party with the Israeli
          Registrar of Companies and 30 days have passed from the date the merger was approved by the shareholders of each party.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Antitakeover Measures</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Companies Law allows us to create and issue shares having rights different from those attached to our ordinary shares, including shares providing certain preferred rights,
          distributions or other matters and shares having preemptive rights. As of the date of this annual report, we do not have any authorized or issued shares other than our ordinary shares. In the future, if we do create and issue a class of shares
          other than ordinary shares, such class of shares, depending on the specific rights that may be attached to them, may delay or prevent a takeover or otherwise prevent our shareholders from realizing a potential premium over the market value of
          their ordinary shares. The authorization of a new class of shares will require an amendment to our Articles of Association which requires the prior approval of the holders of a majority of our shares at a general meeting. Shareholders voting in
          such meeting will be subject to the restrictions provided in the Companies Law as described above. In addition, the Israeli Securities Law and the rules and regulations of the TASE also limit the terms permitted with respect to a new class of
          shares created by a public company whose shares are traded on the TASE, and prohibit any such new class of shares from having voting rights.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25;">
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="DESCRIPTIONOFAMERICANDEPO"><!--Anchor--></a>DESCRIPTION OF AMERICAN DEPOSITARY SHARES</div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The ADSs trade on Nasdaq.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Each of our ADSs represents 15 of our ordinary shares deposited with the principal Tel Aviv office of either Bank Hapoalim B.M. or Bank Leumi Le-Israel, as Custodian for the
          Depositary. Our ADSs trade on Nasdaq.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The form of the deposit agreement for the ADS and the form of American Depositary Receipt (ADR) that represents an ADS have been incorporated by reference as exhibits to this
          Annual Report on Form 20-F. Copies of the deposit agreement are available for inspection at the principal office of The Bank of New York Mellon, located at 101 Barclay Street, New York, New York 10286.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">You may hold ADSs either (A) directly (i) by having an American Depositary Receipt, also referred to as an ADR, which is a certificate evidencing a specific number of ADSs,
          registered in your name or (ii) by having ADSs registered in your name in the Direct Registration System, or (B) indirectly by holding a security entitlement in ADSs through your broker or other financial institution. If you hold ADSs directly,
          you are a registered ADS holder, also referred to as an ADS holder. This description assumes you are an ADS holder. If you hold the ADSs indirectly, you must rely on the procedures of your broker or other financial institution to assert the
          rights of ADS holders described in this section. You should consult with your broker or financial institution to find out what those procedures are.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Direct Registration System, also referred to as DRS, is a system administered by The Depository Trust Company, also referred to as DTC, under which the Depositary may
          register the ownership of uncertificated ADSs, which ownership is confirmed by statements sent by the Depositary to the registered holders of uncertificated ADSs.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The form of the deposit agreement and the form of ADR have been incorporated by reference as exhibits to this registration statement on Form F-3. A copy of the deposit
          agreement is available for inspection at the Depositary&#8217;s office.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">As an ADS holder, we will not treat you as one of our shareholders, and you will not have shareholder rights. Israeli law governs shareholder rights. The Depositary will be the
          holder of the ordinary shares underlying your ADSs. The following is a summary of the material provisions of the deposit agreement. For more complete information, you should read the entire deposit agreement and the form of ADR.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25;">
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Dividends, Other Distributions and Rights</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
        </div>
        <div style="line-height: 1.25;">
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Amounts distributed to ADS holders will be reduced by any taxes or other governmental charges required to be withheld by the Custodian or the Depositary. If the Depositary
            determines that any distribution in cash or property is subject to any tax or governmental charges that the Depositary or the Custodian is obligated to withhold, the Depositary may use the cash or sell or otherwise dispose of all or a portion
            of that property to pay the taxes or governmental charges. The Depositary will then distribute the balance of the cash and/or property to the ADS holders entitled to the distribution after deducting its fees and expenses, in proportion to their
            holdings.</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">9</font></div>
            <div style="page-break-after: always;" id="DSPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
        </div>
        <div style="line-height: 1.25;">
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic;">Cash dividends and cash distributions</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
        </div>
        <div style="line-height: 1.25;">
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Depositary will convert into dollars all cash dividends and other cash distributions that it or the Custodian receives in a foreign currency. The Depositary will
            distribute to the ADS holders the amount it receives, after deducting any currency conversion expenses. If the Depositary determines that any foreign currency it receives cannot be converted and transferred on a reasonable basis, it may
            distribute the foreign currency (or an appropriate document evidencing the right to receive the currency) or hold that foreign currency uninvested, without liability for interest, for the accounts of the ADS holders entitled to receive it.</div>
        </div>
        <div style="line-height: 1.25;">
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
        </div>
        <div style="line-height: 1.25;">
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic;">Distributions of ordinary shares</div>
        </div>
        <div style="line-height: 1.25;">
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
        </div>
        <div style="line-height: 1.25;">
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If we distribute ordinary shares as a dividend or free distribution, the Depositary may distribute to ADS holders new ADSs representing the ordinary shares. The Depositary
            will distribute only whole ADSs. It will sell the ordinary shares that would have required it to use fractional ADSs and then distribute the proceeds in the same way it distributes cash. If the Depositary deposits the ordinary shares but does
            not distribute additional ADSs, the existing ADSs will also represent the new ordinary shares.</div>
        </div>
        <div style="line-height: 1.25;">
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic;">Other distributions</div>
        </div>
        <div style="line-height: 1.25;">
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If the Depositary or the Custodian receives a distribution of anything other than cash or shares, the Depositary will, after consultation with us to the extent practicable,
            distribute the property or securities to the ADS holder, in proportion to such holder&#8217;s holdings. If, however, the Depositary determines that it cannot distribute the property or securities in this manner or that it is not feasible to do so,
            then it may distribute the property or securities by any means it thinks is equitable and practical, or it may sell the property or securities and distribute the net proceeds of the sale to the ADS holders.</div>
          <div style="line-height: 1.25">&#160;</div>
        </div>
        <div style="line-height: 1.25;">
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic;">Rights to subscribe for additional ordinary shares and other rights</div>
        </div>
        <div style="line-height: 1.25;">
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If we offer our holders of ordinary shares any rights to subscribe for additional ordinary shares or any other rights, the Depositary may:</div>
          <div style="line-height: 1.25">&#160;</div>
        </div>
        <div style="line-height: 1.25;">
          <table cellspacing="0" cellpadding="0" id="z3ad2288b54614ee2bae05dc99fcc6a74" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>make the rights available to all or certain holders of ADSs, by means of warrants or otherwise, if lawful and practically feasible; or</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
        </div>
        <div style="line-height: 1.25;">
          <table cellspacing="0" cellpadding="0" id="z2105b5c998fc4eedbfa8b452c8affb5f" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>attempt to sell those rights or warrants or other instruments.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
        </div>
        <div style="line-height: 1.25;">
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In the case of a sale, the Depositary will allocate the net proceeds of the sales to the account of the ADS holders entitled to the rights. The allocation will be made on an
            averaged or other practicable basis without regard to any distinctions among holders.</div>
          <div style="line-height: 1.25">&#160;</div>
        </div>
        <div style="line-height: 1.25;">
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If registration under the Securities Act is required in order to offer or sell to the ADS holders the securities represented by any rights, the Depositary will not make the
            rights available to ADS holders unless a registration statement is in effect or such securities are exempt from registration. We do not, however, have any obligation to file a registration statement or to have a registration statement declared
            effective. If the Depositary does not make rights available to ADS holders and cannot dispose of the rights and make the net proceeds available to ADS holders, then it will allow the rights to lapse, and the ADS holders will not receive any
            value for them.</div>
          <div style="line-height: 1.25">&#160;</div>
        </div>
        <div style="line-height: 1.25;">
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Deposit, Withdrawal and Cancellation</div>
          <div style="line-height: 1.25">&#160;</div>
        </div>
        <div style="line-height: 1.25;">
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic;">How are ADSs issued?</div>
          <div style="line-height: 1.25;">&#160;
            <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Depositary will deliver ADSs if you or your broker deposits shares or evidence of rights to receive shares with the Custodian. Upon payment of its fees and expenses and
              of any taxes or charges, such as stamp taxes or stock transfer taxes or fees, the Depositary will register the appropriate number of ADSs in the names you request and will deliver the ADSs to the order of the person or persons that made the
              deposit.</div>
            <div style="line-height: 1.25;">&#160;
              <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic;">How can ADS holders withdraw the deposited securities?</div>
              <div style="line-height: 1.25;">&#160;
                <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">You may surrender your ADSs at the Depositary&#8217;s office. Upon payment of its fees and expenses and of any taxes or charges, such as stamp taxes or stock transfer taxes
                  or fees, the Depositary will deliver the shares and any other deposited securities underlying the ADSs to the ADS holder or a person the ADS holder designates at the office of the Custodian. Or, at your request, risk and expense, the
                  Depositary will deliver the deposited securities at its office, if feasible.</div>
                <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
                </div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
                  <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">10</font></div>
                  <div style="page-break-after: always;" id="DSPFPageBreak">
                    <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                </div>
                <div style="line-height: 1.25;">&#160;
                  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic;">Requirements for Depositary Actions</div>
                  <div style="line-height: 1.25;">&#160;
                    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Before the Depositary will deliver or register a transfer of ADSs, make a distribution on ADSs or permit withdrawal of shares, the Depositary may require:</div>
                    <div style="line-height: 1.25">&#160;</div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
        <div style="line-height: 1.25;">
          <table cellspacing="0" cellpadding="0" id="z9632a1903d004d1491ecfcfd27900b03" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>payment of stock transfer or other taxes or other governmental charges and transfer or registration fees charged by third parties for the transfer of any shares or other deposited securities; and</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
        </div>
        <div style="line-height: 1.25;">
          <div style="line-height: 1.25">
            <div style="line-height: 1.25;">
              <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zf0223f0b7ab3438893b6439af32c4aac">

                  <tr>
                    <td style="width: 36pt;"><br>
                    </td>
                    <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
                    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div>satisfactory proof of the identity and genuineness of any signature or other information it deems necessary.</div>
                    </td>
                  </tr>

              </table>
              <div style="line-height: 1.25;">&#160;<br>
                <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic;">How do ADS holders interchange between certificated ADSs and uncertificated ADSs?</div>
                <br>
                <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">You may surrender your ADR to the Depositary for the purpose of exchanging your ADR for uncertificated ADSs. The Depositary will cancel that ADR and will send to the
                  ADS holder a statement confirming that the ADS holder is the registered holder of uncertificated ADSs. Alternatively, upon receipt by the Depositary of a proper instruction from a registered holder of uncertificated ADSs requesting the
                  exchange of uncertificated ADSs for certificated ADSs, the Depositary will execute and deliver to the ADS holder an ADR evidencing those ADSs.</div>
                <div style="line-height: 1.25;">&#160;
                  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic;">Voting of the underlying shares</div>
                  <div style="line-height: 1.25;">&#160;
                    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">ADS holders may instruct the Depositary how to vote the number of deposited shares their ADSs represent.&#160;<font style="font-style: italic;">Otherwise, you will not
                        be able to exercise your right to vote unless you withdraw the shares from the Depositary. However, you may not know about the meeting enough in advance to withdraw the shares.</font></div>
                    <div style="line-height: 1.25;">&#160;
                      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Depositary will notify ADS holders of shareholders&#8217; meetings and arrange to deliver our voting materials to them if we ask it to. Those materials will
                        describe the matters to be voted on and explain how ADS holders may instruct the Depositary how to vote. For instructions to be valid, they much reach the Depositary by a date set by the Depositary.</div>
                      <div style="line-height: 1.25;">&#160;
                        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Depositary will try, as far as practical, subject to the laws of Israel and of our articles of association or similar documents, to vote or to have its
                          agents vote the shares or other deposited securities as instructed by ADS holders. The Depositary will only vote or attempt to vote as instructed or as described in the following sentence. If we asked the Depositary to solicit
                          your instructions but the Depositary does not receive voting instructions from you by the specified date, it will consider you to have authorized and directed it to give a discretionary proxy to a person designated by us to vote
                          the number of deposited securities represented by your ADSs. The Depositary will give a discretionary proxy in those circumstances to vote on all questions to be voted upon unless we notify the Depositary that:</div>
                        <div style="line-height: 1.25;">&#160;
                          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;we do not wish to receive a discretionary proxy;</div>
                          <div style="line-height: 1.25">&#160;</div>
                          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;there is substantial shareholder opposition to the particular question; or</div>
                          <div style="line-height: 1.25">&#160;</div>
                          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the particular question would have an adverse impact on our shareholders.</div>
                          <div style="line-height: 1.25;">&#160;
                            <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We are required to notify the Depositary if one of the conditions specified above exists.</div>
                            <div style="line-height: 1.25;">
                              <div style="line-height: 1.25">&#160;</div>
                              <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We cannot assure you that you will receive the voting materials in time to ensure that you can instruct the Depositary to vote your shares. In addition,
                                the Depositary and its agents are not responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions.&#160;<font style="font-style: italic;">This means that you may not be able to
                                  exercise your right to vote and there may be nothing you can do if your shares are not voted as you requested.</font></div>
                              <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-style: italic;"> <br>
                                </font></div>
                              <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
                                <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">11</font></div>
                                <div style="page-break-after: always;" id="DSPFPageBreak">
                                  <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                              </div>
                              <div style="line-height: 1.25;">&#160;
                                <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In order to give you a reasonable opportunity to instruct the Depositary as to the exercise of voting rights relating to deposited securities, if we
                                  request the Depositary to act, we agree to give the Depositary notice of any such meeting and details concerning the matters to be voted upon at least forty-five (45) days in advance of the meeting date.</div>
                                <div style="line-height: 1.25;">&#160;
                                  <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic;">Changes affecting deposited securities</div>
                                  <div style="line-height: 1.25;">
                                    <div style="line-height: 1.25">&#160;</div>
                                    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If there is any change in nominal value or any split&#8209;up, consolidation, cancellation or other reclassification of deposited securities, or any
                                      recapitalization, reorganization, business combination or consolidation or sale of assets involving us, then any securities that the Depositary receives in respect of deposited securities will become new deposited
                                      securities. Each ADS will automatically represent its share of the new deposited securities, unless the Depositary delivers new ADSs as described in the following sentence. The Depositary may distribute new ADSs or ask
                                      ADS holders to surrender their outstanding ADSs in exchange for new ADSs describing the new deposited securities.</div>
                                    <div style="line-height: 1.25">&#160;</div>
                                    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic;">Amendment of the deposit agreement</div>
                                    <div style="line-height: 1.25;">&#160;
                                      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Depositary and we may agree to amend the form of the ADSs and the deposit agreement at any time, without the consent of the ADS holders. If
                                        the amendment adds or increases any fees or charges (other than taxes or other governmental charges) or prejudices an important right of ADS holders, it will not take effect as to outstanding ADSs until thirty (30)
                                        days after the Depositary has sent the ADS holders a notice of the amendment. At the expiration of that thirty (30) day period, each ADS holder will be considered by continuing to hold its ADSs to agree to the
                                        amendment and to be bound by the deposit agreement as so amended. Neither we nor the Depositary may amend the deposit agreement or the form of ADSs to impair the ADS holder&#8217;s right to surrender its ADSs and receive
                                        the ordinary shares and any other property represented by the ADSs, except to comply with mandatory provisions of applicable law.</div>
                                      <div style="line-height: 1.25">&#160;</div>
                                      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic;">Termination of the deposit agreement</div>
                                      <div style="line-height: 1.25;">&#160;
                                        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Depositary will terminate the deposit agreement if we ask it to do so and will notify the ADS holders at least thirty (30) days before the
                                          date of termination. The Depositary may also terminate the deposit agreement if it resigns and a successor depositary has not been appointed by us and accepted its appointment within sixty (60) days after the
                                          Depositary has given us notice of its resignation. After termination of the deposit agreement, the Depositary will no longer register transfers of ADSs, distribute dividends to the ADS holders, accept deposits of
                                          ordinary shares, give any notices or perform any other acts under the deposit agreement whatsoever, except that the Depositary will continue to:</div>
                                        <div style="line-height: 1.25">&#160;
                                          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zd899e4aa4c3643c5a3ccf3a8fa9c5b50">

                                              <tr>
                                                <td style="width: 36pt;"><br>
                                                </td>
                                                <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
                                                <td style="width: auto; vertical-align: top; text-align: justify;">
                                                  <div>collect dividends and other distributions pertaining to deposited securities;</div>
                                                </td>
                                              </tr>

                                          </table>
                                          <div style="line-height: 1.25;">&#160;</div>
                                        </div>
                                        <div style="line-height: 1.25;">
                                          <table cellspacing="0" cellpadding="0" id="zad9e005fc86d47978aee31ab9dd3acc2" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                                              <tr>
                                                <td style="width: 36pt;"><br>
                                                </td>
                                                <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
                                                <td style="width: auto; vertical-align: top; text-align: justify;">
                                                  <div>sell rights as described under the heading &#8220;Dividends, other distributions and rights &#8212; Rights to subscribe for additional ordinary shares and other rights&#8221; above; and</div>
                                                </td>
                                              </tr>

                                          </table>
                                          <div style="line-height: 1.25;">&#160;
                                            <table cellspacing="0" cellpadding="0" id="zefc600300ef5425ba2285cc70a87b084" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                                                <tr>
                                                  <td style="width: 36pt;"><br>
                                                  </td>
                                                  <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
                                                  <td style="width: auto; vertical-align: top; text-align: justify;">
                                                    <div>deliver deposited securities, together with any dividends or other distributions received with respect thereto and the net proceeds of the sale of any rights or other property, in exchange for
                                                      surrendered ADSs.</div>
                                                  </td>
                                                </tr>

                                            </table>
                                            <div style="line-height: 1.25;">&#160;
                                              <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Four (4) months after termination, the Depositary may sell the deposited securities and hold the proceeds of the sale, together with any
                                                other cash then held by it, for the pro rata benefit of ADS holders that have not surrendered their ADSs. The Depositary will not have liability for interest on the sale proceeds or any cash it holds.</div>
                                              <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
                                              </div>
                                              <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
                                                <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">12</font></div>
                                                <div style="page-break-after: always;" id="DSPFPageBreak">
                                                  <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                                              </div>
                                              <div style="line-height: 1.25">&#160;</div>
                                            </div>
                                          </div>
                                        </div>
                                      </div>
                                    </div>
                                  </div>
                                </div>
                              </div>
                            </div>
                          </div>
                        </div>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Charges of Depositary</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We will pay the fees, reasonable expenses and out-of-pocket charges of the Depositary and those of any registrar only in accordance with agreements in writing entered into
          between us and the Depositary from time to time. The following charges shall be incurred by any party depositing or withdrawing ordinary shares or by any party surrendering ADRs or to whom ADRs are issued (including, without limitation, issuance
          pursuant to a stock dividend or stock split declared by us or an exchange of stock regarding the ADRs or deposited ordinary shares or a distribution of ADRs pursuant to the terms of the deposit agreement):</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25;">
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z8aa29d7042c2443f80ea56fb7e598791">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>taxes and other governmental charges;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <div style="line-height: 1.25">
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z7212a2bef615416585ae458ee896139e">

                <tr>
                  <td style="width: 36pt;"><br>
                  </td>
                  <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
                  <td style="width: auto; vertical-align: top; text-align: justify;">
                    <div>any applicable transfer or registration fees;</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25">&#160;</div>
            <div style="line-height: 1.25">
              <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z586d43b68d0f4e03b5cbc7d8d6430c57">

                  <tr>
                    <td style="width: 36pt;"><br>
                    </td>
                    <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
                    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div>certain cable, telex and facsimile transmission charges as provided in the deposit agreement;</div>
                    </td>
                  </tr>

              </table>
              <div style="line-height: 1.25">
                <div style="line-height: 1.25">&#160;</div>
                <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="za0830177be0c43aaa44d63ada175c424">

                    <tr>
                      <td style="width: 36pt;"><br>
                      </td>
                      <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
                      <td style="width: auto; vertical-align: top; text-align: justify;">
                        <div>any expenses incurred in the conversion of foreign currency;</div>
                      </td>
                    </tr>

                </table>
                <div style="line-height: 1.25">&#160;</div>
              </div>
            </div>
          </div>
        </div>
        <table cellspacing="0" cellpadding="0" id="z48a37f75e9f642929031674d45a1580e" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>a fee of $5.00 or less per 100 ADSs (or a portion thereof) for the execution and delivery of ADRs and the surrender of ADRs, including if the deposit agreement terminates;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z240b9484846246b4ba88992c41e3a209" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>a fee of $.05 or less per ADS (or portion thereof) for any cash distribution made pursuant to the deposit agreement;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z8f17428ebff34052a555a0dfba9f7211" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>a fee for the distribution of securities pursuant to the deposit agreement;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z98ea5bf3cb76491eaa93bcf56555a16b" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>in addition to any fee charged for a cash distribution, a fee of $.05 or less per ADS (or portion thereof) per annum for depositary services;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zc9db2efa6e984842a26180ec02f1eb97">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>a fee for the distribution of proceeds of rights that the Depositary sells pursuant to the deposit agreement; and</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
        </div>
        <table cellspacing="0" cellpadding="0" id="z004d3a12755c40e192af1364b65201d4" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="line-height: 1.25">
                    <div style="text-align: left; line-height: 1.25;">any other charges payable by the Depositary, any of the Depositary&#8217;s agents, or the agents of the Depositary&#8217;s agents in connection with the servicing of ordinary shares or other
                      Deposited Securities.</div>
                  </div>
                </div>
              </td>
            </tr>

        </table>
        <br>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Depositary may own and deal in our securities and in ADSs.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Depositary collects its fees for delivery and surrender of ADSs directly from investors depositing shares or surrendering ADSs for the purpose of withdrawal or from
          intermediaries acting for them. The Depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the fees. The Depositary may collect
          its annual fee for depositary services by deduction from cash distributions or by directly billing investors or by charging the book-entry system accounts of participants acting for them. The Depositary may collect any of its fees by deduction
          from any cash distribution payable (or by selling a portion of securities or other property distributable) to ADS holders that are obligated to pay those fees. The Depositary may generally refuse to provide fee-attracting services until its fees
          for those services are paid.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">From time to time, the Depositary may make payments to us to reimburse us for costs and expenses generally arising out of establishment and maintenance of the ADS program,
          waive fees and expenses for services provided to us by the Depositary or share revenue from the fees collected from ADS holders. In performing its duties under the deposit agreement, the Depositary may use brokers, dealers, foreign currency
          dealers or other service providers that are owned by or affiliated with the Depositary and that may earn or share fees, spreads or commissions.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Depositary may convert currency itself or through any of its affiliates and, in those cases, acts as principal for its own account and not as agent, advisor, broker or
          fiduciary on behalf of any other person and earns revenue, including, without limitation, transaction spreads, that it will retain for its own account. The revenue is based on, among other things, the difference between the exchange rate assigned
          to the currency conversion made under the deposit agreement and the rate that the Depositary or its affiliate receives when buying or selling foreign currency for its own account. The Depositary makes no representation that the exchange rate used
          or obtained in any currency conversion under the deposit agreement will be the most favorable rate that could be obtained at the time or that the method by which that rate will be determined will be the most favorable to ADS holders, subject to
          the Depositary&#8217;s obligations under the deposit agreement. The methodology used to determine exchange rates used in currency conversions is available upon request.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Liability of Holders for Taxes, Duties or Other Charges</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Any tax or other governmental charge with respect to ADSs or any deposited ordinary shares represented by any ADS shall be payable by the holder of such ADS to the Depositary.
          The Depositary may refuse to effect transfer of such ADS or any withdrawal of deposited ordinary shares represented by such ADS until such payment is made, and may withhold any dividends or other distributions or may sell for the account of the
          holder any part or all of the deposited ordinary shares represented by such ADS and may apply such dividends or distributions or the proceeds of any such sale in payment of any such tax or other governmental charge and the holder of such ADS
          shall remain liable for any deficiency.</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">13</font></div>
          <div style="page-break-after: always;" id="DSPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25;">
          <div style="line-height: 1.25; font-weight: bold;">Limitations on Obligations and Liability</div>
          <div style="line-height: 1.25;">&#160;</div>
        </div>
        <div style="line-height: 1.25;">
          <div style="text-indent: 36pt; line-height: 1.25; font-style: italic;">Limits on our Obligations and the Obligations of the Depositary; Limits on Liability to Holders of ADSs</div>
        </div>
        <div style="line-height: 1.25;">
          <div style="line-height: 1.25;">&#160;</div>
        </div>
        <div style="line-height: 1.25;">
          <div style="text-indent: 36pt; line-height: 1.25;">The deposit agreement expressly limits our obligations and the obligations of the Depositary. It also limits our liability and the liability of the Depositary. We and the Depositary:</div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z02e323b280bc445fa838224a67a1c0d2" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>are only obligated to take the actions specifically set forth in the deposit agreement without negligence or bad faith;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zf0e71f7406a443aba887f3c57eb45fbc" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>are not liable if we are or it is prevented or delayed by law or by events or circumstances beyond our or its ability to prevent or counteract with reasonable care or effort from performing our or its obligations under the deposit
                  agreement;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z7ce810041a6540499b49563baf2c31ea" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>are not liable if we or it exercise discretion permitted under the deposit agreement;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z9e9f93facb36496c954abb14df0c022b" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>are not liable for the inability of any holder of ADSs to benefit from any distribution on deposited securities that is not made available to holders of ADSs under the terms of the deposit agreement, or for any special, consequential
                  or punitive damages for any breach of the terms of the deposit agreement;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zba83b75aeb6e455c9a6d3dcbcf2117fd" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-align: left; line-height: 1.25;">have no obligation to become involved in a lawsuit or other proceeding related to the ADSs or the deposit agreement on your behalf or on behalf of any other person;</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z7feb974c6ac84dcfa0848be48a9a7a21" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>are not liable for the acts or omissions of any securities depository, clearing agency or settlement system; and</div>
              </td>
            </tr>

        </table>
        <div style="text-align: justify; text-indent: -36pt; margin-left: 72pt; line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="line-height: 1.25;">
          <table cellspacing="0" cellpadding="0" id="zf65279a29080453a9335195316960950" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
                <td style="width: auto; vertical-align: top;">
                  <div>may rely upon any documents we believe or it believes in good faith to be genuine and to have been signed or presented by the proper person.</div>
                </td>
              </tr>

          </table>
        </div>
        <div style="line-height: 1.25;">
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
        </div>
        <div style="line-height: 1.25;">
          <div style="text-indent: 36pt; line-height: 1.25;">In the deposit agreement, we and the Depositary agree to indemnify each other under certain circumstances.</div>
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="DESCRIPTIONOFDEBTSECURITI"><!--Anchor--></a>DESCRIPTION OF DEBT SECURITIES</div>
        <div style="text-align: center; line-height: 1.25;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We may issue debt securities in one or more series. The specific terms of each series of debt securities will be described in the applicable prospectus supplement relating to
          that series. The prospectus supplement may or may not modify the general terms found in this prospectus and will be filed with the SEC. For a complete description of the terms of a particular series of debt securities, you should read both this
          prospectus and the prospectus supplement relating to that particular series.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">As required by federal law for all bonds and notes of companies that are publicly offered, the debt securities are governed by a document called an &#8220;indenture.&#8221; An indenture is
          a contract between us and a financial institution, acting as trustee on your behalf, and is subject to and governed by the Trust Indenture Act of 1939, as amended. We have entered into an indenture between us and The Bank of New York Mellon, to
          act as trustee, pursuant to which we may issue multiple series of debt securities from time to time. The trustee has two main roles. First, the trustee can enforce your rights against us if we default. There are some limitations on the extent to
          which the trustee acts on your behalf, described in the second paragraph under &#8220;Events of Default &#8212; Remedies if an Event of Default Occurs.&#8221; Second, the trustee performs certain administrative duties for us.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Because this section is a summary, it does not describe every aspect of the debt securities and the indenture. We urge you to read the indenture because it, and not this
          description, defines your rights as a holder of debt securities. A copy of the indenture is attached as an exhibit to the registration statement of which this prospectus is a part. We will file a supplemental indenture with the SEC prior to the
          commencement of any debt offering, at which time the supplemental indenture would be publicly available.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The prospectus supplement, which will accompany this prospectus, will describe the particular series of debt securities being offered by including:</div>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zd64a74cffa174a828ee59594901996cf" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the designation or title of the series of debt securities;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z4f81d35c93044e46b61d6a389f781d0f" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the total principal amount of the series of debt securities;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z7557975d72dc4c0aadb21b9ce9b3123d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the percentage of the principal amount at which the series of debt securities will be offered;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z27b04bc14e1845698ee10bb89785ca73" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the date or dates on which principal will be payable;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zb769d313910749fcb3f920181abbca3c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the rate or rates (which may be either fixed or variable) and/or the method of determining such rate or rates of interest, if any;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">14</font></div>
          <div style="page-break-after: always;" id="DSPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25"> <br>
        </div>
        <table cellspacing="0" cellpadding="0" id="z36d64bab7f8f4eb887de9ee2d72d08cc" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the date or dates from which any interest will accrue, or the method of determining such date or dates, and the date or dates on which any interest will be payable;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z92c54dcdf9ca47bf809713860edbe784" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>whether any interest may be paid by issuing additional securities of the same series in lieu of cash (and the terms upon which any such interest may be paid by issuing additional securities);</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z6418de34ef244149b7ae37c833ed4381" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the terms for redemption, extension or early repayment, if any;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zf95528f5666d4fa4b34f0654bfb48458" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the currencies in which the series of debt securities are issued and payable;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z5d7a91b7f0154d4c9f299f27100900ac" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>whether the amount of payments of principal, premium or interest, if any, on a series of debt securities will be determined with reference to an index, formula or other method (which could be based on one or more currencies,
                  commodities, equity indices or other indices) and how these amounts will be determined;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zd73e2e8e5b894ffcb956311a9bbfa0e6" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the place or places, if any, other than or in addition to the Borough of Manhattan in the City of New York, of payment, transfer, conversion and/or exchange of the debt securities;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zcc7d91fbfdba480eb6877ffd3dceeac6" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the denominations in which the offered debt securities will be issued (if other than $1,000 and any integral multiple thereof for registered securities);</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z776d02e7c17244c8adbac934589dee90" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the provision for any sinking fund;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zc61e19a5be84457d8dcbf137c884847d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>any restrictive covenants;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z5c56bd2f44054c2892b067419ad7dd42" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>any Events of Default (as defined below);</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zc192230a24064b119a32f688f2436d08" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>whether the series of debt securities are issuable in certificated form;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="za622840e0f0d41a58f1d07f8f2375323" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>any provisions for defeasance or covenant defeasance;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zceb2d60728d742ada38792cceea12eea" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>any provisions regarding any future changes or modifications of the terms of the series of debt securities in light of the requirements under applicable law for effecting such changes or modifications;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z4aa0933cd44f489b99699218191bbd7c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>any special Israeli and/or U.S. federal income tax implications, including, if applicable, Israeli and/or U.S. federal income tax considerations relating to original issue discount;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z4b36c5ac8fbf4bad9c45d70a876d5627" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>whether and under what circumstances we will pay additional amounts in respect of any tax, assessment or governmental charge and, if so, whether we will have the option to redeem the debt securities rather than pay the additional
                  amounts (and the terms of this option);</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zac96e1c01c5e4a3a8c63167a757dcbe8" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>any provisions for convertibility or exchangeability of the debt securities into or for any other securities;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zc6eb329a62c24c2aafe3613ec31b7f46" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>whether the debt securities are subject to subordination and the terms of such subordination;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="ze3c7825b3dcc41fa9a74b2e90e9512ec" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>whether the debt securities are secured or unsecured and the terms of any security interests;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z3a270c5ab1fb4c1a886964bfa596ecb5" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the listing, if any, on a securities exchange; and</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zbc2af445c2fa4ebc9a4f6494b5cbac6c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>any other terms.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">15</font></div>
          <div style="page-break-after: always;" id="DSPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">General</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The indenture provides that any debt securities proposed to be sold under this prospectus and the accompanying prospectus supplement, or the offered debt securities, may be
          issued under the indenture in one or more series.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">For purposes of this prospectus, any reference to the payment of principal of or premium or interest, if any, on debt securities will include additional amounts if required by
          the terms of the debt securities.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The indenture does not limit the amount of debt securities that may be issued thereunder from time to time. Debt securities issued under the indenture, when a single trustee is
          acting for all debt securities issued under the indenture, are called the &#8220;indenture securities.&#8221; The indenture also provides that there may be more than one trustee thereunder, each with respect to one or more different series of indenture
          securities. See &#8220;Resignation of Trustee&#8221; below. At a time when two or more trustees are acting under the indenture, each with respect to only certain series, the term &#8220;indenture securities&#8221; means the one or more series of debt securities with
          respect to which each respective trustee is acting. In the event that there is more than one trustee under the indenture, the powers and trust obligations of each trustee described in this prospectus will extend only to the one or more series of
          indenture securities for which it is trustee. If two or more trustees are acting under the indenture, then the indenture securities for which each trustee is acting would be treated as if issued under separate indentures.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The indenture does not contain any provisions that give you protection in the event we issue a large amount of debt or we are acquired by another entity.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We refer you to the particular prospectus supplement for information with respect to any deletions from, modifications of or additions to the Events of Default or our covenants
          that are described below, including any addition of a covenant or other provision providing event risk or similar protection.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have the ability to issue indenture securities with terms different from those of indenture securities previously issued and, without the consent of the holders thereof, to
          reopen a previous issue of a series of indenture securities and issue additional indenture securities of that series unless the reopening was restricted when that series was created.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Conversion and Exchange</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If any debt securities are convertible into or exchangeable for other securities, the applicable prospectus supplement will explain the terms and conditions of the conversion
          or exchange, including the conversion price or exchange ratio (or the calculation method), the conversion or exchange period (or how the period will be determined), if conversion or exchange will be mandatory or at the option of the holder or us,
          provisions for adjusting the conversion price or the exchange ratio and provisions affecting conversion or exchange in the event of the redemption of the underlying debt securities. These terms may also include provisions under which the number
          or amount of other securities to be received by the holders of the debt securities upon conversion or exchange would be calculated according to the market price of the other securities as of a time stated in the applicable prospectus supplement.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Issuance of Securities in Registered Form</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We may issue the debt securities in registered form, in which case we may issue them either in book-entry form only or in &#8220;certificated&#8221; form. Debt securities issued in
          book-entry form will be represented by global securities. We expect that we will usually issue debt securities in book-entry only form represented by global securities.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Book-Entry Holders</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We will issue registered debt securities in book-entry form only, unless we specify otherwise in the applicable prospectus supplement. This means debt securities will be
          represented by one or more global securities registered in the name of a depositary that will hold them on behalf of financial institutions that participate in the depositary&#8217;s book- entry system. These participating institutions, in turn, hold
          beneficial interests in the debt securities held by the depositary or its nominee. These institutions may hold these interests on behalf of themselves or customers.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the indenture, only the person in whose name a debt security is registered is recognized as the holder of that debt security. Consequently, for debt securities issued in
          book-entry form, we will recognize only the depositary as the holder of the debt securities and we will make all payments on the debt securities to the depositary. The depositary will then pass along the payments it receives to its participants,
          which in turn will pass the payments along to their customers who are the beneficial owners. The depositary and its participants do so under agreements they have made with one another or with their customers; they are not obligated to do so under
          the terms of the debt securities.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">As a result, investors will not own debt securities directly. Instead, they will own beneficial interests in a global security through a bank, broker or other financial
          institution that participates in the depositary&#8217;s book-entry system or holds an interest through a participant. As long as the debt securities are represented by one or more global securities, investors will be indirect holders, and not holders,
          of the debt securities.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">16</font></div>
          <div style="page-break-after: always;" id="DSPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Street Name Holders</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In the future, we may issue debt securities in certificated form or terminate a global security. In these cases, investors may choose to hold their debt securities in their own
          names or in &#8220;street name.&#8221; Debt securities held in street name are registered in the name of a bank, broker or other financial institution chosen by the investor, and the investor would hold a beneficial interest in those debt securities through
          the account he or she maintains at that institution.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">For debt securities held in street name, we will recognize only the intermediary banks, brokers and other financial institutions in whose names the debt securities are
          registered as the holders of those debt securities, and we will make all payments on those debt securities to them. These institutions will pass along the payments they receive to their customers who are the beneficial owners, but only because
          they agree to do so in their customer agreements or because they are legally required to do so. Investors who hold debt securities in street name will be indirect holders, and not holders, of the debt securities.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Legal Holders</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our obligations, as well as the obligations of the applicable trustee and those of any third parties employed by us or the applicable trustee, run only to the legal holders of
          the debt securities. We do not have obligations to investors who hold beneficial interests in global securities, in street name or by any other indirect means. This will be the case whether an investor chooses to be an indirect holder of a debt
          security or has no choice because we are issuing the debt securities only in book-entry form.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">For example, once we make a payment or give a notice to the holder, we have no further responsibility for the payment or notice even if that holder is required, under
          agreements with depositary participants or customers or by law, to pass it along to the indirect holders but does not do so. Similarly, if we want to obtain the approval of the holders for any purpose (for example, to amend an indenture or to
          relieve us of the consequences of a default or of our obligation to comply with a particular provision of an indenture), we would seek the approval only from the holders, and not the indirect holders, of the debt securities. Whether and how the
          holders contact the indirect holders is up to the holders.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">When we refer to you, we mean those who invest in the debt securities being offered by this prospectus, whether they are the holders or only indirect holders of those debt
          securities. When we refer to your debt securities, we mean the debt securities in which you hold a direct or indirect interest.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Special Considerations for Indirect Holders</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If you hold debt securities through a bank, broker or other financial institution, either in book-entry form or in street name, we urge you to check with that institution to
          find out:</div>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zabfd1e2ba4d04b6daf5a237ec616db5e" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>how it handles securities payments and notices;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z796d1703748f4eb5a32a1a05d405c303" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>whether it imposes fees or charges;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z92386c6764464a9982751f38f3bec7b3" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>how it would handle a request for the holders&#8217; consent, if ever required;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z874d523acc594d24a8ca4278e6e84ef5" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>whether and how you can instruct it to send you debt securities registered in your own name so you can be a holder, if that is permitted in the future for a particular series of debt securities;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z25ace4a7d8e24c73b98e77d9abdab9e1" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>how it would exercise rights under the debt securities if there were a default or other event triggering the need for holders to act to protect their interests; and</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zafff5699182645528bd57c235c93c867" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>if the debt securities are in book-entry form, how the depositary&#8217;s rules and procedures will affect these matters.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Global Securities</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">As noted above, we usually will issue debt securities as registered securities in book-entry form only. A global security represents one or any other number of individual debt
          securities. Generally, all debt securities represented by the same global securities will have the same terms.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Each debt security issued in book-entry form will be represented by a global security that we deposit with and register in the name of a financial institution or its nominee
          that we select. The financial institution that we select for this purpose is called the depositary. Unless we specify otherwise in the applicable prospectus supplement, DTC will be the depositary for all debt securities issued in book-entry form.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">A global security may not be transferred to or registered in the name of anyone other than the depositary or its nominee, unless special termination situations arise. We
          describe those situations below under &#8220;Special Situations when a Global Security will be Terminated.&#8221; As a result of these arrangements, the depositary, or its nominee, will be the sole registered owner and holder of all debt securities
          represented by a global security, and investors will be permitted to own only beneficial interests in a global security. Beneficial interests must be held by means of an account with a broker, bank or other financial institution that in turn has
          an account with the depositary or with another institution that has an account with the depositary. Thus, an investor whose security is represented by a global security will not be a holder of the debt security, but only an indirect holder of a
          beneficial interest in the global security.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">17</font></div>
          <div style="page-break-after: always;" id="DSPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Special Considerations for Global Securities</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">As an indirect holder, an investor&#8217;s rights relating to a global security will be governed by the account rules of the investor&#8217;s financial institution and of the depositary,
          as well as general laws relating to securities transfers. The depositary that holds the global security will be considered the holder of the debt securities represented by the global security.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If debt securities are issued only in the form of a global security, an investor should be aware of the following:</div>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z6eb57e143b96486397c9bcaef0f6907e" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>An investor cannot cause the debt securities to be registered in his or her name and cannot obtain certificates for his or her interest in the debt securities, except in the special situations we describe below.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z89625dfd926b49cabd27635850234079" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>An investor will be an indirect holder and must look to his or her own bank or broker for payments on the debt securities and protection of his or her legal rights relating to the debt securities, as we describe under &#8220;Issuance of
                  Securities in Registered Form&#8221; above.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z70030cf0a27a45aab62a8f315fbce6e3" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>An investor may not be able to sell interests in the debt securities to some insurance companies and other institutions that are required by law to own their securities in non-book-entry form.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zccf23bc90321413f9717ead0c8b660d3" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>An investor may not be able to pledge his or her interest in a global security in circumstances where certificates representing the debt securities must be delivered to the lender or other beneficiary of the pledge in order for the
                  pledge to be effective.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z0751b951d4f34342a8a1d8378044e63c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>The depositary&#8217;s policies, which may change from time to time, will govern payments, transfers, exchanges and other matters relating to an investor&#8217;s interest in a global security. We and the trustee have no responsibility for any
                  aspect of the depositary&#8217;s actions or for its records of ownership interests in a global security. We and the trustee also do not supervise the depositary in any way.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z7b47feb8b14d4fd79842dcb83d8e2e84" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>If we redeem less than all the debt securities of a particular series being redeemed, DTC&#8217;s practice is to determine by lot the amount to be redeemed from each of its participants holding that series.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z76df566e85074cd18e86937613b7e588" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>An investor is required to give notice of the exercise of any option to elect repayment of its debt securities, through its participant, to the applicable trustee and to deliver the related debt securities by causing its participant to
                  transfer its interest in those debt securities, on DTC&#8217;s records, to the applicable trustee.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z51197ef35ea743eb9b6da3419ee6a794" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>DTC requires that those who purchase and sell interests in a global security deposited in its book&#8209;entry system use immediately available funds. Your broker or bank may also require you to use immediately available funds when
                  purchasing or selling interests in a global security.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zf84234233a4341be8950f1c28bc79828" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Financial institutions that participate in the depositary&#8217;s book&#8209;entry system, and through which an investor holds its interest in a global security, may also have their own policies affecting payments, notices and other matters
                  relating to the debt securities. There may be more than one financial intermediary in the chain of ownership for an investor. We do not monitor and are not responsible for the actions of any of those intermediaries.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Special Situations when a Global Security will be Terminated</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In a few special situations described below, a global security will be terminated and interests in it will be exchanged for certificates in non&#8209;book&#8209;entry form (certificated
          securities). After that exchange, the choice of whether to hold the certificated debt securities directly or in street name will be up to the investor. Investors must consult their own banks or brokers to find out how to have their interests in a
          global security transferred on termination to their own names so that they will be holders. We have described the rights of legal holders and street name investors under &#8220;Issuance of Securities in Registered Form&#8221; above.<br>
          <br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">18</font></div>
          <div style="page-break-after: always;" id="DSPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The applicable prospectus supplement may list situations for terminating a global security that would apply only to the particular series of debt securities covered by the
          prospectus supplement. If a global security is terminated, only the depositary, and not we or the applicable trustee, is responsible for deciding the names of the institutions in whose names the debt securities represented by the global security
          will be registered and, therefore, who will be the holders of those debt securities.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Payment and Paying Agents</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We will pay interest (either in cash or by delivery of additional indenture securities, as applicable) to the person listed in the applicable trustee&#8217;s records as the owner of
          the debt security at the close of business on a particular day in advance of each due date for interest, even if that person no longer owns the debt security on the interest due date. That day, usually about two (2) weeks in advance of the
          interest due date, is called the &#8220;record date.&#8221; Because we will pay all the interest for an interest period to the holders on the record date, holders buying and selling debt securities must work out between themselves the appropriate purchase
          price. The most common manner is to adjust the sales price of the debt securities to prorate interest fairly between buyer and seller based on their respective ownership periods within the particular interest period. This prorated interest amount
          is called &#8220;accrued interest.&#8221;</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Payments on Global Securities</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We will make payments on a global security in accordance with the applicable policies of the depositary as in effect from time to time. Under those policies, we will make
          payments directly to the depositary, or its nominee, and not to any indirect holders who own beneficial interests in the global security. An indirect holder&#8217;s right to those payments will be governed by the rules and practices of the depositary
          and its participants, as described under &#8220;&#8212;Special Considerations for Global Securities.&#8221;</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Payments on Certificated Securities</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We will make payments on a certificated debt security as follows. We will pay interest that is due on an interest payment date by check mailed (or additional securities issued)
          on the interest payment date to the holder at his or her address shown on the trustee&#8217;s records as of the close of business on the regular record date. We will make all payments of principal and premium, if any, by check at the office of the
          applicable trustee in New York, New York, and/or at other offices that may be specified in the prospectus supplement or in a notice to holders against surrender of the debt security.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Alternatively, if the holder asks us to do so, we will pay any cash amount that becomes due on the debt security by wire transfer of immediately available funds to an account
          at a bank in the United States, on the due date.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Payment When Offices Are Closed</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If any payment is due on a debt security on a day that is not a business day, we will make the payment on the next day that is a business day. Payments made on the next
          business day in this situation will be treated under the indenture as if they were made on the original due date, except as otherwise indicated in the attached prospectus supplement. Such payment will not result in a default under any debt
          security or the indenture, and no interest will accrue on the payment amount from the original due date to the next day that is a business day.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Book-entry and other indirect holders should consult their banks or brokers for information on how they will receive payments on their debt securities.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Events of Default</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">You will have rights if an Event of Default occurs in respect of the debt securities of your series and is not cured, as described later in this subsection.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The term &#8220;Event of Default&#8221; in respect of the debt securities of your series means any of the following:</div>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z92d239ac5bc848c3adbafc11a88c8704" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>We do not pay interest on a debt security of the series within thirty (30) days of its due date.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z9b05a80693e647029bf4704cc40091bf" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>We do not pay the principal of, or any premium on, a debt security of the series on its due date.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">19</font></div>
          <div style="page-break-after: always;" id="DSPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25"> <br>
        </div>
        <table cellspacing="0" cellpadding="0" id="z507a272ee68846778c8de9a00090dcf8" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>We do not deposit any sinking fund payment in respect of debt securities of the series within two (2) business days of its due date.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="ze43dc7eaa6c74ed4bec824cc2f69513e" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>We remain in breach of a covenant in respect of debt securities of the series for sixty (60) days after we receive a written notice of default stating we are in breach. The notice must be sent by either the trustee or holders of at
                  least 25% of the principal amount of debt securities of the series.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z714f070ad16c43e5be77d601ae417468" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>We file for bankruptcy or certain other events of bankruptcy, insolvency or reorganization occur.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z1ac80510ea42488c86792cf601a6ee24" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Any other Event of Default in respect of debt securities of the series described in the applicable prospectus supplement occurs.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">An Event of Default for a particular series of debt securities does not necessarily constitute an Event of Default for any other series of debt securities issued under the same
          or any other indenture. The trustee may withhold notice to the holders of debt securities of any default, except in the payment of principal, premium or interest, if it in good faith considers the withholding of notice to be in the best interests
          of the holders.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Remedies if an Event of Default Occurs</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If an Event of Default has occurred and has not been cured, the trustee or the holders of at least 25% in principal amount of the debt securities of the affected series may
          declare the entire principal amount of all the debt securities of that series to be due and immediately payable. This is called a declaration of acceleration of maturity. A declaration of acceleration of maturity may be canceled by the holders of
          a majority in principal amount of the debt securities of the affected series if (1) we have deposited with the trustee all amounts due and owing with respect to the securities, and (2) no other Events of Default are continuing.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Except in cases of default, where the trustee has some special duties, the trustee is not required to take any action under the indenture at the request of any holders unless
          the holders offer the trustee reasonable protection from expenses and liability (called an &#8220;indemnity&#8221;). If reasonable indemnity is provided, the holders of a majority in principal amount of the outstanding debt securities of the relevant series
          may direct the time, method and place of conducting any lawsuit or other formal legal action seeking any remedy available to the trustee. The trustee may refuse to follow those directions in certain circumstances. No delay or omission in
          exercising any right or remedy will be treated as a waiver of that right, remedy or Event of Default.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Before you are allowed to bypass your trustee and bring your own lawsuit or other formal legal action or take other steps to enforce your rights or protect your interests
          relating to the debt securities, the following must occur:</div>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z69499fdf06ba46acaeb64fbf00517531" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>You must give your trustee written notice that an Event of Default has occurred and remains uncured.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z3a37db6fda5e41d68b91da19f2eb96a9" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>The holders of at least 25% in principal amount of all outstanding debt securities of the relevant series must make a written request that the trustee take action because of the default and must offer reasonable indemnity to the
                  trustee against the cost and other liabilities of taking that action.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z13e0f13ebbd64226a95d46c493dc708c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>The trustee must not have taken action for sixty (60) days after receipt of the above notice and offer of indemnity.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z0eaac524ed4d40c2b2d090aa5de00985" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>The holders of a majority in principal amount of the debt securities must not have given the trustee a direction inconsistent with the above notice during that sixty (60) day period.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">However, you are entitled at any time to bring a lawsuit for the payment of money due on your debt securities on or after the due date.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Holders of a majority in principal amount of the debt securities of the affected series may waive any past defaults other than:</div>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z6c9693253c784c5e830e82a2ac25650a" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the payment of principal, any premium or interest; or</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z639b356672ca496b99800c708607bd33" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>in respect of a covenant that cannot be modified or amended without the consent of each holder.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Book-entry and other indirect holders should consult their banks or brokers for information on how to give notice or direction to or make a request of the trustee and how to
          declare or cancel an acceleration of maturity.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Each year, we will furnish to each trustee a written statement of certain of our officers certifying that to their knowledge we are in compliance with the indenture and the
          debt securities or else specifying any default.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">20</font></div>
          <div style="page-break-after: always;" id="DSPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Merger or Consolidation</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the terms of the indenture, we are generally permitted to consolidate or merge with another entity. We are also permitted to sell all or substantially all of our assets
          to another entity. However, we may not take any of these actions unless all the following conditions are met:</div>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zcfb6a8c57ac24601801e46ebe567c043" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Where we merge out of existence or sell our assets, the resulting entity must agree to be legally responsible for our obligations under the debt securities.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="ze0d162257be74c8591ae2b61f1f76c08" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>The merger or sale of assets must not cause a default on the debt securities and we must not already be in default (unless the merger or sale would cure the default). For purposes of this no&#8209;default test, a default would include an
                  Event of Default that has occurred and has not been cured, as described under &#8220;Events of Default&#8221; above. A default for this purpose would also include any event that would be an Event of Default if the requirements for giving us a notice
                  of default or our default having to exist for a specific period of time were disregarded.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zc5487c6c9f934d0781b61caeefcd5a99" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>We must deliver certain certificates and documents to the trustee.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="ze33914f62f9d4f0c91af5a992b8d09b8" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>We must satisfy any other requirements specified in the prospectus supplement relating to a particular series of debt securities.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Modification or Waiver</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">There are three types of changes we can make to the indenture and the debt securities issued thereunder.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold;">Changes Requiring Approval</font>&#160;<font style="font-weight: bold;">by the Holders of the Debt Securities</font></div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">First, there are changes that we cannot make&#160;without specific approval by the holders of the debt securities. The following is a list of those types of changes:</div>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z071af8909ea84c9988a36d91cc65a573" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>change the stated maturity of the principal of, or interest on, a debt security;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z6a6de1051866473d878f026592b66ffa" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>reduce any amounts due on a debt security;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z212fa0e6424e4969a17025683a141460" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>reduce the amount of principal payable upon acceleration of the maturity of a security following a default;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zbffff066c6ea479788bcf52aa854f3d0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>adversely affect any right of repayment at the holder&#8217;s option;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z8938f015533a4e2e99e1078876d9e935" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>change the place (except as otherwise described in the prospectus or prospectus supplement) or currency of payment on a debt security;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z4ee07c9e12d847c285ef3663c3369303" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>impair the right of a holder of the debt securities to sue for payment;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z33c8b7212a4b49299fe94d1e6e19e606" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>adversely affect any right to convert or exchange a debt security in accordance with its terms;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z093d95febbec4aeab84507f32ee8b557" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>modify the subordination provisions in the indenture in a manner that is adverse to holders of the debt securities;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z1255d20269ac4377a97e6ac96a60a034" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>reduce the percentage of holders of debt securities whose consent is needed to modify or amend the indenture;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zdec9fd222a85447db883597f43741f90" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>reduce the percentage of holders of debt securities whose consent is needed to waive compliance with certain provisions of the indenture or to waive certain defaults;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z12c2944955e1490ead0d3521818bfb15" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>modify any other aspect of the provisions of the indenture dealing with supplemental indentures, modification and waiver of past defaults, changes to the quorum or voting requirements or the waiver of certain covenants; and</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z2566f1d86d814f01969c7b83ec95447d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>change any obligation we have to pay additional amounts.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">21</font></div>
          <div style="page-break-after: always;" id="DSPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Changes Not Requiring Approval</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The second type of change does not require any vote by the holders of the debt securities. This type is limited to clarifications and certain other changes that would not
          adversely affect holders of the outstanding debt securities in any material respect. We also do not need any approval to make any change that affects only debt securities to be issued under the indenture after the change takes effect.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Changes Requiring Majority Approval</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Any other change to the indenture and the debt securities would require the following approval:</div>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zb8fad8515c8446bfa44f0b8cd7b5b4d5" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>If the change affects only one series of debt securities, it must be approved by the holders of a majority in principal amount of that series.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zdfd7385314094323bf39110b894f73c8" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>If the change affects more than one series of debt securities issued under the same indenture, it must be approved by the holders of a majority in principal amount of all of the series affected by the change, with all affected series
                  voting together as one class for this purpose.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In each case, the required approval must be given by written consent.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The holders of a majority in principal amount of all of the series of debt securities issued under an indenture, voting together as one class for this purpose, may waive our
          compliance with some of our covenants in that indenture. However, we cannot obtain a waiver of a payment default or of any of the matters covered by the bullet points included above under &#8220;&#8212;Changes Requiring Approval&#160;by the Holders of the Debt
          Securities.&#8221;</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Changes Requiring the Israeli Court Approval</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the Companies Law, any compromise or arrangement between a company and its shareholders or its debenture holders regarding a substantial change in the repayment terms of
          the debentures, which includes a payment reduction or postponement of repayment, including the arrangement or compromise under which the debentures will be repaid, in whole or in part, by issuance of other securities to the debenture holders, is
          regarded as a &#8220;Debt Arrangement.&#8221; Debt Arrangements are subject to a special procedure specified under the Companies Law and are subject to, among other things, the approval of a competent Israeli court, and to the appointment of an expert on
          behalf of the court, for examination of the proposed debt settlement.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Further Details Concerning Voting</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">When taking a vote, we will use the following rules to decide how much principal to attribute to a debt security:</div>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zca4383b041044c4b9a3b15cf70a36eae" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>For original issue discount securities, we will use the principal amount that would be due and payable on the voting date if the maturity of these debt securities were accelerated to that date because of a default.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z8746cb0283594dd0a6fde1b07ca342e6" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>For debt securities whose principal amount is not known (for example, because it is based on an index), we will use the principal face amount at original issuance or a special rule for that debt security described in the prospectus
                  supplement.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zc885796a597b4fe0aa207133557ce66e" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>For debt securities denominated in one (1) or more foreign currencies, we will use the dollar equivalent.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Debt securities will not be considered outstanding, and therefore not eligible to vote, if we have deposited or set aside in trust money for their payment or redemption or if
          we, any other obligor, or any affiliate of us or any obligor own such debt securities. Debt securities will also not be eligible to vote if they have been fully defeased as described later under &#8220;Defeasance &#8212; Full Defeasance.&#8221;</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We will generally be entitled to set any day as a record date for the purpose of determining the holders of outstanding indenture securities that are entitled to vote or take
          other action under the indenture. However, the record date may not be more than thirty (30) days before the date of the first solicitation of holders to vote on or take such action. If we set a record date for a vote or other action to be taken
          by holders of one (1) or more series, that vote or action may be taken only by persons who are holders of outstanding indenture securities of those series on the record date and must be taken within eleven (11) months following the record date.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Book-entry and other indirect holders should consult their banks or brokers for information on how approval may be granted or denied if we seek to change the indenture or the
          debt securities or request a waiver.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">22</font></div>
          <div style="page-break-after: always;" id="DSPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Defeasance</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The following provisions will be applicable to each series of debt securities unless we state in the applicable prospectus supplement that the provisions of covenant defeasance
          and full defeasance will not be applicable to that series.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic;">Covenant Defeasance</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under current U.S. federal tax law and the indenture, we can make the deposit described below and be released from some of the restrictive covenants in the indenture under
          which the particular series was issued. This is called &#8220;covenant defeasance.&#8221; In that event, you would lose the protection of those restrictive covenants but would gain the protection of having money and government securities set aside in trust
          to repay your debt securities. If applicable, you also would be released from the subordination provisions described under &#8220;Indenture Provisions &#8212; Subordination&#8221; below. In order to achieve covenant defeasance, we must do the following:</div>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zbe006dd4ba9c408894ecb6821e1d6129" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>If the debt securities of the particular series are denominated in dollars, we must deposit in trust for the benefit of all holders of such debt securities a combination of money and U.S. government or U.S. government agency notes or
                  bonds that will generate enough cash to make interest, principal and any other payments on the debt securities on their various due dates and any mandatory sinking fund payments or analogous payments.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z31d7362152fa490e9763b89628376f4c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>We must deliver to the trustee a legal opinion of our counsel confirming that, under current U.S. federal income tax law, we may make the above deposit without causing you to be taxed on the debt securities any differently than if we
                  did not make the deposit and just repaid the debt securities ourselves at maturity.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zc595f393d24545a5b364c9458cda65cb" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>We must deliver to the trustee a legal opinion of our counsel stating that the above deposit does not require registration by us under the Investment Company Act of 1940, as amended, or the 1940 Act, and a legal opinion and officers&#8217;
                  certificate stating that all conditions precedent to covenant defeasance have been complied with.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z5488f9921c1342bbb195f3af41d6f6f1" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Defeasance must not result in a breach of the indenture or any of our other material agreements.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z6e8a9675f6924880920351ced2af75cb" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Satisfy the conditions for covenant defeasance contained in any supplemental indentures.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If we accomplish covenant defeasance, you can still look to us for repayment of the debt securities if there were a shortfall in the trust deposit or the trustee is prevented
          from making payment. In fact, if one of the remaining Events of Default occurred (such as our bankruptcy) and the debt securities became immediately due and payable, there might be a shortfall. Depending on the event causing the default, you may
          not be able to obtain payment of the shortfall.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic;">Full Defeasance</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If there is a change in U.S. federal tax law, as described below, we can legally release ourselves from all payment and other obligations on the debt securities of a particular
          series (called &#8220;full defeasance&#8221;) if we put in place the following other arrangements for you to be repaid:</div>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z13a1173a9c0b4f4392ed753441e9c3ea" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>If the debt securities of the particular series are denominated in dollars, we must deposit in trust for the benefit of all holders of such debt securities a combination of money and U.S. government or U.S. government agency notes or
                  bonds that will generate enough cash to make interest, principal and any other payments on the debt securities on their various due dates and any mandatory sinking fund payments or analogous payments.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zd8933bbd5c1345e0aff620cb4583b2d1" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>We must deliver to the trustee a legal opinion confirming that there has been a change in current U.S. federal tax law or an IRS ruling that allows us to make the above deposit without causing you to be taxed on the debt securities any
                  differently than if we did not make the deposit and just repaid the debt securities ourselves at maturity. Under current U.S. federal tax law, the deposit and our legal release from the debt securities would be treated as though we paid
                  you your share of the cash and notes or bonds at the time the cash and notes or bonds were deposited in trust in exchange for your debt securities and you would recognize gain or loss on the debt securities at the time of the deposit.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z899171d54ae4468988406d795c0d9746" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>We must deliver to the trustee a legal opinion of our counsel stating that the above deposit does not require registration by us under the 1940 Act and a legal opinion and officers&#8217; certificate stating that all conditions precedent to
                  defeasance have been complied with.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z4666af6e3ae846a38be267d30970d06e" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Defeasance must not result in a breach of the indenture or any of our other material agreements.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z280f6b4cb4f04c47aa98898e16007975" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Satisfy the conditions for covenant defeasance contained in any supplemental indentures.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If we ever did accomplish full defeasance, as described above, you would have to rely solely on the trust deposit for repayment of the debt securities. You could not look to us
          for repayment in the unlikely event of any shortfall. Conversely, the trust deposit would most likely be protected from claims of our lenders and other creditors if we ever became bankrupt or insolvent. If applicable, you would also be released
          from the subordination provisions described later under &#8220;Indenture Provisions &#8212; Subordination.&#8221;</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">23</font></div>
          <div style="page-break-after: always;" id="DSPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Form, Exchange and Transfer of Certificated Registered Securities</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If registered debt securities cease to be issued in book-entry form, they will be issued:</div>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z0d967c0097ef45f0a253746540794d78" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>only in fully registered certificated form;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z465d040ccec0492f89ae332e45fe9312" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>without interest coupons; and</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z3de27391fdfb41c9bb316ba391042057" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>unless we indicate otherwise in the prospectus supplement, in denominations of $1,000 and amounts that are multiples of $1,000.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Holders may exchange their certificated securities for debt securities of smaller denominations or combined into fewer debt securities of larger denominations, as long as the
          total principal amount is not changed and as long as the denomination is greater than the minimum denomination for such securities.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Holders may exchange or transfer their certificated securities at the office of their trustee. We have appointed the trustee to act as our agent for registering debt securities
          in the names of holders transferring debt securities. We may appoint another entity to perform these functions or perform them ourselves.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Holders will not be required to pay a service charge to transfer or exchange their certificated securities, but they may be required to pay any tax or other governmental charge
          associated with the transfer or exchange. The transfer or exchange will be made only if our transfer agent is satisfied with the holder&#8217;s proof of legal ownership.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If we have designated additional transfer agents for your debt security, they will be named in your prospectus supplement. We may appoint additional transfer agents or cancel
          the appointment of any particular transfer agent. We may also approve a change in the office through which any transfer agent acts.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If any certificated securities of a particular series are redeemable and we redeem less than all the debt securities of that series, we may block the transfer or exchange of
          those debt securities during the period beginning fifteen (15) days before the day we mail the notice of redemption and ending on the day of that mailing, in order to freeze the list of holders to prepare the mailing. We may also refuse to
          register transfers or exchanges of any certificated securities selected for redemption, except that we will continue to permit transfers and exchanges of the unredeemed portion of any debt security that will be partially redeemed.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If a registered debt security is issued in book-entry form, only the depositary will be entitled to transfer and exchange the debt security as described in this subsection,
          since it will be the sole holder of the debt security.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Resignation of Trustee</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Each trustee may resign or be removed with respect to one (1) or more series of indenture securities provided that a successor trustee is appointed to act with respect to these
          series and has accepted such appointment. In the event that two (2) or more persons are acting as trustee with respect to different series of indenture securities under the indenture, each of the trustees will be a trustee of a trust separate and
          apart from the trust administered by any other trustee.</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">24</font></div>
          <div style="page-break-after: always;" id="DSPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Indenture Provisions &#8212; Subordination</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Upon any distribution of our assets upon our dissolution, winding up, liquidation or reorganization, the payment of the principal of (and premium, if any) and interest, if any,
          on any indenture securities denominated as subordinated debt securities is to be subordinated to the extent provided in the indenture in right of payment to the prior payment in full of all Designated Senior Indebtedness (as defined below), but
          our obligation to you to make payment of the principal of (and premium, if any) and interest, if any, on such subordinated debt securities will not otherwise be affected. In addition, no payment on account of principal (or premium, if any),
          sinking fund or interest, if any, may be made on such subordinated debt securities at any time unless full payment of all amounts due in respect of the principal (and premium, if any), sinking fund and interest on Designated Senior Indebtedness
          has been made or duly provided for in money or money&#8217;s worth.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In the event that, notwithstanding the foregoing, any payment by us is received by the trustee in respect of subordinated debt securities or by the holders of any of such
          subordinated debt securities before all Designated Senior Indebtedness is paid in full, the payment or distribution must be paid over to the holders of the Designated Senior Indebtedness or on their behalf for application to the payment of all
          the Designated Senior Indebtedness remaining unpaid until all the Designated Senior Indebtedness has been paid in full, after giving effect to any concurrent payment or distribution to the holders of the Designated Senior Indebtedness. Subject to
          the payment in full of all Designated Senior Indebtedness upon this distribution by us, the holders of such subordinated debt securities will be subrogated to the rights of the holders of the Designated Senior Indebtedness to the extent of
          payments made to the holders of the Designated Senior Indebtedness out of the distributive share of such subordinated debt securities.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">By reason of this subordination, in the event of a distribution of our assets upon our insolvency, certain of our senior creditors may recover more, ratably, than holders of
          any subordinated debt securities or the holders of any indenture securities that are not Designated Senior Indebtedness or subordinated debt securities. The indenture provides that these subordination provisions will not apply to money and
          securities held in trust under the defeasance provisions of the indenture.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Designated Senior Indebtedness is defined in the indenture as the principal of (and premium, if any) and unpaid interest on:</div>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zef662ad758eb4bfa898552c7c9f62349" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>our indebtedness (including indebtedness of others guaranteed by us), whenever created, incurred, assumed or guaranteed, for money borrowed, that we have designated as &#8220;Designated Senior Indebtedness&#8221; for purposes of the indenture and
                  in accordance with the terms of the indenture (including any indenture securities designated as Designated Senior Indebtedness); and</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zd76804b65baa4f06a8e7e0fd6a8ca8d9" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>renewals, extensions, modifications and refinancings of any of this indebtedness.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If this prospectus is being delivered in connection with the offering of a series of indenture securities denominated as subordinated debt securities, the accompanying
          prospectus supplement will set forth the approximate amount of our Designated Senior Indebtedness and of our other indebtedness outstanding as of a recent date.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Secured Indebtedness</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Certain of our indebtedness, including certain series of indenture securities, may be secured. The prospectus supplement for each series of indenture securities will describe
          the terms of any security interest for such series and will indicate the approximate amount of our secured indebtedness as of a recent date. In the event of a distribution of our assets upon our insolvency, the holders of unsecured indenture
          securities may recover less, ratably, than holders of any of our secured indebtedness.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">The Trustee under the Indenture</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Bank of New York Mellon serves as the trustee under the indenture.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Certain Considerations Relating to Foreign Currencies</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Debt securities denominated or payable in foreign currencies may entail significant risks. These risks include the possibility of significant fluctuations in the foreign
          currency markets, the imposition or modification of foreign exchange controls and potential illiquidity in the secondary market. These risks will vary depending upon the currency or currencies involved and will be more fully described in the
          applicable prospectus supplement.</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">25</font></div>
          <div style="page-break-after: always;" id="DSPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="line-height: 1.25;">
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="DESCRIPTIONOFSUBSCRIPTION"><!--Anchor--></a>DESCRIPTION OF SUBSCRIPTION RIGHTS</div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We may issue subscription rights to purchase our ordinary shares and/or our ADSs. These subscription rights may be issued independently or together with any other security
          offered hereby and may or may not be transferable by the shareholder receiving the subscription rights in such offering. In connection with any offering of subscription rights, we may enter into a standby arrangement with one or more underwriters
          or other purchasers pursuant to which the underwriters or other purchasers may be required to purchase any securities remaining unsubscribed for after such offering.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The prospectus supplement relating to any subscription rights we offer, if any, will, to the extent applicable, include specific terms relating to the offering, including some
          or all of the following:</div>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z6480d332ada74000910afb62e1c31b09" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the price, if any, for the subscription rights;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z31165e602c1f4db09eab3c22da410f42" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the exercise price payable for each ordinary share and/or ADS upon the exercise of the subscription rights;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zc1162896fe344fbc953968d2990d210a" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the number of subscription rights to be issued to each shareholder;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z3528bc4e7e904023b75091a8e006243c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the number and terms of the ordinary shares and/or ADSs which may be purchased per each subscription right;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z904eb999352749a896292f4ed7905632" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the extent to which the subscription rights are transferable;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z5913d4b6b77a44698c66dee1fc5346f1" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>any other terms of the subscription rights, including the terms, procedures and limitations relating to the exchange and exercise of the subscription rights;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z2430b78c240d4263af415715c8051715" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the date on which the right to exercise the subscription rights shall commence, and the date on which the subscription rights shall expire;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zb4e1b42ca9904427ae4c7f7d556e687e" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the extent to which the subscription rights may include an over-subscription privilege with respect to unsubscribed securities; and</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zd57030970ddf444fb327000d52307eaf" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>if applicable, the material terms of any standby underwriting or purchase arrangement which may be entered into by us in connection with the offering of subscription rights.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The description in the applicable prospectus supplement of any subscription rights we offer will not necessarily be complete and will be qualified in its entirety by reference
          to the applicable subscription right agreement, which will be filed with the SEC if we offer subscription rights. For more information on how you can obtain copies of the applicable subscription right agreement if we offer subscription rights,
          see &#8220;Where You Can Find More Information&#8221; beginning on page 31 and &#8220;Documents Incorporated by Reference&#8221; beginning on page 32. We urge you to read the applicable subscription right agreement and any applicable prospectus supplement in their
          entirety.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="line-height: 1.25;">
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="DESCRIPTIONOFWARRANTS"><!--Anchor--></a>DESCRIPTION OF WARRANTS</div>
          <div style="text-align: center; line-height: 1.25;">&#160;</div>
        </div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We may issue warrants for the purchase of ADSs. We may issue warrants independently of or together with ordinary shares (including ordinary shares represented by ADSs) offered
          by any prospectus supplement, and we may attach the warrants to, or issue them separately from, ordinary shares (including ordinary shares represented by ADSs). Each series of warrants will be issued under a separate warrant agreement to be
          entered into between us and a bank or trust company, as warrant agent, all as set forth in the prospectus supplement relating to the particular issue of offered warrants. The warrant agent will act solely as our agent in connection with the
          warrant certificates relating to the warrants and will not assume any obligation or relationship of agency or trust with any holders of warrant certificates or beneficial owners of warrants. The following summaries of certain provisions of the
          warrant agreements and warrants do not purport to be complete and are subject to, and are qualified in their entirety by reference to, all the provisions of the warrant agreement and the warrant certificates relating to each series of warrants
          which we will file with the SEC and incorporate by reference as an exhibit to the registration statement of which this prospectus is a part at or prior to the time of the issuance of any series of warrants.</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">General</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The applicable prospectus supplement will describe the terms of the warrants, including as applicable:</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z5c0a334fab1b43b498a5c27adf5ee77b" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 6%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 6%; vertical-align: top;">
                <div style="line-height: 1.25;">&#9679;</div>
              </td>
              <td style="width: 88%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">the offering price;</div>
              </td>
            </tr>

        </table>
        <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z0175d8a3086d425882dac5e82fde35b0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 6%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 6%; vertical-align: top;">
                <div style="line-height: 1.25;">&#9679;</div>
              </td>
              <td style="width: 88%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">the aggregate number or amount of underlying securities purchasable upon exercise of the warrants and the exercise price;</div>
              </td>
            </tr>

        </table>
        <div style="margin-left: 72pt; line-height: 1.25;">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zcace0acccb4344c29559a4cd3b171cc3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 6%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 6%; vertical-align: top;">
                <div style="line-height: 1.25;">&#9679;</div>
              </td>
              <td style="width: 88%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">the number of warrants being offered;</div>
              </td>
            </tr>

        </table>
        <div style="margin-left: 72pt; line-height: 1.25;">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">26</font></div>
          <div style="page-break-after: always;" id="DSPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="margin-left: 72pt; line-height: 1.25;"> <br>
        </div>
        <table cellspacing="0" cellpadding="0" id="z9d2c350854774b9686a1ecb07d797891" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 6%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 6%; vertical-align: top;">
                <div style="line-height: 1.25;">&#9679;</div>
              </td>
              <td style="width: 88%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">the date, if any, after which the warrants and the underlying securities will be transferable separately;</div>
              </td>
            </tr>

        </table>
        <div style="margin-left: 72pt; line-height: 1.25;">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zfbe02bd49f0b4dcabac7950f80ef0a24" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 6%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 6%; vertical-align: top;">
                <div style="line-height: 1.25;">&#9679;</div>
              </td>
              <td style="width: 88%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">the date on which the right to exercise the warrants will commence, and the date on which the right will expire, or the Expiration Date;</div>
              </td>
            </tr>

        </table>
        <div style="margin-left: 72pt; line-height: 1.25;">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zd227fa2ba37a4468b64d526cb495ad41" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 6%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 6%; vertical-align: top;">
                <div style="line-height: 1.25;">&#9679;</div>
              </td>
              <td style="width: 88%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">the number of warrants outstanding, if any;</div>
              </td>
            </tr>

        </table>
        <div style="margin-left: 72pt; line-height: 1.25;">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z7f67ec10d69f45feb1f23ebda4270803" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 6%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 6%; vertical-align: top;">
                <div style="line-height: 1.25;">&#9679;</div>
              </td>
              <td style="width: 88%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">any material Israeli and/or U.S. federal income tax consequences;</div>
              </td>
            </tr>

        </table>
        <div style="margin-left: 72pt; line-height: 1.25;">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z439d579680bc429aba076c88d54205c9" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 6%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 6%; vertical-align: top;">
                <div style="line-height: 1.25;">&#9679;</div>
              </td>
              <td style="width: 88%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">the terms, if any, on which we may accelerate the date by which the warrants must be exercised; and;</div>
              </td>
            </tr>

        </table>
        <div style="margin-left: 72pt; line-height: 1.25;">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zd5a2238b032f4e9a9cd5508d242c0c5a" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 6%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 6%; vertical-align: top;">
                <div style="line-height: 1.25;">&#9679;</div>
              </td>
              <td style="width: 88%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">any other terms of the warrants, including terms, procedures and limitations relating to the exchange and exercise of the warrants.</div>
              </td>
            </tr>

        </table>
        <div style="margin-left: 72pt; line-height: 1.25;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Warrants will be offered and exercisable for U.S. dollars only and will be in registered form only.</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Holders of warrants will be able to exchange warrant certificates for new warrant certificates of different denominations, present warrants for registration of transfer, and
          exercise warrants at the corporate trust office of the warrant agent or any other office indicated in the applicable prospectus supplement. Prior to the exercise of any warrants, holders of the warrants to purchase ordinary shares will not have
          any rights of holders of ordinary shares, including the right to receive payments of dividends, if any, or to exercise any applicable right to vote.&#160;</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Certain Risk Considerations</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;Any warrants we issue will involve a degree of risk, including risks arising from fluctuations in the price of the underlying ordinary shares or debt securities and general
          risks applicable to the securities market (or markets) on which the underlying securities trade, as applicable. Prospective purchasers of the warrants will need to recognize that the warrants may expire worthless, and, thus, purchasers should be
          prepared to sustain a total loss of the purchase price of their warrants. This risk reflects the nature of a warrant as an asset that, other factors held constant, tends to decline in value over time and that may, depending on the price of the
          underlying securities, become worthless when it expires. The trading price of a warrant at any time is expected to increase if the price of or, if applicable, dividend rate on, the underlying securities increases. Conversely, the trading price of
          a warrant is expected to decrease as the time remaining to expiration of the warrant decreases and as the price of or, if applicable, dividend rate on, the underlying securities, decreases. Assuming all other factors are held constant, the more a
          warrant is &#8220;out-of-the-money&#8221; (i.e., the more the exercise price exceeds the price of the underlying securities and the shorter its remaining term to expiration), the greater the risk that a purchaser of the warrant will lose all or part of his
          or her investment. If the price of the underlying securities does not rise before the warrant expires to an extent sufficient to cover a purchaser&#8217;s cost of the warrant, the purchaser will lose all or part of his or her investment in the warrant
          upon expiration.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition, prospective purchasers of the warrants should be experienced with respect to options and option transactions, should understand the risks associated with options
          and should reach an investment decision only after careful consideration, with their financial advisers, of the suitability of the warrants in light of their particular financial circumstances and the information discussed in this prospectus and,
          if applicable, the prospectus supplement. Before purchasing, exercising or selling any warrants, prospective purchasers and holders of warrants should carefully consider, among other things:</div>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z6036f5f5b90e493d80e6dd5c45164ae8" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 6%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;&#160;</div>
              </td>
              <td style="width: 6%; vertical-align: top;">
                <div style="line-height: 1.25;">&#9679;</div>
              </td>
              <td style="width: 88%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">the trading price of the warrants;</div>
              </td>
            </tr>

        </table>
        <div style="margin-left: 72pt; line-height: 1.25;">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z55ecc5f7592648e7b73901a15a79b5c3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 6%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 6%; vertical-align: top;">
                <div style="line-height: 1.25;">&#9679;</div>
              </td>
              <td style="width: 88%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">the price of the underlying securities at that time;</div>
              </td>
            </tr>

        </table>
        <div style="margin-left: 72pt; line-height: 1.25;">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z87a72ac2fbae485b837be35d16836e81" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 6%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 6%; vertical-align: top;">
                <div style="line-height: 1.25;">&#9679;</div>
              </td>
              <td style="width: 88%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">the time remaining to expiration; and</div>
              </td>
            </tr>

        </table>
        <div style="margin-left: 72pt; line-height: 1.25;">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z06dea29ff23e416a96da54ee638c361f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 6%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 6%; vertical-align: top;">
                <div style="line-height: 1.25;">&#9679;</div>
              </td>
              <td style="width: 88%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">any related transaction costs.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Some of the factors referred to above are in turn influenced by various political, economic and other factors that can affect the trading price of the underlying securities and
          should be carefully considered prior to making any investment decisions.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Purchasers of the warrants should further consider that the initial offering price of the warrants may be in excess of the price that a purchaser of options might pay for a
          comparable option in a private, less liquid transaction. In addition, it is not possible to predict the price at which the warrants will trade in the secondary market or whether any such market will be liquid. We may, but will not be obligated
          to, file an application to list any warrants on a U.S. national securities exchange. To the extent that any warrants are exercised, the number of warrants outstanding will decrease, which may result in a lessening of the liquidity of the
          warrants. Finally, the warrants will constitute our direct, unconditional and unsecured obligations and, as such, will be subject to any changes in our perceived creditworthiness.</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">27</font></div>
          <div style="page-break-after: always;" id="DSPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">&#160;Exercise of Warrants</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;Each holder of a warrant will be entitled to purchase that number or amount of underlying securities, at the exercise price, as will in each case be described in the
          prospectus supplement relating to the offered warrants. After the close of business on the Expiration Date (which may be extended by us), unexercised warrants will become void.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;Holders may exercise warrants by delivering to the warrant agent payment as provided in the applicable prospectus supplement of the amount required to purchase the underlying
          securities purchasable upon exercise, together with the information set forth on the reverse side of the warrant certificate. Warrants will be deemed to have been exercised upon receipt of payment of the exercise price, subject to the receipt
          within two (2) business days of the warrant certificate evidencing the exercised warrants. Upon receipt of payment and the warrant certificate properly completed and duly executed at the corporate trust office of the warrant agent or any other
          office indicated in the applicable prospectus supplement, we will, as soon as practicable, issue and deliver the underlying securities purchasable upon such exercise. If fewer than all of the warrants represented by a warrant certificate are
          exercised, we will issue a new warrant certificate for the remaining amount of warrants.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">&#160;Amendments and Supplements to Warrant Agreements</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;We may amend or supplement the warrant agreement without the consent of the holders of the warrants issued under the agreement to effect changes that are not inconsistent with
          the provisions of the warrants and that do not adversely affect the interests of the holders.<font style="font-weight: bold;">&#160;</font></div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25;">
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="DESCRIPTIONOFUNITS"><!--Anchor--></a>DESCRIPTION OF UNITS</div>
          <div style="text-align: center; line-height: 1.25;">&#160;</div>
        </div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We may issue units comprised of one or more of the other securities described in this prospectus in any combination. Each unit will be issued so that the holder of the unit is
          also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included security. The unit agreement under which a unit is issued may provide that the securities included
          in the unit may not be held or transferred separately, at any time or at any time before a specified date.</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The applicable prospectus supplement will describe:</div>
        <div style="text-align: justify; line-height: 1.25;">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zd6e22ca90a194eb9bf3d30f94e282e8e" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 6.67%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 6.67%; vertical-align: top;">
                <div style="line-height: 1.25;">&#9679;</div>
              </td>
              <td style="width: 86.67%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">the designation and terms of the units and of the securities comprising the units, including whether and under what circumstances those securities may be held or transferred separately;</div>
              </td>
            </tr>

        </table>
        <div style="text-align: justify; margin-left: 64.349pt; line-height: 1.25;">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z27ecc1e7cd3943299a6ac28ab43ab744" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 6.67%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 6.67%; vertical-align: top;">
                <div style="line-height: 1.25;">&#9679;</div>
              </td>
              <td style="width: 86.67%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">the material terms of a unit agreement under which the units will be issued;</div>
              </td>
            </tr>

        </table>
        <div style="text-align: justify; margin-left: 64.349pt; line-height: 1.25;">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zeb5b010c677c432c993c4c5ac3279761" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 6.67%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 6.67%; vertical-align: top;">
                <div style="line-height: 1.25;">&#9679;</div>
              </td>
              <td style="width: 86.67%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the units; and</div>
              </td>
            </tr>

        </table>
        <div style="text-align: justify; line-height: 1.25;">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z60af0fd5dd964c7ebd955727478a6425" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 6.67%; vertical-align: top;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 6.67%; vertical-align: top;">
                <div style="line-height: 1.25;">&#9679;</div>
              </td>
              <td style="width: 86.67%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">whether the units will be issued in fully registered or global form.&#160;</div>
              </td>
            </tr>

        </table>
        <div style="text-align: justify; text-indent: 28.35pt; line-height: 1.25;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The applicable prospectus supplement will describe the terms of any units. The preceding description and any description of units in the applicable prospectus supplement does
          not purport to be complete and is subject to and is qualified in its entirety by reference to the unit agreement and, if applicable, collateral arrangements and depositary arrangements relating to such units. For more information on how you can
          obtain copies of the applicable unit agreement if we offer units, see &#8220;Where You Can Find More Information&#8221; beginning on page 31 and &#8220;Incorporation of Certin Documents by Reference&#8221; beginning on page 32. We urge you to read the applicable unit
          agreement and any applicable prospectus supplement in their entirety.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">TAXATION</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The material Israeli and U.S. federal income tax consequences relating to the purchase, ownership and disposition of any of the securities offered by this prospectus will be
          set forth in the prospectus supplement offering those securities or incorporated by reference from our Annual Report on Form 20-F or other public filings we make with the SEC.</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">28</font></div>
          <div style="page-break-after: always;" id="DSPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="PLANOFDISTRIBUTION"><!--Anchor--></a>PLAN OF D<a name="PLANOFD"><!--Anchor--></a>ISTRIBUTION</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The securities being offered by this prospectus may be sold:</div>
        <div style="line-height: 1.25;">
          <div style="text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;">
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7b07538011a2418ab28023e06dfb405f">

                <tr>
                  <td style="width: 72pt;"><br>
                  </td>
                  <td style="width: 36pt; vertical-align: top; align: right;">&#9679;</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>through agents;</div>
                  </td>
                </tr>

            </table>
            <div style="text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z107e3a5391684fc9b736be422cc3bf0e">

                <tr>
                  <td style="width: 72pt;"><br>
                  </td>
                  <td style="width: 36pt; vertical-align: top; align: right;">&#9679;</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>to or through one or more underwriters on a firm commitment or agency basis;</div>
                  </td>
                </tr>

            </table>
            <div style="text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf412274b81b34a24a1401e51620584c5">

                <tr>
                  <td style="width: 72pt;"><br>
                  </td>
                  <td style="width: 36pt; vertical-align: top; align: right;">&#9679;</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>through put or call option transactions relating to the securities;</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd86df44dc8ff484a86f7dd8a443cfbc5">

                <tr>
                  <td style="width: 72pt;"><br>
                  </td>
                  <td style="width: 36pt; vertical-align: top; align: right;">&#9679;</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>to or through dealers, who may act as agents or principals, including a block trade (which may involve crosses) in which a broker or dealer so engaged will attempt to sell as agent but may position and resell a portion of the block
                      as principal to facilitate the transaction;</div>
                  </td>
                </tr>

            </table>
            <div style="text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0e6e0e79683f4c868c6de658ece6b4ba">

                <tr>
                  <td style="width: 72pt;"><br>
                  </td>
                  <td style="width: 36pt; vertical-align: top; align: right;">&#9679;</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>through privately negotiated transactions;</div>
                  </td>
                </tr>

            </table>
            <div style="text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z068b3fc46c814f4689acbdea9367b617">

                <tr>
                  <td style="width: 72pt;"><br>
                  </td>
                  <td style="width: 36pt; vertical-align: top; align: right;">&#9679;</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>purchases by a broker or dealer as principal and resale by such broker or dealer for its own account pursuant to this prospectus;</div>
                  </td>
                </tr>

            </table>
            <div style="text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb097eaff8763480382e9dc0eb734e1f5">

                <tr>
                  <td style="width: 72pt;"><br>
                  </td>
                  <td style="width: 36pt; vertical-align: top; align: right;">&#9679;</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>directly to purchasers, including our affiliates, through a specific bidding or auction process, on a negotiated basis or otherwise; to or through one or more underwriters on a firm commitment or best efforts basis;</div>
                  </td>
                </tr>

            </table>
            <div style="text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z43f96f91ad2740d7ae45a182182141b0">

                <tr>
                  <td style="width: 72pt;"><br>
                  </td>
                  <td style="width: 36pt; vertical-align: top; align: right;">&#9679;</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>exchange distributions and/or secondary distributions;</div>
                  </td>
                </tr>

            </table>
            <div style="text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4e9c1676dbea4ef295e24a57c23bdd6a">

                <tr>
                  <td style="width: 72pt;"><br>
                  </td>
                  <td style="width: 36pt; vertical-align: top; align: right;">&#9679;</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>ordinary brokerage transactions and transactions in which the broker solicits purchasers;</div>
                  </td>
                </tr>

            </table>
            <div style="text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zfbcc7b4cc546498d8542cf29545aae40">

                <tr>
                  <td style="width: 72pt;"><br>
                  </td>
                  <td style="width: 36pt; vertical-align: top; align: right;">&#9679;</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>in &#8220;at-the-market&#8221; offerings, within the meaning of Rule 415(a)(4) of the Securities Act to or through a market maker or into an existing trading market, on an exchange or otherwise;</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za384d99eff184a1db16beb49db01ebf7">

                <tr>
                  <td style="width: 72pt;"><br>
                  </td>
                  <td style="width: 36pt; vertical-align: top; align: right;">&#9679;</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>transactions not involving market makers or established trading markets, including direct sales or privately negotiated transactions;</div>
                  </td>
                </tr>

            </table>
            <div style="text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za0360bedc1c44fa7af4e700f75152ba1">

                <tr>
                  <td style="width: 72pt;"><br>
                  </td>
                  <td style="width: 36pt; vertical-align: top; align: right;">&#9679;</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>transactions in options, swaps or other derivatives that may or may not be listed on an exchange or</div>
                  </td>
                </tr>

            </table>
            <div style="text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z42574ca6b5a34a7ab819ddcd20fee7f9">

                <tr>
                  <td style="width: 72pt;"><br>
                  </td>
                  <td style="width: 36pt; vertical-align: top; align: right;">&#9679;</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>through any other method permitted pursuant to applicable law; or</div>
                  </td>
                </tr>

            </table>
            <div style="text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z333abe72c95f43e2a949dbb52f2f7920">

                <tr>
                  <td style="width: 72pt;"><br>
                  </td>
                  <td style="width: 36pt; vertical-align: top; align: right;">&#9679;</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>through a combination of any such methods of sale.</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;">&#160;</div>
          </div>
        </div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">At any time a particular offer of the securities covered by this prospectus is made, a revised prospectus or prospectus supplement, if required, will be distributed which will
          set forth the aggregate amount of securities covered by this prospectus being offered and the terms of the offering, including the name or names of any underwriters, dealers, brokers or agents, any discounts, commissions, concessions and other
          items constituting compensation from us and any discounts, commissions or concessions allowed or re-allowed or paid to dealers. Such prospectus supplement, and, if necessary, a post-effective amendment to the registration statement of which this
          prospectus is a part, will be filed with the SEC to reflect the disclosure of additional information with respect to the distribution of the securities covered by this prospectus. In order to comply with the securities laws of certain states, if
          applicable, the securities sold under this prospectus may only be sold through registered or licensed broker-dealers. In addition, in some states the securities may not be sold unless they have been registered or qualified for sale in the
          applicable state or an exemption from registration or qualification requirements is available and is complied with.</div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The distribution of securities may be effected from time to time in one or more transactions, including block transactions and transactions on The Nasdaq Capital Market or any
          other organized market where the securities may be traded. The securities may be sold at a fixed price or prices, which may be changed, or at market prices prevailing at the time of sale, at prices relating to the prevailing market prices or at
          negotiated prices. The consideration may be cash or another form negotiated by the parties. Agents, underwriters or broker-dealers may be paid compensation for offering and selling the securities. That compensation may be in the form of
          discounts, concessions or commissions to be received from us or from the purchasers of the securities. Any dealers and agents participating in the distribution of the securities may be deemed to be underwriters, and compensation received by them
          on resale of the securities may be deemed to be underwriting discounts. If any such dealers or agents were deemed to be underwriters, they may be subject to statutory liabilities under the Securities Act.</div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Agents may from time to time solicit offers to purchase the securities. If required, we will name in the applicable prospectus supplement any agent involved in the offer or
          sale of the securities and set forth any compensation payable to the agent. Unless otherwise indicated in the prospectus supplement, any agent will be acting on a best efforts basis for the period of its appointment. Any agent selling the
          securities covered by this prospectus may be deemed to be an underwriter, as that term is defined in the Securities Act, of the securities.</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">29</font></div>
          <div style="page-break-after: always;" id="DSPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">To the extent that we make sales to or through one or more underwriters or agents in at-the-market offerings, we will do so pursuant to the terms of a distribution agreement
          between us and the underwriters or agents. If we engage in at-the-market sales pursuant to a distribution agreement, we will sell any of our listed securities to or through one or more underwriters or agents, which may act on an agency basis or
          on a principal basis. During the term of any such agreement, we may sell any of our listed securities on a daily basis in exchange transactions or otherwise as we agree with the underwriters or agents. The distribution agreement will provide that
          any of our listed securities which are sold will be sold at prices related to the then prevailing market prices for our listed securities. Therefore, exact figures regarding proceeds that will be raised or commissions to be paid cannot be
          determined at this time and will be described in a prospectus supplement. Pursuant to the terms of the distribution agreement, we also may agree to sell, and the relevant underwriters or agents may agree to solicit offers to purchase, blocks of
          our listed securities. The terms of each such distribution agreement will be set forth in more detail in a prospectus supplement to this prospectus.</div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If underwriters are used in a sale, securities will be acquired by the underwriters for their own account and may be resold from time to time in one or more transactions,
          including negotiated transactions, at a fixed public offering price or at varying prices determined at the time of sale, or under delayed delivery contracts or other contractual commitments. Securities may be offered to the public either through
          underwriting syndicates represented by one or more managing underwriters or directly by one or more firms acting as underwriters. If an underwriter or underwriters are used in the sale of securities, an underwriting agreement will be executed
          with the underwriter or underwriters, as well as any other underwriter or underwriters, with respect to a particular underwritten offering of securities, and will set forth the terms of the transactions, including compensation of the underwriters
          and dealers and the public offering price, if applicable. The prospectus and prospectus supplement will be used by the underwriters to resell the securities.</div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If a dealer is used in the sale of the securities, we or an underwriter will sell the securities to the dealer, as principal. The dealer may then resell the securities to the
          public at varying prices to be determined by the dealer at the time of resale. To the extent required, we will set forth in the prospectus supplement the name of the dealer and the terms of the transactions.</div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We may directly solicit offers to purchase the securities and may make sales of securities directly to institutional investors or others. These persons may be deemed to be
          underwriters within the meaning of the Securities Act with respect to any resale of the securities. To the extent required, the prospectus supplement will describe the terms of any such sales, including the terms of any bidding or auction
          process, if used.</div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Agents, underwriters and dealers may be entitled under agreements which may be entered into with us to indemnification by us against specified liabilities, including
          liabilities incurred under the Securities Act, or to contribution by us to payments they may be required to make in respect of such liabilities. If required, the prospectus supplement will describe the terms and conditions of the indemnification
          or contribution. Some of the agents, underwriters or dealers, or their affiliates may be customers of, engage in transactions with or perform services for us or our subsidiaries.</div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Any person participating in the distribution of securities registered under the registration statement that includes this prospectus will be subject to applicable provisions of
          the Securities Exchange Act of 1934, as amended, or the Exchange Act, and the applicable SEC rules&#160;and regulations, including, among others, Regulation M, which may limit the timing of purchases and sales of any of our securities by that person.
          Furthermore, Regulation M may restrict the ability of any person engaged in the distribution of our securities to engage in market-making activities with respect to our securities. These restrictions may affect the marketability of our securities
          and the ability of any person or entity to engage in market-making activities with respect to our securities.</div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Certain persons participating in an offering may engage in over-allotment, stabilizing transactions, short-covering transactions, penalty bids and other transactions that
          stabilize, maintain or otherwise affect the price of the offered securities. These activities may maintain the price of the offered securities at levels above those that might otherwise prevail in the open market, including by entering
          stabilizing bids, effecting syndicate covering transactions or imposing penalty bids, each of which is described below:</div>
        <div style="line-height: 1.25;">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zcf1b8b2a403a4cc0a82d8546bc31e965" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 38.5pt;"><br>
              </td>
              <td style="width: 33.5pt; vertical-align: top; align: right;">&#9679;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>a stabilizing bid means the placing of any bid, or the effecting of any purchase, for the purpose of pegging, fixing or maintaining the price of a security.</div>
              </td>
            </tr>

        </table>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" id="z981a4f2587b04f0aac5b9ef877e13fce" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#160;&#9679;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>a syndicate covering transaction means the placing of any bid on behalf of the underwriting syndicate or the effecting of any purchase to reduce a short position created in connection with the offering.</div>
              </td>
            </tr>

        </table>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="0" id="ze1c3577fc0cf4c919088f939691308b6" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#160;&#9679;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>a penalty bid means an arrangement that permits the managing underwriter to reclaim a selling concession from a syndicate member in connection with the offering when offered securities originally sold by the syndicate member are
                  purchased in syndicate covering transactions.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">30</font></div>
          <div style="page-break-after: always;" id="DSPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">These transactions may be effected on an exchange or automated quotation system, if the securities are listed on that exchange or admitted for trading on that automated
          quotation system, or in the over-the-counter market or otherwise.</div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If so indicated in the applicable prospectus supplement, we will authorize agents, underwriters or dealers to solicit offers from certain types of institutions to purchase
          offered securities from us at the public offering price set forth in such prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. Such contracts will be subject only to
          those conditions set forth in the prospectus supplement and the prospectus supplement will set forth the commission payable for solicitation of such contracts.</div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition, ordinary shares, ADSs or warrants may be issued upon conversion of or in exchange for debt securities or other securities.</div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Any underwriters to whom offered securities are sold for public offering and sale may make a market in such offered securities, but such underwriters will not be obligated to
          do so and may discontinue any market making at any time without notice. The offered securities may or may not be listed on a national securities exchange. No assurance can be given that there will be a market for the offered securities.</div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Any securities that qualify for sale pursuant to Rule&#160;144 or Regulation S under the Securities Act, may be sold under Rule&#160;144 or Regulation S rather than pursuant to this
          prospectus.</div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In connection with offerings made through underwriters or agents, we may enter into agreements with such underwriters or agents pursuant to which we receive our outstanding
          securities in consideration for the securities being offered to the public for cash. In connection with these arrangements, the underwriters or agents may also sell securities covered by this prospectus to hedge their positions in these
          outstanding securities, including in short sale transactions. If so, the underwriters or agents may use the securities received from us under these arrangements to close out any related open borrowings of securities.</div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We may enter into derivative transactions with third parties or sell securities not covered by this prospectus to third parties in privately negotiated transactions. If the
          applicable prospectus supplement indicates, in connection with those derivatives, such third parties (or affiliates of such third parties) may sell securities covered by this prospectus and the applicable prospectus supplement, including in short
          sale transactions. If so, such third parties (or affiliates of such third parties) may use securities pledged by us or borrowed from us or others to settle those sales or to close out any related open borrowings of shares, and may use securities
          received from us in settlement of those derivatives to close out any related open borrowings of shares. The third parties (or affiliates of such third parties) in such sale transactions will be underwriters and will be identified in the
          applicable prospectus supplement (or a post-effective amendment).</div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We may loan or pledge securities to a financial institution or other third party that in turn may sell the securities using this prospectus. Such financial institution or third
          party may transfer its short position to investors in our securities or in connection with a simultaneous offering of other securities offered by this prospectus or in connection with a simultaneous offering of other securities offered by this
          prospectus.</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="LEGALMATTERS"><!--Anchor--></a>LEGAL<a name="LEGAL"><!--Anchor--></a> MATTERS</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Yigal Arnon &amp; Co., Jerusalem, Israel, will pass upon certain legal matters regarding the securities offered hereby under Israeli law and McDermott Will &amp; Emery LLP, New
          York, New York, will pass upon certain legal matters regarding the securities offered hereby under U.S. federal securities law. Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will
          name in the applicable prospectus supplement.</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">EXPERTS</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The financial statements and management&#8217;s assessment of the effectiveness of internal control over financial reporting (which is included in Management&#8217;s Report on Internal
          Control over Financial Reporting) incorporated in this Prospectus by reference to the Annual Report on Form 20-F for the year ended December 31, 2019 have been so incorporated in reliance on the report of Kesselman &amp; Kesselman, Certified
          Public Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;&#160;</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">WHERE YOU CAN FIND MORE INFORMATION</div>
        <div style="text-align: justify; line-height: 1.25;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have filed with the SEC a registration statement on Form&#160;F-3, including amendments and relevant exhibits and schedules, under the Securities Act covering the ordinary shares
          to be sold in this offering. This prospectus, which constitutes a part of the registration statement, summarizes material provisions of contracts and other documents that we refer to in the prospectus. Since this prospectus does not contain all
          of the information contained in the registration statement, you should read the registration statement and its exhibits and schedules for further information with respect to us and our ordinary shares. Our SEC filings, including the registration
          statement, are also available to you on the SEC&#8217;s Web site at&#160;<u>http://www.sec.gov</u>.</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">31</font></div>
          <div style="page-break-after: always;" id="DSPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="text-align: justify; line-height: 1.25;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We are subject to the information reporting requirements of the Exchange Act that are applicable to foreign private issuers, and under those requirements we file reports with
          the SEC. Those other reports or other information may be inspected without charge at the locations described above. As a foreign private issuer, we are exempt from the rules under the Exchange Act related to the furnishing and content of proxy
          statements, and our officers, directors and principal shareholder are exempt from the reporting and short-swing profit recovery provisions contained in Section&#160;16 of the Exchange Act. In addition, we are not required under the Exchange Act to
          file annual, quarterly and current reports and financial statements with the SEC as frequently or as promptly as United States companies whose securities are registered under the Exchange Act. However, we file with the SEC, within four months
          after the end of each fiscal year, or such applicable time as required by the SEC, an annual report on Form&#160;20-F containing financial statements audited by an independent registered public accounting firm.</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="INCORPORATIONOFCERTAINDOC"><!--Anchor--></a><a name="INCORPORATION"><!--Anchor--></a>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The SEC allows us to incorporate by reference our publicly filed reports into this prospectus, which means that information included in those reports is considered part of this
          prospectus. Information that we file with the SEC after the date of this prospectus will automatically update and supersede the information contained in this prospectus.</div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This prospectus incorporates by reference the documents listed below, which have been previously filed with the SEC:</div>
        <div style="text-align: justify; line-height: 1.25;">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z045a7c3b2b0143a1ae57786ccaabd61b" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 6.67%; vertical-align: top;">&#160;</td>
              <td style="width: 6.67%; vertical-align: top;">
                <div style="line-height: 1.25;">&#9679;</div>
              </td>
              <td style="width: 86.67%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">our Annual Report on Form 20-F for the year ended December 31, 2019, filed with the SEC on March 12, 2020; and</div>
              </td>
            </tr>

        </table>
        <div style="text-align: justify; text-indent: -36pt; margin-left: 72pt; line-height: 1.25;">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z0dcd33ea3afd4a9c88527ff17d42b86b" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 6.67%; vertical-align: top;">&#160;</td>
              <td style="width: 6.67%; vertical-align: top;">
                <div style="line-height: 1.25;">&#9679;</div>
              </td>
              <td style="width: 86.67%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">our Report on Form 6-K filed with the SEC on May 20, 2020, May 26, 2020 (two filings), May 27, 2020, May 28, 2020, June 1, 2020, June 3, 2020, August 6, 2020, August 19, 2020 (two
                  filings), September 24, 2020, September 25, 2020, October 29, 2020, October 30, 2020, November 18, 2020, November 23, 2020 and December 16, 2020 (two filings)&#160; (in each case, to the extent expressly incorporated by reference into our
                  effective registration statements filed by us under the Securities Act).</div>
              </td>
            </tr>

        </table>
        <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We also incorporate by reference into this prospectus and any accompanying prospectus supplement additional documents that we may file with the SEC under sections 13(a), 13(c),
          14 or 15(d) of the Exchange Act from the date of this prospectus supplement until we have sold all of the securities to which this prospectus supplement relates or the offering is otherwise terminated.</div>
        <div style="text-align: justify; line-height: 1.25;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The SEC maintains an Internet site at http://www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers like us that file
          electronically with the SEC.</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We will furnish without charge to you, on written or oral request, a copy of any or all of the above documents, other than exhibits to such documents which are not specifically
          incorporated by reference therein. You should direct any requests for documents to:</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="margin-left: 36pt; line-height: 1.25;">BioLineRx Ltd.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; </div>
        <div style="margin-left: 36pt; line-height: 1.25;">Modi&#8217;in Technology Park&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; </div>
        <div style="margin-left: 36pt; line-height: 1.25;">2 HaMa&#8217;ayan Street&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; </div>
        <div style="margin-left: 36pt; line-height: 1.25;">Modi&#8217;in 7177871, Israel </div>
        <div style="margin-left: 36pt; line-height: 1.25;">Attention: Corporate Secretary&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; </div>
        <div style="margin-left: 36pt; line-height: 1.25;">Tel.: +972-8-642-9100 &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; </div>
        <div style="margin-left: 36pt; line-height: 1.25;">e-mail: <u>info@BioLineRx.com</u></div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The information relating to us contained in this prospectus is not comprehensive and should be read together with the information contained in the incorporated documents.
          Descriptions contained in the incorporated documents as to the contents of any contract or other document may not contain all of the information which is of interest to you. You should refer to the copy of such contract or other document filed as
          an exhibit to our filings.</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="ENFORCEABILITY"><!--Anchor--></a>ENFORCEABILITY OF CIVIL LIABILITIES</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We are incorporated under the laws of the State of Israel. Service of process upon us and upon our directors and officers and the Israeli experts named in this registration
          statement, substantially all of whom reside outside of the United States, may be difficult to obtain within the United States. Furthermore, because substantially all of our assets and substantially all of our directors and officers are located
          outside the United States, any judgment obtained in the United States against us or any of our directors and officers may not be collectible within the United States.</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">32</font></div>
          <div style="page-break-after: always;" id="DSPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have been informed by our legal counsel in Israel, Yigal Arnon &amp; Co., that it may be difficult to assert U.S. securities law claims in original actions instituted in
          Israel. Israeli courts may refuse to hear a claim based on a violation of U.S. securities laws because Israel is not the most appropriate forum to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine
          that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact which can be a time-consuming and costly process. Certain matters of procedure will
          also be governed by Israeli law.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Subject to specified time limitations and legal procedures, Israeli courts may enforce a United States judgment in a civil matter which, subject to certain exceptions, is
          non-appealable, including judgments based upon the civil liability provisions of the Securities Act and the Exchange Act and including a monetary or compensatory judgment in a non-civil matter, provided that among other things:</div>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z59ce81d9fb1f4cf7b91612da2a0e5edc" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#9679;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the judgments are obtained after due process before a court of competent jurisdiction, according to the laws of the state in which the judgment is given and the rules of private international law currently prevailing in Israel;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z278d012ea1dd43dbb751d35876011a7c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#9679;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the prevailing law of the foreign state in which the judgments were rendered allows for the enforcement of judgments of Israeli courts;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z2e4c91475e4b4ae39aa8f61b75425494" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#9679;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>adequate service of process has been effected and the defendant has had a reasonable opportunity to be heard and to present his or her evidence;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z3c597d001dc44a54a5aec671516f3876" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#9679;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the judgments are not contrary to public policy of Israel, and the enforcement of the civil liabilities set forth in the judgment is not likely to impair the security or sovereignty of Israel;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zc05f2aeba21f438eb387fed4a33de876" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#9679;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the judgments were not obtained by fraud and do not conflict with any other valid judgments in the same matter between the same parties;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z2eaf898a3bce4553b088177a10f66c7e" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#9679;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>an action between the same parties in the same matter is not pending in any Israeli court at the time the lawsuit is instituted in the foreign court; and</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zfe408500d078460bbbdd21f7ef5d7cd8" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">&#9679;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the judgment is enforceable according to the laws of Israel and according to the law of the foreign state in which the relief was granted.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Generally, an Israeli court will not enforce a foreign judgment if the motion for enforcement was filed more than five years after the date of its award in the United States,
          unless Israel and the United States have agreed otherwise on a different period, or if an Israeli court finds exceptional reasons justifying the delay.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If a foreign judgment is enforced by an Israeli court, it generally will be payable in Israeli currency, which can then be converted into non-Israeli currency and transferred
          out of Israel. The usual practice in an action before an Israeli court to recover an amount in a non-Israeli currency is for the Israeli court to issue a judgment for the equivalent amount in Israeli currency at the rate of exchange in force on
          the date of the judgment, but the judgment debtor may also make payment in foreign currency. Pending collection, the amount of the judgment of an Israeli court stated in Israeli currency ordinarily will be linked to the Israeli consumer price
          index plus interest at the annual statutory rate set by Israeli regulations prevailing at the time. Judgment creditors must bear the risk of unfavorable exchange rates.&#160;</div>
        <div style="line-height: 1.25;">
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        </div>
        <div style="line-height: 1.25;">
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Puglisi &amp; Associates is the U.S. agent authorized to receive service of process in any action against us arising out of this offering. The address of Puglisi &amp;
            Associates is 850 Library Avenue, Newark, Delaware 19711.</div>
        </div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="EXPENSES"><!--Anchor--></a><a name="EXP"><!--Anchor--></a>EXPENSES</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
          <div style="text-indent: 36pt; line-height: 1.25;">The following is an estimate of the expenses (all of which are to be paid by us) that we may incur in connection with the securities being registered hereby. Each prospectus supplement describing
            an offering of securities will reflect the estimated expenses related to the offering of securities under that prospectus supplement.</div>
        </div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">&#160;&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z5e512feb3e4241c6a86d1de75c5a2427" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 85%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">SEC registration fees</div>
              </td>
              <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">$</div>
              </td>
              <td style="width: 12%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;">
                <div style="line-height: 1.25;">
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">7,506.65</div>
                </div>
              </td>
              <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 85%; vertical-align: bottom;">
                <div style="line-height: 1.25;">FINRA filing fee</div>
              </td>
              <td style="width: 1%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 1%; vertical-align: bottom;">
                <div style="line-height: 1.25;">$</div>
              </td>
              <td style="width: 12%; vertical-align: bottom; text-align: right;">
                <div style="line-height: 1.25;">
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">10,820.78</div>
                </div>
              </td>
              <td style="width: 1%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 85%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">Legal fees and expenses</div>
              </td>
              <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">$</div>
              </td>
              <td style="width: 12%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="text-align: right; line-height: 1.25;">*</div>
              </td>
              <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 85%; vertical-align: bottom;">
                <div style="line-height: 1.25;">Accountants fees and expenses</div>
              </td>
              <td style="width: 1%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 1%; vertical-align: bottom;">
                <div style="line-height: 1.25;">$</div>
              </td>
              <td style="width: 12%; vertical-align: bottom;">
                <div style="text-align: right; line-height: 1.25;">*</div>
              </td>
              <td style="width: 1%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 85%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">Printing Fees</div>
              </td>
              <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">$</div>
              </td>
              <td style="width: 12%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="text-align: right; line-height: 1.25;">*</div>
              </td>
              <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 85%; vertical-align: bottom;">
                <div style="line-height: 1.25;">Miscellaneous</div>
              </td>
              <td style="width: 1%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25;">$</div>
              </td>
              <td style="width: 12%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="text-align: right; line-height: 1.25;">*</div>
              </td>
              <td style="width: 1%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 85%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">Total</div>
              </td>
              <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 4px double;">
                <div style="line-height: 1.25;">$</div>
              </td>
              <td style="width: 12%; vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); text-align: right;">*</td>
              <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
            </tr>

        </table>
        <div style="text-indent: 35.3pt; line-height: 1.25; font-weight: bold;">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z7a01d438da354d2d9926a85f8259469f" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">*</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>These fees and expenses depend on the securities offered and the number of issuances and accordingly cannot be estimated at this time.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">33</font></div>
          <div style="page-break-after: always;" id="DSPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
      </div>
      <br>
    </div>
    <div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25;">13,636,365 American Depositary Shares Representing 204,545,475 Ordinary Shares</div>
      <div style="line-height: 1.25"><br>
      </div>
      <div style="text-align: center; line-height: 1.25;">Warrants to Purchase 13,636,365 American Depositary Shares Representing 204,545,475 Ordinary Shares</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25;">Placement Agent Warrants to Purchase 681,818 American Depositary Shares Representing 10,227,270 Ordinary Shares</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; text-indent: 18pt; line-height: 1.25;"><img width="298" height="43" src="image4.jpg"></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25;"><img width="168" height="5" src="image5.jpg"></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25;">PROSPECTUS SUPPLEMENT</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25;"><img width="168" height="5" src="image5.jpg"></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold; font-size: 16pt;">H.C. Wainwright &amp; Co.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25;">September 18, 2022</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25">&#160;
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25"><br>
      </div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image0.jpg
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0-!W@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH0!1110 4444 %%%% !1129H 6BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MNB%<%X4O-\2#-=U$<J#7'41M!DE%%%9FH4444 %%%% !1110 4444 %%%%
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M^>GM)Q2MH.Y<\_WIRS\=:SO,IPEXIV$GJ7S/QUIGG^]4S+Q3?,HL#>II)/\
M)UJU:39;K6.LGR]:L6LN&ZU%BD=3;OD5:K(M)L]ZU4.14R1:'4445)04444
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M'>E^T=.:HN2<4$G(IV&BX;CY\9IPN.O-4,GS*4$Y-)("VEQUYJ>*ZQWK+4D
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MY-,9>U6,?-32/FH:U,GN-1>U.*X-/4?,*<X^:A(T&A>*:J_-4ZCY:8!S182
MK3-O)J?'%, ^8T):"&*N:3;\V*E0<&@#]Y189&4Q2%*G<4A'(HL,K[<"G;?E
MJ204I'R"BPR +2E>*>!2D<46T'T(@N:3;4T8ZTF.M"0D0[><TNVI<<48XI6
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MI,0=Z4=31[TG>A  [TE*.E)3$Q:*!13$%)2]J*8!111WH *2EHH 2BCO2&I
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M<4UJE X%(.I$131S4KCY:9'R:FXA *::D7H:C-" L)]RHW^]4B?<J.7[PIH
M'WZ ?G-)_%29^:F# =Z</NTT=#3A_JZ!@Q^04-VII^Z*4]J0"'K3^JXIO\5.
M7J:;V!C#UI>V::>IIX_U=(0REI*4]JJX#AUI[?=Q3!]\4YC4ME(;;<WD8]Z^
MC?AVF-(%?.-GS?QC_:KZ6^'Z8T9:X<0]#>EN=E1117"=(4R3[AI]-?[A^E"
MXG6_]?\ C68*T]:_U_XUF+UKLCL<\@'WJ;_%3A_K#2'[]:(S8]_NTD8YI7I5
M'%("-NM)CBE/4TN/DH0V '%,[U*H^6HSU-6B!5Z8H;IBA.M(_P!ZD] %6@GY
MJ04&F(5NF:8.M2'_ %=1U(QSG)IW\-,-*#1<:W'GH*3O133UI+8O8<OWJ3O1
M11<+"'K3F'RTE./W* 8Q>AIJT].C5&G6D2B<'Y:V]$?$E8.>*U]';$H^M9R-
M8[G:+]T4M-3[@^E.KE-PHHHH #69JB9BK3JE?KF/\*<=R6</<IB0U7[5>OUV
MR&J-=,3&2%3BFR<M2]*:W)K5;&3'1_>I>DH^M)']ZE/WZB14#J-*DX45T2<K
M7(Z3)\ZBNMB.4%<\UH=$1]%%%9EA1110 4444 ,DX0UR&MOG=76SG$9^E<5K
M#Y9JT@9SW,RVZ4YOO&F6_2G-]ZNB)BV(>!24Z3M2#I5]"5J':K%FNZ93[U7-
M7]+3=(/K42V-([G7Z<N(A5^JUFN(A5FN66YN@HHHJ1A1110 5QWCO_D#R5V-
M<=X\_P"0-)6E/XC.IL?-5W_R$YOK2C[IIE[_ ,A&7ZTH^[7JPV.60O\ RSJ.
MI/X:9WK1D6 =:>.M-%+28XCUZFA?NM30: :E[E"=J>WW!3#3L_+20^HE+WI@
M/-/[5: 5.IIOK0#@TE2 _P#Y9T,?D%-S\N*">*!#F/*TO_+2F$\BES\U "-]
MXT@ZT'K1WJK@#]::.M./-"BD0T#G.*=_RSJ+.34H_P!75""(<T2]13D'%-EI
M]0&8S3],^744_P!X4*,BBRXOU/\ M5G(+ZGTYX+DWZ8G^Z*ZFN,\ R;].'LH
MKLZ\BI\1Z$/A"L?Q)_R!KC_<-;%8WB7_ ) ]Q_N&B'Q"J?"?,>N'_37^M9?\
M-:6NG_3W^M9G:O7CL<4MQD7WZF?[U0Q_>-2&M2!*ZKP)_P AF'_?%<IVKJO
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M[;X>R[;R,?[5?1>G'-HA]J^:? TFS4XA_M5]):2<V*'VKAQ".JB7ZY[QC_R
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M7S;9?\?T?^]7TGX!_P"02*X<3L53W.RHHHKSSM"BBB@ HHHH **** "BBB@
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M!B2Z>YV0I:0=*6N [0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** $;[I^E>#_%4_O/\ @5>\-]T_2O!_BKS+_P "K?#_ !F5
M78\M%/%,%2#[M>LMCCCN1I]\T]OO"F)]\T]NM,;+MA_Q\J?>OH[P5_R"X?\
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MWJ?)S0P0R#Y95KZ&^&YSI4/TKYY3B05]!?#1LZ5#]*X\1\)O#<]%KGO&/_(
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M]"_X"*[D+7$_#W_CP'^Z*[FO*K/WCLI+0;MHVTZBLC4;MHVTZB@!NVC;3J*
M&[:-M.HH ;MHVTZB@!NVC;3J* &[:0K3Z2@3&[>:Q?$J_P#$O;Z5N=ZQ?$W_
M "#F^E:4_B1,EH?-?BG_ (_G_P!ZL)/NUM^*#_I\G^\:Q8ONUZT'H<<D3?\
M+,4/]T4#D8I9.@K1[$K<C'WQ7NWPQ/\ HD7TKPH??%>Y_##_ (]H_I7%B-C:
M&YZF*P/&/_(OW'TK?%8/C#_D 3_2N".YU=#Y@U(?\3*3ZU5FZ"KFI#_B:2?6
MJDG->O3V.&6XB=12'_6FG)]W--_BS6A,=R2Q_P"/U/\ >KZ2^'W_ ""*^;[(
M?Z9'_O5](_#_ /Y!%<.)V-Z>YV5%%%<!U!1110 4444 %%%% !1110 4444
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MGTR%N/8\5<TU=T@JE(>*T]'7+K6,MC:!UMFN(E^E6JAMQB,5-7.]SH"BBBD
M4444 %%%% !7'^./^07)]*["N0\<?\@F2M*7Q&57X3YKO_\ D)S?6D3[AI=1
M_P"0E+]::A^2O4@<R&'I3F^Z*83SBG$\"MI$/<M6/_']#]:^C/ W_(*CKYRT
M_F^B^M?1O@;_ )!<=<>(^$NG\1V-%%%>:=P4444 %%%% !1110 4444 %%%%
M !1110 4444 4=6_Y!TW^[7S-XX_Y"+U],ZO_P @Z;_=KYE\<?\ (1?ZUTT#
MFJ[G,#_5"G1=:8/]4*='UKTH'.65^_2R]OK3%/[P4Z0\BJEL/J>B_#P9O(_]
MX5[]'_JU^E>!?#CFZ7_>%>^Q_P"K7Z5Y%?XCMI[#JQ/$O_((N/\ <-;=8?B8
M_P#$IG_W#44_B">Q\S:Y_P ?K_6LD]*UM<_X_7^M9#=*]:&QP2)8ONFA?OTR
M(\&G#KFM$'05^]=+X!_Y#,7^^*YASQ73^ O^0Q%_OBL*NQM ^G;;_CW3Z5+4
M5M_Q[I]*EKRGN=:V.:\6_P#(/D_W37S9K?\ R%3]:^E/%O\ R#I?]TU\TZV?
M^)HQ]Z[,.<M;<@/2H#]UJE)^6HV^[7H(YV1Q_<-6K7_7)]:JI]VK5I_Q\(/>
MIF4CZ)^'O_(/'^Z*[BN'^'O_ !X?\!%=Q7D5?B9VT_A"BBBLS0**** "BBB@
M HHHH **** "BBB@ HHHH *P_$__ "#6^E;E8?B?_D&M]*NG\2$]CYH\3_\
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MI6_X=_U_X5E4V-8G6CI2T#I17*= 4444 %%%% !1110 4444 %%%% !1110
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M4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M44 %%)0* %HI*6@ HI.]+0 444G:@!:*3M10 A^[7&Z]_P ?#5V)Z5QVN_\
M'PU:0W,IO0QO2D/6E-(:ZD8L%ZT[/S"D4<T'[X^M*0XG8Z /]'K;'2L70/\
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M%%%<!U!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/_>KZ1^'P_XE%?.%E_Q^1_[U?2/@#_D$5Q8G8WI[G8T445P'4%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 C?=/TKP?XH\S
M?\"KWAONGZ5X1\3_ /7'_>KHP_Q&=38\L8<U,GW<U&>]2+_JJ]/H<?4A _>&
MGT@^]3V^\*IDDVFC_3U'O7TKX+_Y!</^[7S9IP_XF*_6OI/P9_R#(?\ =KBQ
M&QO1W.KI&^X?I2TC?=/TKSSK/G[XGC_2F_WJ\WCZ&O2OBA_Q\M_O5YLO2O3P
M[T..>XY_]70OW:#TI5KJ(1&_6O6?AC]^.O)6ZUZS\,OO1UA7V)6Y[;%]P53U
M:/S+*08[5<A_U8IMVF^!A[5YE_>.VWNGSEXWM=EQ(<5PWMZ5ZK\0;3;+(<5Y
M9C]Z17HTGH<[1(.U-?K3J:U;$,>G IK<&G=%%))VK1;&9&PRM;7AF7R[Y>>X
MK(49JWH\FR_'UKGJ*Z-(GTOX;G\RTCY["NE'2N%\'7.^W09["NZ7[M>=56IU
MTWH+11161H%%%% "'I7B7Q7_ -9)7MK?=->)?%7[\E;4/B,JNQY+$<"EFZ"F
MH<**=+VKU8G'+<8@XQ4Q'RBHTZU,1Q3D*YWWPW_X_5_WJ^@8_N+]*^??AK_Q
M_+_O5]!1_<7Z5YF)^([*6P^N?\7_ /( NO\ <-=!7/>+_P#D W7^X:PAN:3V
M/E>['^G/_O&G+1>#_3W^II4ZUZU/8X@'6A_6D[TYON9K6XI$47$N:W[>?;%U
MKGUX8&M 2[4'-935Q7-7[3\G6F?:>>M9OG\=:C$_S'FHL4F;'VG)ZU)]JXZU
MBI/G/-/^T?+UJ6AW-5;GYNM/^T_*>:QQ/[TOG^]%@3-3[3\G6D^U<8S67Y_O
M3!/\^,TN4JYLM<].:1KKG.:RC/[TUI_ESFA1%<V1=<=:0W7/6L@7'R#FD>XY
M'-/EU%<UVNN<9IZW/R]:Q#<?.!FIDG]Z.4=]#4^TY/6FO=?-G-9BS]>:8\_'
M6AQ$GH:YN_E'->@> )]\IY[UY,UQ\@YKTCX;2[YC]1652.AI%ZGN,7^K7Z5)
M4<7^K7Z5)7"=*V"BBB@84444 %-D^X:=37^X?I0)['%:YS-^-92]<UJZSS,?
MK66OW:[(;'-(1ASFE' I2/EI#QBK)8Y.*FA;$M0]"*<AQ)42*B:D<O%2>;Q6
M>LE/\SY#6=M32^A<\[BCSJH>;QUH\WWHL%R\9J!-5'S>>M'F\]:+ 7C-[TOG
M<50\WWH\WCK18"_YU'G51$O'6D,OO18?0O\ G>]'G50\WFE\WGK0D*Y>\[WH
M\[WJB)>O-)YO%.P7+_G>]-$O)YJF)>*0RXH0^A?,V1UK*N3F8U,)<FJ\IS*:
MI&;>I":.]'\5+5]"4-/6G@?,M)3U'[Q/K4RV&MSL=#7%O6Q69I"XMQ6G7)+<
MZ8A1112&%%%% !1110 5CZPFY2?:MBJ&HINB8^U5%V8I;'!SKB<TE6+Q,3&J
MX[5TP,&&,5%_RTJ9N"*C_P"6M;=#-$PY6EMSB=?K2)T--C.)16,BT=MISY@%
M9^LO\IJSI;_N!6=K3UDEJ7?0Y\?>/UH;K2K]ZA_O5T(RD,;D"G+UH'-+TJ@W
M%;KFFIS(/K3S]VDB&9!]:RDQI'6:,F$%;XZ5D:4F(Q6O7-+<Z(A1114E!111
M0 4444 %%%% !7&>.?\ D&2&NSKC?'7_ ""9#6M+XC.IL?-U_P#\A*7ZTB?<
M-&H_\A"3ZTU3\M>I3.04_P"KI.J4A^[2IR*T>Q/4C'WJ1OO4O>D/WJ3V$MQ*
M8HQ4A%(RXK***DQK?<I#]T4XCBC'%58$QK=5H_Y:5(13<?-2L-L9_&:=_":"
M.:7'%%B;ZC%Z4K_=%*!2D<46"XT4AX>GJ/F%#K\]) -I#TI^*'%-HEC$^[0_
M:GJM(PH:*0X=*<O)H4?(:(^E5$9)3U^Z:93N@K1[%$3&G6O-PH]ZC8_-BI+'
MF[4>]93^$GJ?0'PX3%I^ KT?M7 ?#I,67X5W]>34W.RGL%8GB7_D$7'^X:VZ
MQ/$W_((N/]PT0^(<]CYDUO\ X_'^M97:M37/^/Y_K67VKU:?PG#(?'T-"_?I
M(CPU"_>K5$H5_O&NJ\!?\A>+_?%<G(:ZOP%_R%X?]\5SUOA-8'TU;?\ 'NGT
MJ6HK;_CW3Z"I:\M[G:MCGO%7_(-E_P!VOF;7O^0FWUKZ8\5_\@R7_=-?,NN<
MZDWUKLP^QRUMRG'U-.'&::G6G-Q7H& SL:GMO]<G^\*@%36O_'P@]Q4RV&?1
M?P]_Y!X_W17<5P_P]_Y!X_W17<5Y%7XF=U/X0HHHK,L**** "BBB@ HHHH *
M*** "BBB@ HHHH *Q?$G_(.;Z5M5B^)/^0<WTJX?$B9;'S/XJYU)_P#>K(CZ
MBM;Q/SJ4G^\:RD^[FO5I['!)C@?WAI9C\M,!^:EG/ K9B6Y"@YKW;X6_\>T0
M]J\+C'(KW/X7_P"IC'M7%7V-Z6YZQ7/>,?\ D 3_ .[70US_ (Q_Y%^X^E<$
M/B.E['RYJ9_XFLGUIB]#2ZIQJDGUIJ_=KUH;'&Q4/RFDIJFGK6G0E;$EG_Q^
MQ_[U?2'P_P#^017S;9'_ $U/]ZOI'X>G_B45Q8G8UI[G9T445P'6%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 C?=/TKPCX
MG_ZX_P"]7N[?=/TKP?XH\3?\"KHP_P 1G4V/+ST-2#_55&:<#\E>F<?48.M2
M'[PJ)3\YJ3O5,GJ6M._Y"*_6OI+P9_R#(?\ =KYKTX_Z>I]Z^E/!?_(+A_W:
MXL1L;TMSJZ1ONGZ4M(WW#]*\\ZSP#XH?\?+?[U>;+7H_Q//^E-_O5YO'TKT\
M.M#CGN/I1WI*7M75U)1$W6O6?AG]Z.O)FZUZU\,?O1UA7V(6Y[;#_JQ]*609
M0T1?<%.;I7E/<[U\)Y)\0K7<)&Q7BDZ[+EA[U]#^.;7?:2-BOG[54\N\<>]=
M]%G/(@S2&FL>E .6KJ1GT)"?E%+)TII-*>8R:M;&8D?2GV3;+S/O449^2EB.
MV4-[UG-%(]S\$7F8T&?2O486W(#7AW@>\_>1KGN*]KL7W0@UYU9:G329;HHH
MKG-PHHHH 1ONFO$_BK]^2O;#TKQ3XJ?ZZ05M1?O&578\@'05(_(%1U)U0UZL
M3B>XB'FIB>*KITS4Q/R"G(+'?_#3_C^7_>KZ#C_U:_2OGSX:_P#'ZO\ O5]!
MQ_ZM?I7F8GXCMI;#JY[Q?_R KK_<-=#7/^+O^0!=?[AK&'Q%SV/EF\_X_P!_
MJ:5.M)=_\?K_ %-(M>K3^$XO(">:<?N8J-C\XIYZXK1BEL1'J*F9OE%1-UH<
M_+4M$#M_%-!^8TP'Y,TY>E38M(<C=:7=Q3%ZTA/S8HL!,&XI=U1@T T6&F2;
MN:C4_.:6D'WJ20Q^[BFEODI#2?PT*(NHX-\M([<BFT&GRBOJ.+?O!4RO5?\
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MQF,T(3.&U%,2M5)1S6IJB8F:LQ!R:ZH&,A'ZU&/OYI[FFKZUNC-$J\ TQ?\
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M=BG)2=J%ZU/4?0#U--%.--%-AU)#_JZN:<N9E^M4B?EQ6EI2YE'UK)EK<[2
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M;_Q^K]:^E?!7_(+A_P!T5PXC8WI;G5TC?</TI:1_N'Z5YYUGS[\3_P#C[?\
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M,/\ OBL*NQK ^F[;_CW3Z"I:BMO^/=/I4M>4]SM6QSWBO_D&2_[IKYFUH?\
M$S;ZU],^*O\ D&R_[IKYHUK_ )"K?6NW#'+6W*+=,4F,BE;K2C[IKOZ&70C
M^:I;/_C\4^]1K4EI_P ?:_6IEL!]&?#[_CP'^Z*[BN(^'W_(/'^Z*[>O(J_$
M=M/8****S+"BBB@ HHHH **** "BBB@ HHHH **** "L/Q-_R#F^E;E8?B?_
M )!K?2JA\0GL?,OB?_D)2?[U9D8P*U/$_P#R$G_WJS5[5ZM/8XWN/ZC%0D<U
M,O6HNYK8A[BH,N#7NGPO_P"/>/Z5X;'7N?PO_P"/>/Z5QXC8UH[GJ=<_XQ_Y
M $_TKH*Y_P 8?\@&?Z5P0^(Z9;'R_J@_XF4@]ZK,.*M:I_R%)/K5<]*]6&QQ
M#*D_@J.I/^6=:$H2P_X_D_WJ^D_A]_R":^;+#_C^C_WJ^E/ '_()%<6)-:>Y
MV=%%%<)V!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 (WW3]*\'^*',Q_P!ZO>&^Z?I7A/Q/_P!<?]ZNC#_$9U-CRPCFI /W
M>:8>]2#_ %5>GT.3J0@?-4O3BF=ZD/WA5LS)].'^GJ/>OI+P5_R#(1_LU\W:
M=_R$5^M?2/@O_D'1?[M<.)V-Z6YUE(WW#]*6D;[I^E>>=A\__% ?Z4W^]7FR
M#%>E_%#_ (^6_P!ZO-5KTZ&QQSW)%'-(>M+']ZD;[QKJ(&2<D5ZQ\,.'C->3
MM7K'PRZQUS5MAK<]NB^X*?3(O]6*?7F/<[5L(>E87B"#S;1N.U;U4M0B\RV<
M>U.+LR9K0^:?%5MY=VQQW-<L.M>A>-[79.YQZUY\*]&DSED3=%%/ ^6HS]U:
MF_AKJZ&17?KBF#K3Y/O5$OWJE@$G7-=1X5N/+G3GO7,/]TUJZ%*8YT^M95$5
M%GTKX:EWV49]JZ*N-\'3A[&/G^&NQ!XKS:J]X[*;T%HHHK,T$/2O$OBN/WTA
M]J]M/2O$_BM_K)*VH?$95=CR".GN*:O05(_:O51QO<:HYQ4C_=%,7[]/DZ42
M#J>A?#/F[7_>KZ C^XOTKP#X8?\ 'T/]ZOH"/[B_2O-Q/Q'72V'5SWB__D W
M0_V#70USOC#_ ) =S_N&L:?Q%U/A/EJ\'^GO]31VI;S_ (_V^M)7K4]CC#M1
M_#F@]*!]RM43(;2L.E)V%.?M4O<3&@?-3SUIJ_?IS=:"EN*.E--/7[IIAZ5:
M 7'%%+_ *3N*.@+8 .:/XJ=_%2#[YJ4)C>]-(^;-//6DIE"XXI"*<?NBAN@I
M$D8'S4-]ZG+]^FO]XT-B>X$T].F:CJ1?]70"!AWKTKX8_P#'P?J*\V;[HKTO
MX9?\?!^HKFK_  FM/<]WB_U:_2GTV/\ U:_2G5Y9VA1110 4444 %-D^X?I3
MJ:_W#]* 9P^N#]]^-9:]*U=;_P!<?K64G2NN&QC(EQ\M1]ZE/^KJ,_>%:+8S
M88^:G>U!^^*!]\T^A U1UI3R,T+_ !4#[AI/<!JGYJ=T_&HQUJ1OX: #OBFM
MUQ3C]\4U_O4 .'(IG\5/CZ&H^] $AZ9I#2G[@H;^&@!P':D[XI>XI!_K#0-C
M32C[N:&H7[AJ@8#IFHP/G-2?\LZ8.M-$DGM2$=J4_>%#=:2*0RG=J0=:6AE(
M:!S71Z$/F-<]71Z#UK"1JCID^[3J0=*6N4U"BBB@ HHHH **** "BBB@!DHR
MIKE-8CPQ-=:W2N:UQ<"M(&4SG<<TTCFI<5'_ !UT1,WL- YH]Z4=32#[IJI&
M8#UIK>M'\%*WW141&Q4Z8IC_ 'J>O6FR?>K1 QR<BD;AJ6+K1)UJ9#1>T]-T
MH-=I9KB%?I7)Z2N2IKL+<8B7Z5S3-H;DM%%%9FH4444 %%%% !1110 4444
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M 5B>)_\ D&M]*VZQ/$O_ "#6^E5#XA2V/F3Q/_R$W_WJS0>!6EXG_P"0F_\
MO5EC[M>K3.-[DBFHR>:<#\M,8\BMF0_B)(SS7NGPO_X]X_I7A2_?%>Z?"_\
MU$?TKCQ&QK1^(]4KGO&/_(!G^E=#7/>,O^1?N/I7!#<Z9['S!JI_XF4A]ZKY
MXJ;5O^/]S[U!_"*]:&QQ,2GY^2H^].!JR%N.L/\ C^3_ 'J^D_A_SI KYKL/
M^/Y/]ZOI/X>_\@>N+$FU/<[6BD'2EKA.P**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@!&^Z?I7A'Q0XF/^]7N[?=/TKP;XI'
M]]_P*NC#_$9U-CS ]#4@/[NHC3Q]VO3Z''U& _-4AZBH5/SFI!5DK<M:<?\
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M(OK3W'2O56QQ/<1/NTLO*"A>E*>13*9Z!\,_^/Q?]ZOH6/\ U:_2OGKX:?\
M'ZO^]7T+'_JU^E>9B?B.FEL.K \7?\B_=_[AK?K \7?\B_=_[AK&'Q%SV/E:
M]_X^G_WC2#[HI;O_ (_7'^T:,<5ZU/8XV!'%-J4#Y341K5$,8/OF@=Z4#FE
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MD]RS:\,3&.^7GN*^BO#4^^VCY["OF?1I/+OA]:^@?!USYD*#/85R5EH5#<]
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MU128XA2=Z=1CBDRA4ZTT_>-.3K2'J:74!X^X:CJ1?NXJ,]:8!2KUH XH'WJ
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M'->D_%#_ (^6_P!ZO-DZUZF'^$XY[DAZXJ/^(U+_ !U$?OFNHRZC37K?PO\
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M2IB.(YON UZ'\,?^/H_[PKSIC^[%>A_#$_Z4?]ZIK?"7#<]_B_U2_2GTR/\
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M<_\ $RD/O4,1X-2ZQ_R$)/K4$?2O6I'$]R1?2E]J:O6G?Q&M1,2R_P"/Y/\
M>KZ2^'__ ""17S;9?\?Z?[U?27P^_P"017#B36DM3LZ***X#K"BBB@ HHHH
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M  ^_Y!X_W17<5Y%3XCMI_"%%%%06%%%% !1110 4444 %%%% !1110 4444
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M-Z>YV=%%%<)TA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-O\ C^7_ 'J^@XO]6OTKYZ^''_'\G^]7T+%_JU^E>=B=SII#ZP/%W_(OW?\
MN&M^L#Q=_P B]=_[AKGAN7/8^5+H_P#$S;ZFGGK4-V?^)BY]S4F>*]6EL<TR
M0?=-1]J>.E1G[V*V,Q_5<58AMRYSBJT?+XKHM-M-Z9Q63=BDC,:S/I4*V9WG
MBNJ-A\F<5"+#YNE1?4OH<Z;,YZ4&R..E=,VG\CBE.G^U2WJ2UH<M]C/'%:%M
M9';TK5%A\V,5J6NG_)THYA6.>%C\_2D>Q.>E=4NG]\4CZ=_LTN8:1RZ61P>*
M;]A/I75#3_:@Z=\V,4)C1RYL3MZ4PV1STKK!I_.-M1G3^>E%P2.8-C[4"Q]J
MZK^SODSMI/[/^7[M',%M3EC8G!XI$L2!TKJVT[I\M T[#8VT)E'--8G8.*[W
MP#;[)^G>LHZ?QTKKO!UKY<QX[UE594-6>F1_ZM?I3J1/N#Z4M<1T!1110 44
M44 %-?[AIU-?[AH XC7>)_QK,7I6GK_$X^M9B]17;#8YI;W TX]!2?Q49JF3
MU(Y/]8*T+)<UGGDYK6T]<@5G(I%I(>#0(?D/%7TA^7I2B'CI6=S0SS#\@XH,
M7W>*T##\N,4GDY/2BX% P_..*!#\YK1\GGI1Y/S9Q1<#.$7)H$/R'BKYAP>E
M*(?EQB@9GF']V.*&A^[Q6AY/RXI3#THN(SC#\XXI?)^?I5_R><XI?)YZ4TP,
MY8?O<4"'Y#Q6@(>O%'D\=*5P,\P_N^E-\GE>*TO)^7&*3R>>E)L"G)%W]JR[
MA<2&NBDB_=DUA7:X8TX[D%%>K4 _(:;GDT \5LA /2B7^&A.7Q1)3D,Z+0#T
M^M=3VKD_#QZ?6NL[5R3W-8;!1114%A1110 4444 %9>JOB,CVK3-86M28X]J
MJ.Y$F<M<MF0TT]!396S,:#]VNN",6&<N*7^/-1(<M4K>M,S(R?F-3P\L*K,>
M:LVW,BBE+8N.QV&DK_HJU4UQ,J*T-,7%NM5M87*5SWU-+:')R# -1P\FIKC@
M-5> ULB'H/Z,U"'Y2*'X--!^<"M"%N(?O8I^>5II_P!=BFY^?Z5G(T1U^D29
M05O*<BN5T23*_C741'*5SR-8L?1114%A1110 4444 %%%% !7'^.O^0/)785
MQ_CK_D$25I2^(SJ;'S7J'_(0D^M0R=15B_'_ !,9?K41&>:]:&QS/894:_?-
M38^7-,VXYJC(6+[U>K>!K?? A(KRN$?O5'O7M'P_@S:Q\5%5VB6M6=)+9CCB
MD:R&1Q6X]MG'%#6W3BN%3U-^70Q39#TIRV8P>*V?LWM2BVXZ42F$(ZF$MD.>
M*?\ 8QY?2MD6W7BG?9OEQBDYA*.IA?8Q@<4&S&1Q6Y]FXZ4?9N>E+G#E,/[&
M-W2HA9?O#Q70_9N>E1BU^<\4<X<IDBR'EMQ4268QTKH!;?*>*8MKQTHYM!<N
MABR68\M>*8UD,KQ6^]ME1Q33;<CBFIC43&^Q#TJ,6?SGBN@^S>U1_9OF/%"F
M#CH8-S9C[._':O'_ !G'LF<5[W<6W[AN.U>(>/XMETXK>G(PDK'!PU/WJ&W'
MS&IP.M=<7H0)_%49^\:F XS3".M$MBWJC4\)'&NV_P#OBOJ?2CFS3Z"OE;PO
MQKMO_OBOJ;1CFQ3Z"O-KFU$TJP?%'_(,F_W36]6%XG_Y!4W^Z:PI_$:U?A/F
M/7_^0HWUK-;I6GKW.HL?>LMNE>M3V.%BP]&IW:FQ5)CG%:+82(^U=3X#_P"0
MS#_OBN78=:ZCP#SK,7^^*QK?"7#<^G;?_CW3_=%2U%;_ .H3_=%2UY#.];'.
M^*_^07-_NFOF76_^0BWUKZ;\5_\ (,F_W37S+K@_XF3?6N[#'+6W*C?ZH5'3
MQRN*;CFN\P0&BR_X_5^M.(XI+,?Z6OUK.>P^I]&_#K_CP_X"*[NN'^'@QIX_
MW17<5Y57XCNA\(4445F6%%%% !1110 4444 %%%% !1110 4444 %8?B;_D'
M-]*W*P_$W_(.;Z54/B(G\)\S^)O^0C+_ +QK&C^[6UXH'_$QD_WC6/&.U>O2
M^$X9;@_W:!TIT@XH0?+5 QH^\*]T^%O^HC^E>&J.:]S^%P_<1_2N7$_";T-S
MU:L#QC_R+UQ]*WZY_P 8_P#(OW'TK@CN=,MCY>U3_D(R?6JK=JN:F/\ B92?
M6JA'->M2V.%[DB=12/\ ?-*O3-(W3-:O8F^HMA_Q^I_O5])_#[_D$5\VV _T
MV/\ WJ^D_A^,:0*X,1L;T]SLJ***X3J"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH :_W#]*\'^*7^N_X%7O+?</TKP?XH\S
M'_>KHP_Q&=38\K;[PI]!%.Q\N:]-'%(A7[YJ<]*B4?/4[#I30(DT[_C\7ZU]
M*^"O^05#_NBOFS3A_IRCWKZ3\%?\@N'_ ':X<2;4GJ=92/\ </TI:1ON'Z5P
MG6?/OQ/_ ./M_P#>KS:'O7I?Q0'^E-_O5YM$*]2CLCCGN.:D/04\CFD(KI,R
M&7J*]:^%G^MBKR>09->M?"T?O(JY:VQ<=SVY/NBGTU/NBG5YKW.Q;!1112&%
M%%% %:[3="WTKPKXA6F'<X]:]ZF&4/TKR/X@V>4<X[5T4'J8U%H>)Q# Q[U-
MGI22)L<CWH'2O2@[G.)-]]:7M37Y84_^&J0A(QR:CDZ&IXQ44@ZTB"729"ET
MOUKZ%\$W.^RB&>U?.MI\EPI]Z]Q\!768D7/:N6JM#:#/50<I7BWQ4_UTGTKV
M:,YB_"O&?BE_K)*Y:/Q&E5^Z>.K]\T]NE(!\U/8<5ZBV.5[C!_JZ>OW:3'R4
M]!Q36QH=_P##@?Z<G^\*^A8_]6OTKY^^&PS>K_O"OH*/_5K]*\W%?$=-(=7/
M^+_^1>N_]PUT%<]XO_Y%^Z_W#7/#<J>Q\HW?_'^_^\:E'W13;P?Z>_U-/09%
M>K26AR3>HX=*C/\ K*F XJ,CYZV8@@_X^,>]>A:!9;[<G':O/X!_I*_6O8_"
MMCOL@<=JYJCL5%:E;^S_ -WTJ,:?S]VNO&G?+C%-_LWG[M8N9I8Y9]/Y7BG'
M3_\ 9KJ6T[D<4IT_CI4\VH-:'(+I_P"\Z5IVMA\AXK8&G?-G%7X+'"]*.<FQ
MSZ6''2E>P^4<5TBV7M2M9<=*7.4EJ<S]@Y'%*UA\_2ND^Q<CB@V7S=*',.70
MYM;#YSQ49L.3Q74+9?,>*:;'D\4*8['."P_=]*0V'RCBNF%C\G2D^P\=*.<3
M1SC6'*\4&P^<<5TALNG%*;+YNE"F.QSAL>>E;WARV\N0\=ZE^Q>U:.E6_EN>
M*SG*Y5-6-X?=%+2#I2U@;!1110 4444 %-?[AIU-?[AH XCQ!_KU^M9B_>%:
MFN\SCZUEC[U=D-CGFA1_K#3>YIW\6:;WJV9H0#BMO2URJUD ?+6[HZY(%929
MI$VUC^44OE^U6 GRBC;6-S6Q7\NFK'R:M[::$Y-%PL0>7[4>7[58VT;:+A8J
MM'R*=Y?M4[)2[:=PL5_+H\NK.VC;2N%BMY='E^U6-M&VBX6*_E^U'E^U6-M+
MMHN%BMY?M1Y=6-M&VE<+%>2/]RU<U?K@FNL=?W9%<SJJX9JN#U):,0]:2G 9
M)I,?*:W1F$?^LI).IIR>M-EXQ3D!O>'>H^M==VKD?#_!'UKKNU<D]S:&P444
M5!84444 %%%% "-TKF==?]Y72R?<-<CK3YEJX;F<S /^N-2-]VF8_>9J1_N5
MV1,601=:G;[M1PBI#Z4F9D#]JO62YF6JCKTK3TR/=(I]ZF3T-(['76"XA%0:
MDFY*MVJXB%,O$W(:YKZFZ6AQ%ZN-PJK#P*T-13$N*I!=HK=&4@D[4S_EHM2-
MR!30/FS6JV(B'_+Q47_+1JG _>9J-EPQ-9R*1L:&^ ?K77VYS&*XG2&VMCWK
ML[0YC%836AI LT445F:A1110 4444 %%%% !7(>./^03)77UR'CG_D$R5=/X
MC.IL?-U]_P A&7ZU&HRAI]\?^)C+]::GW37KT]CF>PP_<I&'RBACQBD)^4"J
M,GN.A_X^$^M>\?#R+-G&:\'M^;E/K7T!\.E_XE\9K&N_=9I#XCNO)R:4P>U6
M0.:4CBO+N=B6A4\GBG"'CI4^.*=CBBXDBKY-'DU:Q28YHN-HK^1[4>3[59Q1
MBE<=BMY'M2>1STJUBC%%PL5O)XZ4GD>U6L48HN%BL8.*3R*M8HQ1<+%;R?:F
MF#FK>*0BG<36A0GA_<MQVKP?XDIMO7%?0,X_<M]*\!^)I_T^2NFB[G-51YQ;
M??:IUZ-4%OPQ-3*>&KOB]# >O^KIA'RTJGY,4G7(JY%K8O>'.-<M_P#?%?4F
MAG-BGTKY9\/G_B=V_P#OBOJ3P^<Z>GTKS:YK1W->L/Q/_P @F?\ W#6Y6%XG
M_P"03/\ [AKGI_$;5/A/F77.;Y_K62_W16MK7_'^X]ZR7]*]>EL<+'Q]JE/^
MLJ*+FI,_O*T0AC_>-=/\/_\ D,Q_[XKF'^\:Z?X?\:S'_OBN>O\ ":0/IVW_
M -0GT%2U%;_ZA/H*EKRF=RV.>\5?\@V7_=-?,VO?\A-OK7TSXK_Y!DW^Z:^9
M==.=2;ZUVX8Y:VY3CY.*#UI(^#0QYKN1C$>?]726G_'TG^]2$_+BBU/^EI_O
M5,]@ZGTC\/\ _D'+_NBNVKB/A\<Z</\ =%=O7DU/B.VG\(4445F:!1110 44
M44 %%%% !1110 4444 %%%% !6)XF_Y!S?2MNL3Q-_R#F^E5#XB9_"?-'BK_
M )"+?[U9$?45K^*?^0B_^]6,AZ&O7A\)P2W'R=:6/[II&.:$/!JD)CHQ7N7P
MO_U$?TKPV+K7N?PP_P!1']*Y,3L;T-SU.N?\8?\ (!G^E=!7/>,/^0#/]*X8
M?$=,MCYCU,?\3.3ZU3[FKFIG_B9R?6J?>O7IG"]QZ_<-(W^KH!^7%-)^3%7+
M8DFL?^/R+_>KZ3\ _P#()%?-6GG-['_O5]*> ?\ D$BN'$;'13W.QHHHKA.H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&
M^Z?I7A/Q/_UQ_P!ZO=F^Z?I7A'Q//[X_[U=&'^(BIL>88^4T?\LJ/X31_P L
M\5Z<3A>Y&/O"K#=15<'YJF)R130(GT__ )"*_6OI+P5_R#8?]VOFW3_^0@OU
MKZ2\%?\ (,A_W:XL3L:T?B.LI&^Z?I2TC?=/TK@.P\!^*/\ Q\M_O5YM'UKT
MCXH'_26_WJ\VC/->G1V..>Y+_'33UIP^]3&/-=70S0TBO6_A?_K(Z\D/45ZU
M\,/];'7+6V+6Y[:GW13J;']P4ZO->YV+8****0PHHHH :PR*\_\ '=KNMG./
MX:]!-<KXO@\RS?C^&M*3M(SGL?-FHQ^7<,/>JP/%:^OP^7<OQWK$#<5Z=)G*
M.'-//^KJ-.]/)^2M.HI$L7W:9(.:=$?EIK]Z"41I\LH->K> +K]XJY[5Y.3Q
MFN]\#W7EW"\UA41<7J?0=LVZW!]J\?\ BC]Z2O5]+E\RU!]J\G^*7WY*Y*2]
M\TJ?">0#[U2/VJ)3\U22GI7I+8YP[4]*C!XIZFFMBST7X:#-V/\ >KW^/_5K
M]*\ ^&9_TL?[U>_1_P"K7Z5YN*^(Z:0^N>\7_P#(!NO]PUT-<]XO_P"0#=?[
MAK"'Q&DMCY7O1_I[_4TZ/K1>_P#'^_U-$9Y->M1V.&>X\=#3.].SC-,S\U:R
M&A\'_'S'_O"OH+P7:AM-4X_A%?/=L?\ 3(Q_M"OI3P,O_$K3_=%<-=Z&L%J;
M'V,;NE*+(9Z5I;!NI=@S7(Y&MC+-F,]*4V8V]*TME*4&VES UH97V(>E3I:@
M#I5S9Q4@6AR%8I?91GI2FU'I5W;S2[12N4D4?LH]*/LHSTJ]M%&T4KCL4?LH
MSTI/LH]*O[11M%%PL4?LHQTIOV49Z5H;:3;S3N)HI?91Z4AMAZ5?"\4A7BBX
MVM"E]F&.E300[#4X48I0,4FP2'T445)84444 %%%% !37^X:=3)/N&@&<5K?
M^N_&LNM36O\ 7_C67WKLCL82 TG<4I]*3O6CV,V3 <5O:$,R#Z5@@_)6_H!_
M>5A/8T@=*%XHVT^BN<W&;:-M/HHN S;1MI]%%P&%:-M/HHN S;1MI]%%P&;:
M-M/HHN S;1MI]%%P&;:-M/HI 1E>,5S&M#$C5U5<OKO#M6D-R&<^G5J/X#0O
M>DS\A%=*,6*/]6*9-T6GC[F*CEYQ3$MCH-!ZK76]JY+0>HKK!TKEJ;F\-A:*
M**S+"BBB@ HHHH CF.(F^E<7JC[I377WC[8F^E<1?/NE/UK2"U(D4AUS3Y?N
M"FBED.0*ZEL8/8(AQ2_\M,41_=--S^\S3('..E;&C)DCZUCL>170Z(G K*>Q
MI%'20C""B9<H:<GW:5_NFN;J;K8XS54Q<BLZ48K:U=/W^:Q9NE=$=S)B?PTU
M1\I-&?EHZ*:U,T.7IFF2#BGI]VF,<\5+*ZEBP;;*/K7:6+9C%</:G$@/O78Z
M8^8EK&9:Z&K1116)L%%%% !1110 4444 %<?XZ_Y!$E=A7'>.O\ D$25I3^(
MSJ;'S;J!_P")A)]::AI=0_Y"$GUIJ=17K4]CE>PR0_O,4S.213I/]=FHQ]XU
M;,B:U/\ I"_6OH7X<_\ (,C-?/-I_P ?"_6OH;X<_P#(*CKGQ'PLUANCT(4M
M(*6O*.U;"=Z6D[TM (*04O:D% =1:***!A1110 4444 %%%% !2&EHH @N/]
M0WTKY]^)Q_XF#U]!W'^H?Z5\]_$[_D(O75A]SFJGG<7 J4&HH_NU(*[X',Q5
M/S8I5^\PIBC]Y3E^^QJY;%_9+6@'_B=P?[XKZD\-'.FI]*^6M"_Y#4/^_7U'
MX7YTQ/I7G8@UH[F[6#XH_P"05/\ [IK>K!\4?\@J?_=-<]/XC>?PGS-K/_(2
M8>]9+??(K6UK_D)M]:RF_P!837K4]CAD.AY#4[/--@Z-2FM8DB,>M=/X"XUF
M+_?%<N>E=1X#_P"0S#_OBN:ML7#<^GK?_4)_NBI:BM_^/=/]T5+7E,[UL<YX
ML_Y!4W^X:^9-9.=0?ZU]-^+?^05-_N&OF/5_^0@_UKMP^QRUMRH.*&/S"EQQ
M2,.17<C) QYQ2VG_ !^+]::WWZ?9C_3%^M$MA/<^COAX<Z?_ ,!%=R*X7X=_
M\>'_  $5W0KR*OQ,[8;"T445F:!1110 4444 %%%% !1110 4444 %%%% !6
M)XE_Y!S?2MNL/Q+_ ,@YOI5T_B1%3X3YH\3\ZC)_O&L53\M;7B;_ )"$O^\:
MQ%^X:]:&QPO<DSE:4'BD'W*!S5();CHO]8*]U^&/^IC^E>%1?ZP5[K\,?]3'
M]*Y<5L:4?B/4ZY[QC_R +CZ5T-<_XQ_Y $_TK@A\2.N6Q\P:H?\ B8R?6JC=
M15O5?^0C)]:IMU%>O#8XGN.)^8"F$_,12G[XII'[PU<MB62::?\ 3D_WJ^EO
MA_\ \@BOFG31_IR_[U?2WP^_Y!%<.(V-Z9V8HI!2UPG4%%%% !1110 4444
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MTC\2/1A2TW-+FO*.U!WI:3-&:!BT"DS29I@.HI,T9I +129I,T6 =129HS0
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M)FC-%@%HI,T9H 6DHS29IB8[M249I,T Q:6F9IV: 0M(:3=03Q2 44M-!IU
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M!1?ZM?I7SW\-?^/Q?]ZOH2+_ %2_2O-Q/Q'31'USWB__ ) %T?\ 8-=#7/\
MB_\ Y%Z[_P!PUC3^(VGL?*5X?^)DQ]S4JFJ]Y_R$'_WC4F?E%>Q2V.&>Y/$>
M#3'/STJ'BHV/[RG((DMF?]-3_>%?1_@=O^)<O^Z*^;K0_P"FI_O5]$>"I,:>
MO^Z*XZRNC2+U.X+_ "9H#\55:4>52++\O6N7E-E(N;Z-]5?-]Z!+SUI<HU(M
M;Z0/P:K&7WIJS#!YI\HTRV'XH9^*J+-QUI7E^4<T<NH*6I;WT;N:J^;P.:7S
M>>M+E#F+.[FC=5;S>>M EHY0YBSNXHW56\WBD\WBCE%<M;J W-5C+[T"4;^M
M)Q!LLEN:-_%56E&ZCS?E/--1!/4LA^*1GP*JK-QUI))AMHY=0YBW&^35FLRV
MEW-6D.E3)6*@[BT445!84U_N'Z4ZF2?</TH0'%ZR?WWXUF>U:6M?Z\?6LW^,
M5UQ.:>Y$?OXIWI3#_KC3ZU>Q" GG-=1H!X6N58_+74>'S^[7Z5S3V-8'3#I2
MT@Z4M8&X4444 %%%% !1110 4444 %%%% !1110 4444 (>E<GKW^L:NL;I7
M):_]]JJ),MC$8_+0IXQ3">!2J?FQ75'8PEH'?%#]12#_ %Q%!^]5,DW-$_UJ
M_6NO7I7(:'_K%^M=>OW:Y:FYT4]A:***S+"BBB@ J*=ML9-2U5OFVPFFMQ,Y
M#5Y,RGZUEBK6HONF/UJIW%=4%H8S ]<4_/%1_P =.SP:TZ$=0)RPJ4'BJP/-
M3 _+4,(K4T]+3]]GWKLH!A!7+Z2G(-=7&,**PJ&T1]%%%9&A!<C,1KCM13;.
MQKM9!E#7*:Q'B1C6M-F<D80.'-2$\57<X>I2>16\3%CE]*;GYB*4??Q4*G]X
MU4T3U'^]7]+?;<@U0_@-3V+;6!K.9<6=U:MN4&K=9NGMNC7Z5I=JYY'1'8**
M**D84444 %%%% !7'>.O^01(*[&N-\<_\@J05I3W(GL?-U^/^)A)]:;VJ2_'
M_$QE^M, ^6O6I['*]B'_ ):4A')IQ'.:&'&:J1G((>''UKV+P#<>79QC->/)
MPXKTCPC=>5 @S4U-8AU/5?MW/6G"^'K7*#4/F/-*NH\'YJ\]QU.F+T.I^W#/
M6D^WCGFN6_M'C[U-_M'_ &JI1"YU27W7FAK[*]:Y;^T,=Z/[0SQNJG &]3JT
MOOEZTUKX%AS7+KJ/^U2#4,YYI*(<QU?V[OFFB^^8G-<O_:/RYW4G]H<9S1RB
M4M3K?M_R'FF)>_+UKEAJ/;=2KJ&.]+ET'S'5M?#'6D^W<CFN5_M')QNH.H?[
M5)QT)N=:+\;^M(;[D\URBZCWW4K:CQ]ZI<2KF_)>_NGYKQCQ])YET]>@R7_R
M'GK7F7BZ7S+IJWA$QD<O$/E%.EY(HC'%.QG/M77%:&+W 4T?>)IPZ4I&!FJZ
M%K0OZ&/^)K!_O5]-^%AC3$^E?,^AC_B;V_\ O"OISPVN-.3Z5YN)W-J.YM5A
M>*/^05/_ +IK=K$\3#_B4S_[IK"G\1T3^$^8-='_ !,F^M98^\:U=='_ !,'
M/O64>*]2F<+);<?*U!'-.@'!H(^?%:HD8:ZGP)_R&8?]\5RYZFNJ\!<ZQ%_O
MBL*WPFD-SZ:M_P#CW3_=%2U%;_ZA/H*EKR6=RV.?\4#.G2_[IKYF\0C&J,/>
MOISQ*,Z?)_NU\T>)%QK!'O7;0V.6MN9A^X*:1R*D SQ3<<UW0,XD;??J6V.+
MA?K3&'-.@_UR_6G+8E[GN_@*XV6?7M7:_;0.]>9>$;KR[7KVKI'U'!ZUYM2-
MV=%-G5"^'K0+T>M<LFH\]:5=0Y/-1R&ESJ?MH]:/MH]:Y8ZA\O6C^T/EZT<@
M*1U/VT>M'VT>M<LVH<CFC^T/GZT<@<QU/VWWH^VCUKE_[0^;K2+J'7FER#N=
M3]M'K2?;1CK7+_VA\O6D.H_(#NHY YCJ?MH]:7[:/6N5.H=.:4ZC\PYHY!<Q
MU'VT9ZT"]'K7+?VC\WWJ%U'D_-1R!<ZK[:,=:Q/$%V&LFY[52.H?+]ZLK6;[
M=9'FJIQU(F]#R+Q$VZ^?_>K'8?+6EK#;[QOK5!Q7IQ6AR]2+'RT\#BC'%/4<
M&DAM#8O]<M>^_#,?Z'%]*\$A'[T?6O?OAH/]!B^E<^(^$TH/WCTFL#Q=SH,_
MTK?K"\5C.AS_ $KSX?$=4]CY:UK_ )"D@]ZK'HM6]<'_ !-Y![U5QP*]>'PG
M$MQ"/G%2+US32.]/_AS5VT"0ML<7:GWKV[P==;-.QFO#X3BX4^]>I^&;S99X
MS6$T*.YZ,U]^[ S2F]&U>:Y9]0XQNI?[0^3K7/RZG3<ZO[</6C[<,]:Y1=1^
M7[U+_:/'WJ7**YU)OAZTOV[CK7*'4.G-+_://WJ?*),ZK[<,=:#?<=:Y7^T?
MF^]0-0Z_-1RZCN=2+X>M-^W#?G-<N-0X/S4?VAQG-+E!/0ZO[=QUIBWP]:Y@
MZCP/FI/[0^;K3Y0OH=7]N'K1]N'K7*_VC\WWJ!J/7YJ.4+G5&^'K2"^'K7+?
MVAP>:3^T?E^]1RA?4ZA;[YCS2O?#'6N6_M#'>AM0YZTE$&SIQ>_)C-(]]TYK
MF!J'.,TTZASUJN45SK1?<=:2"]S<]:Y8:A\GWJ=9W^;D<U$HC3U/2K:3>@JS
M67I<N^%3[5J5S26IT+81_N'Z5X-\4O\ 7?\  J]Y;[I^E>#_ !0_UQ_WJVP_
MQ$5-CRQAEJ=VH R#3\?N\UZ2.)D"#YS5A?N&H@,&IO:F2B73O^/U?K7TIX*_
MY!4/^[7S9IX_T]1[U])^"O\ D&0_[M<6).BD]3K*1_N-]*6D;[A^E<)UGSY\
M3O\ C[?_ 'J\XA[UZ1\3Q_I;?[U><1CFO3H;(XI;L>13'' J7'S8IC#FNHCJ
M12#I7K7PMXEBKRAAFO6?AB,/'7-6V+CN>W1_=%/ID7W!3Z\Q[G8M@HHHI#"B
MBB@ HHHH H:FF^T85X+XYM,32''>OH&Z7=$17CGCRSX<X[FNJA*QA51XV!B4
M_6ICUIKKB=OK3FZ9KMB<[$[TIH7D"G,/F%;(AD;K\M-<9058*\5'MSD5#!&M
MX=E\NZ3ZUN>)9O,C/TKF=*?R[E?K6OJ\WF1FIMH4V<X1S35'-2.*3&*TZ$H#
MZ4W'-+_RTQ2X^8TAO<]!^&H_TQ?]ZOH2+_5K]*^?_AJ/],7_ 'J^@(_]6OTK
MS<1\1U41]8'B[GP_=C_8-;]8/BL9T*Z'^P:QA\1I/8^3[]<:@_U-. ^45)J:
M8U)_J:1!FO7I/0XI;BKTIA'[RI *;CYLU4AI:!;\7:G_ &J]V\(W6RQ49_A%
M>%1\3J?>O5O#UYY=JHSVKGG&X[V/1VOOW>,TB7WR]:Y9M1[9H34.O-8\NA29
MU0OO>@7PSUKEEU'KS2?VC_M4N4I,ZMK[WIBWW!YKF6U#Y?O5&-1YZT<I5SJE
MOO>E>^&.M<L-0^;[U*=0Y^]3Y=1)G5"^X'-'VX9ZURPU#C[U)_:/R_>I.(7.
MJ^W>]'VX>M<J=1^7[U!U'@<T<H7U.J^W>]'V[WKE!J/S?>I3J//6GR F=5]N
M]Z47XW]:Y3^T?]JD_M'GK4R@.YU;7WS=:3[=P>:Y?^T,_P 5(VH?[5)1)3U.
MG6^XZTCWV5ZURYU#'>D_M#/>FXZ@V=AIUUODQGO72H<K7GNA7F^XQGO7?P',
M8K"HC6F2T445D:A3)/N&GTV3[A^E" XC6O\ 7_C6;_&*U-8_UWXUF>]=<-CF
MGN0G_6FGBF_Q9IXK66Q$=QC#Y:Z?P_\ ZM?I7-R#FNG\/CA:YJAM#8Z0=*6@
M=**P-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0]*Y/7Q\[5UAZ5RNN
MCYVJHB>QSW:@??I5'6E'K75 YY#1_K2:3^*G>]-[UIT(ZF[H?^L7ZUUZ_=KD
M-$_UB_6NO7I7'4W.FGL+1116984444 %9^IOB$UH5D:N^(S3CN)[''7?S3'Z
MU%BI'^:5J0#BNR"T.>1&!\]*1UIZCG-(XQ5,ELA J5.PI",4^(9<"H94=SI=
M)C^5:Z1?NBL72D_=K]*VATKFFS>(M%%%04(>E<YK$>2U=)6-J<>X-5PW):.*
MF'[S\:?W%.G7]\WUIHZ5U1.:6XO\6:A _>-4W\.:9COZU0A>B&GVQQBF-TQ3
MH>"*SGL5 ['27S&![5LCI7/:(^3BN@'2N:1TQV%HHHJ1A1110 4444 %<;XX
M_P"09)795QOCG_D%25I3^(B>Q\XWW_(1E^M,7[AI;\_\3&7ZTQ3\IKUJ>QR/
M88U*_P!P4TGYL4K'Y:<B7N ^^M=AH-SY:+S7&J>16YI]QY:#FB6Q+W.Q6^.]
MN:%O^#S7.+>_,>:3[;@XS7(UJ;)Z'1_;OEZTW[=[USWVWG&::+SD\U5@3.E-
M][T+??-UKG/MG'6A+SOFK:T&V=(+_D\TBWW!YKG#>X[T@O?>E8B^ITAOODZT
M&^^0<US9O>V:=]L^7K2L%]3H1?\ /6I/MWO7,)><]:>;WCK2L-LZ(7_S'FE-
M]QUKF?MO/6G_ &SWH:"YT2WQQUI7O^!S7.?;,'K3'OO>I:&F=%)?<=:X[Q!)
MYEP35XWN<<UCZG)O8FM((B11CZ4Y/NM4:'BI!PI]ZZ49=1HZ4]ON"F+][%.D
MZ8I]"F:>@C.L6W^\*^G= &+!/H*^9/#GS:Q;_P"^*^G="'^@)]!7FXG<Z*.Y
MJUB^)O\ D$3_ .X:VJP_$Y_XE,_^Z:YJ?Q&\_A/F37?^/]_K62_2M;6_^0BX
M]ZR6^]BO5IG"R>#I2G_64V \&@GYZV)&M]XUU7@#_D,1_P"^*Y1SR:ZGP"?^
M)Q%_OBN>ML:1W1].6_\ J$^@J6HK?_4)]!4M>4SN6QB^(5S82?[M?-/BD8UL
MU]-ZZN;"7_=KYE\7?+K1KKPYS5MS*3[QI.YI$/.:">:]")FAIHB/[T?6D8\T
MD1_?42V(9Z/H%WY=N!GM6I)J'S=:X[3;O9%C/:K+W^6ZUR26II3>AU$>H<GF
MG)J')YKE5O\ '>E6_P"3S4V+N=4VH?)UI/[0^0<UR[7_ !UH^W_+UH:&F=0V
MH<KS0=0^<<URYO\ D<T-?\YS18+G4C4/F/-(NH?>^:N76_[YI/M^#UHY1MG4
M_P!H?(>:0ZA^['-<Q]OXZTW^T.V:.45]3JFU#[O-!U#YQS7+F_XZTT7^3G-)
MQ"YU/V_YSS0FH<GYJY@WW?--6_YZTK:"OJ=4=0^7K5+4KW=:8S6$VH<XS45U
M>[H,9JX1U)D]#G+YM]R?K5>3[PI9GW3GZTV0UVQ6AB%.7H:83\N:7.!4]2WL
M/@_UH^M?0'PV&-/B^E?/UO\ Z]1[U]"?#@8TV+Z5S8CX1T?C/0JQ/% SHLWT
MK;K&\3#.C3?2O/A\2.R>Q\NZ\N-8E^M45K3\1+C59#[UE XKUH['!U'GI3O^
M65,)YIX^[BM8A(C0XE7ZUW.B76RWQFN$!_>?0UT.GW6R'K64T)'6/??-UI_V
M[Y>M<RU[WS2F]^7K6+B:MG1)?'8>:7[=\O6N=6\^4\TGVWG&:+ F=(U]P.:/
MMWS#FN=:\XZT@O<GK3L%SH_MWS]:!?'GFN<:]YZT"]]Z.74+G1"^^4\T?;OD
MZUSGVWWI?MG&,T*([G1F^X'-!OOF'-<W]M]Z/MO?-/E%<Z3[=\_6@7W)YKG%
MO>>M(;W!ZTF@N=(+X[3S2?;OEZUSPO..M-^V]LT6'<Z,WW YI?MV6'-<W]M]
MZ5;W)ZTK!<Z/[=\_6F?;OF/-8#7O.<TS[9[U5A7.D^W?(>:ET^^S<CFN6-[@
M=:FTV]_TL#/>LYK0:>I[[X?D\RV3Z5OCI7*>$I/,M4_W:ZNN*>YUK81ONGZ5
MX1\3_P#6G_>KW=ONGZ5X/\4>)C_O5KA_B(J;'F"_=:G?\L::O0BG-]S%>BCB
M&]A4G<5$IR:D'2J0HD^G_P#(17ZU](^"O^0;#_NU\VZ>?]/4^]?27@G_ )!D
M/^[7'B=C6E\1UM(WW3]*6D;[A^E<!VGS_P#%#_CZ;_>KSB/K7HOQ//\ I;?[
MU><Q<BO3H['#+=DO\=-;K1GYLT-75T)ZC37K'PR^]'7DKG%>L_# Y>.N:ML6
MMSVZ'_5BGTR+[@I]>8]SL6P4444AA1110 4444 ,<9!KS7QW:[H'./6O3#7%
M^,+?S+5SCL:UI.S,JBT/G"Z39<N/>H'/RUHZO'Y=XX_VC68YXKT8,YF2)]T4
M]_O+4<1XI['YA6Q$B6HE^^U.W4S.&I,2)+5MDX^M:%W+O3%9BG:X-3O)N.*7
M0")^U#=!2.>:1S\M5T&ABG]_3Q]\U I_>9J4'YJ3V!GI'PU_X_%_WJ]_C_U:
M_2OG[X;'_3%_WJ^@8_\ 5K]*\S$;G50V'5A^*!G1;G_<-;E8WB49T6Y_W#6,
M-S2>Q\KZPN-3?ZU#%UJYKBXOG/O5&(UZU,XI;DGK3:6FUH]RF XD7ZUW&DW>
MR!>>U<+GYQ]:Z"RNML/7H*AHF3.K^W?-UH6_PQYKG%O><YIAOL/UK-H$SIUO
M_O<TW[?[USGVW ZTGVWWI6+3.H:^^0<U']N^8<USXO<KC-,6\YZTN4;>ATWV
M[Y^M OOF/-<X;WG.:3[;WS3L*YT@ON#S0+_Y.M<V;W ZTBWO&,T.(7.D:^^4
M<T-?<#FN<-YGC-!O>.M'*%]3HEOOGZT[[<=W6N9%[SG-/^V]\T[#B]3HOMQ]
M:;]O]ZY\WF!UJ/[;SUI2139U"W_'6D:^Y'-<XM[SC- O<MUJ%$B^IT3WW/6F
M+?\ S'FL![SCK40O>3S1):#Z'H7AB\W7F,]Z];LVW0*?:O!/"5YNO@,_Q5[M
MIC;K53[5RU=C6GN7:***P-PIK_</TIU,D^X?I0!QFL?ZX_6LK^"M36>)OQK*
MSQ75#8YIC13QU%-7TI>];/8B.XZ3[PKI?#_;Z5R[-GFNF\/'I]*YZAO#8Z>B
MBBN<U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KEM=^^U=3VKEM?X+?
M6JCN)G/IU:D'W32 ]: >U=43GD*?N4P]J?[5&W6M.A!O:)_K5^M=>.@KCM#_
M -8OUKL5^Z*XZBU.BF+11169H%%%% "'I6!K4GRM6](<(:Y;6Y.&JXDR,%>7
M:C^$TU#R?>E8X.*[(;'/(<O2FR=10IIA.6H9(YA3[<9F%(?NU)9C,PK-[&D4
M=EIB8B'TK3JEIZXA7Z5=KFEN;H****D85GWZ94UH54NURAJH[B>QP]TN)W^M
M5U^X:N:BNV9OK5,=*ZHO0Y9;B_\ +*D;[JTO\.*:QZ"K1+"3J*6/[U-<\41G
MFHEL7 Z/0Y,2D5U*G*BN+TB3;-78Q'*"N61TQV)****D84444 %%%% !7'>.
MO^01)78UQ_CH?\2>2M*?Q&=38^:]0_Y"$GUI@Z5)J _XF$OUI@'%>M3V.9D7
M_+2E8TN/GS33UJI$,1:MQ3;4JJ!@4\=,42^$GJ6UN3GK36N3O'-5<\TAR6S7
M.EJ6MBW]I/F=:%N3O/-5,_-FE&<DU5AW+:W)VMS0ER=O6J:DX-*#@5;0FRV]
MR<#FF_:3D<U58Y I"?F%38"X;D[^M/\ M)QUJB?O9I^>*+"ZEA+D\\TK7)V=
M:IJ<9H)^7%*P[ZEHW)VCFI/M)R.:H'H*>#TH:%T+K7!W=:@:Y.[K43'G-0MU
MS4VU&F6Q<G<.:9<ONCS58'YA4TO^KQ6B0I$:_=%2OP!4:#*BI7Y%:D=2-/\
M6TZ3K34_UF:5^M-[#9L^%AG6(/\ ?%?3VBC%BGTKYG\))G6(/]\5]-Z4NVS0
M>U>9B3IHE^L'Q1_R"IO]TUO5A^)QG29_]TUST_B-I['S)K7_ "$V^M9)_P!:
MU:VM?\A)C[UE,,.37JP.*0^W^ZU'>D@Z'WI6&*U1 R3I74^ O^0Q#_OBN6;D
M5U/@,?\ $XA_WQ6%;8TAN?3UO_Q[I_NBI:BMO^/=/H*EKRF=RV,_6%SI\O\
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MI2)+KW)V]:@^TGUJ-C\M0-WI20'7>#KDG45Y_BKZ.T5MUDI]J^8?!SXU)?\
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M<GBD7KFD'2@=*'L-"24JG"&FR]*!TI)!(=_#BG?PBF#K3J&$1.]-D-/-1O\
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M)]PTY#^[Q3!PM(A^;%=<2%N2-T%-<\K3NIQ4;GF@0[/[P4H^^:C4\YIV>33
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MU/O6-1Z#1]#^"X?+L%X["NN%8'AF'R[!./X170"O-J/4ZZ2T"L'Q1_R"IO\
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MKN*XKP&/^);$?]D5VM>74^([:>PC?=/TKP3XJ?Z[_@5>]M]T_2O!?BGS,?\
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M%N(W^M KI-!_UOX5S3']X#72Z!_K ?:L*AO$Z>BBBN<U"BBB@ HHHH ****
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MO:FJ>&IY&!3%'!K:)(\?Z@FF9^04\#_1R*81\HIH!2>E)GYZ4CI28^?-'48
M_.:4'.:0#YS0HZTQ"]J7M1CBC'%0(<*C/WZ?3#_K*H9(3Q4:GDT\]*8HY-+H
M K'Y:3.%%##Y:"/D%- @)QCWIV?FQ3&'2E_C%);@.8TQ>AIS4U.])B6XY*LY
M^3-5E%3_ /+,4(OJ5[@X%>K?":3[@_VJ\GNONUZ;\*'Q+'_O5S8C8N/Q'T G
MW13JCB.4%25YK.U;!3)/N&GTR3[AH6XSA]=.)Q]:S ?G K1U[_CX7ZUFK_K!
M75$YY#Q_K"*;GDTX?ZXTSNU:="$)GC-=1X?Z*?:N6_@-=3X>^XOTK"9K$Z<=
M*6D'2EKG-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH #TKDM=XF8UUIZ
M5R6O_P"L;ZU<-R9&#FF$_-BG4PCYQ73$QEN2+UQ2KU-(OWJ5>IJV9&UH?^N7
MZUUXZ5Q^A_ZX?6NP'2N6KN=-/86BBBLC0AN3B,UPFJRYN&'O7:WS[8C7 Z@<
MW+?6M8+0RF-!^0FF;N*</]4:BQQ6Z,25S\JTY*9)]Q:>G44^@T,E/SXK3TI,
MR"LQN9ZW=(B^;-3+8N.YU%J/D%6:AMQA*FKFEN;(****D84444 %%%% !2'I
M2T4 8&JIDM7,R##L/2NNU%,LU<G=#;(]:1,IE16ZTX_ZO-1H.M2-_JL5TQ,7
MN+_ #3&IQ^XM-(Y%-CAN3V;[9@*[#29-W'M7%0\7%=;HK<US3-HF_11161H%
M%%% !7'>..=*D%=C7'>-_P#D&R?2M:7Q$3V/G"]'_$RE^M)C-.OO^0E-]:1.
ME>O36AR/88_!S4<BX&:DE^[1+_J5JI&2(XQQ3]O%$?2GTT-[D6.<4F*<OWS2
M#H:B3&A,?+F@C"BG_P#+.D;[HIQ&R/;@BI .<4C=5IX^_0]Q+<,4S&>:E/>F
MK]UJ:&AN.*3;CFG?P4K?<% (:10!SBG'[PH/WZ Z$9&: .#3QU--7[K4$L:!
M\N:=CY:%_P!73F^X*EE1& <T]Q\N*:/O"G-]_%2RF0^U)(-PI6X8T#YA4O8S
M9=T6'?=IQWKW[P-:^7"K8[5XIX;M]]TG'>OH3PK;^791G':N2J]#:DCI%Z4Z
MD%+7$=:V"L+Q/_R"IO\ =-;M87B?_D%3_P"Z:NG\0I;'S/KH_P!/8^]9X&%S
M6EKG_'Z_UK//W!7K4]CDEN1D8/UIY':A^JTK??K4@A/4UU'@(?\ $XB_WQ7+
MM]XUU/@'_D+Q_P"^*YJ_PA'<^FK;_4)]!4U0VW^H3_=%35Y;W.Z.P4C?=I:.
MU)%'F7Q&MO,LSQWKPC4H_+E_&OHWQO;^99'BOG_Q!#Y<YX[UW46<D]S*BY8&
MIT^^:@@^[4ZGFNZ)FD.(YIN/FQ4IZ"H_^6E#%U #YJ#S2_QFD'>J6P,93B/D
MS333S_JQ4O<9'WI^/FIO\0J0_?%-B6XPC)Q2J.#3A]\T+_%4]"B/'>EQQ3A]
MPTA^Z*;$QNW'XT@&#BI&Z+33_K!2N*0TC+8IV,CZ4#_6&G1\AJ9#V&@<9HV\
M9IR_ZLTI_P!75&BV&"FL.<49Y%.;&\5+W)>XR&/?.%]Z]H^'UGA0<>E>1Z='
MOO0/>O>O =J%M\X[5QUV:P.]A&%%34Q!Q3ZX&=<=@HHHI#&2#*&O,_']GYD.
M<=J]./2N-\8VPDM&X[&M:3U,*VQ\XWT?ERM]:K*,KFM77(?+F?CO67'_ *H5
MZ,&<XN,8IV*&_AIQ^\*W1(TC/%&*<O\ K#0.K4P6PW;WI,<YJ0?<--_A% V)
MMQ2@?,*<W1:/XQ0'43'S8H ZT[_EI2+U:@8S'%.Q\E'\)I3_ *N@2&J,4$<T
MOI2O]X47 9C/% %/7[])W-*X=!NW/-&.*>OW#3?X:&#!AP*;VI[_ '1311$H
M5!VIW7BD7[U*GWC0WJ UAQ18_P#'ZI]Z<WW33;+_ (^U^M14^$SZGTCX$&-.
MB/\ LBNTKC? O_(,A_W1795Y-7XCNI;"-]T_2O!_BA_KC_O5[PWW3]*\&^*'
M^N;_ 'C6F'^(578\P3G-2KPN:BA^ZU3?\LZ]*.YRH&& #ZTW'-/E_P!6M-_B
M%7T)6Y-IXQ>K]:^DO!7_ ""X?]VOF^Q_X_U^M?1_@G_D&0_[M<6)V-Z>Z.MI
M&^X?I2TC?=/TKSSJ/G[XH#%TW^]7G,7"&O1_BE_Q\G_>KS=.E>I0V.*>[% R
M,4C#BI$ZTUNIKJ(ZD3C(KUSX5CYHC7DA^Z:]=^%G2*N:ML:+<]L3[HIU-3[H
MIU>6]SK6P4444AA1110 4444 %%%% !1110!R?BRW\RT;CM7SWXC@\FY<8ZF
MOI?781):MQVKY]\:6^R[.!WKKH,YZBU.-AX.*GVYJ!>)*LQ\DUZ,=C  /E-,
MV]ZE'W33?X*I@)T%-<4YONBD?M3Z$=2!O2NZ\"VV^\0X]*X5O]9BO4?AY;[I
MU.*Y*VQM$]RL1BTB'HHJU4%L,0(/:IZ\Q[G5'8****10AZ5P?CNU\VR/%=[7
M->*;<2V+<=JTIOWC.HM#Y@U>+R[P^QJ%#N85K>)X/+O7X[FL>W.37IT]CCD3
MRKA!46W%6)_]6*B;^&M(LEB ?+BDV\XIX^^* /G-5T$A@&0?:DQQFI%Z-2#_
M %9HN,;CC-&,&G'_ %8I6ZK0V(81\V*,<TYO]8*!]^D)C*:1SFG]S2=J8QQ'
MRTW;@T]O]6*5NJT@&,O.*-N>*>?]8*!]\TT!'MS3<?-4JC[U,I(!&'RYI$'-
M/8?(*1>HH$MQ0/FQ4HZ8II_U@IP^\:$6BM<CY#7H?PL?$\?^]7GUQ]QOI7<?
M#%]MS&/]JN:OL7'<^C;8YA4U-5:R.;93[59KS7N=JV"F2?</TI]-?[A^E(9P
MVMC,_P"-9J#G-:FL?ZX_6LQ/NUU1V.5[B_Q9II'/UIS?=H/\-:D]2-A@XKI_
M#_4#VKFW_P!:*Z7P_P#ZS\*YY&T3IATI:**P-@HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH .U<GKW,K5UE<IKO\ K6JH[DR.?4=:3&3FG)U:E'W371%F
M+ <#-)TI?X*0]!6A#6IM:)_KE^M=>.E<AHG^N7ZUUXZ5RU?B-Z>PM%%%9FAE
MZI)MC-<3=C,I/O76:S)A2*Y2;EJW@8R&+]W%-V\XIXZTN/FK8R&L.![4J]*7
MUIJ_<-( 09FKJ=*BPH-<Q;C=(*[/38\1+]*F>QI U(QA:?2 8%+7,S<****0
M!1110 4444 %%%% %"\3()KD-27;(?<UVURN4-<=K*XD_&K@9S,L#!^M.([4
M[^):/^6M=,3%C3TQ0!D9I3]XTY/NFJ8T1KQ)FNGT9L8KF3P:Z#2'P%KGEN:H
MZH=!2TV,Y44ZL30**** "N.\<<:7(:[&N-\=_P#((D-:4OB(J;'SA?G_ (F,
MOUI@; HU _Z?)]:B+8(KV*9R/8>[9H=LQ@5$6^:D#9)%.1F2QMQ4FZJZ'K3M
MU%P>XX'YC2YIF>:">:F0T2 _+BFL>@I,\TS/S&G'8;V)&/(IRGG-1,>*5#\N
M:+BB2,U"GY343-2@\4^@#L\8IQ/R"H<_-3B>* N/W<BAV^;-1*:';BBX7)5/
M-'0&HT/ I[=*+DO< ?DI2?E%1YXI0>*EE1' \T;LO4:GAJ1#DU++W"8X.:2$
M[G ]:;<GY119#=<(/>H;T):/0/"5ION(^.]>\:)%Y=H@]J\E\%6>9X^*]FL8
M]D*CVKBJO0WI(M"EHHKF.D*P/%!_XE<W^[6_7/>*?^09-_NU=/XB9;'S9KA_
MT]A[UFYXQ5_7#_Q,F^M9@/S$5ZM)Z')+<ESDCVH)^>F1'.ZDSS6IE<;(>375
M> 3_ ,3>+_?%<G*>*ZGP$?\ B;P_[XKFK[%1W/IZV_U"?05-4%K_ *A/]T5/
M7F/<[H[!111211S?B>#S;,C%> >+K;RYCQWKZ0U>+S+<C%>$>/+79(3CUKJH
MLY:BU/.H3CBI@?FJ!.),5)GYZ]&#,T62?EI@/.:0M\E1@_(30Q6U)-W.:53P
M:@9OE%/4\4[D,7/S4_/RXJ#/[P4\'YB*"T*#\U2,><U I^8T]C\M-DK<>&^;
M-&[%0[N*<QX%242@_)3<]J:#Q30?FH)N2L>!3<Y<4TGBFJ>:0,ES\Y-.C. U
M1$TJGBGU)'J?D-!;Y,4S/%-W<XJBDPS2;_G%)GAJ@5LM4M@=%H,?F7RU]#>$
M(/+LU..JUX-X4AWWB'%?1>@0^78Q\?PUY^(>IO31LCI2T"BN0Z4%%%% Q#6!
MXCA\RU88[5OFLW5(_,A(]JNGN95=CYR\76WE7#\5R43?PUZ-X_M?+N6X[5YH
MAQ.17HP9S6+&[)^E/#9-5D;+-4B'-;Q9#T9,I_>9I0>34>:,\U8B3/RD4W=Q
MBD)J//S4KC)BW I-W.:CW=:0'B@9-N^;- :H2WRYIV>!1U!#RV.*=GY*@<_.
M*?GBE<5]1V[I0S<U$#R:-WRF@?0F1OFS2%N:CC/&:1SR*!7)U/R&F[N,4T'B
MF9^:@+DSGY135/%-)XI%/R&DF4F2@]Z53R34.?W>:=GBAL&2,>*2R/\ I:_6
MHR:=9'_3E^M1-Z$'TIX$.=-A'^R*[2N(\!'_ (E\7^[7;UY=3XCNI["-]T_2
MO!/BB?WQ_P!ZO>V^Z?I7@?Q3_P!>?]ZKH?$*KL>80G@U-GY<56C/S5+GY\5Z
MD3E)9#E%I%.33&.121'K5]"5N7;(_P"G+]:^D/!/_(+A_P!VOFRR/^EK]:^D
M_!'_ ""H?]RN#$[&]/<ZVD;[I^E+2/\ </TK@.H^?OBD?]);_>KS9#\IKT;X
MI'_2F_WJ\VB/R&O3H;')-:DZ&FN:1#\M-D/%=-S%[B9^4UZ]\*S_ *JO'B:]
M>^%9^>.N:L]#6.Y[@GW13J8GW13Z\UG6M@HHHI#"BBB@ HHHH **** "BBB@
M"CJ2;[=A[5X5XYM?W[-CIFO>[E=T3#VKQ[QQ:Y61L=,UT468U#QN3Y9*EB:H
M[P;7/UIL3?**]*F]#GZE@-UI<_+BH<_-3R><5I(.HX]!2.>E)FFL>*&S,8.9
M17L_PZM_E1L=J\9@7=*OUKWSX>V^+.)L?PUR5GHS:)Z7#Q&OTJ6F)PHI]>:S
MK04444AA65K4?F6C#VK5JI?)O@8>U5!ZDSV/FWQI;>7=L<=S7'0'#UZ7X_M=
MLS''K7F0^66O2ILXI+4M.V0!37/2HU;+D4YSQ6T2'L*&^;-.)QS4 /RYJ1S^
MZ4U700]3P:;GY<4BGBF$_/B@"8_<%(3DB@'BF \T#Z#R?GH!^:FDT#K2$*>M
M)2M3:+@AY/R"E8]*9GBC-,!Y/ST9PQIN>::YH&B13P:C_BQ2J>*;_P MA0@Z
M$AZ8IH^]3OXR*;WI$Q'D_.*,X:F9YI&-4BD-N#\OUKL?AU)LO8Q[UQ=R>%KJ
MO K[-3B'O7+7V-8[GTUIIS9H?:KE9^CG-A&?:M"O->YV1V"F2?<-/J.7[AH0
M,XK6/]<?K68OW:T]9_UWXUE]ZZ8;'/):CC]VDSDBD--0\FM";#W_ -8*Z70/
MO@^U<RW7-=-H'13[5A(UCN=/VHI!TI:P-@HHHH **** "BBB@ HHHH ****
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M*P"F#J:?2 4^A7D)2TH'S8H(YJ>HK"GD4W%/'(-)CY:!)#<<4E2$?+3.],+
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MV@CZ8MO^/=/H*EJ*W_U"?05+7"=2V"BBB@8AJ*X3?$1[5*:1AE#30CSSQ'8
MASBO*=;M"KMQ7NFM6V]&XKS'7-.R[?+793EH<\D>7F [FXJ%HCCI752:80S?
M+51]..<;:WYC"VIA)$=O2D>,Y'%;ZZ><=*:^GG(XH4BK&%Y9WCB@1'>>*W#I
MYW9Q2KIYW9Q34M L8(C/S<4"([#Q6Z-/.3Q2_P!G';C;2Y@L8)B.P<4&(_+Q
M6\=..T#%!T\\<4<VH&$T1\P<4@B.\\5O'3SNSB@:>=V=M'-J%C!6(_-Q2K$=
MIXK=&GD9XI5TXXQBGS!8P7B.WI2-$?EXK??3CCI2?V<3CBA2"QA&([QQ2QQ$
MRGBMPZ<=V=M30:83)G;4RD.Q!I%L6F''>O5O#=A\BG%<AI&F%9A\O>O4="M-
MD*\5C*1=CIM.B\N!:T*@MUVQ"IZY).[.B*"BBBI*"BBB@ I#2TAH$R*>/>A%
M<!XGL V_BO1",BN9UVV\P-Q6D'J1-:'@.N6A65N.]<YY1STKTK7]-_>,=O>N
M4.G')^6NR,M#"2, Q''2E$1QTK=.GGTI1IY]*U4B+:G/-&=XXH$9\SI6Z=/.
M[.*/[/._.*3EJ%C!$9RW% C.P\5NC3R">*!IYVGY:7,%C!,9V#BGR1G:O%;?
M]G';C;3FT\D#CI1S!8P3$=PXI/*._I6\=/.X<4?V>=_2GS!8PXXCEN*1(C@\
M5OIIY&[BD&GD9^6CF%8P7C.SI08S\O%;K:>=O2C^SR=O%/F'8PY(CO7BD\L^
M9TK??3R6!Q3?[/._.*7-H"1@K&<MQ3EC)C8XK;&GG)XI4L#L(Q4W!HP?+.S.
M*>(CM'%;9TX[.E*M@<=*J^@[&,D1QTI]E$?MZ\=ZVEL#CI3K.P(O5..]8R81
MW/<O @QI\8_V:[2N3\&Q>791_P"[765R3W.N&PU_N'Z5X-\41^];_>->\O\
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MQ1BEHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (*6BB@ HHHH *
M0C-+10 W%&*=24Q"8HQ3J*06$ I:**!A1110 4AI:* $Q1B@T4Q=0Q0**6D
M4444#"BBB@ HHHH **** "BBB@ HHHH **** "D[TM)0)B8I"*=13$(!2TE+
M0 M%%%(H**** "BBB@ HHHH *0]*6B@!!2T@I:!(*3O2T4#"BBB@ HHHH *2
MEHH 0"EHHH **** "DQ2T4 %%%% "$44M% A,4F*=WI#3!AB@"BEH ****0P
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHI=0"BBBF
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !2=Z6D[T"8M%%% PHHHH ****
M"BBB@!#TI1TI#TI1TH%U"BBB@84444 %%%% !1110 4444 %%%% !1110 44
M44 %(:6D- GL%'>BCO3$(:44AI10"W%HHHI%!1110 4444 %%%% !1110 @Z
MTM(.M+0)!1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I#2
MTAH$]A:***!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
(4 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image4.jpg
<TEXT>
begin 644 image4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0A!WH# 2(  A$! Q$!_\0
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M110 44E+0 44E+0 4444 %%%% !1110 4444 %%%% !1110 44F:6@ HHHH
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M(B/;32O-3E:;MK5#1&!Q2[:D YI2O%0WJ!#MHVU*JT$<T 1[:3;4VWBD"\T
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M)CFF A'%(HIYZ4BBI :PYIV/EH(YI>U #%'-#"G <T,* $ XIN/FJ0=*3'-
M",.*%%./2@4 ,(YIV/EH(YI>U #%'-/(I .:=28F-Q1BG44"L1L*51Q2D4HI
ME(;CFE(XI<<TO:D4, I&'-/%(1S0A,,?+3 .:D[4@%,0UA2J*4BE% A<48I:
M*!B8HQ2T4 )BC%+10!&PYH XIQHQQ5"8P#FG$<4 <TXT,:&@<4A'-/%(1S4L
MH81Q0HIQ%"B@3&L.:;BI"*3% A%'-*PI0.:4T 18I0.:=BE YH 1AQ2**>>E
M % #".:=CY:".:7M0!&!S0PYIX%!%)@(!Q3<<U(.E)CFA -(H IV*,5=QC,4
MI%.Q1BA@-44C#FG@4,*AB&XXI .:?VH YI1 1A28IYI,5H"&8YIS#BEQS2GI
M4@,44$<TY101S0 F.*11S3^U(!S2 :PI0.*4BE'2@"/'S4YAQ2XYI3TH :HX
MII'-2"D(YH 0CBD44\]*0"@!K#FEQ\M*1S2]J & <T,*<!S2D4P&J.*;CYJD
M'2DQS0 $<4P"I#TI * &XIQ'%&*=VH&R+'-!%/QS010  <4S'S5)VI,<T"$8
M<4*.*<>E H0#".:=CB@CFE[4@0@%(1S3A01390@'% '-.I.]-"$84**4THJ0
MZ!BDQ3J2D(0"C%+2T"0UAQ3%'-2&F@<U0QK"E XI2*4=* (\?-3B.*7'-*::
M :HI".:>*0CFF 8XI *?VI!4L:V&,.: .*<11CBA A .:&%. YH- ,:HXIN/
MFJ0=*3'- A".*113STI * &L.:=CY:".:7M0 Q1S3L4 <TZDQ,3'%1X^:I>U
M-QS3&(PXI%%//2@"@!A'-.QQ01S2]JH!@'-#"G#K0128" <4@'-/'2D YI (
MPXH4<4XT#I0!'CYJ<1Q2XYI3TH 8HH8<TX"@CFCJ 8^6FJ.:?VI .: '8HQ2
MT4 %%%% !1110 57GJP:JSFF@%@JQ5> U8%# **6BD F**6B@!*#2T4 )1BE
MHH 2@4M% "4=J6B@!**6B@!**6B@!#0*6B@!**6B@!!12T4 )12T4 (:*6B@
M!**6B@!!012T4 )B@4M% "&BEHH 2BEHH 2BEHH 2BEHH 2BEHH 3%&*6B@!
M*,4M% "8H%+10 E%+10 E!I:* $I:** "BBB@ HHHH *2EHH 2C%+10 F**6
MB@!**6B@!!0:6B@!**6B@!#12T4 )12T4 (**6B@!**6B@!**6B@!*#2T4 )
M12T4 )0*6B@!**6B@!*#2T4 )12T4 )0*6B@!*.U+10 @I:** "BBB@!**6B
M@!**6B@!**6B@!**6B@!#12T4 %%%% !1110 4444 (:**6@!**6B@!**6DH
M *!12T )1BBEH 2@TM% "8HI:* $H%+10 E':EHH 2C%+10 E&*6B@!**6B@
M!**6B@!!12T4@&TN**6D@$-%+15 )BBEHH 044M% "44M% "&BEHH 2BEHH
M044M% "44M% "4=J6B@!*#2T4 )12T4 )12T4 )12T4 )BBEHH 2BEHH 2@4
MM% "44M% "44M% "44M% "4"EHH **** $I:**0!24M%,!#12T4 )12T4 (*
M*6B@!**6B@!**6B@!*#2T4 )12T4 )0*6B@!**6B@!*6BB@ I*6B@!*!2T4
M)1VI:* $HI:* $HI:* $-%+10 E%+10 @HI:* $HI:* "BBB@ HHHH ****
M$-4KDXJZU9]V:I#1);'(JX*H6AXJ^M#$Q:***D HI*6D 44E!I= %HHHJD 4
M444 %%%% !1110 4444 %%%% !1110 444E)@+1124 +12&EHZ@%%)WI:0!1
M2"EIH HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
ME+4@%%(** %HHI*8"T4E+1U ****8!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1124F M%(:6CJ 4444P"BBB@ H
MHHH 2@4&@4Q=1:***0PIN>:<:9WIH:'"EI!2TA"4M(:!0);BT444#"BBB@ H
MHHH **** "BBDI,!:***: **** "BBB@!****BXPHHHH0"T4458@HI.]+4@%
M%(**.@"T44E,!:*2EHZ@%%)2T@"BD%% "T44E,!:***8!124M) %%%%, HHH
MH **** "BBDI,!:***: ***04NH"T444P"BDHJ>@"T4=J2@!:*0TM/J 44E+
M2 **044= %HHHJ@"BBB@ HHHH **** "BBDI=0%HHHI@%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 C=*H70J^:J7"U2 9:CBKRU5MUP*M"A@+1114@)2T44@$H
M-+118 HHHI@%%%% !1110 4444 %%%% !1110 4444 %)2T4F 4E+10 AI:*
M* $[TM%%%@$%+110@"BBBF 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% "4M%%*P!24M%%@"DI:* $I:** "BBBF 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E+128"&EHHHZ@%
M%%%, HHHH **** $- HI:!=0HHHH&%,[T^F]Z:&A12T"BD(0T"BEH$@HHHH&
M%%%% !1110 4444 %(:6BDP"BBBF 4444 %%%% "4445 PHHI:$ 44458A.]
M+112L @HI:*+ %)2T4 (:6BB@!*6BBBP!24M%%@"D%+10 4444P$I:**2 **
M**8!1110 4444 %)2T4F 4444P"BBBEU ****8""BEHI6T *2EHH ****.H"
M4M%% ""BEHHMH 4444P"BBB@ HHHH **** "DI:*0!1113 **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ JM..*LU6G-- + .*L57MZL4, HHHI %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444E "T4E+0 4
M444 %)2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% "4445/4 I:2EIH HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 54N35HU3N::$Q]L>*M54M>E6Z&,****0!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%)0 M)WI:2DP%HHHI@%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4E+24GN M%%%, HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HI,TM !1110 4444 %%%% !1110 44E+2Z@%%%%, HHHH
M*2@T@IB>XIH%!H% =1:***0PHI*6@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH 2BBBI *6BBF@"BBBF 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% "'I5.XJVW2JDU4A#[;I5JJUOT
MJS4L84444 %%%% !2&EIIH&A12TU:=0(**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#2TTTHI"%HHHI
MC"BBB@!#2 T/TIJ&@"2D[TM%)@%%%%, HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBDI,!:***8!1110 4E+24F M%%%-
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444'I0 VG"HR>:>.
ME)#8M%%%,04444 )2TAH% NHM%%% Q*6DI:2 ****8!1110 E)2T4R1*444M
M T%%%%(8TFE%-;K3EZ4#8M)2TAH$Q:*04M !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444F E%%%2@%HHHJP"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH 2EI*6@2"BBB@8AH%(U(M ^@^BBB@04
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !124M( HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 UNE59:MMTJK+3Z 20=*G
MJ"#I4]( HHHH **** "F-3Z:::&@6G4@I:0F%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%)2T %%)2T %%%% !112'I0 9I:CSS4E #3
M2CI2&E%(2W%HHHIC"BBB@!C]*:G6GMTIJ"@"2DI:830)L=FEJ,&GB@!:***!
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%)10 M%)2T %)2TE
M)@+1244P%I,T4PGF@"2D-(#3J3 ****$ 4444P"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ H/2B@]* (C]ZI!TIF.:>*F)3"EIK4"K)'4444@$- H--
MIDMZCZ2BBDQW"EI**E#%I,T&F$U:$/HIJFG4!<2EI**!!3J93A0-"TA-%-8T
M@&GK4B]*CZU(.E!706D-+3:"6**6D%+0""BBB@84444 %%%% !1110 44E%
M"T444 %%%% "9I>U,SS3ATI %+24M) %%%%4 4444 %%)2T %%%)0 M%)2T
M%%%% !1110 4444 %%%)0 M%)2T %%)10 M(:6B@!M.IM+3$@S2U&3S3QTI#
M&M0M*U"TBN@ZBBBF2%%)10 M%%% !1110 4444 %%%% !1110 4444 %%%%
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M13=U+NH 6BF[J7-,0ZBF[J-U(8ZBF[J-U #J*;NHW4 .HINZC=0 ZBF[J-U
M"TM,W4H:F ZBF[J-U(!:83S2[JB9N:: E!IPJ(-3P:!(?1112&%%%%( HHHI
M@-;I4>ZG2'BH-W- $V:!UJ'=4JGB@"4=*#3=U(S4 QXI:8II] D%%%% PHHH
MH **** "BBB@ HHHH *0TM(: $IA/-&:A9^:9+994\4ZHD;BG;J10K&A:C=J
M5&I] )::U+FD/-(!%%/I!2T %%%% !1110 56GJS56XZ4GN ZWZ58JM;'BK-
M, J*2I:BD^Z::$S/N+GR\\UF2Z@ W6JNM7GDN1FN7N-5P3\U:16IE(ZQM3'K
M2+J@_O5PCZSS]ZF?VU_M5IRDW/0?[4']ZFR:F-O6N#&M?[5(VM<?>IJ(KG;Q
MZF-W6I6U,?WJX!=8P?O4\ZS_ +5$EJ.^IWHU08^]31J@W?>K@_[:_P!JD&M?
M[5'*%]3T!M4&.M-74Q_>K@_[:S_%2?VUC^*ERC;.\_M,;OO4\ZH-OWJ\_P#[
M:_VJ=_;?^U1R@F=XNIC/WJ1M4&?O5P?]M8_BI/[:S_%3Y0OJ>@#5!M^]3/[3
M&?O5P@UO_:H_MG_:I<H[G>-J@_O4]-4&WK7GW]M?[52+K7'WJ'$FYV[ZF-WW
MJ3^U!C[U<(^L_P"U3!K7/WJI($SOQJ0]:LQ7X)'->?QZOG^*M.UU/)'S4F@N
M>@070(ZU<27=WKDK2^R!S6Y:7&['-8N)HI:&RIS2GI4<1R*>W2HZEIZ$?\52
MCI4/\53#I38)@33'.%S2L>:AN&VP$T@92ENPK8S2)=Y/6N=O;_9,1FFVU_N;
MK5I&3>IV44NZIP:R+&;>!S6HAS4M%)CZ6DHJ64A:;WI:3O2!CQTIC&GU%(<5
M2&]AP-*>E,0YHD.%H)1!/-L'6J+7HSUJ#4[GRU/-<Z^H\GYJT41-G2-?@=ZA
M.H#=UKE9=4Q_%5<ZKS]ZGRDMG9'4!CK3?[0'K7&G5O\ :IO]K?[5-1!,[+^T
M!GK4G]H#'6N)_M;G[U/&K?[5#B2=B=0'K1_: ]:XTZK_ +5-_M;_ &J+%7.W
M&H#'6F'4!ZUQPU;_ &J#JO'WJ7**YV!U >M/34!CK7%?VK_M4\:K_M4VB9,[
M3^T!GK2-J QUKC?[5_VJ0ZM_M4<I*9UQU 9ZTY=0'K7%MJO^U3DU7_:JK%)G
M<KJ QUJ:"]#-UKAUU7C[U:.GZCO<<UFXFESN(Y<BI<Y%9=K/N45HH<BI:*N(
M/O5..E1 <U**D:$:JLKXYJR_2LZ[?:A-1U$]R*>["C&:K0WHW]:Q+^_VL1FJ
M,.H_/UKHC'W2&]3NX;G=WJRKYKF["\W@<UL12Y[U#B7<T0>**8IXIPJ0N.%+
M3:=2*04444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I*6DI, HHI*
M2!@U)0YIH/%:$/<@NY-L1K!%UB8\]ZT]3EVPM7&M>XN3SWK2*(DSM+:XR!S5
MU9,US%A=[@.:VHILCK4R0XO0T U/!JHDE6$.:FQ29+1245)84&BD8\4Q7(99
M-HK*N[T*#S4U]-L!YKD=3U'9GFK2,Y/0M7.H@,>:HMJ8_O5S-YJV&/S5FMJ_
M/WJU2,6]3KY-1R>M36VH#>.:XC^U,_Q58M]3^<?-0T%SU2PO@P'-;L,N\"O-
M])U+<RC-=SIT^]5YK.2-8,UZ44T4^LS1!1112*"BBB@ HHHI7 ****8"4M%(
M:2 :S8%4KJXVJ>:L3-A37/:I=;$/-:)$MB2WXW'FDCU >M<E<:GB0_-4:ZK_
M +5;):&=SM3J ]:?#?AFZUQ)U;_:J>RU3=+]ZDXZ F>C6\VX#FK8-<_IESO"
M\UNH<BL6C1,>30#3&/-"FI'<D-)2]J:>E,0UWP*HS707O4EU)M0USE[>[2>:
MM1)<B_-?@9YK-EU ;^M8=WJF,_-63-JO.=U:J)DWJ=Q'J@V_>IW]J#^]7GXU
MK!QNIQUOC[U/E%<[[^U!ZT?VH/6N!76_]JD.M\_>I<H7.^_M0?WJ#J@_O5P/
M]M<?>H&MY_BHY17.^_M08^]49U,9^]7#'6O]JF_VS_M52B/H=Y_:@Q]ZA-3&
M?O5P/]M?[5.&M8_BHY=!)G>/J8_O4?VH,?>K@SK6?XJ;_;7^U1RZ V=\FIC=
M]ZIGU08^]7GR:S_M5(VM<?>I2CJ.^AW0U0?WJ<-3'K7 ?VU_M4\:U_M5+0DS
MOSJ@Q]ZH_P"U!_>KA3K?'WJB;6_]JE8JYW_]J#'WJ2/40TG6N"&M9_BJU9ZK
MOF W4FBD>F6L^X#FM)#D5RVE76]5YKI86R!421K$GHHI#TJ"B.1J@,N*=,V!
M69//M[TT(O\ G^]'GUD_:O>D^U>].PKFN)Z=Y]8_VKWIXN?>BP-FKY_O2>?[
MUDFZ]Z#=>].P7-;S_>C[160+KWIINN>M*P7-GS_>CS_>L@77'6C[5SUHL%S7
M\_WH\_WK':Z]Z!=<=:=@N;'G^]'G^]8_VKGK2M=<=:+#;-7S_>E\_P!ZQUNO
M>E^U>]%@N;'G^])Y_O63]JXZTT77/6BPKFQY_'6HVFYK.^T^]'GY[T6"YJ++
M4RR5DI/SUJTDM%@3-)6S3ZK0MFK%2T.XM%%%(84&BD;I0!!,V!5)I<&IKA\"
MLJ:;!H%<O>=S4RS\=:QA<>]*+K'>@+FU]H]Z:9_>LC[5[T"ZR>M,&;D<N:LJ
M<BL>WFSCFM2(Y6AH2)J***104F:4]*CSS0!)1110 4444 %%)2T %,<\4^H)
MC@4T)D3R8JL\WS5'/+CO5%Y_>F2]S52X&.M/^T>]8?VO!ZT\W7'6E8LU7N/>
ME2X]ZQ&N_>A;OGK3Z".B6;-2J^:QH;G/>M""3-2,O"EIJGBG4 %%%% !1110
M 54N:MFJ=S2>XT.MNE6JJVW2K5,&(:9)]PT\U')]QOI31#/-/%MUY<K<]ZX*
M\U$@'FNN\;$^<WUKS2_D(!K:",I;CI-4.\_-49U4_P!ZL"68AS4)F/K6Z1G?
M4Z==5./O4IU0_P!ZN968^M/\X^M7RDMZG1?VH<_>I?[4/]ZN;,Q]:!,<=:F2
M&F="VJG/WJ7^U3C[U<TTISUI?...M'*-LZ1=5/\ >H;53_>KFDF.>M*\Q]:.
M74=SI!JIQ]ZD&JG/WJYP3'%()CNZT<HDSI6U4X^]2#53_>KG6F..M-68XZT<
MN@VSI/[5.?O4XZH<?>KF/..>M2&8[:.4+G0#53_>J3^U3_>KF%E.>M/\T^M#
MB2V=$^J''WJC35#N^]6 TIQUJ-93NH2!,["'4SQ\U;EAJ.<?-7G\,YXYK;L;
MK&.:4D#9Z=87V<<UUFF7.['->66%]C'-=GHE]N91FLVBHL]'MVR!5@]*R[*;
M<HYK2!R*P:U-T]"/^*IEZ5%_%4J]*&"(W-5KYL6C'VJR]4M2.+)_I4H;/--6
MO=MTPSWJ*QO\N.:RM>FVW;\]ZS[*]P_6NB*T.>^IZWI-SN4<UT$4H(KSS1]1
MPH^:NGM]0![U$D-/4Z0/Q2@UFPW6[O5Z-LUBS4EHHHI(8^J\QJ?M5:>J6XWL
M+$W%)/)A*A63:*IWMUMC/-7;4ALP=?NMJ-S7%2:A\QYK5\0WV0PS7#RW7S-S
M71&.A',:%SJ6&^]54ZE_M5B7-U\W6JANO>AQ);.B.IG^]2?VD?[U<U]I/K2_
M:#ZT[#N=)_:7^U3EU,_WJYG[2?6A;DYZT6%<ZAM2X^]4?]I?[5<\UR<=:9]I
M/K22!,Z4:F?[U/.I<?>KEQ<G/6GFY..M#B#9T8U+G[U._M+_ &JYE;DYZTIN
M3ZT6)DSI_P"TN/O4W^TN?O5S8NCCK0+D^M/E)N=$^I?[5*FI?[5<T]R?6B.Y
M/K3L.YU:ZD?[U;>C7^Z4<UY^MR?6MW1+O$HYJ'$NY[+IUQN5>:Z"!MPK@]*O
M>%YKL;";>HYJ)K0N+U-("G"FCI2@U@:"/TK'U)ML3&MA^E86L'%NYJ4M1,\]
MU>^VS,,UEPZA\_6JNOW.VY;FL*&]_>=:[8K0Q;U/4]'O-P'-=1;7&2.:\ST6
M^P!S77V=_P CFHDBDSLXI,K5A#FL.VN\J.:U+>3=6+*3U+=**2E%2:(6BBBD
M4%%%% !1110 4444 %%%% !1110 4444 %%%% !24M(:3 *0=:6FTD)C7I!]
MTTKT@^[6JV%U,/6Y-MNU>;S7F+MAGO7H'B)L6KUY'=W.V];GO6R6AC)G<Z7>
M9QS72V]QD=:\YTN]QCFNHMK_ ('-#1-]#K8ILGK5Z%\UR]O>Y8<UMVD^['-0
MUH7%FMFEJ-6R*=FLC6XO>FR'"TZH+EMJFFMQ-Z&!K$^U6YKS?7-0VLW-=GK]
MSM5N:\IUZ[_>-S71%&$F9M]J7S'YJRCJ1S]ZJ-Y.2QYK.,ISUJVC)LZ6/4">
M]68=0^<<US$4QQUJQ'.=PYH:T'<]*T/4<R+\U>I:'<[U7FO!]$N]LJ\UZSX<
MO\JG-9R6AI%GI$9R*EJC:2[U'-717.SHB+1112*"BBB@!*#114] %HI*6F@"
MD/2EIIZ4T)E2Z;"&N)U^YV1MS79WG^K:O.O%$NV-ZV@C*3.,N]1Q,WS=ZK#4
MC_>K#OKHB=N>]5ENB>];Q1!TQU/C[U7-+U'=< 9[UQK7)]:TM&G)N1SWIS14
M3VW09]ZKS781'Y:X+PPVY4KO(?NBN26Y2W!SS0AYI&'-"=:DHG'2F.V!2DX%
M5)Y< U20I/0I:C-MC/-<-JE[M9N:Z/5KO$;<UYSK%[\S<UTQCH8R94O]2P3\
MU8\NI<'YJH7UX23S65)<G;UJK$W-)]5(?[U.;53M^]7,O,?,ZTK3';UJ^45S
MI$U4_P!ZFMJIW?>KG$F/K2-*=W6CE"YT_P#:IV_>IJ:J<_>KF_..WK2),<TE
M$+G3-JI_O4O]J''WJYIICZTHF.WK3Y1WT.@&JG=]ZGG53C[U<R)3NI[3''6G
MRB3.C&J''WJ8=5.[[U<^LQQUIAE.ZCE!O4ZA=5./O4IU4_WJYL3''6D\X^M)
MQ"YT?]JG/WJE&JG;]ZN5\XYZU*)SMZUFT3?4Z(ZL<_>J-]5/]ZN=,QSUIC3$
M]Z31HF=/'JI_O5JZ7J1:X7YN]<*DQ]:V=%G)NU&>]9R1:/=- N-Z+S7<6IRH
MKSOPP<QI7H=I]P5FS1,N4C=*6D;I69H4;AL"L"^FP>M;EV< UR^H/\QJEN3T
M&BX]Z3[1SUJD&HW<UI8ALO\ VCWJ19^.M9NZI%;BE8&7&N.>M--Q[U39N:0M
M5)!T+@N/>F-<<]:J;J8S9-)+4%L:"W''6E%QSUJ@'XI=U%@9<>X]Z5+CCK5!
MFS0K<4[:#+WVCYNM*UQQUJANYI6?BFD-EQ+CWI3<<]:HJU*6YI6U!,O&X^7K
M35N/FZU3W\4U6YH2$:?VCWJ59N.M9@>I5?BE;0#2CF^;K5^.7@5AQ2?-5^.7
M@4@-^U?-75-9%G+6G&V:EC1/10.E%06%-?[M.IK_ ': ,RZ; -85U+@FMN\'
M!KG+T\FF01^?[TPW//6JI>H6?F@#0-SQUI4N,GK6:9.*=&_-5;4&SI;.;)'-
M=#;-E!7)6,G(KI[-\H*;0D:':BD'2EK,T$/2HL_-4IZ5%_%0!*.E+2#I2T %
M(:6D- F I:;3J 0AZ55N&P*M-TK.O'PIIH3,F\EP36:TW!YJ2\EY-9S/Q5(E
M;CFN/GZT\W/R]:SW/STXMQ3++!N?>A;GYNM4B:$)W4 =#:S9QS6W:/G%<W9=
MJZ.R7@5F,UTZ4^F1]*?0 4444 %%%% "&JD_-6VZ55FI%(=;]*LU7@Z58H)$
M-12GY&^E2FH9ON'Z52)D>4^-%S*WUKR_41UKU3Q@,N]>6ZG]XUT11A)G,W'#
M&J^<U8N?O&JRUT1,VQXZU+VJ'O4P^[6B1DWJ,)H!H/6DH<2DP-%.I.]*Q38"
M@\T4"BP7U$[4#K2]Z*+ F!YI*44&BP7T$[TIZ4N.*2BP7$J0=*8:D7I3Y1-Z
MC#UI,8IQ^]2D<4FM17%1L5>@N-I'-9N<4";::F2&F=7:WVW'-=AX<U#=*O->
M71W9 ZUU7AB]_?KSWK.2-%L>\Z7<;D7FNAB.Y:XG1+G<B<UV5HVY!7/-&L&3
M8YIXI,<TM9LL8PK.U4XLG^E:9K*U@XLW^E.*U!GBGB5]MTYKF8;S;)U[UO>*
MGQ.]<*;G;(>>]=:6AS/<]#TS5-H'S5T]GJN2/FKRBSORI'-=+I^H\CFLYHH]
M8TZ]WD<UTUJ^Y17FVBWNYEYKT#3I=RK7/)&JW-:F]Z=VIG>H*9)VJK/5GM52
MX; K2.XI,HS2[0:Y_5KW;&W-:-[/M!YKC-<O<1-S6ZB9-G-ZS?[V89KE9[CD
M\U)?WNZ9AGO6/<3]>:W2,FQT\^3UJH9^>M0R2YJMYOS46&V7_-]Z>LE4/,XJ
M5'XH:%S%EI:02^]57?FF^9187,7O.XZTTR^]5!)07HL-/0MB7WIWG<=:H^92
MB2BPKEWS?>CSJI&2D\RBP29>$WO3O-]ZSQ)S4GF<4^4B^I9:6E6;'>J6^@2<
MU3B5<TUE]ZU=+N=L@YKG5DXJ[9S[7J&BDSU+2;_[O->C:)/OC'->)Z5>X9>:
M]8\,W.^)>:RFM#2+U.U4_+0#S3(VS'0IYKFL:MDIZ5A:WQ:O]*W>U86O?\><
MGTI16H/8\+\33[;I^:Y:*[_>=>];/BV3%W)7&)<8E//>NR*T,3T'2K_;CFNM
ML=1Z<UY=87FTCFNFL;_IS2:!'J%A?[L<UU6GS;P*\PTN^RPYKO\ 19MX6N:1
M?4ZA>E/IB=*?4,VB%%%%(H**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@!*2EHJ4)C&I/X33C2-]PUH2CE?$QQ9N?:O$-2N-M\_/>O;/%)Q9/]*\!
MUB;;?/\ 6NI+0PF;FGWVTCFNCM=1X'->=6MY@CFMNVO^.M)D)GH-GJ&7'-=9
MIMSN YKRNPOLRCFN\T6YW!>:BQI$[J%L@5-GFJ=F^5%62>:RMJ:IDHZ52OWV
MH:N \5D:M+MC/-$5J$MC@_$MU@/S7E.M7.9&YKO/%%UC?S7ENJ3[I#S77%'.
MS-F?<U5VIV=S4K+Q6JC<S8B'%2*_S5 .*7/-#CH!N:;<[)!S7I?AC4<E>:\?
M@F*,.:[?PQ??.O-8S6AI$^@='G\Q!S6X.E<?X:N-\:\]JZV-LBN62.B#)*6F
MBG5!:"BBB@8E%!HJ0"EI*6F@"D-+2&FA,HWH_<M7EWBU\1O7J=Z/W#?2O)O&
M+8C?\:V@8R/(M1GQ.W/>H()LCK5?5)/](?ZU#:29%=4$+H:#2\]:UM#D_P!)
M'UKG7?YJV=!?_25^M*8D>Y^$SE4KT*(?**\\\'G*I7HD?W17'(TB(PI%'-2$
M4WH:DIC)6P*R+R?:IYK1NGPM<WJ-QA6YK>$;HSFS!UJ\PC<UYMK%[\[<UU.N
MWG#<UYQJUUEVYKJBM#%E&YN=S'FJ;2Y'6J[S98\TS?S18ELD/)S2GI0.E K1
M(EO4%XI&IV*0CBAK4+C,TY:9WJ4#BBP[B&G#I2446"XF.:4TM)3:"X"D(YI:
M7%"07#M2$TM--2T*X4[/%,%+6;0(&-,ZFE;I2)4S1<6/'%:FAO\ Z:OUK+/2
MM#0N=07ZUDS1,]Y\*KF*.O1+8805P'A-/W,?TKT*$805BS1;D](>E I3TK,V
M,R_X4UR=\<L:ZO4N$-<C>'YC5+<AE0&E%,%2"M40%.!IM&:=ABFDHHH :>*:
M.:'H3I0 9YIQZ5&?O4]ONT )UHZ4B4-UH&.I.M+_  TT?>JEL#%Z4M(W%*.E
M*PD)GFCI3<_-3FZ4@'*:?NQ42&AC\U'0"TC5:CEK.5N*F22H&;UI+TK;MWR*
MY>VEY'-=!9/E128&H.E!I%Z4IK,OH H;I0*#TH!&;>K\IKF+T<FNKO5^0UR]
M\.35H3,=SBH6-23=:A/2CJ2-+4Z-N:B/6G)UJDA-FU9/R*ZFQ?Y17'V;?,*Z
MC3WX%-K0$;J_=IU,C/RBGUB:B'I3,<U)28H 44444 %)2TWO3$PI10:!0);C
M9/NUC:A)A36O*?DKGM3D^4TXA(P[J7)-4]U+-)EC4(/-43U'$9YHQ4@'RTU?
MO4%D3KBEB7)%/D%20)F@#2L5^85T]HF%%<_8I\XKJ;9,1BH8RPHXIU(*6D 4
M444 %%%% "-56:K1JI<<4AHD@JQ5:VZ59HZB$-03_</TJ<U!/]QOI5QW(F>7
M>+S\[UY9JA^9J]0\8G]XU>6:J>373$YV<W<'+&H5I\QRYIJUT11E)AWJ4?=J
M/O3^U;11D(:2E-)3L5<=VI.]%%*P[BF@4AH%%@OJ'>E[4E%%@N H- HHL%Q>
MU)WHHHL%Q32J>*::;NQ18+C_ .*I#]VH@>:D7FDT*Y&PJ!NM6G'%0,O-3)%(
M0$XK?\/3;)QSWK!Q6CILGE2 UE)&B9[=X>O,A.:]&TV3=&*\8\-7N2G->MZ)
M+NB'TKGFM#2#-ZDH'2BL#44]*R-9_P"/-_I6L:RM:_X\7^E5#<39X)XM;_2)
M*\_D;]X?K7=>+6_TJ05P;_ZPUWI>Z<[W+4$A&*VK&ZPPYKGT.*M6\^UQS64T
M.YZ=H5Y\R\UZ=HMSO5>:\1T6\PR\UZIX;NMX7FN:2-4>@H<B@]:BMVRHJ8]:
MR-&!/%9=_+L!YK28\5SNM3[%;FM8(B1@ZG>X#<UPFN7N4;FM75[_  6YKA]6
MO=P/-=<48R,*YGS,W/>J4SYILLN9#43-FMK&4AC'BH?XJE--V\T)"N.'2I%I
MJBGGBAQ%<C:DI30!S18+A2TI'%*!FBPT]".E%!'-.QQ185QM)3P*:PYHL#EJ
M(.M2=J:!3A32)N---[U(PIF*IHJX]6XJS ^#5,&IHSBLVBXLZ'3[G:Z\]Z]8
M\*7N8U&:\2AGV.O/>O2?"=]]P9K*:-(GM5K+NA%6$ZUDZ7-OMUYK6CKE:L:7
MN3_PU@:__P ><GTK?/W:Y[7C_HC_ $J8;EO8^>O%P_TN2N''$IKO/%BYNI*X
M=UQ(:[8K0PN7K63&*VK6ZVD<U@0G%64N-K=:EA$[[2;SYUYKU#PU/O"\UXAI
M-W\Z\UZUX0N-Y3FN9HL]-B/RBI:@A/RBIZR9O'8****104444 %%%% !1110
M 4444 %%%% !1110 4444 %%%%# 2BBDI(3$-(WW:5J:?NFK(OJ<GXJ_X\9/
MI7SQKQQ>R?6OHCQ3_P >3_2OG;Q'Q>2?6NN.QSR>IEPS8/6M2"YP.M<]')\U
M74GQWH>Q"W.JL+O$HYKT+P_=[MO->06=UB4<UZ#X9N\LHS69K$]ETV3<BUI=
MZPM'DW(OTK>'2LF:Q&NVU:YK7+G;&W-;MT^U#7$>(KK"-S5P6HI,\Z\3W62_
M-><WTFZ0UU?B*ZW,W-<9,^Z2NJ*,&+&N34SIQ2P)FK#I\M=$8F;*&WFC94^R
MI/+^6E)"*6,&NC\/S;)%Y[UA.F#6AI<GEN*PFC6+/>?"MW\B\UWUK+N6O(?"
MM[P@S7IVF3;T%<<S:#U-Q:?4:?=IXK,U0M%%%(H0T445'4 I,TM,S\U4@)*0
MT#I13!E2]_U#5Y+XS7]V]>N7@_<-7E7C-/W3_2MZ9A(\(U0?Z0_UJ&U&!5W4
MD_TA_K5:%<5UQ1#8/]ZMG03_ *2OUK*9:U-"_P"/I?K2FM 1[GX0;"I7HT1^
M45YKX3;"I7HMNV5%<<EJ:)EH]*A=L5(3Q52Y?:M0D$F4+^XP#S7(ZI=_*W-;
M&IW. >:XC5KSAN:ZZ:T,Y.YSVMW6=W-<%J,FYFKI-5N=Q;FN4NFW,:Z$C-E#
M&34@2G*G-3K'Q3L0V1@<4H%*1SBGA:T2(8TBFFI<4QAS0UJ%R';\U2"EVTJB
MAH=QM)3V%-I6"X=J***;0KB4M%%"07"D(I13\5+0-D5+BE(YIP'%0T-,B8<4
MB"G,* *SDC1"D5J>'H\ZBOUK- R:Z'PQ#NU!..]8LN+/=O"T.+>/CM7<1CY1
M7,>'(=MK&<=JZE1P*YY&T!U!Z44'I4&J,O4_N&N/O#\QKK]3^X:X^]^\:I;D
MLJ@T\&HE-/4ULB1Y-)FD8TP&J%<DS2YI@/-./2D-C'-*G2HR:<IXH! ?O4YC
MQ24TF@5QR4C]: :0T#'@_+35^]29XI1UJK:"0YZ%^[32: >*.@P_BIS=*9WI
M2>*D!T=(PYI8Z5A0 @/%*&Q3*:3BHL,TK:3D5T=A)P*Y.V?D5T-A)THL!TL9
MRM/-00'Y!4U9,=]!12T@I:12V*EV,H:YF_3!-=5.,K7/:C'UJXB9S$R_-4>W
MBK4R_-30G%/J242G-*JU9:.FA*M;"9+;G#"NCT^3I7-(<,*V;&3D4VM 1UL#
M9458K/M'RHJ^.E8R5F:(6BBBI&%%%% !3>].I*8F!I**1N!0(AG;"&N8U.3@
MUOW3X0URNHR9)JT2V8TC?,:1.:9(?F-21#(JFA(F!^6FJ?FI"<<4@-2:$K#-
M6[:/I56,;C6K:Q]*0%^RB^85T<(P@K*M(NE:\8PHJ6,?1112 **** "BBB@!
M*J7-6ZJW/2H0T%MTJW52WX%6ATJD# U#/]P_2IC4$_W&^E7'<SGL>4^,C^\:
MO*]5/WJ]4\9?ZQZ\JU7JU=4#F9S+G]X:<!36_P!8:D KIBC&>XF*6G8HQ6Z1
MG<;13L48JFA7&T4[%)2L.XE%.Q1BBP7&T4M+BBP7&T4[%)BBP7$HIP%&*+!<
M;4;=:FQ3"N318:8+TJ6/K3 .*>G!HL*^HZ0<5"14SGBH3426AI<3%21OL-,I
MCMBL&BXL[WPO=_.G/>O;/#DVZ%>>U?/?ANXVR)SWKW'PK<;H5Y[5SS1:W.]0
MY2EID!S'4E<QN!K+UO\ X\)/I6H:RM;_ ./"3Z54=Q2/GGQ8?],DKB6'SFNV
M\6#_ $R3ZUQA'SFO4BO=.=C2<"HUEQ)3Y.!57/[RL9H:.ITBX(9>:]:\)3%M
ME>,Z2WSBO8/!@SLKDF:H]4LS\@JT:K6@P@JT:Q->A#*V!7&>)+C:K<UUEX^U
M#7G?BFZX;FMJ:,FS@M:O?F;FN-OKHL3S6KK-SEVYKFIGW-7;!&3('?+4JG-(
MRT+6UM#*3'4N*,4ZG%&=Q4'-*]*HQ2/3Y=0N,H4<T4HI207%8<4Y!Q2'I2K1
M;028QA\U*1Q0W6E[4D@;$6FN.:<*1NM-H5Q0.*%ZTHZ4+UII#3%<<5%4S=*B
M-.P[D?>IE-0D<U+'S6<D:(:TI5Q]:[GPK>8=!FN#N!AJZ3PY/LE3FL)HU1]"
MZ#/NMEY[5TT/(%<'X:N=T"#-=U;'*"N6HBX[EEONUSFO'_17^E=$_P!VN;UX
M_P"C/]*BGN:2/!_%(S=/]:XB5?G-=QXH_P"/E_K7$R_?->A%:'.-0X%1-*0]
M3=JJR#YJRGN5$V=+N")!S7L?@:;<R5XAIS8E%>S> &RR5@RSV2W^Z*L"J]O]
MP58K!FT=A:***DL**** "BBB@ HHHH **** "BBB@ HHHH **** "DI:2DP"
MDI>U%-"8QZ;_  FG/3#]VK1E+<Y?Q./]"?Z5\[^)^+J3ZU]%>)A_H+_2OG?Q
M,,W4GUKJAL<SW.21L-4WF$5$%^8T\KQ5-: ]R>WG(D%=[X5N<RKSWKSF,X>N
MT\*RXF7GO63-(GOOA]]R+]*ZA?NUQ_AAMR)]*[)1\M8LWCL9NH-MC->:^)[C
M"MS7I&J\0FO*/%,GWZWAL9R/,-<G+.WUKG0=TE:^KMEV^M9<2Y:NB",6:-LO
MRBK#CY:BAX6GR-Q77%:&3(L<U,%&VH-U2J_%)H9!*O-+;ML84YQFHAPU<TT7
M$]$\,W>"@S7KFAW&Z->:\(T&YV.G->O>&[K<B\UQ5$:PW/18CE!4@JK;-F(5
M9%8'0.HHHH*$HHHJ!@>E1?Q5*>E18^:J0B4=*6D'2EI@5KO_ %+5Y=XR'[E_
MI7J-W_J&KROQDW[IZZ*)C,\4U ?Z2_UJFHQ5O4&_TA_K5-377$P9(1\M:&A_
M\?8^M4/X:O:)_P ?@^M.>Q2/;/"I^5/I7HUJ?E%><^%.52O1K4?**XJFY?0M
MGI6=J#[8S6CVK'UA]D)^E1'<4CC]7NL;N:X+5KO[W-=%K-URW-<)JESDGFNN
M",V9%_/N)YK&<Y:K5S)EC5/O71%$28Y5JRJ_+4*5-NPM6T9ME=OOU*!Q4+'Y
MZE!XJ[$W%[5$WWJDSQ49^]18!V/EIJ=:=GY::O6BP"O4=2-S3,<T6"XE%+CB
M@"BP7$HI2*,46"X#K4H%1KUJ0=*EH74C<<TX#Y:1NM/'W:AHJY"1S1BG'K3:
MR9I<>GWJZWPG%F_3ZUR,?WQ7<>$4_P!-C/O6,D5%GOVAQ@64?TK<'2LC1N+*
M/Z5K=JY9;G33V"@]**#TJ31&5J7W#7'W_P!XUV&I?=-<A?#YC36XBDO2G+UI
M%%*HKHZ$BOTIBT]QQ3!31"W'#K3F/RTT4IZ4AR(QUIU %+CFCH-#OX:B[U-_
M#4>.:$3U"BEQ24^I8E**,4HJB4)12XI<4BAM%+012:U ?'3V'%-CIS=*30$!
MZU'(>*E:HI*5@)+=N16_8/\ ,*YV#@BMRQ/(I,#K;9OD%6JH6C?**OCI6,@B
M**6D%%2:+88XR*Q=33@UMFLS4$R#5(DY29/FJ,+5RXCP351CBK$,=>*BQ3V>
MF9JHB(R<-6C92?,*S6ZU:M&PXJ@.OL7R!6NIXK T]^!6Y&<@5E/<M$E%%%9E
M!1110 4AI:0T Q*9(<"GU!,V :I$=#/O7PAKE+Y\N:Z&^DX-<S=G+&M$B#/?
MK4\/W:A(R:GCX6JD$1CGYJ7M3&^_4JC(J&:HLVJY-;MI'R*RK*/D5T%I'R*E
M@:5M'A:NCI44*X6IJ@84444 %%%% !1110 E5YQ5FJ\U0QH9#Q5I>E5(ZM)T
MIQ![CJKS_</TJQ5:X^X?I6D=S*>QY7XQ'SO7E.K=6KUCQ>/F>O)]6^^U==,Y
M9'-N/WAJ1!D4Q_OFI8ZZH(REN!%&*>:2NB)BV- HQ3AUH-585]!N.*;WJ3M4
M?\5"0TQV*,4[M0*+"OJ1GK3L<4T_>J0=*&AW&XIK=:D%,?K0D),4#BC%*O2E
M[T6!L;BG!,T&I4^[2L%]2$KBCI3WZTQJ+#OJ(QJ%CS3\U&W6IDM#5,=FHI3Q
M4@Z5#+TKF9<#8T2;9*O/>O;?"%QF-.:\#TZ39*OUKV;P9<91.:YYHU/8[,YA
M%6*HZ<V8!5^N1FZV$-9&M_\ 'B_TK8/2L;6_^/)_I54]PEL?/_BH?Z7)]:XP
MCYS7;>*O^/N2N,/WS7KQ7NG))ZE:6JO\56YZK ?-7/4*1LZ1_K17L_@A,[*\
M8TC_ %H^M>V>!1G97',V@>GP#"BIFZ4Q.%%.8\5B:]#)U:39$?I7E'BF[^_S
M7IFOR[8&^E>,>*;KYGYKJI(PD]3AM4N,R'FLP'<:=?2EI*9!R:[::(9*R?+4
M8'-66'RU!CFMTCGDQP'% ZTY>E-'WJ$C,?T%1L:>W2HLT[ %/[4P4_M4VU$V
M%+TIH-*33L'46DH[4@/-"07'4E#&@=*+"Z!2TWO2D\46'<=UIK"E0T-1U*1"
M:DM^6IK=*?:_?K-FL1MXN*OZ--LG3GO5:\'%1V#[)U^M8S1K ]S\*76Y4&?2
MO4;(YA4^U>*^$+GYD&?2O9M-?=;I]*XZAK#<OO\ =KF=?/\ HK_2NED/RUS6
MO?\ 'J_TK.&XYG@_B@_Z4]<:W+FNO\4'_2W^M<@?OFO1CL8/<0CBH9%JP:8R
M_+6<QIZA8\3#ZU[/\/.72O%[3B?\:]F^'7+I7/(T6Q[5 /D'TJ:HH?N#Z5)7
M.S:.PZBBBI- HHHH **** "BBB@ HHHH **** "BBB@ HHHH *2EI*3 7M24
MM)30#6J,]*D:HSTJD8SW.;\3#_0'^E?/'B,9O)/K7T3XF_Y![_2OG?Q#_P ?
MLGUKJAL<SW.6*?-3]GRU(PYIRK\E;):"N4",/74^&'Q.OUKF)1AZZ#PTW^D+
M]:P9<6?07A)MT:?2NX7[M<'X-YC3Z"N]'2L);G1$R]7&+=J\>\5/R]>Q:UQ:
MM]*\6\5O\TE;429GF.IG+GZU5@2K%\<R'ZTD"\5V01SR)QPM12/4CG"U4D.:
MZXK0R>X;Z<LG.*AR<4U6.^AH:- <K4;#!J2/E:9+7+-&D2_IUQLE7GO7K'A6
M[R$YKQ6"4K,OUKT_PE=<IS7'-&L3W"P?= M7UK$TF8- O-;:]!7(SI0^BDS2
MTD,2BEI*74!3TIF.:?28J@%'2DI:0T"96O3_ *.WTKR3QF_R/^->M7W_ ![-
M]*\?\9D[9/QKIHF4SQO46_TA_K56-LU+J!_?O]:K1&NJ!@RWGY:OZ)_Q]CZU
MG_PU?T3_ (^Q]:<P3/</"(RJ5Z1 ,**\Y\&C*QUZ5$,**X9[FD23M7/>(GV6
MS?2NB/2N5\5R;;1OI4QW',\HUJZ^=^:XK4+C)/-;FLW/[U^>]<C=S9)YKNIF
M,BO(^6I@J/=EJE'2NE(RDR1#0SXI%J*1N:.I"W'9R:D!J%3Q3LUK;0GJ2$TW
MO29HHL,=GBD!IN>:*+ 2=::1S3EI#UHL)"XXI .:<?NTU>M%@ BEQQ2-3ATH
ML P=:>33!UIS=*EH.HG6G#I35I:RD'4&J.I'Z5%61HA8S^]'UKT'P@O^DH?<
M5Y[&?WZ_6O2O!\?[Y#]*RDC1'N>D'_1(_I6MFLG21BU3Z5J=JY9[G1!Z#Q2G
MI2+3CTK-FZV,K4Q\AKD+T?,:[#4_N&N1O/O&K@2RB!3@*!2UNC-L0C-,(Q4M
M1M30EN&.*0=:=VIB_>I) ]R3%&*>>E-H&P[4FVE'6G$<4 AF*81S4E,/6F@0
MN.* .:>/NTU?O52V&#"A1Q2O2K]VCH S'-##BC^*G/TI,81T,>:1*1CS2 0B
MHV%2]J8122$AJ<,*V+(]*R.C"M2S;@5+&=/9/TK5'W16'8OR*W%^Z*QEN.(X
M444G>I*%-4+Q=PJ_5:=<BFA,YN[CQFL6X.TUTE['P:YJ\&&-6(J^9S3PU5<_
M-4RFFB>H\U);MB2F=J;$<2U2$]SJM/?@5T$)R!7+:?)TKI+5L@5$RT7:*04M
M9&@4444 %%%% #352X;"FK;5G7;84U<3*1A7\G)%8<YR36C?2?.:RY#DUJB2
M(#)J3H*$'-$G%!1 ?OU;A7-5!R]:-HF2*B1HC3LHNE;UM'TK-LX^E;ENG%2]
M@+"# I](.*6H&%%%% !1110 4444 %5IZL56N3Q4,:W&1U;3I5.&KB]*<=@>
MXZJ\_P!P_2IS4$_W&^E:1W,Y['EWB\?,]>4:N/F:O6?%P^=Z\IU@?,U=E,XY
M'+O_ *PU*E1-_K34JUUP1A)CS244E;Q,V)FDS2-3,U0):$F>*CSS1FFYYH0[
M$V>*,U'FC- 6%)YIX/%0YYIV: L29IC'FDS32:$%B4'BES48-&: L29J17P*
MKYHWXH&D2,W--+4PM3 W-1<:1)2$9HIX'%3)Z%;$=,D7(J0CFE*Y%<YK BMS
MLE7ZUZQX,GX3FO)3\LB_6O2/!T^&C&:PF:'OFDOFV7Z5JCI6#H;YM5^E;R]*
MY9HWB+VK%US_ (\G^E;9Z5B:]_QXR?2G3W">Q\_^*6_TN2N.)^<UU?BIO]-D
M^M<@3\YKUX_"<<MQLO-0@<U,W--4?-6-1%1-32QB05[1X";)2O&+ 8<5[%X
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MAXJM]XU)*>*2$;C75'8S9&ZXJ(#YJMS)BH0M-E1+,9XI)3Q3$-$IXKEJ(T1
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M>+?^/J2N$?F0_6O1I'+4 =*KO]^K..*@<?-6[,%N:6E?ZT5[9X"_@KQ32O\
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M_P#6&O2I['%,G!R*A8_-4B_=J%_OUOT,%N:FE_ZT?6O:O 75*\4TO_6"O:O
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M![3#]P5/4$/W!]*GKBEN=""BBBD4%%%% !1110 4444 %%%% !1110 4444
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MZ*X:FYV4]A3TK(UK_CR?Z5KUE:R/]"?Z5G'<M['S_P"+Q_I$E<"?]:?K7?\
MB_\ X^)*X$C]Z?K7J4=CSZH_'%0M]ZK':H'^]70]CG1H:5_KA]:]H\"_P5XO
MI7^N'UKVCP-_!7#5.RCL>K0_=%4=:_X\V^E78?NBJ6L_\>3?2N/J=,MCPGQB
M/GDKS<_ZQOK7I/C#[\E>;M_K&^M>C3V.&H-:FXI6HKHZ&2$7@UZ#X+;YT^M>
M>GBN^\$\NGUKDJ[F]/8]ZT#_ % ^E;M8?A__ % ^E;E<$MSLCL+2GI2"E/2I
M-"NQ^>IE^[4+#YJF7[M)$A0:4450= I*6B@!:***104F*6B@!C5')]TU*U12
M?=-4C&9QOBO_ (\G^E?/NM_\?DGUKZ!\5_\ 'D_T-?/VM_\ 'Y)]:[Z6QQS1
MCCK4A^[48ZU)_#6R,D11?ZZO4/ 7^O3ZUYA%_KJ]/\!?Z]/K6<MC6+/=;(_N
M5^E96OG_ $23Z5J67^I7Z5D^(/\ CTD^E<L?C.M_ > >*O\ C[?ZUQC??-=G
MXJ_X^W^M<8WWS7? \][DL=2'[M,2GM]VJD$1;+_7"O8O  ^=*\=LO]>/K7L?
M@#[Z5RU-CJAL>QP?<'TJ:H8/N"IJX9;G3'8=1114F@4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4C=#2TC=#0A/8YGQ3_ ,@Z3Z5\W>(O
M^/Z3ZU](>*3_ ,2Z3Z5\W^(O^/Z3ZUWT#BJ;F&G6I#TJ-.M2GI7;U.5[D)^]
M6YH/^N7ZUAGK6YH/^N'UK"HC>D>[>"?N)7H0Z5Y[X)^XGX5Z%VKSJFYW0V.?
M\3_\>#?2OGSQ+_Q\2?6OH+Q.?] ;Z5\^>)?^/B3ZUM1,:IR@ZFD;I0.IH8UU
MHXY$/>IH_O#ZU!WJ:(_,*'L2CVSX;_ZM*]<AYCKR/X<?ZM*]<M_NUQU3KH[F
M;JT&Z(\5Y=XCM<;^*]>ODW1&O.O$EOPW%339M-:'B.L1[93]:HQ#BMO7XL2G
MZUBIP*[8,YI$PIV.*C4T\GBNC="B9UUP]7M$GVW2\]ZHW7+4[36VW(/O6<D7
M%GNOAFZS&G->DZ<^Y5KQGPQ=\(,UZUHLNY%YKBJHUBSHUZ4ZFITIU<C-UL%(
M:6D- ,IWW_'NWTKR7QA]U_QKUJ^_X]V^E>2>+_NO^-=>'.2J>07P_?M]:CBZ
M5+>_Z]OK4"' KO@<DMR&<_-6AH?_ !]#ZUF3'+5IZ%_Q]#ZU$RHGNO@OHE>E
MI]T5YKX+'"5Z4OW1]*\ZKN=U/8R==_X\7^E?/OBW_CXDKZ!UX_Z"_P!*^??%
MG_'Q)6E$B9P3\2'ZU/$>*@D^^?K4T72O4I['),F'6G2CY*8#S2R'*U;V,UN.
MMGVTZ2XP_6J\1Q44S?/7--&J--;CY.M-%QSUJDC_ "4!^:S:&B\UQ[THN..M
M4"]*'XJ;!T+GVCGK2M<<=:H;^:<7XHL!=6X]Z0W'/6J2O2%^:=@ZFAY_'6HS
M<>]5=_%,+4)#1=^T>]'VCWJENHWT[#+;W''6DCN3GK5-WXIL;<T6 OO=<]:T
M]&N<W2\]ZYV1L&M/16_TM?K42+1[OX6DW(E>BVQ^1?I7FGA(Y2.O2[8?NU^E
M<M0VIDC=:>O2F-UIZ]*R>QT"F@4M)4@+333J:::$S*U/[AKD;P?,:Z_4ON&N
M2O/O&M8&+,_O4R]*A[U,O2M^A(R2HE.#4LE0]ZGH!?B?Y*CEDI(S\M12FD,;
MYO-3)+QUJGWJ9.E #VEYI/-]ZB?K3:I"+:2TUY>:B2D?K4C)O-XH2;FH.U*G
M6FQLL/+0LO%0/0O2I8B7SN:<9>*K?Q4\]*EC1,):<)*KK3@:0/<F9LBJ[=:D
M)XJ)JL;V&]ZF7I4(ZU.O2F0BU9C][73VB?**YNQ'[VNKM5^45$C5%^$58J*(
M5+6+-!*6FYYIU( IIIU---  I&&:44M!*,N\CRIKEKU,.:[&Z7*&N6OT^<U<
M3)[F')P:(^33IA@TR,\U:W$6@/EJ)A\U3+]VHF^]1U ,XK2LI.*RF.*MVC\5
M=@+MR^5-8\OWZT)GXK-<_-32&AR5:4<56CJR#\M)E%9_OU<M5R15)S^\K1LA
MDBH8'0:='TK<C7 K+T]< 5K#I64C1"T445(PHHHH **** "BBB@ HHHH ***
M* $;I566K1Z55FI,.I)!TJ>J\'2K%)#"J\_W&^E3FH)_N-]*TCN9SV/+_%Q^
M9Z\IU7[[5ZIXP^^U>6:G]XUWTMCAGN<W-]XU"#@U//\ >-56/-=",NI94Y6H
MF'-/C/RTA'S54A+<;BBG,.*94,:8N:0]**&Z46*3&YS0>*1>M#46'<6C- Z4
MT=:+!<D%+24=J!7U&D\THIAZU(.E%AW"I%Z5'4J=*<=R'L,/6@\BANM(M;$$
ML0IS#FEC%*XI]25N&?EJ(BG9I#4LI,:JYD'UKT+PG'\Z5P42YD7ZUZ1X3C^9
M*Y*AT4]CV/0DQ;+70K]VL31EQ;+6T.E<$]SKI[#JS-9'^@O]*TA6=K/_ !XO
M]*S6YKT/G[Q=_P ?,E<$P_>&N^\7?\?4E<&_^L->K1V//J#ATJO)]ZK*]*KR
M?>KI9S+<O:7_ *X5[1X%_@KQ?3/]:/K7L_@3JE<-?<[*)ZM%]T53UC_CR;Z5
M;B^Z*JZO_P >3?2N/J=70\*\8?ZR2O-9.)#]:]*\8?ZR2O-)?]8WUKT*>QQ5
M!IH7K24J]:W>Q@A9.!7>>!N73ZUP<O05WO@,?.GU%<E0Z8;'OF@#]P/I6W6+
MH7^H'TK:-<,MSLCL I:8.M/J$4B(CFI!THQS2TP$HI:* $[44M% !1110,**
M2EI(!K5')]PU*:CD^X:M$-:G$^+/^/-_I7S]KG_'W)]:^@/%G_'H_P!#7S_K
MO_'W)]:[H;''41C(>:E[5$G6I#6R.<2+_6UZ;X!_X^$^M>9Q?ZRO3? '_'PO
MUJ)[%09[K9_ZE?I6/X@_X])/I6S:?ZE?I6+XA_X])/I7+#XSL;]P\ \4G_2W
M^M<<WWS77^*?^/Q_K7(-]\UZ,=CB9-'TI7/%)'THDJ6.*'V7^N%>R?#[[Z5X
MW9?ZX5['\/?OI7-4V-X'LL/W!4U10_<%2UQ/<ZH;"T445)H%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %-;I3J:W2A">QR_BD_P#$OD^E
M?./B+_C^D^M?1GBG_CPD^E?.?B'_ (_9/K7H43BJ;F&G6GM4<?6GO78MCEZD
M9K;\/\SCZUB&MOPY_P ? ^M95%H;TSWKP6,(GT%=^/NUP/@S_5I]*[W^&O-J
M;G=#8Y[Q.?\ 06^E?/GB8_OY/K7T#XG_ ./%OI7S]XG_ -?)]:VI&%4Y1#R:
M1S1'U--DZUU')(C-20'+CZU$W2G6Q_>#ZTF*)[E\./\ 5)7K5N?E%>2_#C_5
M)7K,'05RU#II;DEPNY*XGQ);_(W%=V1E:Y?Q#!F-N.U8P=F=,EH>">)8L2M]
M:Y5C@UW/BJ'$C<=ZX6;AZ[8,Y9CU:G%N*A4TK-Q77#5&:()N31;?)*#2L,TT
M?*<TIHM,[[PQ=_O%&:]I\.3;D3Z5\^>&[@BX49[U[GX5FW(G-<55&L6=_&<B
MI*@@.5J>N)[G3'80T4&DH$]RI??\>[?2O)?&'W7KUF^_U#5Y-XP^X_XUU4#E
MJ;GC]Y_Q\-]:JEL5:N_^/A_K5&4XKO@<S6I%(<FM;0.;H?6L4FMGP]_Q]K]:
MBH5%'O7@P?*E>D+]RO.?!OW$KT4?<KSJOQ'93V,;7C_H3_2OG_Q6?](DKW[7
M_P#CR?Z5\_\ BK_CXDK:B3,X9OOGZU(G IA'SGZU(*]&F<<AV>:0MD4QC30W
M-;-$(D!Q4,GWJE[5"_6N>2-(CE;BES4:]:<W2LK#8X'-&ZFI2'K341#\T;LT
MG\-(.M%ACB<49XIC4HZ46$.W4C&FCK2OTH:&*II">:$Z4UNM%@N#'BGPCFHS
M4T YI20R*?AJT]$_X^E^M9=S]ZM/0_\ CZ7ZUE(TB>Z>$.4CKTZW'[M?I7F7
M@X?+'7I\/^K7Z5R5=SI@AQ'-**7%)61HQ:!10*0=1::>E.I&Z4(&9>H<J:Y*
M_P"&-==?_=-<EJ'WC71 PF9PZU(M,%.%:$7$DZ5$.M2R=*8HI,;)EZ5'(.*D
M'2F/TI#Z$"CFIE%-0<U+B@")EI@'-3L.*C4?-51 4+B@KFI"* *=A7U(L4JK
MS3L<TX"I8TQC+30*EQ32*0,9MYI^VE IZBDP(B,4"GN*;VJ 3U&YI&Z4#[U.
M?I5#N1BIEJ):F6KZ 7]/'[T5UMLOR"N6TT?O1776Z_(/I64C1%I!3CTH6ANE
M9&@P'FI*B'WJE'2A@!J,GFGGI49ZT(!PIU-%.%!"*\X^4US>H)R:Z>8?*:P-
M03K5Q):U.6N!\QJ!3@U9NAAC50'FJ(+L9^6F-]ZEC/R4P_>IDWU&2G J6U?B
MH9^E%NW%:I#+4KU48\T^1N:CIV"Y+%4Q.!4,5/D/%)HM;$6<O6OIXRPK'7EZ
MW--7YA64@9TUDN *T:J6JX45;K*6YJM@HHHJ1A1110 4444 %%%% !1110 4
M444 (W2JLM66Z56DI,.H^#I5BH(:GI(;"J\_W&JQ5>X^XU:1W,Y['EOC#[[5
MY9J?WS7J?B_[[UY5J9_>&N^EL<-0Y^<<FJ;=:OW JD1S6Z9D2Q]*>!S4<=3J
M.:M["&N.*BQ5EQQ4&*5A7&XI".*DQ2$57*%R-1S0PJ3;1MH:'?48!Q3=O-2X
MHVT)!<;BC'%/ H(HY17(=O-/ IVVE H:!L9BI%Z4A%.'2A*S$V1/UH0<T-]Z
MG**L3+$8I'IT5))5=1(A[TZF]Z>M9R&B6%?WB_6O3O",>=E>:0C]XOUKU7P=
M'E4KFJ(Z*>QZUI*XMEK4[5GZ8,6ZUH]J\^>YV06@"L_6/^/!_I6@*SM8_P"/
M%_I6:W-.AX!XM_X^I*X)_P#6'ZUWOBW_ (^I*X)_]8?K7K43SZK'KTJ"0<U,
M.E1L*Z6<ZW+FF?ZX?6O9_ O\%>,:9_KQ]:]G\"]4K@K[G91/5(ONBJNK_P#'
MDWTJW#]T54U?_CS;Z5Q]3J>QX7XP^_)7FDO^L;ZUZ9XQ^])7F;_ZQOK7H4]C
MAFR.E7K0W6@5N]C%#GY%=_X$&'3ZBN ')%>B>!UPZ?45RU$=-,]VT+_4#Z5L
MMTK&T+_4#Z5LMTK@EN=L=A@/-/%1 \U(*5BDM!U%%%( HHHH **** "BBB@!
M*6DHJ$]0 TV3[AIQIK_<-:(3.(\6C_0W^E?/FN?\?DGUKZ&\7#_09/H:^>-;
M_P"/V3ZUW0V.&>YD(.:D-- IW:MT<[W%B^_7IW@ ?Z0OUKS*#_65Z?X!'^D)
M]:SJ#@>Y6O\ J5^E8OB#_CTD^E;5I_J5^E8WB#_CU?Z5S4_C.Q_ ?/\ XI'^
MEO\ 6N/;[YKLO%(_TMZXUOOFO2CL<;W)8^E*XXI$I[#BI8XA9_ZX5['\/?OI
M7CEG_KA7L?P^^^E<U1:&\3V:'[@J:H(/N#Z5/7!+<ZX;!1112+"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "FMTIU-;I0A/8Y;Q2/] D^
ME?.7B'_C]D^M?1_BD?\ $OD^E?.'B+_C^D^M=]$XJFYAQ]:<U-CZU(U=RV.7
MJ0FMSP[_ ,? ^M8AZUN^'QB<?6LI[&](]X\&_<3Z5WO\-<#X,^XGX5WX^[7F
M5/B.^.QSGB<?Z"WT-?/OBC_7R?6OH3Q./] ;Z&OGOQ/_ *^3ZUM2,*NYR*=:
M5Q2+]ZGD<5UHY9(K/3[?_6#ZTQNM/AX<?6E(2/<_AMS$GTKUF$<5Y1\,^84K
MUJ,<5QU&=%-$XZ5B:U%NC;Z5MCI5#4(]Z'Z5@MSI>QX7XNM\._%>;7B[9#7K
M_C*WPS\5Y1J*;9#79!Z'--&>IYI6-,!^:E:N^EL9,>JY%1R# JQ$N5J*<8IS
M07+^@R;;@?6O</"$^53FO!]);;./K7LG@V?A.:XJB-8L]=M7RHJX#Q658294
M5J+TKAFM3H@Q:***DHIWW^H;Z5Y+XQ^X]>MWH_T=OI7DGC'[K_C75ASGJ(\>
MO/\ CX?ZU0EJ]>_\?#?6J+<UWQW.5[D!K:\/_P#'VOUK'(YK:T ?Z2OUJ*A4
M3WGP;]V/Z5Z,/N5YOX+^['7I ^Y7FU?B.R"T,37Q_H3_ $KY^\4_\?,E?0>O
MC_07^E?/OBC_ (^I*VHLB9Q##YS3P.*1Q\YIZCBO3IG'+<B>HEZU+)42]:V9
M")L<5&PJ9.::XYK"1:(@M*PXJ4+Q3<4N4=]1BC%!7FGXQ3PM'*)[C-O%- J?
M;3&6A(+D1&:4#BI N:,46!$6WFE(S4I7BD H:"Y&!BFD<U,1BF[:.4:(L5/
M*;MJ2(5,D45;K[U:.AG_ $I?K6==?>J_H7_'XOUK"2-(GO7@X?)'7IT/^J7Z
M5YEX/_U<=>F0_P"K7Z5Q5=SI@R7M2=Z**Q-&% HHH#J+2'I2TAH&9E_]TUR=
M_P L:ZS4>$-<I><DUT0V,9HS:<*:W!IPZ5JD8L'Z4U13SS2 <TF5NAX'%1O4
M^/EJNWWJ0P0<U)2 4O:D,:U,'6E)YI#5(EL?FC--4YH)YJR>HZES3>U(#S4-
M#1)331FDJ>H-CA3A3!3LTA]!6&::1Q3UYI&%*P1(<?-3FZ48YI:'N,C%3(.*
MB/!J>,<5?09I:9_KA77VX^05R&F?Z\5V4 _=BLIFB)A0W2EI#TK$T(P.:EI@
M'-/IL!#TJ,]:EIA'-" !3A313J&2ADGW36)?KP:W'^Z:R+Y?E-5$F6AR%X,,
M:H#K6G?C!-9J=:HR;+2?=IO\5"GB@=:M$=1DWW:CAXJ64<5&G%;)%BMUI!0:
M<HYIB)$XH>G8P*C-2S1"Q#+UOZ8GS"L2!<N*Z33DZ5C(#H(!\HJ>HH1\HJ6L
M7N:+86BBBD4%%%% !1110 4444 %%%% !1110 UNE5GJRW2JTM UN20]*GJO
M!5BD@857N/N'Z58JO<?<-7'<SGL>6^+_ +SUY1J1_>FO5O&)^9Z\EU,_O37=
M3V.*H9,]4R.:M2')JNPKH1BP7K5A*KCK4J-S6G0"9^E0&I6;BH<TXHACQTI.
M]&>*3/-62.(I *7-)28=0[TN.*2ES0@$%!HI":8=!V.*3O0#Q10 II.U(31F
MDQ]2,_>J113>]/'2D@9-'224T-BACFK&1]Z>G6H^]/SBLI"2+<'^M7ZUZWX,
M3,:5Y#:G,J_6O9/!0_=)]*PGL=-,]4T\8@%7JIV/^I%7*\V6YV1V 5F:R?\
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M?/7H_@?ED_"N>H=E(]TT(?N!]*W16)H8_<#Z5MUY\]SJB%)2TTFI*'44@I:
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MQIV:8I^8TZNJ)R2&OTIL/WQ]:5^E)!_K!]:F8X'M_P -_P#5I7L-K]P5X_\
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M\Q^8TQ>E=*,&5W^_6UH9Q<+6-)]ZM71FQ<+30^A[=X3D^5*] 63Y17F7A:;
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M+C_I$E<#_P M3]:[SQ<?])DK@C_K3]:[J)QU"P.E,:I(^5J*0\UT,P+VE?\
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M('J<Y>Q]:P;E<$UU%['UKF[Q<$TS-F=CFI0>*81S2H>:UCL(G2G _O!31TI
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MFH:G8YH(K-O4?40#BD YIPZ4 <T)@(PXH2E;D4+Q3N2-(YIQ'%!'-+VHN-C
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M4@.!6BD2]R.4_/33]VE?EJ/X::9#0V/K1(>:5!S4<Q^:BXTBS'RE=1X+B/\
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M)/K6L'J936IRP^\:G RM5\_-5A#\E;IDVU*S_?KH/#W^N'UKGI/]970>'?\
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M@0U*S?+6C$(@RU;NFC&*PH3\U;^G]12 Z:U^[5NJMK]RK59LM!1112&%%%%
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MM]*\&\1#]_)]:UAH8RW.)N/O&DC; I]P/F-0+P:=]1)#YC\M)8M^]'UI)O\
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M4P12 Z*S'RBKPZ53M!\E71TJ9%1"BBBI*"BBB@ HHHH **** "BBB@ HHHH
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M+]@'I1<+:G'G3/:D&E_[-=A]@&>E!T\>E%PMH<C_ &9_LTG]F>U=@+ >E(;
M>E%Q6T.0_LSVIPTS_9KK/L ]*<M@/2GS:":.0.F>U+_9?^S77-8#/2E_L\8Z
M5+8CD!IG^S2G2_\ 9KKEL!GI3FT\8Z4FRT<6VE_[-2VEAMG'%=6=/&.E0PV6
M)^E0V:Q1H:5;[%7BN@0<52M(=J#BKXZ5FRT@IU-[THZ5!:(+@9%9<L>36Q(,
MBJ4D?-6AE%8:5H>.E75BXI3%09F>D.#5R&.GB*IXTI(":(86I*:HXIU(T044
M44 %%%% !1110 4444 %%%% !1110 AHH-%,74KSKE:RY(OF-;$@R*I21\U2
M(926*I/)^7I5F..I?+H8F99@YJ2*/FK;Q41Q\TRD6+=<59%1QKBI:AED%R,I
M6/+'DFMJ<96L]TYIK8EE-8<]JF\GBK,<53>50-;&88?:@0\UH-%[4U(N:8-$
M<4>*NQK3%CP:G0<4F,>.E+114@%%%% !1110 4444 (:8:DJ)NM-")%I'Z4+
MTI30QE*9*I/%DUIR+4!CJD0R@(:<8.*NB+FG&+BDP1EO!4?DX/2M4Q5"T6#T
MH)L1018-:<2X JO%'5Q!@4BD/%+112+"BBB@ HHHH *SK[I6C5"]%)@%CTJ_
M5&RZ5>H0"&DIU-JB6-9<U7>.K51,*:(D5DB&>E2^6/2I%6GXIW%8K-$,5%Y0
MW5<84P+S5)D6U(3$,4J1"IR.*512N6HE9HANIQB^7I4Y7FEQQ1<?*55B&>E*
M\0JP%YH9:+ZARD B&WI31$-U6@.*3;S1<.4@>(8Z4)$,=*L,*%'%%] Y2J8A
MNIQB&VIBO-.(XHN'*5DB&>E.,0J95I2*&Q.)5>(;:@$/S=*T&7BH@G-5&6@E
M$@\H>E3Q1^U/VU(@J6]"D@"T\"BEJ#1(****0PI*6DI, IK=*=2&DMP>Q3EC
MS4 AYJ\XJ)5YK=/0YI+WB+R1CI41@&[I5_;Q493FDV6HE5H?EZ5):QX-3LG%
M+"N#4WT+BB>E%%+2*0AJ)Q4U1L* 8Q:E XI@%2"@E;B8II04^@T%%9H^:3RQ
M4Y%)BJN9M$2QBD>,5.!2$47!K0K"(4\15+BG 4-DJ) 8A0(JG(H HN5RD'E#
M/2E\H>E38I<47#E*XB'I2-$/2K&*0BBXFBOY=)Y0]*GQ1BG<BQ!Y0IPCYJ7%
M.Q1<:0U8ZD"4H%.J&;10W&*A<<U.:C(YI QJBIA3 *?2904445(P-1.*EIK"
MJ1+&QBI#35%*:8$;C(JN8\U9-)MJT[$M:E3RAZ4OE#'2K.VC;57%8KK$,T\Q
M"I0O-/(I-DN)7$0]*/*&:L8I,4KBY2$Q"D$0]*L8H HN/EU*C1#/2GB(8J8K
MS3@.*=Q\I7$0S37B'I5G%(RT)B42!8AMZ4WRANJT!Q3=O-%PL0M$,4B1#TJP
M1Q2J*+Z!8JF(;J<8AMJ8KS3L<47"Q52(9IDL7/2KBK3'7)HOJ-(K118-7<82
MHT3FIB.*F3+1 1S28YJ0BFXYJD]#.6XV5<QFLU(?WO2M9AE*KK'\]*Y30@A&
M*B>$9Z5>V\4QDJDR;%(P#'2EBAPW2K>SBA4P:&RK$D:X%34Q1Q3ZAE(:PR*J
MR1YJX>E1,*<61):E/RN>E3)$*?MJ111)B2(9(AMZ5!%$-W2KSCY:B1<&DF6+
MMQ4R=*;BGCI0QH6BD-%2,6BBB@84444 %%%% !4;5)3&IH!%I]-%*>E#)0A-
M-(R*0GFE!IV!LISQ ]JIFW&[I6JZYJ$Q\UHI&5BO%"!VJ]&F*:B8J=14R=PC
M'47&****@T8QJ5*4BA>*3*6P^BDI:5QA4#CFIZC8<TQ,:O2E(I0*6J,[$#QY
MJE)#\U:1%0LG-7%DN)62$8Z4XPBK"K2[:?,"B5A"*#",]*M;:3;1<.4K>2,4
M"$>E6=M&VCF#E*QA'I1Y(JSMI=M%PY2IY(STI3"*L[:7;1S!RE40CTI#"/2K
M6VC;1S!RE7R1Z4Y8AZ58VT!:.8EQT*YB&:7RABI]M.V\4KBY="JL7/2G-$*G
M"\TI6DV4HE0P_+598?WW2M(KQ40C^>ALT2+$2X05+2*,+2U!0G>E'2DIU2-#
M6J!EYJP:C(JD,8J\4NVG@4N*&38CVTY13L4HH"PHI:**104444 %%%% !111
M0 4444 %%%% !1110 AHHHIBZC6J!UJP:C(H1+&1K4FVA!3\4VPL0NO%,1>:
MG84U5YHN-(D44ZD%+4E#).150KS5QNE0[:?03"->*DQ0@I] T1.O%-1:E8<4
MBB@!,5(O2DQ2BA@+1112 **** "BBB@ HHHH *C;K4E,-- *O2G4B]*6DP(W
M%,VU*U)BJ1+1&%YIY7BEQ3B.*06(MM1.O-6,4QEYH"PU%J8=*8HJ04 A:***
M104444 %%%% !5&\Z5>JC>=*E@+:=*NU2L^E7:$ 4AI:0U0F)3".:?252(8@
M%.Q12TAC"* *4THIB2U$Q2@4M+2N6D-Q1BG447"PW%!%.HHN%AN*,4ZBBX6&
MXH IU%%PL-Q1BG447"PW%&*=32: L&*;MYIXI:+A89MIP%+11<+!1112&%%%
M% !2&EI*3 **2EJ1L8PIBCFI&I%K5;&#7O"XI-M/I:5S6Q&5I57%/HI#"BBB
M@ I"*6B@!F*=11VIDB4IHH- =!,4F*=10%A,48I:* L-Q2XI:6@$A,48I:*0
M["8HQ2T4!8;BDQ3J*8K#,<T$<4IZTO:F18:!2XH%.I#2 4M%(:1H(:0"BG"E
MU%U#%%+2&AC"EI*6I0"48HI:: 0"FM3Z8:I"8P=:?BFCK3STJF F*7%**6E<
M+#<4N*6B@+"8I,4ZBD%A,48I:* L-Q2XI:*=PL-Q013J*5PL-Q28I])3N%AN
M*4"EI: 2&D4F*?24":$ I"*?330.P@6G'I0*6@"/%(1S3\4A'--$-!CBFA.:
MD%!I%I:#<4FVEIU,0S;2;:DHQ2N-H044M)0+H+3<4ZB@!F*<!2T4!80CBF@8
M-/[48H!B8IU)2T#0AH%!H%('N+1110,**** "BBB@ I#2T4 -H;I2TC=*9)
M3S3EII'-/45;)8[&:393A14C0@6G"BBDV &@44"@!:*6DJ66%%%(:D8ZD(I
M:=5H0S%+2TE,BPF*:5I]% #=M&*?11<=AN*,4ZBBX6&8I<4ZBBX6&8HQ3Z*+
MA8;MI,4^BBX6&8I=M.HHN%AFVDQ4E--.Y+0F*7%**6@$M!F*7%.HI%)#"*0)
MS4E&*!I !Q2&G4TT@8HI:04M (*;BG44#$ HQ2T4 )B@4M)0 M%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 AIN*<:*9+$ I:**!A2 4M% "T444
MAB&F[:=2T (!1BEI*  B@"EHH 2EHHH **** "BBB@ HHHH **** "D(I:*
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M+ ?9]*N52LNE7:: ****8!124M "&@4&@4Q=1*444M (****0PHHHH ****
M"BBB@ HHHH **** "DQ2T4 %)2FFYH&.HHHH$%%%% !1110 E+24M2 E+10:
M: 2EIF>:?3 ;2B@T"@2W"@T4M3T&)1112 .U%%%# ***6F@"BBBJ **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 04-TI:0TF!#_%4PJ+'S
M5*.E2ABTUJ=3338B(?>J85%CYJE%(!:***L I*6B@!*6BB@ HHHH ****0"4
MM)2TD 44450!1110 4444 %%%% !1110 4E+10 4444 %%%%  :;2TTT(3'"
MEIH-.H8PHHHH8"4445 Q:***I""BBBF 4444 %%(:6@ HHHH **** "BBB@
MI*6D[TF M%%%, HHHH **** $HI:* $-(*4T"F3;46DI:2I904445(PHHHH
M,4444,0WO3ATIO>G"B(D+24M%6,**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "D-+10 VG4@I:!(****!A111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %)2TE "T444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4VG4AH$P%+
M0**!A1110 4444 %%%% !1110 4444 %9]]TK0K.OZ '6)XJ_6?8]*T* "BB
MB@!IZTHZ4AI120EN+24M%,8E+110 4444 %%%% !1110 4444 %%%% !1110
M 4E+24F 'I31UIQZ4P=:"EL24444R0HHHI, HI!2T( HHHI@%(>E+2-TH C!
M^:I1TJ$?>J8=* $I:** "BBB@!****AC"EI*6FA!1115 %%%% !1110 4444
M %%%% !112"EU 6BBBF @I:2EI( HHHI@%%%% !1110 4AI:2DP&XYI])BEH
M0"444M+J S'-.HQ138"T4@I:$ 4444P"BBB@!*6DH-3T 6DH%%#V *6DH%)#
M"EI*7M3$)2TE!HZ +2=Z6DH 6BBD%'4 I:2EH 2EI*6F@"BBBF 4E+25+ *:
MU.IK=*<08BU)4:5)5, HHHI )1114]0"EI*6F@"BBBF 4444 --**0THI"ZB
MT444QA1110 4444 %%%% !1110 4444 %%%% "4M)2TD 4E+13 *;WI3TI.]
M)B8ZBBBBPQ****A;C"BBBF E****8A:*0TM/J G>EI.]+2 *2@44= %I*7M2
M4 +1115 )2TE+20!24M)0P%HHHI@%%%% !1110 4444 %%%% !1110 E+24M
M) %%%%,!*6BB@!*6DI:2 ****8!1110 4444 %%%% !1110 4444 %%%% !1
M110 4E+3:!,=1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ I*6B@ HHHH **** "BBB@ HHHH **** "BBB@!#5"\&:
MOMTJG.,TT VT&!5X54@&*MKTIL!:***D!IZTHZ4&EI""BBBF,**** "BBB@
MHHHH **** "BBB@ HHHH **** "DI:*3 0]*:.M/-)BF-"T444""BBB@ HHH
MH0!1110 4AZ4M!H B YJ4=*;CFG4 %%%% !1110 E%+12L E+110@"BBBF 4
M444 %%%% !1110 4444 %%%%+J 4444P"BBBD@"BBBF 4444 %%%% !24M%)
M@%%%%, HHHI=0"BBBF 4444( HHHH **** $I:**5@$HHHI %+1132 2EHHH
M 2EHHHL 4G>EHHL 4444 )2T44 )2T44( HHHI@%)2TE2P"D:G4AIQ :M/IH
M%.JF 4444@"DI:2I8!2T44T 4444P"BBB@!#0*#2TA!1113&%%%% !1110 4
M444 %%%% !1110 4444 )2T44D 4444P"FTZDI"8M%%%,8E%%+4V 2BEHHL
M4E+13L 4444 )WI:** "DI:*+ %)2T4 %%%%,!*6BBD@"DI:*& 4444P"BBB
M@ HHHH **** "BBB@ HHHH 2EHHI( HHHI@%%%% "4M%%) %%%%, HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *2EI*!,6BBB@84444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 U^E59.M6GZ56>F@",596H(JL+TIR 6BBBI **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** $I:2BIZ@+1115 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !24M)4L!:***I %%%% !1110 4E+25+ 6BDI:: ***
M*8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1112 ****
M8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 -?I5:2K+=*K2#FJ0#X:G%0PU/28!1112
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "DI:2I8"T4450!1110 4444 %%
M%% !1110 4444 %%%% !1110 4E+25+W&+1115(04444 %%%% !24&BH8PI:
M2EJD(*2EI*& M%%%, HHHH **** "BBB@ HHHH **** "D-+2&DP%I*6DI +
M112"CJ 4M)2]J $I:2EIH HHHI@%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "'I4$@J<U&XJ
MD 15+4<=24F 4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH 2BD[TM,5PHHI*!7'4444B@HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
MDP"BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %)2TE2P%HHHJD 4
M444 %%%% "&B@T5#W&%+115(04444, HHHI@%%%% !1110 4444 %%%% !11
M10 4444 %%%%*P!1110 4444 %%%%- %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5&
M]24QZ: $I],2GT, HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !24M)0)B4M)13$**3O110 ZBBBD4%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E+128!1113
M **** "BBB@!#10:*A[C%HHHJQ!1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,:
MGTUJ:&A%I]-6G4,&%%%%(04444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %-IU-H$Q>U)2T4Q"4HH- H#J+1112
M*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** $-%!HJ'N M%%%6 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2
M&EI*  4M)2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4E+10 E%+10(2EHHH&%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1112L 4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
D* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image5.jpg
<TEXT>
begin 644 image5.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /6!WT# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ Q1BEHH
M3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:*
M $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6
MB@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1B
MEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,4
M8I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3
M%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:*
M$Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B
M@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BE
MHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48
MI:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%
M&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $
MQ1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@
M!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEH
MH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I
M:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&
M*6B@!,48I:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** #(HR*910 _(HR*910 _(HR*910 _
M(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR*91
M0 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR
M*910 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _
M(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR*91
M0 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR
M*910 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _
M(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR*91
M0 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR
M*910 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _
M(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR*91
M0 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR
M*910 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _
M(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR*91
M0 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR
M*910 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _
M(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR*91
M0 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR*910 _(HR
M*910 _(HR*910 _(HR*910 _(HR*910 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45\1_P#"
M=>+_ /H:M<_\&,O_ ,51_P )UXO_ .AJUS_P8R__ !5 'VY17Q'_ ,)UXO\
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M7Q'_ ,)UXO\ ^AJUS_P8R_\ Q5'_  G7B_\ Z&K7/_!C+_\ %4 ?;E%?$?\
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M8R__ !5 'VY17Q'_ ,)UXO\ ^AJUS_P8R_\ Q5'_  G7B_\ Z&K7/_!C+_\
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MUXO_ .AJUS_P8R__ !5 'VY17Q'_ ,)UXO\ ^AJUS_P8R_\ Q5'_  G7B_\
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M&,O_ ,51_P )UXO_ .AJUS_P8R__ !5 'VY17Q'_ ,)UXO\ ^AJUS_P8R_\
MQ5'_  G7B_\ Z&K7/_!C+_\ %4 ?;E%?$?\ PG7B_P#Z&K7/_!C+_P#%4?\
M"=>+_P#H:M<_\&,O_P 50!]N45\1_P#"=>+_ /H:M<_\&,O_ ,51_P )UXO_
M .AJUS_P8R__ !5 'VY17Q'_ ,)UXO\ ^AJUS_P8R_\ Q5'_  G7B_\ Z&K7
M/_!C+_\ %4 ?;E%?$?\ PG7B_P#Z&K7/_!C+_P#%4?\ "=>+_P#H:M<_\&,O
M_P 50!]N45\1_P#"=>+_ /H:M<_\&,O_ ,51_P )UXO_ .AJUS_P8R__ !5
M'VY17Q'_ ,)UXO\ ^AJUS_P8R_\ Q5'_  G7B_\ Z&K7/_!C+_\ %4 ?;E%?
M$?\ PG7B_P#Z&K7/_!C+_P#%4?\ "=>+_P#H:M<_\&,O_P 50!]N45\1_P#"
M=>+_ /H:M<_\&,O_ ,51_P )UXO_ .AJUS_P8R__ !5 'VY17Q'_ ,)UXO\
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M7Q'_ ,)UXO\ ^AJUS_P8R_\ Q5'_  G7B_\ Z&K7/_!C+_\ %4 ?;E%?$?\
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M8R__ !5 'VY17Q'_ ,)UXO\ ^AJUS_P8R_\ Q5'_  G7B_\ Z&K7/_!C+_\
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MUXO_ .AJUS_P8R__ !5 'VY17Q'_ ,)UXO\ ^AJUS_P8R_\ Q5'_  G7B_\
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M&,O_ ,51_P )UXO_ .AJUS_P8R__ !5 'VY17Q'_ ,)UXO\ ^AJUS_P8R_\
MQ5'_  G7B_\ Z&K7/_!C+_\ %4 ?;E%?$?\ PG7B_P#Z&K7/_!C+_P#%4?\
M"=>+_P#H:M<_\&,O_P 50!]N45\1_P#"=>+_ /H:M<_\&,O_ ,51_P )UXO_
M .AJUS_P8R__ !5 'VY17Q'_ ,)UXO\ ^AJUS_P8R_\ Q5'_  G7B_\ Z&K7
M/_!C+_\ %4 ?;E%?$?\ PG7B_P#Z&K7/_!C+_P#%4?\ "=>+_P#H:M<_\&,O
M_P 50!]N45\1_P#"=>+_ /H:M<_\&,O_ ,51_P )UXO_ .AJUS_P8R__ !5
M'VY17Q'_ ,)UXO\ ^AJUS_P8R_\ Q5'_  G7B_\ Z&K7/_!C+_\ %4 ?;E%?
M$?\ PG7B_P#Z&K7/_!C+_P#%4?\ "=>+_P#H:M<_\&,O_P 50!]N45\1_P#"
M=>+_ /H:M<_\&,O_ ,51_P )UXO_ .AJUS_P8R__ !5 'VY17Q'_ ,)UXO\
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M7Q'_ ,)UXO\ ^AJUS_P8R_\ Q5'_  G7B_\ Z&K7/_!C+_\ %4 ?;E%?$?\
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M8R__ !5 'VY17Q'_ ,)UXO\ ^AJUS_P8R_\ Q5'_  G7B_\ Z&K7/_!C+_\
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MUXO_ .AJUS_P8R__ !5 'VY17Q'_ ,)UXO\ ^AJUS_P8R_\ Q5'_  G7B_\
MZ&K7/_!C+_\ %4 ?;E%?$?\ PG7B_P#Z&K7/_!C+_P#%4?\ "=>+_P#H:M<_
M\&,O_P 50!S]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%+BC% "44N*,4 )12XHQ0 E%+BC%
M "44N*,4 )12XHQ0 E%+BC% "44N*,4 )12XHQ0 E%+BC% "44N*,4 )12XH
MQ0 E%+BC% "44N*,4 )12XHQ0 E%+BC% "44N*,4 )12XHQ0 E%+BC% "44N
M*,4 )12XHQ0 E%+BC% "44N*,4 )12XHQ0 E%+BC% "44N*,4 )12XHQ0 E%
M+BC% "44N*,4 )12XHQ0 E%+BC% "44N*,4 )12XHQ0 E%+BC% "44N*,4 )
M12XHQ0 E%+BC% "44N*,4 )12XHQ0 E%+BC% "44N*,4 )12XHQ0 E%+BC%
M"44N*,4 )12XHQ0 E%+BC% "44N*,4 )12XHQ0 E%+BC% "44N*,4 )12XHQ
M0 E%+BC% "44N*,4 )12XHQ0 E%+BC% "44N*,4 )12XHQ0 E%+BC% "44N*
M,4 )12XHQ0 E%+BC% "44N*,4 )12XHQ0 E%+BC% "44N*,4 )12XHQ0 E%+
MBC% "44N*,4 )12XHQ0 E%+BC% "44N*,4 )12XHQ0 E%+BC% "44N*,4 )1
M2XHQ0 E%+BC% "44N*,4 )12XHQ0 E%+BC% "44N*,4 )12XHQ0 E%+BC% "
M44N*,4 )12XHQ0 E%+BC% "44N*,4 )12XHQ0 E%+BC% "44N*,4 )12XHQ0
M E%+BC% "44N*,4 )12XHQ0 E%+BC% "44N*,4 )12XHQ0 E%+BC% "44N*,
M4 )12XHQ0 E%+BC% "44N*,4 )12XHQ0 E%+BC% "44N*,4 )12XHQ0 E%+B
MC% "44N*,4 )12XHQ0 E%+BC% "44N*,4 )12XHQ0 E%+BC% "44N*,4 )12
MXHQ0 E%+BC% "44N*,4 )12XHQ0 E%+BC% "44N*,4 )12XHQ0 M%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)
MFC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +1
M29HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "
MT4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0
M M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,
MT +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)F
MC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +12
M9HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T
M4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0
MM%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T
M +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC
M- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129
MHS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4
MF:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M
M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T
M+129HS0 M%)FC- "T4F:,T +129HS0 E%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%=!_P@GC
M#_H5-<_\%TW_ ,31_P ()XP_Z%37/_!=-_\ $T <_170?\()XP_Z%37/_!=-
M_P#$T?\ "">,/^A4US_P73?_ !- '/T5T'_"">,/^A4US_P73?\ Q-'_  @G
MC#_H5-<_\%TW_P 30!S]%=!_P@GC#_H5-<_\%TW_ ,31_P ()XP_Z%37/_!=
M-_\ $T <_170?\()XP_Z%37/_!=-_P#$T?\ "">,/^A4US_P73?_ !- '/T5
MT'_"">,/^A4US_P73?\ Q-'_  @GC#_H5-<_\%TW_P 30!S]%=!_P@GC#_H5
M-<_\%TW_ ,31_P ()XP_Z%37/_!=-_\ $T <_170?\()XP_Z%37/_!=-_P#$
MT?\ "">,/^A4US_P73?_ !- '/T5T'_"">,/^A4US_P73?\ Q-'_  @GC#_H
M5-<_\%TW_P 30!S]%=!_P@GC#_H5-<_\%TW_ ,31_P ()XP_Z%37/_!=-_\
M$T <_170?\()XP_Z%37/_!=-_P#$T?\ "">,/^A4US_P73?_ !- '/T5T'_"
M">,/^A4US_P73?\ Q-'_  @GC#_H5-<_\%TW_P 30!S]%=!_P@GC#_H5-<_\
M%TW_ ,31_P ()XP_Z%37/_!=-_\ $T <_170?\()XP_Z%37/_!=-_P#$T?\
M"">,/^A4US_P73?_ !- '/T5T'_"">,/^A4US_P73?\ Q-'_  @GC#_H5-<_
M\%TW_P 30!S]%=!_P@GC#_H5-<_\%TW_ ,31_P ()XP_Z%37/_!=-_\ $T <
M_170?\()XP_Z%37/_!=-_P#$T?\ "">,/^A4US_P73?_ !- '/T5T'_"">,/
M^A4US_P73?\ Q-'_  @GC#_H5-<_\%TW_P 30!S]%=!_P@GC#_H5-<_\%TW_
M ,31_P ()XP_Z%37/_!=-_\ $T <_170?\()XP_Z%37/_!=-_P#$T?\ "">,
M/^A4US_P73?_ !- '/T5T'_"">,/^A4US_P73?\ Q-'_  @GC#_H5-<_\%TW
M_P 30!S]%=!_P@GC#_H5-<_\%TW_ ,31_P ()XP_Z%37/_!=-_\ $T <_170
M?\()XP_Z%37/_!=-_P#$T?\ "">,/^A4US_P73?_ !- '/T5T'_"">,/^A4U
MS_P73?\ Q-'_  @GC#_H5-<_\%TW_P 30!S]%=!_P@GC#_H5-<_\%TW_ ,31
M_P ()XP_Z%37/_!=-_\ $T <_170?\()XP_Z%37/_!=-_P#$T?\ "">,/^A4
MUS_P73?_ !- '/T5T'_"">,/^A4US_P73?\ Q-'_  @GC#_H5-<_\%TW_P 3
M0!S]%=!_P@GC#_H5-<_\%TW_ ,31_P ()XP_Z%37/_!=-_\ $T <_170?\()
MXP_Z%37/_!=-_P#$T?\ "">,/^A4US_P73?_ !- '/T5T'_"">,/^A4US_P7
M3?\ Q-'_  @GC#_H5-<_\%TW_P 30!S]%=!_P@GC#_H5-<_\%TW_ ,31_P (
M)XP_Z%37/_!=-_\ $T <_170?\()XP_Z%37/_!=-_P#$T?\ "">,/^A4US_P
M73?_ !- '/T5T'_"">,/^A4US_P73?\ Q-'_  @GC#_H5-<_\%TW_P 30!S]
M%=!_P@GC#_H5-<_\%TW_ ,31_P ()XP_Z%37/_!=-_\ $T <_170?\()XP_Z
M%37/_!=-_P#$T?\ "">,/^A4US_P73?_ !- '/T5T'_"">,/^A4US_P73?\
MQ-'_  @GC#_H5-<_\%TW_P 30!S]%=!_P@GC#_H5-<_\%TW_ ,31_P ()XP_
MZ%37/_!=-_\ $T <_170?\()XP_Z%37/_!=-_P#$T?\ "">,/^A4US_P73?_
M !- '/T5T'_"">,/^A4US_P73?\ Q-'_  @GC#_H5-<_\%TW_P 30!S]%=!_
MP@GC#_H5-<_\%TW_ ,31_P ()XP_Z%37/_!=-_\ $T <_170?\()XP_Z%37/
M_!=-_P#$T?\ "">,/^A4US_P73?_ !- '/T5T'_"">,/^A4US_P73?\ Q-'_
M  @GC#_H5-<_\%TW_P 30!S]%=!_P@GC#_H5-<_\%TW_ ,31_P ()XP_Z%37
M/_!=-_\ $T <_170?\()XP_Z%37/_!=-_P#$T?\ "">,/^A4US_P73?_ !-
M'/T5T'_"">,/^A4US_P73?\ Q-'_  @GC#_H5-<_\%TW_P 30!S]%=!_P@GC
M#_H5-<_\%TW_ ,31_P ()XP_Z%37/_!=-_\ $T <_170?\()XP_Z%37/_!=-
M_P#$T?\ "">,/^A4US_P73?_ !- '/T5T'_"">,/^A4US_P73?\ Q-'_  @G
MC#_H5-<_\%TW_P 30!S]%=!_P@GC#_H5-<_\%TW_ ,31_P ()XP_Z%37/_!=
M-_\ $T <_170?\()XP_Z%37/_!=-_P#$T?\ "">,/^A4US_P73?_ !- '/T5
MT'_"">,/^A4US_P73?\ Q-'_  @GC#_H5-<_\%TW_P 30!S]%=!_P@GC#_H5
M-<_\%TW_ ,31_P ()XP_Z%37/_!=-_\ $T <_170?\()XP_Z%37/_!=-_P#$
MT?\ "">,/^A4US_P73?_ !- '/T5T'_"">,/^A4US_P73?\ Q-'_  @GC#_H
M5-<_\%TW_P 30!S]%=!_P@GC#_H5-<_\%TW_ ,31_P ()XP_Z%37/_!=-_\
M$T <_170?\()XP_Z%37/_!=-_P#$T?\ "">,/^A4US_P73?_ !- '/T5T'_"
M">,/^A4US_P73?\ Q-'_  @GC#_H5-<_\%TW_P 30!S]%=!_P@GC#_H5-<_\
M%TW_ ,31_P ()XP_Z%37/_!=-_\ $T <_170?\()XP_Z%37/_!=-_P#$T?\
M"">,/^A4US_P73?_ !- '/T5T'_"">,/^A4US_P73?\ Q-'_  @GC#_H5-<_
M\%TW_P 30!S]%=!_P@GC#_H5-<_\%TW_ ,31_P ()XP_Z%37/_!=-_\ $T <
M_170?\()XP_Z%37/_!=-_P#$T?\ "">,/^A4US_P73?_ !- '/T5T'_"">,/
M^A4US_P73?\ Q-'_  @GC#_H5-<_\%TW_P 30!S]%=!_P@GC#_H5-<_\%TW_
M ,31_P ()XP_Z%37/_!=-_\ $T <_170?\()XP_Z%37/_!=-_P#$T?\ "">,
M/^A4US_P73?_ !- '/T5T'_"">,/^A4US_P73?\ Q-'_  @GC#_H5-<_\%TW
M_P 30!S]%=!_P@GC#_H5-<_\%TW_ ,31_P ()XP_Z%37/_!=-_\ $T <_170
M?\()XP_Z%37/_!=-_P#$T?\ "">,/^A4US_P73?_ !- '/T5T'_"">,/^A4U
MS_P73?\ Q-'_  @GC#_H5-<_\%TW_P 30!S]%=!_P@GC#_H5-<_\%TW_ ,31
M_P ()XP_Z%37/_!=-_\ $T <_170?\()XP_Z%37/_!=-_P#$T?\ "">,/^A4
MUS_P73?_ !- '/T5T'_"">,/^A4US_P73?\ Q-'_  @GC#_H5-<_\%TW_P 3
M0!S]%=!_P@GC#_H5-<_\%TW_ ,31_P ()XP_Z%37/_!=-_\ $T <_170?\()
MXP_Z%37/_!=-_P#$T?\ "">,/^A4US_P73?_ !- '/T5T'_"">,/^A4US_P7
M3?\ Q-'_  @GC#_H5-<_\%TW_P 30!S]%=!_P@GC#_H5-<_\%TW_ ,31_P (
M)XP_Z%37/_!=-_\ $T <_170?\()XP_Z%37/_!=-_P#$T?\ "">,/^A4US_P
M73?_ !- '/T5T'_"">,/^A4US_P73?\ Q-'_  @GC#_H5-<_\%TW_P 30!S]
M%=!_P@GC#_H5-<_\%TW_ ,31_P ()XP_Z%37/_!=-_\ $T <_170?\()XP_Z
M%37/_!=-_P#$T?\ "">,/^A4US_P73?_ !- '/T5T'_"">,/^A4US_P73?\
MQ-'_  @GC#_H5-<_\%TW_P 30!S]%=!_P@GC#_H5-<_\%TW_ ,31_P ()XP_
MZ%37/_!=-_\ $T <_170?\()XP_Z%37/_!=-_P#$T?\ "">,/^A4US_P73?_
M !- '/T5T'_"">,/^A4US_P73?\ Q-'_  @GC#_H5-<_\%TW_P 30!S]%=!_
MP@GC#_H5-<_\%TW_ ,31_P ()XP_Z%37/_!=-_\ $T <_170?\()XP_Z%37/
M_!=-_P#$T?\ "">,/^A4US_P73?_ !- '/T5T'_"">,/^A4US_P73?\ Q-'_
M  @GC#_H5-<_\%TW_P 30!S]%=!_P@GC#_H5-<_\%TW_ ,31_P ()XP_Z%37
M/_!=-_\ $T <_170?\()XP_Z%37/_!=-_P#$T?\ "">,/^A4US_P73?_ !-
M'/T5T'_"">,/^A4US_P73?\ Q-'_  @GC#_H5-<_\%TW_P 30!S]%=!_P@GC
M#_H5-<_\%TW_ ,31_P ()XP_Z%37/_!=-_\ $T <_170?\()XP_Z%37/_!=-
M_P#$T?\ "">,/^A4US_P73?_ !- '/T5T'_"">,/^A4US_P73?\ Q-'_  @G
MC#_H5-<_\%TW_P 30!S]%=!_P@GC#_H5-<_\%TW_ ,31_P ()XP_Z%37/_!=
M-_\ $T <_170?\()XP_Z%37/_!=-_P#$T?\ "">,/^A4US_P73?_ !- '/T5
MT'_"">,/^A4US_P73?\ Q-'_  @GC#_H5-<_\%TW_P 30!S]%=!_P@GC#_H5
M-<_\%TW_ ,31_P ()XP_Z%37/_!=-_\ $T <_170?\()XP_Z%37/_!=-_P#$
MT?\ "">,/^A4US_P73?_ !- '/T5T'_"">,/^A4US_P73?\ Q-'_  @GC#_H
M5-<_\%TW_P 30!S]%=!_P@GC#_H5-<_\%TW_ ,31_P ()XP_Z%37/_!=-_\
M$T <_170?\()XP_Z%37/_!=-_P#$T?\ "">,/^A4US_P73?_ !- '/T5T'_"
M">,/^A4US_P73?\ Q-'_  @GC#_H5-<_\%TW_P 30!S]%=!_P@GC#_H5-<_\
M%TW_ ,31_P ()XP_Z%37/_!=-_\ $T <_170?\()XP_Z%37/_!=-_P#$T?\
M"">,/^A4US_P73?_ !- '/T5T'_"">,/^A4US_P73?\ Q-'_  @GC#_H5-<_
M\%TW_P 30!S]%=!_P@GC#_H5-<_\%TW_ ,31_P ()XP_Z%37/_!=-_\ $T <
M_170?\()XP_Z%37/_!=-_P#$T?\ "">,/^A4US_P73?_ !- '/T5T'_"">,/
M^A4US_P73?\ Q-'_  @GC#_H5-<_\%TW_P 30!S]%=!_P@GC#_H5-<_\%TW_
M ,31_P ()XP_Z%37/_!=-_\ $T <_170?\()XP_Z%37/_!=-_P#$T?\ "">,
M/^A4US_P73?_ !- '/T5T'_"">,/^A4US_P73?\ Q-'_  @GC#_H5-<_\%TW
M_P 30!S]%=!_P@GC#_H5-<_\%TW_ ,31_P ()XP_Z%37/_!=-_\ $T <_170
M?\()XP_Z%37/_!=-_P#$T?\ "">,/^A4US_P73?_ !- '/T5T'_"">,/^A4U
MS_P73?\ Q-'_  @GC#_H5-<_\%TW_P 30!S]%=!_P@GC#_H5-<_\%TW_ ,31
M_P ()XP_Z%37/_!=-_\ $T <_170?\()XP_Z%37/_!=-_P#$T?\ "">,/^A4
MUS_P73?_ !- '/T5T'_"">,/^A4US_P73?\ Q-'_  @GC#_H5-<_\%TW_P 3
M0!S]%=!_P@GC#_H5-<_\%TW_ ,31_P ()XP_Z%37/_!=-_\ $T <_170?\()
MXP_Z%37/_!=-_P#$T?\ "">,/^A4US_P73?_ !- '/T5T'_"">,/^A4US_P7
M3?\ Q-'_  @GC#_H5-<_\%TW_P 30!]OT444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
+ %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
